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The first chapter outlines the synthesis of pyrazolo[3,4-d]pyrimidines as inhibitors of Protein 
Kinase D, a potential target for cancer therapy. The second chapter describes the synthesis of 
novel inhibitors of Botulinum Neurotoxin A1. First, the synthesis of a constrained analog that 
contains a dibenzo[b,g][1,5]thiazocine is discussed. Second, we explore the use of a Staudinger 
aza-Wittig reaction to produce 1,2,4-triazines and report the progress towards an inhibitor of 
BoNT/A with increased metabolic stability.    
The third chapter describes the development of antagonists of the androgen receptor, a 
potential target for the treatment of castration-resistant prostate cancer. A small library of 
analogs was synthesized to assess a structure-activity relationship of a hit compound. The new 
lead compound was tested in vivo and further optimized to improve its metabolic stability. This 
chapter also describes the synthesis of small molecule affinity labeled conjugates to identify the 
mechanism of action of the antagonists. The final chapter of this dissertation describes the 
progress towards the total synthesis of 9-desmethylpleurotin.  
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1.0  SYNTHESIS OF SMALL MOLECULE INHIBITORS OF PROTEIN KINASE D 
1.1 INTRODUCTION 
Since the early 2000s, protein kinase D (PKD) has been a target for cancer therapy1-10 due to its 
association with a number of tumors, including prostate,2,10-15 breast,16-19 pancreatic,9,20-25 
lymphoma,26-28 and colon29-30 cancer. PKD forms a subgroup of the Ca+2/calmodulin-dependent 
kinase (CAMK) family and consists of three isoforms, 1, 2, and 3 (Figure 1.1). Initially, PKD1 
and PKD3 were thought to be a subclass of PKC and were named as PKC µ,31 and ν,32 
respectively. The three isoforms each have specialized roles in signaling pathways, which stem 
from their varying expression in different tissues.30,33  
 
Figure 1.1. The PKD family. 
Structurally, the three PKD isoforms show greater than 70% similarity (Figure 1.1). The 
cysteine rich domains (CRD) C1a and C1b, and the catalytic domain show high homology for 
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PKD1–3. The order of the domains is also conserved for the three isoforms and contains the 
CRD, a Pleckstrin Homology (PH) domain, and the catalytic kinase domain. The CRD are 
cysteine-rich zinc fingers that bind DAG (diacylglycerol) and PMA (phorbol ester).34 The PH 
domain is involved in the autoinhibition of PKD.35-36 Upon activation by PKC, PKD1 is 
phosphorylated at Ser 744, 748, and 916.37 Once PKD is phosphorylated, it can maintain its 
activity through auto-phosphorylation in the presence of an agonist.22,36-37  
PKD has been shown to play important roles in a number of cellular pathways including 
cell migration and invasion through protein exocytosis from the trans Golgi network (TGN), 
activation of the Ras-Raf-MEK-ERK pathway, inhibition of the JNK pathway, response to 
oxidative stress via NF-κB activation,33,38-39 and nuclear export of histone deacetylases 
(HDAC’s).37,40-44 In hypoxic tumors, PKD2 overexpression is important for tumor 
vascularization through stabilization of hypoxia inducible factor 1α (HIF1α), and subsequent 
NF-κB activation. Heat shock protein 90 (HSP90) plays an important role in regulating the 
stability of PKD2 and could be used for synergistic therapy to treat hypoxic tumors.45-46 
PKD activation begins with extracellular signaling via G-protein coupled receptors 
(GPCR) or a receptor tyrosine kinase (RTK). This signaling activates phospholipase C, which 
hydrolyzes PI4,5P2 (phosphatidylinositol-4,5-bisphosphate) into the corresponding DAG and IP3 
(inositol-1,4,5-triphosphate). DAG can bind to the CRD of nPKC, which in turn phosphorylates 
PKD, or directly binds to the CRD of PKD.36,42,47-48 Once PKD has been phosphorylated, it 
circulates through the cytosol where it can phosphorylate Ras and Rab interactor 1 (RIN1).49 The 
phosphorylated RIN1 releases Ras, which triggers the extracellular signal-regulated kinase 
(ERK) pathway involved in cell proliferation.49-50 Overexpression of PKD is involved in the 
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upregulation of ERK and has been shown to be present in a number cell types including prostate 
cancer cells,51 mouse embryonic fibroblasts (Swiss 3T3),52-53 and endothelial cells.54  
PKD can also downregulate the c-Jun N-terminal kinase (JNK) pathways through 
phosphorylation of c-Jun.40,55-56 JNK is a subgroup of the mitogen activated protein kinases 
(MAPK) and is responsible for inflammatory/immune response, apoptosis, cell proliferation, and 
cell motility.57-60 Dysregulation of these pathways has been implicated with tumorigenesis.61 
The catalytically active PKD can also enter the nucleus, phosphorylate class II HDAC’s 
(5 and 7)62-67 and trigger their nuclear exocytosis.41 HDAC’s have been shown to be important in 
transcription and cardiac muscle contraction. Moreover, class II HDAC’s can silence protein 
expression through DNA methylation.68 In certain tumor types PKD is downregulated as a result 
of this gene silencing.21-22,69-70 Dysregulation of PKD can cause cardiac hypertrophy and heart 
failure, and is one reason why PKD is being targeted as an upstream effector of HDAC 
export.67,71-74 
PKD has been demonstrated to be important in cell migration and invasion events that 
lead to the metastasis of cancer. PKD plays a key role in the regulation of protein transport from 
the trans Golgi network (TGN) to the cell surface.75-77 PKD has been shown to mitigate cell 
motility through phosphorylation of proteins involved in cell migration/invasion, including 
slingshot-1-like (SSH1L),25 cortactin,78-81 and Par-1.82 Phosphorylated SSH1L can further bind to 
the 14-3-3 protein, which results in the release of F-actin into the cytosol. The release of F-actin 
then feeds into the cofilin remodeling of membranes of migrating cells.17,83-87 PKD also inhibits 
F-actin remodeling by phosphorylation of RIN1, which activates c-Abl. c-Abl then alters the 
conformation of the adaptor protein Cullin-RING ubiquitin ligases (CRL), preventing activation 
of the F-actin remodeling proteins and disrupting cell motility.50 PKD has also been associated 
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with the regulation of spatial memory through the stabilization of F-actin in dendritic spines.88 
PKD also regulates matrix-metalloproteinases (MMP’s) that are responsible for the degradation 
of the extracellular matrix (ECM).89-90 These MMP’s have been shown to play an important role 
in the metastasis of multiple cancers.25,91-95 Recently, PKD1 has been shown to regulate focal 
adhesions, attachment sites connecting cells to the ECM, through the localization of αvβ3 
integrin and phosphatidylinositol-4-phosphate 5-kinase type-l gamma (PIP5Klγ).96 PKD 
isoforms 1 and 3 have been found to regulate the cell cycle through microtubule modulation 
during mitosis.97  
PKD can also be activated as a response to oxidative stress through a PKC dependent 
Src-Abl pathway.98-100 PKD is phosphorylated at the PH domain, which allows for further 
phosphorylation on the CRD followed by PKCδ phosphorylation of the activation loop.38,98,101-104 
Phosphorylated PKD can phosphorylate the IKK complex that signals Nf-κB to induce 
expression for manganese superoxide dismutase (MnSOD) from the mitochondria, which then 
quenches ROS in the cytosol.100,102,105  
Each of these pathways plays an important role in either cell survival or cell death and for 
this reason PKD represents a complex but viable target for cancer therapy. 
1.1.1 Small Molecule Inhibitors of PKD 
The ATP binding domain of PKD was the target of early PKD inhibitors.106 Unfortunately, the 
ATP binding domain is highly conserved within the kinome and was the main downfall of early 
PKD inhibitors because they were non-selective and inhibited other kinases, resulting in off 
target effects. Over the past 15 years, potent PKD-selective inhibitors have been developed 
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targeting both the ATP binding domain and allosteric sites. In general, most ATP-competitive 
inhibitors are less kinase-selective due to the highly conserved nature of ATP binding sites.106 
One of the earliest known PKD inhibitors, staurosporine (Figure 1.2), has low nanomolar 
PKD inhibition but also inhibits numerous other kinases, including protein kinase C (PKC), 
protein kinase A (PKA), and CAMK II.107 Recently, fluorescein-staurosporine conjugates have 
been synthesized for their use as tools to monitor binding of other ATP competitive inhibitors.108 
The staurosporine type inhibitors including Gö 6976 (Figure 1.2) have been well studied for their 
kinase activity and exhibit low nanomolar inhibition of both PKC and PKD.33,107,109-111   
The stilbene resveratrol was found to inhibit many proteins including PKD and required 
high micromolar concentrations for any observable inhibition effect (Figure 1.2). Resveratrol has 
been extensively studied as a cancer preventative and therapeutic but is limited due to its poor 
solubility, low bioavailability, and photochemical stability.112 Despite these limiting factors, 
several formulations and analogs of resveratrol have been developed for the treatment of cancer 
and various diseases.112 The flavonol, quercetin, was found to have low micromolar inhibition of 
PKD and PKC in addition to a number of other proteins and has been well studied for its use in 
the prevention and treatment of cancer (Figure 1.2).113 The polysulfonylated naphthylurea, 
Suramin, was initially used for the treatment of sleeping sickness and parasitic diseases and later 
found be an effective activator of PKD (Figure 1.2).114 Based on its ability to decrease tumor 
growth, Suramin has been advanced into a number of clinical trials including a combination 
treatment with paclitaxel in a phase I/II clinical trial for metastatic breast cancer 
(NCT00054028), a phase II clinical trial in combination with docetaxel for the treatment of non-
small cell lung cancer (NCT01671332), a phase I clinical trial for bladder cancer 
(NCT00006476), and a phase III clinical trial for the treatment of castration resistant prostate 
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cancer (NCT00002723) (Figure 1.2). The marine-derived macrolactone bryostatin 1 was shown 
to activate PKD and PKC leading to alterations in cell aggregation and proliferation through 
localization of β-catenin.115 Bryostatin 1 has been used in numerous (>40) clinical trials for the 
treatment of cancer, HIV, and Alzheimer’s disease.116-117 
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Figure 1.2. Early PKD modulators. 
The novel 3,5-diarylazole 1.1 was identified from a HTS against PKD1 and had moderate 
kinase inhibition (PKD1 IC50 = 2.3 µM).118 Subsequent structural optimization of 1.1 afforded 
compound 1.2 a potent, selective, and orally bioavailable inhibitor of PKD. Analog 1.2 exhibited 
modest isoform selectivity with a 9-fold and 3-fold selectivity for PKD1 over PKD2 and PKD3 
respectively along with >1000-fold selectivity against a panel of 230 kinases.118 PK data for 1.2 
indicates that there is moderate oral bioavailability (38%) with a short plasma half-life (1.2 h). 
Combined, the selectivity, activity, and PK data for 1.2 make it a viable target for further 
optimization. 
The 2,6-naphthyridines, developed by Novartis, have emerged as novel PKD inhibitors 
(Figure 1.3).119-120 The 2,6-naphthyridine inhibitor 1.3 was identified in a HTS and shown to be 
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ATP-competitive PKC/PKD inhibitor. A series of modified 2,6-naphthyridines was used to 
investigate PKD as a possible therapeutic target for cardiac hypertrophy, since PKD is a 
downstream effector of nuclear export of class II HDAC’s.41,67,73-74,121-122 Subsequent SAR 
studies led to the orally available 1.4, which was shown to block phosphorylation of PKD and 
nuclear export of class II HDAC’s (Figure 1.3).119 Additionally, when 1.4 was administered in 2 
rat cardiac hypertrophy disease models it was found to have no effect. Unfortunately, it was 
unclear whether this was the result of PKD inhibition by 1.4 or the ability of 1.4 to also inhibit 
glycogen synthase kinase 3 β (GSK3β), which is known for its role in antihypertrophy.123 An 
Using molecular modeling and conformational analysis, the 2,6-naphthyridine core was 
truncated to a bipyridyl.119-120 Further optimization produced a new lead, BPKDi, a potent pan-
PKD inhibitor that inhibits autophosphorylation of PKD and provides increased retention of 
HDAC4 and HDAC5 in cardiomyocytes (Figure 1.3).120 In a PK panel in rats, BPKDi performed 
poorly due to high clearance, low solubility, and poor bioavailability. Attempts to improve the 
PK parameters were met with compounds less active or selective against PKD. To assess the in 
vivo activity, BPKDi was administered sc daily at 5 mg/kg in two rat models with no reduction in 
cardiac hypertrophy was observed.  When higher doses of BPKDi were administered, a 
significant increase in blood pressure was observed, however, adequate plasma concentrations 
were reached at this dosing concentration. The lack of in vivo activity for these compounds 
ultimately led to their discontinuation as targets for the treatment of hypertrophy.  
Cancer Research Technologies (CRT) produced the potent, orally available pan-PKD 
inhibitor CRT0066101 (Figure 1.3).21 CRT0066101 was shown to have single-digit nanomolar 
pan-PKD activity in vitro. In a human pancreatic cancer tumor xenograft model, CRT0066101 
was administered orally daily at 80 mg/kg for 28 days halting tumor growth completely.21 In rat 
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pancreatic acinar cells, CRT0066101 promoted apoptosis and decreased necrosis in pancreatitic 
cells.23,124 In malignant brain tumor cells, glioblastoma multiforme, CRT0066101 decreased cell 
migration and invasion events through inhibition of PKD2.125 CRT0066101 was antiproliferative 
in vitro in low micromolar concentrations against multiple colorectal cancer cell lines.126 
Subsequent administration of CRT0066101 in HCT116 xenograft nude mice displayed 
significant inhibition of tumor growth.126 When used in combination with Regorafenib, 
CRT0066101 demonstrated a synergistic effect  on the inhibition and cell proliferation in 
metastatic colorectal cancer.127  Additionally, CRT0066101 has also been shown to inhibit 
estrogen receptor negative breast cancer both in vitro and in vivo.19 CRT0066101 remains a 
promising inhibitor of PKD for the treatment of cancer. In addition to CRT0066101, CRT also 
developed the pyrazine benzamide CRT5, which was a potent selective pan-PKD inhibitor (IC50 
= 1.5 nM) and decreased VEGF-induced endothelial migration, cell proliferation, and 
tubulogenesis (Figure 1.3).128  
 The pyrazolo[3,4-d]pyrimidine 3-IN-PP1 was identified from a recent SAR of 1-NM-
PP1, a previously known inhibitor of Src and calcium dependent kinases,15,129-130 as a potent (in 
vitro IC50 = 33 nM) pan-PKD inhibitor (Figure 1.3).131 Based on the interesting trends with the 
SAR, 3-IN-PP1 was proposed to have a alternate binding mode in the ATP binding pocket of 
PKD with the structure flipped 180° compared to other classically modeled kinase inhibitors.131 
3-IN-PP1 is a promising new inhibitor that has potential for further structural development. 
Recently, the pyrazolo[3,4-d]pyrimidine 1.5 was identified as a low nanomolar pan-PKD 
inhibitor from a novel LC-MS based kinase screening technique (Figure 1.3).132 This HTS 
technique allows for the rapid proteome profiling of new inhibitors of protein kinases and other 
purine-binding proteins.133-134 
 9 
N
N
HN NH2
N
1.3
HN
N
N
N
HN
O
N
N
NH
HO
NN
CRT0066101
H2N
H2N
N
N
N
N
H
N
H
O
BPKDi
N
N N
N
NH2
N
O
N
O
N
HN
NHO
CN
1.1 1.2
1.5
N
N
N
N
H
N
H
1.4
N
O
N
N N
N
NH2
H
N
3-IN-PP1
N
H2N
NH
O
N
O
CRT5
N
N N
N
NH2
1-NM-PP1
 
Figure 1.3. Recent inhibitors of PKD. 
1.1.2 Small Molecule Inhibitors of PKD: Previous Work in the Wipf Group 
Over the past 10 years, the Wipf group has been attracted to developing small molecule 
inhibitors of PKD as a potential target for cancer therapy. A library screen of the NIH SMRL 
produced the first potent PKD specific inhibitor CID 755673 with an in vitro IC50 of 180 nM 
(Figure 1.4).135 Previous work in the Wipf group aimed to improve potency of CID755673 which 
led to the synthesis of the more potent kb-NB142-70 with an in vitro IC50 of 28 nM.135-137 
CID755673 and kb-NB142-70 were effective in reducing prostate and colorectal cancer cell 
proliferation and migration in vitro.126,138 Unfortunately, no therapeutic effect was observed 
when kb-NB142-70 was administered to mice bearing PC-3 xenografts.138 Subsequent PK 
analysis of kb-NB142-70 revealed that it had a plasma half-life of 6 min that can correlate 
directly to poor in vivo efficacy. Attempts to improve the metabolic stability of kb-NB142-70 
resulted in kmg-NB4-23 that was slightly less potent with an in vitro IC50 of 124 nM (Figure 
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1.4). Unfortunately, the poor solubility of kmg-NB4-23 (<0.4 mg/mL) prevented the in vivo 
biological characterization of this compound. The benzoxoloazepinolones were found to bind 
non-competitively with ATP indicating a potential alternative binding mode or location. An 
allosteric inhibitor may exhibit increased kinase selectivity making this scaffold a viable lead for 
further development.  
SD-208 was identified from a targeted kinase inhibitor library screen and was found to be 
a potent, selective, orally bioavailable ATP-competitive inhibitor of PKD in vitro and in vivo 
(Figure 1.4).139 A subsequent SAR of SD-208 revealed key binding interactions were required 
for potency in PKD and did not result in any analogs with increased potency. Finally, Ro139 was 
identified from a HTS campaign and was found to have low nanomolar activity against PKD in 
vitro (Figure 1.4).140 Subsequent analog synthesis and biological characterization by WST-1 
assay141 revealed that analogs of Ro139 were selective towards rectal carcinoma RKO cells with 
low micromolar inhibition. 
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Figure 1.4. PKD inhibitors developed in the Wipf Group. 
1.2 RESULTS AND DISCUSSION 
The pyrazolopyrimidine 1-naphthyl-PP1 (PP1) was identified as a novel ATP competitive pan-
PKD inhibitor (Figure 1.5).15 Initially, PP1 was developed for analog specific mutants of src 
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kinases.129 This scaffold was used to probe the ATP binding sites of gatekeeper mutant proteins 
that provide a more accessible binding pocket for new inhibitors.129,142 PP1 has been shown to be 
highly selective for PKD over PKC and other members of the CAMK family.15 To validate the 
analog specific mutant approach, PP1 was tested against the gatekeeper mutant of PKD that had 
been transfected and overexpressed in human embryonic kidney (HEK293) cells. PP1 showed a 
12-fold increase in activity from the wild type to the mutant. This suggests that the mutant PKD 
could be used to assess structural modifications of PP1 to develop a more potent PKD inhibitor 
as shown by Bishop and coworkers.142 Additionally, PP1 derivatives are active in mutants of 
ERK1/2 containing a single amino acid alteration.143 PP1 is a potent pan-PKD inhibitor that has 
an IC50 of 155 nM and has been shown to inhibit growth and cell proliferation in prostate cancer 
(PC3 cells).15 We envisioned 4 zones of modification around the PP1 core to identify the 
substituent effect on the biological activity (Figure 1.5).  
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Figure 1.5. Zones of structural modification around PP1 core. 
1.2.1 Synthesis of Pyrazolo[3,4-d]pyrimidine-Based Analogs 
Our synthetic approach to the PP1 analogs utilized a late stage Suzuki cross coupling at 
halogenated C-3 with a variety of aryl boronic acids. We proposed that intermediate 1.7 could be 
formed by nucleophilic aromatic substitution with an amine at C-4 and subsequent halogenation 
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at C-3. Precursor 1.8 could be readily formed by a Vilsmeier-Haack reaction and hydrazine 
cyclization of commercially available barbituric acid 1.9 (Scheme 1.1).     
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Scheme 1.1. Retrosynthetic approach to PP1 analogs. 
The synthesis of PP1 and its analogs began with the tandem Vilsmeier-Haack 
chlorination and formylation reaction on commercially available barbituric acid (1.9) to give the 
trichloropyrimidine 1.10 in moderate yields.144 Condensation and cyclization with methyl or t-
butyl hydrazine afforded the pyrazolo[3,4-d]pyrimidines 1.8 in good yields. Initially, the 
cyclization with t-butyl hydrazine hydrochloride was low yielding due to poor solubility of the t-
butyl hydrazine hydrochloride salt in THF at -78 °C. Attempts to freebase the hydrazine to 
improve the reaction were unsuccessful. After screening several solvents and solvent 
combinations, it was determined that addition of a solution of the hydrazine hydrochloride in 
acetonitrile to a THF solution of pyrimidine affords the desired product 1.8 in good yields. 
Regioselective aminolysis of 1.8 at the C4-position with ammonia or methylamine gave amines 
1.11 in great yields. Initial attempts to iodinate at C-3 to form the 3-iodo intermediate with 
iodine, Barluenga’s reagent, or N-iodosuccinimide were unsuccessful.15 Gratifyingly, treatment 
with bromine afforded 3-bromo-pyrazolopyrimidines 1.7 in good yields. The C-3 bromide 1.7 
was functionalized via a Suzuki cross coupling using a variety of aryl boronic acids to give the 
arylated compounds 1.12. The low yields in some cases are the result of the arylation at both C-3 
and C-6 to afford diarylated products. Finally, the 6-chloro substituent was reduced via a 
catalytic hydrogen transfer reaction to give the desired products 1.13 in poor to excellent yields 
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(Scheme 1.2). Overall PP1 and 17 analogs were prepared with varying substitution at the 
pyrazole nitrogen R1, aryl ring at R2, amine R3, and C-6 position.  
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Scheme 1.2. Synthesis of PP1 analogs. 
1.2.2 Biological Activity of PP1 Analogs 
The in vitro PKD1 inhibition for PP1 and analogs was determined at 1 µM using a radiometric 
kinase assay.15 The 17 analogs of PP1 showed that the PKD binding pocket was very resistant to 
structural modifications of the parent structure (Table 1.1). Modifying R1 from a bulky t-butyl to 
a smaller methyl group resulted in a 50% loss in activity (entry 7). Replacement of the naphthyl 
group at R2 with other aryl substituents also eliminated PKD activity. Analogs with methylation 
at R3 were completely inactive and further confirmed the importance of the hydrogen bonding 
interactions within the binding pocket.129 Electrophilic analogs (R4=Cl) were also completely 
inactive. Unfortunately, the PP1 analog with a 6-chloro substitution was never synthesized and 
therefore no direct comparison can be made about the chloro substitution on activity of PP1. 
Based on the steep SAR observed, this series was deprioritized in favor of new cores.  
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Table 1.1. In vitro radiometric kinase inhibition assay for PP1 analogs against PKD1.15 
N
N
NHR3
N
N
R1
R2
R4
 
Entry Compound Structure PKD1 % inhibitiona R1 R2 R3 R4 
1 PP1 t-butyl 1-naphthyl H H 80% (PP1) 
2 1.13a t-butyl 1-naphthyl methyl H <10% 
3 1.13b t-butyl (4-MeO)phenyl H H <10% 
4 1.13c t-butyl (4-MeO)phenyl methyl H <10% 
5 1.13d t-butyl (4-F)phenyl H H <10% 
6 1.13e t-butyl (4-Ph)phenyl H H <10% 
7 1.13f methyl 1-naphthyl H H 32% 
8 1.13g methyl 1-naphthyl methyl H <10% 
9 1.13h methyl (4-MeO)phenyl H H <10% 
10 1.13i methyl (4-MeO)phenyl methyl H <10% 
11 1.12h methyl (4-MeO)phenyl H Cl <10% 
12 1.12i methyl (4-MeO)phenyl methyl Cl <10% 
13 1.13j methyl (4-CF3O)phenyl methyl H <10% 
14 1.12j methyl (4-CF3O)phenyl methyl Cl <10% 
15 1.13k methyl (4-F)phenyl methyl H <10% 
16 1.12k methyl (4-F)phenyl methyl Cl <10% 
17 1.13l methyl (4-Ph)phenyl methyl H <10% 
18 1.12l methyl (4-Ph)phenyl methyl Cl <10% 
aPKD1 %inhibition was determined at 1 µM concentration as previously described.15,140    
1.3 CONCLUSIONS 
PP1 was identified in an initial library screen and was found to be a potent PKD inhibitor with 
selectivity against similar kinases.140 To validate the initial results, PP1 was resynthesized and 17 
analogs were prepared to probe the effect of substitution around the PP1 core (Figure 1.3). 
Unfortunately, we discovered that the PKD binding pocket was very resistant to our structural 
modifications. The limited SAR produced compounds with no activity or poor activity, with PP1 
remaining the most active analog (Table 1.1). The parent PP1 blocked 50% of PKD activity at 
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100 nM. A subsequent assay of PP1 against closely related kinases PKCα, PKCδ, and 
CAMKIIα had shown no inhibition even at concentrations as high as 10 µM.  Although all new 
analogs of PP1 were inactive, PP1 was established as a potent pan-PKD inhibitor having 
antitumor activity in prostate cancer cells.15 
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2.0  SYNTHESIS OF BOTULINUM NEUROTOXIN A METALLOPROTEASE 
INHIBITORS 
2.1 INTRODUCTION 
The Clostridium genus of gram-positive bacteria includes several human pathogens that are well 
known for their toxicity, including C. botulinum (botulism), C. tetani (tetanus),145-147 and C. 
perfringens (clostridial necrotizing enteritis).148-149 The toxicity of C. botulinum is due to 
botulinum neurotoxins (BoNT’s), which are a family of proteins consisting of eight serotypes 
(A-H).150-154 The resulting disease, botulism, is characterized by flaccid muscle paralysis, leading 
to respiratory failure and death. Of the eight serotypes, BoNT/A is the most potent neurotoxin 
with an LD50 of less than 1 ng/kg.155 There are five subtypes of BoNT/A (1-5) that contain 
unique characteristics.156-157 In 1942, methods to effectively purify crystalline BoNT/A were 
developed leading to its use in the treatment of muscle disorders and increasing its potential for 
use in biological warfare.158-164 Today, BoNT’s are classified by the CDC as a class A 
biothreat.165 Even with early detection, effective treatments of BoNT intoxication are limited and 
prophylactic. Several low-dose injectable forms of BoNT/A (Botox, Dysport, Xeomin) and 
BoNT/B (Myobloc) have been approved by the FDA for the treatment of a number of 
neuromuscular, urological, pain, and cosmetic disorders.146-147,155,166-195 
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BoNT’s are metalloproteases196 that consist of a 100 kDa heavy-chain (HC) and a 50 kDa 
light-chain (LC), both linked by a single disulfide bond (Figure 2.1).197-200 The HC contains two 
50 kDa domains, the C-terminal binding domain (HCC) and the N-terminal translocation domain 
(HCN). The LC is the catalytic domain containing zinc in the active site. Toxicity arises after 
disulfide cleavage, which enables release of the LC into the intracellular membrane.201 
 
Figure 2.1. Structure of BoNTA (PDB: 3BTA) rendered in PyMol, HCC (Blue), HCN (Pink), LC (green), 
catalytic Zn (grey). 
There are four main methods of BoNT intoxication including ingestion, wound, 
intentional intoxication (bioterrorism), or unintentional intoxication (side effect of therapeutic 
treatment).202-203 Ingestion is the most common form of intoxication and occurs only with a 
preformed complex BoNT that consists of three components: BoNT, hemagglutinins (HAs; three 
HA-70, three HA-17, and six HA-33), and “non-toxic” non-hemagglutinin (NTNHA) also 
referred to as “non-toxic” neurotoxin associated proteins (NAP’s). The complex provides heat 
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and hydrolytic stability as well as aid in intestinal absorption.204-208 The HA and NTNH proteins 
are shed as BoNT circulates through the blood stream.203 Homogeneous BoNT shows 
remarkable stability and rapid distribution in the bloodstream.203 BoNT localizes at 
neuromuscular junctions (NMJ) where the heavy chain (HCc) binds to extracellular membrane 
gangliosides (Figure 2.2).209-211 Once bound to the membrane, BoNT triggers a recycling of 
synaptic vesicle membrane proteins (SV2) that cause endocytosis of the BoNT.212 The newly 
formed vesicle is acidified by an ATP activated proton pump, which causes the translocation 
domain HCn to insert into the vesicle membrane.213-214 The translocation domain HCn opens a 
pore within the vesicle that facilitates the extension of the LC out of the vesicle and into the 
cytosol.145,214 Recently, it has been shown that the stability of the HC/LC complex under acidic 
pH increases and that under an acidic pH the LC interacts and permeates the anionic 
phospholipid bilayer.215 Once exposed to the cytosol, the disulfide bond is reduced,214 releasing 
the free LC into the cytosol. The LC of BoNT then facilitates hydrolysis of the soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins that facilitate 
pore formation along the synaptic membrane and are crucial in releasing the neurotransmitter 
acetylcholine into the synaptic cleft. There are three SNARE proteins that are targeted by the 
different serotypes of BoNT’s: vesicle associated membrane proteins (VAMP also known as 
synaptobrevin) are targeted by BoNT B,216 D,217 F,218 and G,197 synaptosomal associated protein 
of 25 kDa (SNAP-25) is targeted by BoNT A, C, and E,219-220 and syntaxin is targeted by BoNT 
C.202,221 BoNT/A cleaves SNAP-25 at Gln197 and Arg198 to produce a very stable truncated 
peptide that will not form the SNARE complex responsible for membrane fusion, thus inhibiting 
the release of acetylcholine into the NMJ (Figure 2.2).222-223  
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Figure 2.2. Mechanism of BoNT intoxication.191,202 
The mechanism of zinc-mediated hydrolysis is exemplified by the reaction of SNAP-25 
with the LC of BoNT/A. Cleavage begins with coordination of the catalytic zinc, to the carbonyl 
of the amide, thereby activating the amide toward hydrolysis. Water then adds into the amide to 
form a tetrahedral intermediate that is stabilized by the catalytic zinc and adjacent Tyr366 residue. 
Subsequent elimination of the amine generates Gln197 acid (Scheme 2.1).222 
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Scheme 2.1. Mechanism of SNAP-25 hydrolysis.223 
To date, the only approved treatments of BoNT’s are vaccines (antitoxins). In 2013, the 
Botulism Antitoxin Heptavalent (BAT) was approved by the FDA and is the current standard of 
care for BoNT intoxication of adults.191 These vaccines work as prophylactic treatments and only 
remain effective for a few months to one year.224 In addition, the vaccines are expensive to 
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produce (ca. $2100/dose), and are made from equine botulinum antitoxin that has been shown to 
have adverse effects in ~10% of the population.191,225 The monoclonal antibodies produced by 
vaccines are only effective if applied before exposure to the toxin as the toxins have been found 
in the motor neurons within minutes to hours after exposure.226 Due to the lack of a readily 
available treatment of BoNT’s and the possibility of a widespread bioterrorism event, the 
development of a small molecule inhibitor of BoNT/A LC is highly desirable.  
2.1.1 Peptide Based Inhibitors of BoNT’s 
Initial inhibitors of the LC were peptides and peptidomimetics that mimic the truncated SNAP-
25 (amino acids 187-206) and have been primarily used as chemical probes and in assay 
development for the measurement of inhibition of BoNT’s.227-234  Early work by Schmidt and 
Bostian used a truncated SNAP-25 (amino acids 187-206) to monitor the proteolytic activity of 
BoNT/A LC. After screening a number of truncated peptides it was discovered that the relative 
size and sequence of the truncated peptide was important and that the 17-mer had the highest 
kcat.227,235 Schmidt and Stafford developed a HTS FRET (fluorescence resonance energy transfer) 
assay that uses the modified SNAP-25 fragment SNRTRIDEAN[dnpK]RA[daciaC]RML as a 
FRET substrate.236 The FRET substrate for this assay tends to suffer from photodegradation or 
fluorescence quenching and is usually run along with HPLC analysis to eliminate false 
positives.236-239 Janda and coworkers developed another HTS that relies on a modified SNAP-25 
fragment (FITC)-TRIDEANQRATK(DABCYL)M known as SNAPtide, which is more resistant 
to photodegredation and has higher bench stability.240-243 When using SNAPtide as a FRET 
substrate the N-terminal fluorophore, fluorescein isothiocyanate (FITC), is quenched by the C-
terminal 4-((4-dimethylamino)phenyl)azo) benzoic acid (DABCYL).243 These substrates are also 
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used in HPLC assays to measure the extent of proteolysis of the truncated peptide that can be 
directly correlated to a ligand binding affinity or IC50. 
In the search for more potent and specific small molecule non-peptidic inhibitors 
(SMNPI’s) of BoNT/A, extensive work has focused on using computational models of the 
binding site and known SAR to probe for a more potent or specific structure. Based on the 
previous work on modified SNAP-25 fragments by Schmidt and coworkers, the pseudo-peptide 
mpp-RATKM (Figure 2.3) was developed. It was initially identified through a cysteine scan of a 
SNAP-25 (187-203) fragment and further optimized through SAR to provide a mpp-RATKM 
that had a Ki of 300 nM.228-229,231,244 Burnett and coworkers used this pseudo-peptide along with 
conformational and docking studies of a library of previously known active compounds to 
elucidate the pharmacophore of BoNT/A LC (Figure 2.3).202,238,244-247  
Compound I1 was derived from the SNAP-25 fragment QRATKML and is the most 
potent non-zinc chelating peptide mimetic to date.222 In the Wipf lab, several peptidomimetics 
have also been previously synthesized as a hybrid of RRGC248 and I1 resulting in 3 new peptides 
with Ki’s ranging from 0.3 µM to 1 µM.233 Further development of these peptides has led to 
cyclic peptides analogs.249 Unfortunately, even shorter peptides suffer from high polar surface 
areas (>300), which could cause limited cell permeability that may lead to a poor therapeutic 
profile. The shorter tetrapeptide (RRGC) could be a potential lead compound for further 
backbone modifications as it has the lowest MW of all truncated peptides and a promising Ki of 
160 nM. Compound RRGC was shown to be protective and non-toxic to chick motor neurons at 
600 µM along with an intracellular stability over 24 hours (Figure 2.3).  
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Figure 2.3. Structures of peptide-like inhibitors of BoNT/A. 
2.1.2 Small Molecule Inhibitors of BoNT’s  
As peptides often suffer from high metabolism and low absorption, significant efforts have been 
made toward pinpointing a small molecule non-peptidic inhibitor of BoNT. As a result a variety 
of small molecule scaffolds have emerged in the literature for the treatment of BoNT over the 
past 30 years.  
Hydroxamic acids have emerged as very potent inhibitors of BoNT LC. The catalytic 
domain has been cocrystalized to elucidate their binding mode, showing that the hydroxamic 
acids chelate zinc in the active site.250-252 The earliest potent (< 1 µM) nonpeptidic hydroxamic 
acid inhibitor 2.1 was identified from a screen of a small library of hydroxamic acids (Figure 
2.4).239,252-253 Hydroxamic acid 2.1 had a promising in vitro IC50 of 0.4 µM but was found to be 
toxic in neuroblastoma N2a cells at 5 µM. Subsequently, in two separate mouse studies, 2.1 did 
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not show significant protection in BoNT intoxicated mice versus the controls.253-256  In silico 
screening of 2.5 million hydroxamic acid derivatives led to the discovery of 2.2 that 
demonstrated low µM in vitro activity and promising in vivo survival with 60% survival 
compared to the control after 48 h.257-258 Despite concerns due to hydroxamic acids being flagged 
as potentially concerning functionalities, several examples of FDA approved drugs contain this 
moiety.259-261  
Covalent inhibitors of BoNT/A LC have also been investigated, which act by binding to 
the free Cys165 produced by disulfide bond reduction during the release of the LC into the 
cytosol.262-263 These compounds are noncompetitive inhibitors of BoNT and covalently bind 
through the Michael acceptor acrylonitrile. Compound 2.3 was identified from a 70,000 
compound library screen and was further optimized to 2.4 that had shown increased selectivity 
for BoNT/A LC in a chick neuronal cell-based assay (Figure 2.4).  IC50 values for 2.3 and 2.4 
were calculated using a HTS FRET assay and verified using an HPLC assay.235-236 Advantages 
of these selective covalent inhibitors include increased biochemical efficiency since their binding 
is not in equilibrium and can outcompete endogenous ligand binding at lower concentrations as 
exhibited by numerous FDA approved covalent drugs. Unfortunately, the possible off target 
effects of these covalent inhibitors include alkylation or reaction with glutathione, which could 
lead to potential toxicity.264  
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Figure 2.4. Hydroxamic acid and covalent inhibitors of BoNT. 
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The antimalarial aminochloroquinolines (ACQ) have also been explored as inhibitors of 
BoNT’s (Figure 2.5). Compound 2.5 (also known as Q2-15) was discovered from a HTS of the 
NCI diversity set of a variety of ACQ containing substrates.238 In particular, 2.5 was shown to 
inhibit BoNTA with an IC50 of 11 µM. More recently a series of hybrid structures such as 2.6 
were synthesized and found to have submicromolar IC50 of 0.3 µM in an in vitro assay. Although 
compounds such as 2.6 show submicromolar in vitro inhibition of BoNT they suffer from high 
MW and LogP, which raises concerns regarding aqueous solubility and potentially short half-
lives in vivo. 
The quinolinol 2.7 was discovered as a result of several iterations of virtual screening, hit 
validation, and safety evaluations (Figure 2.5).265 Compound 2.7 was shown to be efficacious 
both in in vitro with 97% inhibition of BoNTA/LC at 20 µM and ex vivo in a mouse phrenic 
nerve diaphragm assay (MPNHDA) by significantly slowing the onset of muscle paralysis at 10 
µM. Recently, two independent efforts to optimize this scaffold yielded 2.8266 and 2.9.267 A small 
SAR of the quinolinol 2.7 afforded compound 2.8 with an improved in vitro IC50 of 0.6 µM and 
slowed the onset of muscle paralysis at 20 µM in the MPNHDA assay.266 A crude library screen 
of sulfonylated quinolinols, hit validation, and SAR optimization yielded sulfonamide 2.9 with a 
similar in vitro efficacy to 2.7 (1.6 µM) and slowed the onset of muscle paralysis at 20 µM in the 
MPNHDA assay.267 Interestingly, inhibition kinetics of quinolinol 2.9 have shown that the 
inhibition is uncompetitive with respect to SNAP-25 binding.267  These compounds containing 
the quinolinol moiety remain interesting scaffolds in the pursuit of inhibitors of BoNT as they 
display promising physiochemical properties and show low µM activity in both in vitro and ex 
vivo assays (Figure 2.5).  
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Finally, NSC 240898 displayed a dose-dependent protection of SNAP-25 in chick spinal 
motor neurons with low cytotoxic effects even at 40 µM (Figure 2.5).244 Based on its biological 
activity and low cytotoxicity, NSC 240898 is an attractive target for further development. 
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Figure 2.5. Other small molecule non-peptidic inhibitors of BoNT. 
2.1.3 Structure-Activity Relationship of NSC 240898: Previous Work in the Wipf Group 
Despite the dose-dependent protection of SNAP-25 and low cytotoxicity of NSC 240898, its 
activity against BoNT was relatively poor (IC50 = 10 µM). In a effort to enhance the potency and 
learn more about the BoNT binding pocket, Wipf and coworkers investigated the SAR around 
NSC 240898 with structural modifications on the indole, diaryl ether, and polar end groups.268 
The structure was divided into 5 major structural zones for modification (Figure 2.6). 
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Figure 2.6.  Zones for structural modifications of NSC 240898. 
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The SAR of the NSC 240898 scaffold showed a number of modifications that could be 
tolerated within the binding site (Table 2.1). Position R1 in zone 3 tolerated functionalization 
with -OMe and –Cl, with the resulting analogs achieving similar potency to the parent scaffold 
NSC 240898. This indicates that there is an available pocket in the binding site that allows minor 
variations in steric bulk without a loss in potency. The diaryl thioether linkage was found to 
increase potency, which is most likely due to the smaller bond angle leading to closer proximity 
of the terminal imidazolines for hydrogen bonding with Glu56. Interestingly, NSC 377363 (Table 
2.1, entry 15) with a NH in place of the diaryl ether was equipotent to NSC 240898 
demonstrating that both a hydrogen bond donor and hydrogen bond acceptor are tolerated in the 
binding site. Alternating R2 and R3 with amidine (Am) and imidazoline (Im) substituents showed 
some flexibility in the binding site, but substitution at R3 was more potent. The terminal 
substituents R3 and R4 could tolerate either the bis-Am or bis-Im, however, neutral (nitriles, CF3) 
or acidic functionalities (tetrazoles) were inactive (Table 2.1).268-269 The basic Am or Im 
functionality likely interacts through hydrogen bonding within the binding site. Finally, 
shortening the distance between the two polar contacts or removing a polar contact led to a 
decrease in potency. Not only did this SAR reveal new electrostatic and steric information about 
the BoNTA/LC binding site it also led to the identification of compound 2.10 (Table 2.1, entry 
13), as a new more potent lead structure.  
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Table 2.1. Structure-activity relationship of NSC 240898.268 
R4
R1
R2
N
H
Z
R3
Y
X
 
Entry 
Structureb 
% BoNT/A LC inhibitiona X Y Z R1 R2 R3 R4 
1 O CH N H H Am Am 24.7 (±1.5) 
2 O CH N H H Im Im 34.8 (±1.4) 
3 O CH CH H Am H Am 58.8 (± 3.3) 
4 O CH CH H Im H Im 51.4 (± 4.6) 
5 O CH CH H H Am CF3 25.2 (± 3.4) 
6 O CH CH H H Im CF3 43.3 (± 7.2) 
7 O CH CH Cl H Am Am 64.4 (± 2.1) 
8 O CH CH Cl H Im Im 64.8 (± 4.4) 
9 O CH CH OMe H Am Am 58.0 (± 6.7) 
10 O CH CH OMe H Im Im 69.8 (± 1.8) 
11 O N CH H H Am Am 52.7 (± 5.5) 
12 O N CH H H Im Im 46.1 (± 1.2) 
13 S CH CH H H Am Am 80.3 (± 6.7) 
14 S CH CH H H Im Im 67.3 (± 3.6) 
15 NH CH CH H H Am Am 70 
15 O CH CH H H CN CN NIc 
16 O CH CH H H Tet Tet NIc 
17 O CH CH H H Am Am 73.5 (± 7.5)d 
ainhibition of BoNTA/LC at 20 µM using the assay as previously described.247,268 bTet, tetrazole; 
Am, Amidine; Im, Imidazoline; c NI, no inhibition; dNSC 240898. 
2.2 RESULTS AND DISCUSSION 
With only a modest improvement in efficacy from NSC 240898, compound 2.10 remained a 
viable target for the further optimization of efficacy, solubility, and metabolic stability. To 
further optimize 2.10 we constrained the diaryl thioether into an eight membered ring in an 
attempt to increase solubility and potency. Additionally we also investigated the 1,2,4-triazine as 
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a substitution for the imidazoline rings of 2.10 as imidazolines pose a potential metabolic risk 
through hydrolysis or oxidation. 
2.2.1 Synthesis of 3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-
1H-indol-2-yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine  
The previous SAR of NSC 240898268 revealed that the diaryl thioether increased activity versus 
the parent compound due to the decreased bond angle of the aryl rings. It was also noted that 
steric bulk could be tolerated around the diaryl ether (Table 2.1). Conformationally constrained 
analogs of 2.10 were proposed to further increase binding affinity, solubility, and drug-
likeness.270 The thiazocinone and thiazocine inhibitors take advantage of the tight thioether bond 
angle, and further constraint into the 8-membered ring greatly reduces the entropic penalty of 
binding and potentially enhancing binding site interactions of the polar end caps. These analogs 
also have additional hydrogen bond donor and acceptor functionality that may lend to increased 
binding interactions in the active site. The thiazocinone analogs 2.11-2.14 were previously 
synthesized by Drs. Igor Opsenica and Jared Hammill (Figure 2.7).  
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Figure 2.7. Structures of 2.10, lactam, and thiolactam analogs. 
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The diaryl bond angle and conformation of the eight-membered ring mimic the binding 
mode of NSC 240898 (Figure 2.8). Smaller rings produce relatively planar conformations,271 
while larger rings increase steric bulk and are conformationally more labile. 
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Figure 2.8. Bond angle of diaryl (thio)ether linkage.272 
The thiazocine variant of 2.10 was the final member of this constrained series to be 
synthesized. Initially, we envisioned that we could access the thiazocine through a late stage 
reduction of the lactam 2.17 a common building block in the synthesis of the previous 
thiazocinone inhibitors 2.11-2.14 (Scheme 2.2).  
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Scheme 2.2. Retrosynthetic approach to common intermediate lactam 2.17. 
The synthesis of the key lactam intermediate 2.17 began with the condensation of thiol 
2.19 with fluorobenzonitrile 2.20 to form 2.22. Thiol 2.19 can easily be prepared by diazotization 
of aniline 2.18 followed by displacement of the diazo intermediate using potassium O-ethyl 
xanthate.273 The resulting xanthate ester is hydrolyzed to form the thiol. The carboxylic acid of 
2.19 was esterified to afford the methyl ester 2.19.274 The aldehyde 2.21 was reduced using 
sodium borohydride and the resulting alcohol 2.22 was mesylated and displaced with sodium 
azide. The methyl ester 2.23 was saponified then subjected to a Steglich esterification with 
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pentafluorophenol (Pfp) to deliver Pfp ester 2.24. An intramolecular Staudinger ligation was 
used to prepare the corresponding lactam 2.17 in good yield (Scheme 2.3). Attempts to reduce 
the lactam using transition metal catalysis with silanes, Hantzsch ester hydride reductions, 
borohydride reductions, and borane methyl sulfide reductions were unsuccessful and yielded 
complex mixtures of products, dehalogenation, or overreduction.275-277 Using zinc triflate and 
TMDS afforded the product, but reaction mixtures were very difficult to purify due to the 
solubility and polarity of the free amine 2.16.278 
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Scheme 2.3. Synthesis of thiazocinone 2.17. 
Due to the difficulty of reduction of the amide 2.17, the thioamide 2.25 was pursued as a 
synthetic target (Scheme 2.4). Thioamides can be reduced with the use of mild reducing agents 
like Raney-Ni,279 or via S-alkylation and reduction using metal borohydrides.280 Unfortunately, 
forming the thioamide was unsuccessful using a number of precedented methods, including 
Lawesson’s and Belleau’s reagents or P4S10.281-282  
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Scheme 2.4. Attempted synthesis of thiolactam 2.25. 
Dibenzo[b,g][1,5]thiazocines such as the desired intermediate 2.16 have been previously 
constructed by two main routes: the reduction of the corresponding lactam using LAH283-284 or 
via an alkylation approach.285-288 Since LAH reductions were not tolerated on this system due to 
the presence of the nitrile, an alkylation approach was explored. It has been shown that medium 
sized rings could be formed through a Mitsunobu reaction using an N-4-nitrophenylsulfonyl 
(nosyl, Ns) protected amino alcohol.288 
Initially, we synthesized the N-nosyl thiazocine precursor 2.27 to determine if the 
Mitsunobu cyclization would be successful on our substrate. The synthesis of 2.28 began from 
aldehyde 2.21 (Scheme 2.5). Attempts at a classical reductive amination using STAB were 
unsuccessful due to slow imine formation.289 Preforming the imine by CeCl3,290 TiCl4,291 or 
Bronsted acid catalysis292 was also unsuccessful. Gratifyingly, the formation of N-nosyl 
protected amine 2.26 proved successful when aldehyde 2.21 was subjected to a 
titanium(IV)isopropoxide mediated condensation with p-nitrobenzenesulfonamide, followed by 
sodium borohydride reduction. The ester 2.26 was then further reduced to the amino alcohol 
2.27. Unfortunately, neither the Mitsunobu or PBr3 cyclization of compound 2.27 were 
successful in obtaining the N-nosyl thiazocine 2.28. This was most likely due to the fact that our 
system is more strained than what had been previously used by Kan et al. for the Mitsunobu 
cyclization288 and the sulfonamide was not nucleophilic enough to displace the benzylic bromide 
formed under the PBr3 conditions. 
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Scheme 2.5. Synthetic approach to N-nosyl thiazocine 2.28. 
To affect a cyclization, the protected amine was modified to a p-methoxybenzylamine, 
which is more nucleophilic and should be readily removed at the end of the synthesis. 
Combining the aldehyde 2.21 and p-methoxybenzylamine with titanium(IV)isopropoxide and an 
excess of sodium borohydride, delivered amino alcohol 2.29 in a one-pot reaction, albeit in 
modest yield (Scheme 2.6). Sequential reductions of the unreacted ester of 2.29 to the amino 
alcohol 2.29 were low yielding. In attempts to form the thiazocine ring 2.30, only PBr3287 was 
successful. The literature PBr3 conditions287 using chloroform as a solvent afforded clean product 
on small scale, however, our large scale reactions were plagued by a chloroform adduct side 
product. Gratifyingly, when the solvent was changed to THF at a concentration of 10 mM, the 
cyclization proceeded in good yield. The thiazocine core 2.30 was coupled to indole stannane 
2.31 via a Stille cross coupling to afford 2.32.293 The temperature of the coupling proved critical 
to the reaction yield as Boc removal could be observed by NMR analysis at 100 °C. Indole 
stannane 2.31 was prepared by a Boc-protection of 6-cyanoindole followed by metalation of the 
2-position and quenching with trimethyltin chloride. 
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Scheme 2.6. Synthesis of coupling product 2.32. 
Following the successful synthesis of the coupling product 2.32, PMB removal 
conditions were explored. The PMB protecting group removal by conventional methods proved 
unsuccessful. Catalytic hydrogenation294 only returned starting material, while acidic conditions 
such as TFA or HCl led to decomposition and facilitated hydrolysis of the nitriles. Oxidative 
conditions using DDQ led to PMB deprotection with undesired oxidation of the thioether. 
TMSI295 and TBSOTf provided an excellent method for Boc deprotection; however, the PMB 
group remained intact. Chlorosulfonyl isocyanate (CSI) provided the bis-deprotection product 
along with a number of other undesired products. Instead, the PMB protecting group was 
removed using α-chloroethylchloroformate (ACECl) to afford the PMB-deprotected thiazocine 
in good yield.296 Boc deprotection of the indole was accomplished by heating in 4 M HCl in 
dioxane at 80 °C due to the insolubility of the compound in THF or 1,4-dioxane at rt. The HCl 
salt 2.33 was used for the formation of the imidazolines 2.15 using elemental sulfur, ethylene 
diamine, and microwave irradiation.297 Thiazocine 2.15 was obtained as a bis TFA salt, and was 
submitted to the USAMRIID for biological testing (Scheme 2.7). 
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Scheme 2.7. Completion of the synthesis of 2.15•TFA. 
2.2.2 Biological Activity of Thiazocine Analogs 
Following the completion of the synthesis of 2.15•TFA, a sample was tested for BoNT inhibition 
using a variant of the SNAPtide HPLC assay at the USAMRIID. We discovered that the activity 
of 2.15•TFA was very similar to 2.10, further confirming that we are able to introduce steric 
bulk without significant penalties to the activity (Table 2.2).268 However, this also indicates that 
2.15•TFA has not gained any favorable binding interactions within the large binding pocket of 
BoNT/LC. Additionally, it is possible that introduction of the thiazocine may have perturbed the 
imidazoline orientation in the binding site leading to a less favorable interactions that cause a 
slight decrease in activity.  
Table 2.2. Biological activity of NSC 240898 analogs. 
Entry Compound BoNT IC50a (µM) 
1 2.10 5.2 ± 0.1  
2 2.15•TFA 6.3 ± 2.9 
3 NSC 240898 10.7 ± 0.5 
aIC50’s were determined using the previously described SNAPtide HPLC assay.242 Data were 
collected using duplicate data points over two independent assays. 
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2.2.3 Synthesis of 1,2,5,6-Tetrahydro-1,2,4-triazines 
In addition to replacing the diarylthioether in 2.10 with a thiazocine ring to generate compound 
2.15 we wanted to substitute the imidazoline rings as they are prone to hydrolysis and metabolic 
oxidation (Figure 2.9). Based on a previous SAR study, the bis-imidazole analogs were found to 
be inactive because they tend to have other binding modes to chelate Zn.246 1,2,5,6-Tetrahydro-
1,2,4-triazines (1,2,4-triazines) represented an attractive alternative to the imidazoline 
functionality as they maintain a similar pKa while displaying increased hydrolytic stability.298-300 
Thus, a new analog containing terminal bis-1,2,4-triazine moieties should retain the potency of 
the parent compound without being rendered inactive by metabolic oxidation, as even the 
oxidation product has a similar pKa to the parent compound.(Figure 2.9).  
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Figure 2.9. Effect of oxidation on pKa of imidazolines vs 1,2,4-triazines. 
The Wipf group has been interested in constructing 1,2,4-triazines for many years as they 
are a key structural component of the furanosteroid natural product noelaquinone (Figure 
2.10).301-302 Wipf and coworkers’ previous synthesis the DEF fragment of noelaquinone resulted 
in the development of a new method to form 1,2,4-triazines through an intramolecular 
Staudinger aza-Wittig (SAW) reaction.303 The SAW reaction is a useful tool for the synthesis of 
heterocyclic compounds and natural products.304 It combines the Staudinger phosphazine ylide 
formation with the aza-Wittig addition to a carbonyl group.305-309 
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Figure 2.10. Structure of noelaquinone. 
Initial routes to form the 1,2,4-triazines in the Wipf group were pioneered by former 
students Dhezi Fu and David Amantini. These linear approaches began with a reductive 
amination of aldehyde 2.35 on various aromatic hydrazides 2.34a-2.34d. Benzylation and TBS 
deprotection afforded alcohols 2.38a-2.38d. A subsequent mesylation, azidation, and SAW 
cyclization afforded the triazines 2.40a-2.40d in good yields (Scheme 2.8).  
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Scheme 2.8. Linear synthesis of 1,2,4-triazines. 
Fu and Amantini also explored the deprotection of the benzyl group on 2.40a and found 
that catalytic hydrogen conditions over 4 days the product was obtained in modest yields without 
reduction of the C=N bond (Scheme 2.9).  
N
H
NBn
N
N
H
NH
N
H2, Pd/C
MeOH, 4 d, rt
50%2.40a 2.41  
Scheme 2.9.  Debenzylation of triazine 2.40a. 
A more convergent approach was developed by converting the hydrazine to the stable 
hydrazone, which can be unmasked prior to coupling with carboxylic acid or acid chloride 
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moieties.303 The synthesis of hydrazones 2.45a and 2.45b began with the condensation of 
hydrazinoethanol (2.43) onto ethyl pyruvate (2.42) to provide the hydrazone 2.44 (Scheme 2.10). 
The alcohol 2.44 was mesylated and displaced using sodium azide. The corresponding 
azidohydrazone 2.45 was protected with BnBr or PMBBr to afford the shelf-stable 
azidohydrazine precursors 2.46a and 2.46b respectively.  The pyruvate hydrazone 2.46b was 
previously prepared on 45 g scale and found to be bench stable for months with no noticeable 
decomposition according to 1H NMR.   
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Scheme 2.10. Synthesis of hydrazones 2.46a and 2.46b. 
Hydrazine exchange of hydrazones 2.46a-2.46b afforded the desired N(2)-protected 
hydrazines 2.47a-2.47b in good yields. Using peptide coupling conditions or the acyl chloride, 
hydrazides can be formed in varying yields. The corresponding hydrazide can then undergo 
cyclization via a SAW reaction to form the 1,2,4-triazine (Scheme 2.11).  
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Scheme 2.11. Synthetic route to 1,2,4-triazines. 
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2.2.3.1 Screening and Optimization of 1,2,4-Triazines 
To simulate the formation of the 1,2,4-triazine on a more complex system and to further expand 
the substrate scope we synthesized several new triazine systems. In addition to expanding the 
substrate scope we also developed a new hydrazine with a more labile protecting group to allow 
for milder deprotection conditions.   
We synthesized a novel 3,4-dimethoxybenzyl protected hydrazine 2.47c that should be 
more acid-labile than the corresponding PMB-protected derivative. In a similar synthetic 
sequence to previous hydrazines we arrived at azide intermediate 2.45. Alkylation with 3,4-
dimethoxybenzyl chloride afforded hydrazone 2.46c in modest yields. Deprotection using 
hydrazine afforded our desired hydrazine 2.47c in good yields (Scheme 2.12). 
K2CO3, NaI
 DMF, rt, 4 d
O
O
N N
H N3
O
O
N N
R N3
2.45
NH2NH2•2HCl
THF, H2O, rt, 16 h H2N
R
N N3
Cl OMe
OMe2.48
56% 72%
2.46c (R = 3,4-dimethoxybenzyl) 2.47c (R = 3,4-dimethoxybenzyl)  
Scheme 2.12. Synthesis of 3,4-dimethoxybenzyl protected hydrazine 2.47c. 
Since low molecular weight compounds with a high N to C ratio are potentially 
explosive,310 we also determined the thermal stability of azidohydrazines 2.47b and 2.47c by 
differential scanning calorimetry (DSC) to establish the safety profile of these compounds. 
Gratifyingly, we found that compounds 2.47b and 2.47c were stable up to 150 °C and did not 
undergo complete decomposition until >200 °C. 
Azidohydrazine 2.47b was acylated directly via the acyl chloride or by peptide coupling 
conditions with the aromatic carboxylic acid. The corresponding hydrazides 2.50a-2.50c were 
subjected to the SAW conditions to afford the N-protected 1,2,4-triazines 2.51a-2.51c in this 
convergent synthesis (Table 2.3). While the SAW reaction generally proceeded with acceptable 
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to good yields using tri-n-butyl phosphine, we used the conversion of 2.50a to 2.51a to explore 
the scope of the variation of phosphines, solvents, temperature, and reaction times (Table 2.3). A 
solvent switch to 1,2-dichlorobenzene provided similar yields to chlorobenzene. Using aromatic 
phosphines such as P(Ph)3 or PMe(Ph)2 afforded the product in decreased yield and were difficult 
to separate from the corresponding phosphine oxides via chromatography. Finally, using P(Me)3, 
the SAW reaction provided modest yields but the corresponding water soluble phosphine oxide 
was readily separable from the triazine product. 
Table 2.3. Screening of conditions for SAW cyclization. 
OH
O
Ar Ar
H
N
O
N
PMB
N3
PR3
Solvent
Temperature
Time
N
NPMB
H
NAr
2.49a-c 2.50a-c 2.51a-c
H2N
PMB
N N3
Br
O
Ar =
(a) (b) (c)
MeO
N
PMB
2.47b
 
Entry PR3 Solvent Temperature/timec Yield 
1 P(n-Bu)3 o-1,2-dichlorobenzene MW, 180 °C, 1 h 47% 
2 P(n-Bu)3 PhCl MW, 180 °C, 1.5 h 41% 
3 P(n-Bu)3 PhCl MW, 180 °C, 2 h 50% 
4 P(Ph)3 PhCl MW, 180 °C, 1 h 42%a 
5 P(Ph)3 PhCl MW, 180 °C, 1.5 h 38%a 
6 P(Ph)3 PhCl 150 °C, 12 h dec. 
7 PMe(Ph)2 PhCl MW, 180 °C, 1.5 h 37%b 
8 PMe(Ph)2 PhCl MW, 180 °C, 2 h 42%b 
9 P(Me)3 PhCl MW, 180 °C, 1 h 38% 
10 P(Me)3 PhCl MW, 180 °C, 1.5 h 29%; dec. 
aProduct contains P(Ph)3O; bproduct contains PMe(Ph)2O; call reactions used a 50 mg scale of 
2.50a  
 
With the triazine substrates in hand, we investigated the removal of the PMB and 3,4-
DMB protecting group. The PMB proved difficult to remove. The use of reductive conditions 
40 
(H2, Pd/C) returned only starting material, oxidative conditions (CAN) led to deprotection and 
partial oxidation of the triazine, and strongly acidic conditions (TfOH/TFA/anisole) led to 
decomposition. Finally, the PMB deprotection of 2.51b was accomplished using neat TFA at 55 
°C for 30 min, followed by a basic aqueous work up, to afford the deprotected triazine 2.52•TFA 
in good yields (Scheme 2.13). For the deprotection of the 3,4-dimethoxybenzyl analog 2.53, we 
discovered that 4 M HCl in dioxane at 50 °C for 2.5 days afforded the product 2.52 in modest 
yields after column chromatography.   
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Scheme 2.13. Deprotection of PMB and 3,4-dimethoxybenzyl protecting groups. 
2.2.3.2 Efforts Towards the Synthesis of 6-(1,2,5,6-Tetrahydro-1,2,4-triazin-3-yl)-2-(4-(4-
(1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)phenoxy)phenyl)-1H-indole 
To test our hypothesis that these 1,2,4-triazines could be used as isosteres of the metabolically 
labile imidazoline moiety, we proposed to synthesize an analog of 2.10 that contained the 1,2,4-
triazines in place of the imidazolines. Our retrosynthetic approach to compound 2.54 features a 
double SAW cyclization of diazide 2.55 to form the bis-triazine rings of 2.54 (Scheme 2.14). We 
proposed that amide coupling of the diacid to our hydrazine building blocks 2.47a-2.47c would 
give our hydrazide 2.55. The diacid precursor can be formed via a Stille coupling of stannane 
2.31 and aryl bromide 2.57. 
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Scheme 2.14. Retrosynthetic approach to 2.54. 
The synthesis of the bis-1,2,4-triazine analog 2.54 began with the condensation of 4-
bromophenol (2.58) and 4-fluorobenzonitrile (2.59) to form the diarylether 2.57. The indole 
stannane 2.31 was installed via a Stille cross coupling to give nitrile 2.60 that was subsequently 
hydrolyzed over 11 days to afford the Boc-deprotected diacid 2.56 in good yields (Scheme 2.15).  
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Scheme 2.15. Synthesis of diacid 2.56.  
Diacid 2.56 was coupled to the freshly deprotected hydrazines 2.47a-2.47c using 
HATU/HOAt to provide the bis-hydrazides 2.61a-2.61c in modest yields (Scheme 2.16).311 
Previous attempts to couple the hydrazine via the acid chloride, or by activation with 
EDCI/HOBt, DEPC, DPPA, or PyBrOP were unsuccessful, very low yielding, or gave complex 
mixtures of products. The bishydrazides 2.61a-2.61c were subjected to the original SAW 
reaction conditions (PhCl, PBu3), but the reaction was unsuccessful. Although in the model 
system it was found that either PMe3 or PBu3 gave the best yield and, in the case of PMe3, the 
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phosphine oxide was easier to remove (Table 2.3), the conditions didn't translate to the synthesis 
of 2.54. When PMe3 (1 M in toluene) or P(Bu)3 were used in PhCl, the reaction only afforded 
trace product. It was found that the solubility of the starting material/bisphosphazine ylide in 
PhCl/toluene was poor and the compound would precipitate out of solution during the reaction. 
We found that by using PMe3 as a 1 M solution in THF, the bis-1,2,4-triazines 2.62a-2.62c were 
formed in low yields. PMe3/PhCl/THF provided the best results for the SAW cyclization as it 
kept the phosphazine ylide in solution during the reaction. At this point, the remaining step 
involved the removal of the protecting groups. Attempts at removing the Bn protecting groups on 
2.62a through hydrogenation were unsuccessful even after 1 week with 50 mol% Pd/C. 
Unfortunately, the deprotection conditions previously identified for the removal of the PMB 
protecting group used on 2.62b afforded the deprotected product 2.54 as a 1:1:1 mixture with the 
monodeprotected products (Scheme 2.16). Attempts to resubject the mixtures or drive the 
reactions to completion were unsuccessful, as the reactions seem to stop at a mixture of partial 
deprotection or lead to decomposition. We propose that, based on the lack of reactivity and 
product mass distribution, the indole was scavenging the cation intermediates formed in the 
deprotection. Using cation scavengers (Et3SiH, anisole, and thioanisole) did not appear to 
improve the ratio of products. The 3,4-dimethoxybenzyl protected compound 2.62c also proved 
resistant to deprotection conditions.  
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Scheme 2.16. Synthesis of protected bis-1,2,4-triazines 2.62a-2.62c. 
Although the deprotection of the 1,2,4-triazines was unsuccessful, possible alternatives to 
the benzyl protecting groups include the 2-(trimethylsilyl)ethoxymethyl (SEM) or the 2,3,6-
trimethyl-4-methoxybenzenesulfonamide (Mtr) protecting groups. The SEM protecting group is 
a viable option as it can be deprotected using TBAF312-315 or Lewis and Bronsted acids,316-318 and 
is easily installed using SEMCl. The Mtr protecting group has been used in peptide synthesis for 
the protection of the ε-amino function of lysine using Mtr-Cl and is readily cleaved using either 
(0.15 M) methane sulfonic acid in a mixture of TFA and thioanisole319 at room temperature in 2 
h or 1 M HBF4 in TFA at room temperature for 20 min.320-321 The Mtr functionality has also been 
shown to be stable to Staudinger ligation conditions and is lipophilic, and therefore may aid to 
increase solubility during the SAW cyclization.322 
2.3 CONCLUSIONS 
In summary, we have successfully synthesized the final analog (2.15•TFA) of the thiazocine-
based inhibitor series (Figure 2.7). Initial attempts to use the common thiazocinone intermediate 
2.17 from the synthesis of the previous analogs were unsuccessful (Scheme 2.2). Therefore, we 
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developed a novel procedure to form the thiazocine through an activated ring closure using a 
PMB protected amine (Scheme 2.6). This analog will provide additional evidence for the 
hypothesis that constraining the diarylthioether will provide more favorable hydrogen bonding 
interactions within the binding site of BoNT/A LC.  
Additionally, the first bis-triazine was synthesized in an attempt to use 1,2,4-triazine as 
isosteres of cyclic amidines. To date we have been unsuccessful in the deprotection of 2.62 after 
many attempts to remove the Bn, PMB, and 3,4-dimethoxybenzyl protecting groups. In addition 
to our work on the bis-triazine analog, we have further developed the scope of a convergent 
method for the synthesis of 1,2,4-triazines using newly developed azidohydrazine reagents. 
Hydrazines 2.47b and 2.47c were also shown to be thermally stable up to 150 °C by DSC 
analysis.  
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3.0  SYNTHESIS OF ANTAGONISTS OF THE NUCLEAR ANDROGEN RECEPTOR 
FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER   
3.1 INTRODUCTION 
The androgen receptor (AR) is a 110-kDa ligand-inducible transcription factor that is a member 
of the nuclear steroid receptor family.323 AR is responsible for normal prostate function, and 
plays a key role in the progression of prostate cancer (PCa). In humans, the AR gene is located 
on the q-arm of the X-chromosome and is comprised of eight coding exons (Figure 3.1).324 
Genetic disorders associated with AR include androgen-insensitivity syndrome, spinal and 
bulbar muscular atrophy (SBMA), hypogonadism, benign prostatic hyperplasia (BPH), and 
PCa.325 PCa is the third deadliest cancer in men with 161,000 new cases and 27,000 deaths 
expected in 2017, and is typically diagnosed through measurement of prostate-specific antigen 
(PSA) in the blood serum, rectal examination, or biopsy.326 PSA in blood serum is an indication 
that the prostatic epithelium has been disrupted as a result of hyperplasia of the prostate. 
Unfortunately, PSA levels in serum can also be the result of BPH, infection, or chronic 
inflammation. New PCa specific biomarkers are under investigation to reduce false positives 
associated with current detection techniques.327-331 
The AR structure consists of four functional domains: the N-terminal domain (NTD), 
DNA binding domain (DBD), hinge region, and ligand-binding domain (LBD).332-333 The NTD 
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is the largest and least conserved domain in AR that contains activation function-1 (AF-1), 
transcription activation units (TAU) 1 and 5, and contains polyglutamine and polyglycine repeats 
that are involved in regulating AR transcriptional activity by influencing the interaction with 
other receptor regions and altering the tertiary structure of the receptor.334-335 The DBD is highly 
conserved and contains two zinc fingers that are responsible for DNA recognition, binding, and 
stabilization.333,336 The nuclear localizing sequence (NLS) is a short overlapping segment 
between the DBD and the hinge region that functions in nuclear translocation of the androgen-
activated AR.337 The hinge region modulates the conformational changes associated with 
androgen activation and contains a site for phosphorylation.338 The LBD binds to androgens, heat 
shock proteins (HSP’s), and transcriptional co-activators and also contains the activation 
function-2 (AF-2) that stabilizes AR allowing the NTD to interact with co-regulators (Figure 
3.1).333,339  
 
Figure 3.1. AR gene and functional domains.323,325,340-341 
Normal transcriptional activity of AR involves the binding of androgens to the LBD and 
translocation of AR to the nucleus for transcription. In the absence of ligands, the LBD localizes 
AR to the cytosol through binding to HSPs (HSP 90, HSP 70, HSP 56, and p23) that maintain its 
inactive form.323,342-343 The androgen testosterone is produced by the testes (ca. 90-95%) with a 
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small portion produced by the adrenal gland (ca. 5-10%), which is transported to AR-positive 
cells by sex hormone binding globulin (SHBG) and is subsequently reduced to DHT by 5α-
reductase. When DHT binds to the LBD, the HSPs are displaced. This ligand-bound AR 
undergoes homo-dimerization and phosphorylation that results in a conformational change, 
exposing the NLS, which then undergoes translocation to the nucleus.343 The nuclear 
translocated AR-dimer then binds to androgen response elements (AREs), short DNA sequences 
in the promoter or enhancer regions of target genes, as well as non-ARE associated upstream 
promoters of genes.344-345 The AR-ARE complex then binds to co-activators and co-repressors to 
form the co-regulator complex that can either up- or downregulate transcription (Figure 3.1).346 
Dysregulation of these signaling pathways has been tied to the progression of PCa. 
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Figure 3.2. Signaling pathways of AR.323,325,340,343 
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At prognosis, 80-90% of PCa are androgen dependent therefore initial therapies of PCa 
focus on androgen deprivation therapy (ADT) a treatment that was first developed in 1941 by 
Huggins and Hodges.347 ADT is achieved using luteinizing hormone-releasing hormone (LHRH) 
agonists in combination with antiandrogens and is accompanied by a number of side effects.348 
Unfortunately, AR mutations occur causing androgen insensitivity and independence that result 
in PCa advancing to its lethal stage of castration-resistant prostate cancer, CRPC (formerly 
known as hormone-refractory prostate cancer).323,349 The mechanism of CRPC progression is 
associated with several androgen-dependent and androgen-independent signaling pathways of 
the AR.350 Therefore, blocking AR signaling is an attractive therapeutic target for the treatment 
of CRPC.  
AR overexpression has been observed in CRPC cell lines as a result of increased mRNA 
transcription or AR gene amplification.351-352 Androgen insensitivity is thought to develop as a 
result of ADT, where mutations in the AR LBD will allow for more promiscuous ligand binding 
resulting in activation by other endogenous hormones (estrogen, progesterone, cortisone) and 
even antiandrogens such as flutamide.333,353 Mutations in the NTD and DBD could influence 
nuclear localization, co-regulator binding affinity, and transcription.354 Co-regulators of AR are 
proteins that activate (co-activators) or repress (co-repressors) the transcriptional activity of AR. 
Overexpression of the co-activators SRC-1 and TIF-2 have been associated with the progression 
of CRPC as they facilitate ligand binding to AR, resulting in increased nuclear concentrations of 
AR.355 
De novo androgen synthesis is another mechanism of CRPC progression. Interestingly, 
testosterone levels in CRPC tumor cells are four times higher compared to primary tumors even 
with low serum testosterone levels caused by ADT.323 This is a result of gene upregulation in the 
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testosterone biosynthetic pathway that leads to testosterone synthesis from cholesterol, and the 
adrenal androgen dehydroepiandrosterone (DHEA).356-360  
AR splice variants (AR-V’s) emerge from insertions or deletions of exons and more than 
20 AR-V’s have been characterized in prostate cancer cell lines.323 Usually, exons 5 and 7 are 
deleted by RNA splicing factors producing a transcriptionally active AR that lacks the LBD 
(Figure 3.1).361-362 In particular, AR-V7 is the most common AR-V found in CRPC cell lines and 
in place of a LBD or hinge region contains a short variable amino acid sequence (Figure 3.1).363 
Typically found localized in the nucleus, AR-V7 is important in the regulation of target genes 
involved in cancer cell proliferation.363-365 Another splice variant, AR-V3 undergoes SRC 
phosphorylation of the Y534 on the NTD resulting in nuclear translocation.365 Overexpression of 
AR-V7 in patients was correlated to poor clinical outcome, as patients encountered rapid 
resistance to current antiandrogens such as enzalutamide.365-366 Interestingly, AR-V’s are found 
in CRPC cell lines that also express full length AR, and typical treatments of AR were 
ineffective suggesting that AR-V’s can maintain AR transcriptional activity in low androgen 
environments.323,362 Additionally, AR-V’s can also undergo homodimerization and even 
heterodimerization with full-length AR, and that dimerization was required for transcription.367 
AR-V’s have been identified as markers for hormonal resistance and in combination with 
monitoring PSA levels can allow for early detection of the progression of CRPC.368-369 
Ligand independent signaling of AR is also responsible for downstream genomic 
regulation. Growth factor dysregulation can lead to alterations in downstream pathways such as 
the PI3K/AKT pathway that leads to phosphorylation of AR, resulting in increased nuclear 
translocation and transcriptional activity.12,370-372 Mutations in the receptor tyrosine kinase 
pathway (HER2) promote cell growth and survival, and have been associated with progression of 
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CRPC through the activation of Akt.373-375 In PCa, AR can also activate NF-κB in the absence of 
androgens, which leads to cell proliferation.376-377 
Unfortunately, all PCa patients will eventually progress to the incurable lethal CRPC 
stage in which current treatments are only effective in extending patient life by several months. 
Therefore, there is an urgent need for new therapeutics for the treatment of CRPC.  
3.1.1 Treatments of PCa and CRPC 
While ADT is used as a treatment for PCa, it is ineffective towards CRPC. New treatments have 
been developed mainly focused on using antiandrogen antagonists of AR. These antiandrogens 
bind to AR and halt its transcriptional activity. Several FDA approved antiandrogens are now 
available with additional treatments currently in phase II and phase III clinical trials. 
Structurally, antiandrogens can be divided into two classes: steroidal and nonsteroidal. In 
addition to antiandrogens, taxanes and radiopharmaceuticals have also been approved for the 
treatment of CRPC.   
Steroidal antiandrogens are competitive inhibitors of androgens (testosterone and DHT) 
that also reduce plasma levels of androgens and the release of luteinizing hormone.378 
Discovered in 1967, cyproterone acetate (CPA) was one of the first reported steroidal 
antiandrogens (Figure 3.3).379 In patients, CPA was less effective (13% increased risk of death) 
than the nonsteroidal antiandrogen flutamide (8% increased risk of death). In addition to the 
common side effects of ADT, CPA has also been shown to reduce hormonal flares associated 
with LHRH agonists when used as a combination therapy.380-381 Unfortunately, CPA has a very 
limited effect against CRPC.382 
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Flutamide was the first widely used nonsteroidal antiandrogen. The biologically active 
form hydroxyl-flutamide is a result of metabolic oxidation and has a half-life of ~5 hours that 
requires three daily doses (Figure 3.3).382 Apart from the common side effects of antiandrogens 
therapies, flutamide has been found to cause severe diarrhea in 10-20% of the patients that 
ultimately results in the discontinuation of treatment.383 In addition, flutamide has also been 
shown to disrupt liver function in a small subset of patients that was resolved with discontinuing 
treatment.383 Although flutamide is effective in the treatment of PCa, large doses are required 
(750 mg/day) and several undesired side effects make it less desirable than current treatments.  
Nilutamide was the second most widely used antiandrogen for clinical use and has a half-
life of ~38 hours enabling its administration via a once daily dose (Figure 3.3).382 Similar to 
flutamide, nilutamide is also heavily metabolized in the liver due to the presence of the 
nitroaniline functionality, but does not require metabolism to get to its active form as observed 
with flutamide. It has been used in combination with LHRH agonists to prevent hormonal flares. 
Several side effects have been noted in patients that have used nilutamide including delayed 
adaption to dark, alcohol intolerance, pneumonitis, and nausea.383 
The orally available bicalutamide (Casodex®) was approved by the FDA in 1995 and is 
one of the current standards of care for the treatment of both non-metastatic and metastatic 
CRPC (Figure 3.3). Interestingly, bicalutamide is marketed as the racemic drug even though the 
S-enantiomer is rapidly metabolized and cleared while the R-enantiomer is significantly more 
active and metabolically stable in plasma for up to a week.382 Bicalutamide dosed at 150 mg/day 
is well tolerated compared to nilutamide and flutamide as common side effects include breast 
pain, gynaecomastia, loss of libido, and hot flashes.384 
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Figure 3.3. 1st generation antiandrogens. 
The thiohydantoin enzalutamide (Xtandi®; formerly known as MDV3100) was approved 
by the FDA in 2012. It is an orally available antagonist of AR with a half-life of 1 week that acts 
by inhibiting AR nuclear translocation and by reducing the transcriptional activity of AR (Figure 
3.4).385 Patients with CRPC treated with enzalutamide displayed decreased levels of PSA. A 
recent double-blind study comparing the efficacy and safety of enzalutamide and bicalutamide in 
both metastatic and non-metastatic CRPC revealed that patients treated with enzalutamide had 
19.4 months progression-free survival whereas patients treated with bicalutamide had 
progression-free survival of only 5.7 months.386 Side effects of enzalutamide usually include 
fatigue, nausea, diarrhea, musculoskeletal pain, hot flashes, and headache.387-388 Enzalutamide 
also presents a small risk of seizure, as it was shown to inhibit GABA-A currents in vitro.389 
Unfortunately, patients with CRPC develop resistance to enzalutamide after 3-5 months.390 
A more recent thiohydantoin, apalutamide (formerly known as ARN-509) is a new 
investigational drug currently in phase II and phase III clinical trials for its use in combination 
with bicalutamide (NCT02531516), abiraterone acetate (NCT02789878), or radiation 
(NCT02531516) (Figure 3.4). Similar to enzalutamide, apalutamide also inhibits nuclear 
translocation of AR and reduces transcriptional activity, but has been shown to be more effective 
in vivo.391 Additionally, apalutamide has shown low CNS penetration and therefore poses less of 
a risk for seizures than enzalutamide.389 
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Abiraterone acetate inhibits the enzyme CYP17, which blocks the production of 
androgens, reducing levels to less than 1 ng/dL,392 and when used in combination with 
prednisone has been shown to improve progression-free and overall survival by an average of 16 
months vs. 11 months with only prednisone (Figure 3.4).393 Side effects of abiraterone acetate 
include fluid retention, hypokalemia, and hypertension.394-395 When used in combination with 
glucocorticoids, cardiac disorders, and abnormal liver function were also observed.393,395 
The taxanes, docetaxel and carbazitaxel396 are also FDA approved treatments of CRPC 
and act through tubulin stabilization and cell cycle arrest (Figure 3.3). Unfortunately, docetaxel 
suffers from a high affinity to P-glycoprotein (P-gp), which leads to a decrease in intracellular 
docetaxel concentrations and promotes resistance. Further structural optimization led to 
carbazitaxel, the dimethoxy analog of docetaxel, which has decreased P-gp affinity and is 
effective towards docetaxel-resistant tumors.397 In a recent study, taxanes were also found to be 
effective in patients with CRPC with detectable AR-V. Levels of PSA in these patients was 
reduced ~41%.398 
Radium-223 dichloride (Xofigo®; formerly known as AlpharadinTM) was approved by 
the FDA in 2013 for the treatment of CRPC that has metastasized to the bone by acting as a 
calcium mimetic.399-400 Other radiotherapy previously used was external beam radiotherapy for 
the management of localized PCa.401  
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Figure 3.4. 2nd generation treatments of CRPC. 
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Several new scaffolds have emerged in the literature over the past few years as potential 
treatments of CRPC. The tropinol 3.1 was found to have stronger antagonistic behavior than 
bicalutamide with an 87% reduction in luciferase activity at 1 µM (Figure 3.5). In addition to the 
activity against wild-type AR, compound 3.1 also showed promising antiandrogen activity in the 
two most common AR mutants.402 The oxabicyclic compound BMS-641988 was identified from 
a recent SAR and was found to have high binding affinity to AR (Ki = 1.7 nM) acting as a potent 
antagonist in vitro (IC50 = 16 nM). In addition to in vitro activity, BMS-641988 was also 
efficacious in the CWR22-BMSLD1 xenograft model that has shown resistance to bicaluatmide 
and flutamide. Based on its promising PK/PD profile, BMS-641988 was advanced into clinical 
development.403 Efforts to improve the chemical stability of BMS-641988 led to the discovery of 
the bicyclic sultam 3.2, which was also found to have high affinity for AR (Ki = 5 nM) and 
potent antagonist activity in vitro (IC50 = 57 nM). With a promising PK/PD profile, 3.2 was 
tested in human tumor xenograft studies where poor oral exposure was observed and was 
possibly due to high metabolism.404 Ultimately, this result led to the discontinuation of 3.2. 
Physachenolide C was identified from a HTS of a library of natural products and further 
structural optimization of the 17β-hydroxywithanolides for stability and potency. This analog is 
capable of reducing PSA expression, has nanomolar potency to both AR-positive and AR-
negative cell lines, and was shown to be active in human tumor xenograft models. It is proposed 
that physachenolide C acts via sensitizing tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) to induce apoptosis.405 The chlorohydrin EPI-002 and its analogs have been 
shown to inhibit AR-transcriptional activity through covalently binding to the AR-NTD (Figure 
3.5).335,406 Using high resolution solution NMR spectroscopy, Salvatella and coworkers have also 
shown that EPI-002 analogs interact with TAU-5 of the AR-NTD (Figure 3.5).407 In a VCaP 
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human tumor xenograft model, EPI-002 was effective in reducing tumor volume.335 A prodrug of 
EPI-002, EPI-506 (not shown), is currently in phase (I/II) clinical trials (NCT02606123) for the 
treatment of patients with metastatic CRPC.408 The cyanobacteria metabolite sintokamide A 
(SINT1) has also been found to inhibit AR through binding to the AF-1 region of the NTD. 
Additionally, SINT1 has been shown to have low cytotoxicity and also inhibit AR-Vs.409-410 
Binding to the AR-NTD represents a novel mechanism of action to treat CRPC that potentially 
avoids the mechanisms of resistance commonly found with other antiandrogens, such as point 
mutations in the LBD and splice variants.  
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Figure 3.5. Recent inhibitors of the AR. 
3.1.2 High Throughput Screen and Structure Activity Relationship: Previous Work in the 
Wipf Group 
Although a number of treatments available treatments for CRPC, they eventually become 
ineffective as the cancer develops resistance. One therapeutic avenue that has not been developed 
is to block the nuclear localization of AR, therefore removing transcriptional activity of AR and 
blocking the progression of the cancer.  In an effort to identify a viable treatment of CRPC, 
Wang and coworkers developed a high throughput screen to identify small molecules that 
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selectively reduce the nuclear localization of AR in CRPC cells.411 Using a GFP labeled AR 
(GFP-AR) transfected into C4-2 CRPC cells and fluorescence visualization, 219,000 compounds 
from the National Institutes of Health (NIH) molecular libraries screening centers network 
(MLSCN) were screened at a concentration of 20 µM. After screening and hit validation, 3 
compounds were identified that were selective towards GFP-AR with no inhibition of nuclear 
localization of GFP labeled glucocorticoid receptor (GFP-GR) or GFP labeled estrogen receptor 
(GFP-ER) and low micromolar potency in C4-2 CRPC cells (Figure 3.6). The structurally similar 
compounds 3.3 and 3.4 inhibited nuclear localization of GFP-AR in C4-2 cells and localized 
GFP-AR to the cytosol. Interestingly, compound 3.5 decreased nuclear GFP-AR without 
increasing cytoplasmic levels of GFP-AR. This indicates an overall downregulation of AR 
expression and potential inhibition of the activity of AR. Western blot analysis of C4-2 cells 
treated with 3.5 indicated that AR and PSA protein levels were reduced even at concentrations as 
low as 2 µM, suggesting that 3.5 can inhibit AR signaling. The three compounds identified from 
this HTS have structures that are very unique compared to androgens and known AR antagonists 
and as a result may have a different mechanism of action. These mechanisms could involve 
direct inhibition of AR or an indirect inhibition targeting AR cofactors.411 All three HTS hits 
demonstrated low micromolar potency with low cytotoxicity in AR negative cell lines. However, 
structural analogs of 3.3 and 3.4 were found to have antifungal activity, thus raising concerns 
about potential off-target effects.412 The scaffold of 3.5 did not show any precedence for 
biological activity and thus was a more attractive target for further investigations. Cell 
proliferation was inhibited in the AR-positive prostate cancer cell lines LNCAP, C4-2, LAPC4, 
22Rv1, and CWR-R1 that were treated with 3.5 at 1 µM and no cell death was observed at 10 
mM in AR-negative cell lines. A C4-2 mouse xenograft tumor model treated with 3.5 showed 
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tumor growth inhibition with no decrease in the body weight in the mice further indicating little 
to no cytotoxicity.  
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Figure 3.6.  Hits identified from HTS. 
Based on the promising biological activity and low cytotoxicity of 3.5, Wipf and 
coworkers probed the structure-activity relationship of 3.5 by dividing the structure into 5-zones 
for structural modification: the aryl substitution pattern (zone 1), piperazine modifications (zone 
2), carbonyl replacements (zone 3), thioether substitution (zone 4), and variations at the 3,5-
dimethylisoxazole (3,5-DMI) ring (zone 5) (Figure 3.7).349 
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Figure 3.7. Zone of structural modification. 
The analogs were biologically characterized by a Dual-Glo luciferase system in the 
presence of 1 nM of the synthetic androgen R1881 in C4-2-PSA-rl cells and were compared to 
the initial HTS hit 3.5 (EC50 7.3 µM) and enzalutamide (EC50 1.1 µM)(Table 3.1). Initially, 
amides 3.6a-p were synthesized to probe structural changes in zones 1 and 2 to determine the 
effect of substitution around the aryl and piperazine rings. Small modifications on the aryl ring in 
zone 1 revealed that monomethyl substitution in the 3- and 4-positions resulted in a loss of 
activity. The 2-methyl analog 3.6b had 2-fold loss in activity compared to 3.5. Removal of the 
methyl groups resulted in a complete loss in activity. Additional steric bulk was also tolerated 
where the bulky naphthyl substitution of 3.6g was also active (EC50 11.1 µM). Electron 
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withdrawing aryl substituents (2-CN, 3.6e, and 2-F, 3.6f) were also moderately active (EC50 ~12 
µM), however, the analog with the electron-donating 2-OMe, 3.6h, was completely inactive, 
possibly due to an increase in the aniline-nitrogen pKa. As multiple benzylic methyl groups are a 
potential metabolic liability, the 2-methyl substitution was used for further SAR investigations. 
Several analogs with more flexible or constrained amine linkers were prepared to probe the SAR 
around the piperazine in zone 2. The flexible N,N’-dimethylethylenediamine linker in 3.6i and 
the homopiperazine 3.6j had decreased activity. The 2,6-dimethylpiperazines 3.6l and 3.6m were 
also 2-fold less active than 3.5. The more constrained 2,6-dimethylpiperazine analog 3.4k 
resulted in increased activity, with a 2-fold improvement on 3.5. The bridged bicyclic [3.2.1] 
systems 3.6o and 3.6p improved the activity slightly from 3.6b with EC50’s around 8 µM (Table 
3.1). 
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Table 3.1. Structural modifications in zones 1 and 2. 
O
S N
O
N
N R
zone 2
 
Entry Compound Structure EC50 (µM)a Zone 2 R 
1 3.5 Piperazine (2,3-Me)Ph 7.3 ± 2.5d 
2 enzalutamide - - 1.1 ± 0.5e 
3 3.6a Piperazine Ph >25b 
4 3.6b Piperazine (2-Me)Ph 14.5 ± 3.2c 
5 3.6c Piperazine (3-Me)Ph >25b 
6 3.6d Piperazine (4-Me)Ph >25b 
7 3.6e Piperazine (2-CN)Ph 12.0 ± 1.6c 
8 3.6f Piperazine (2-F)Ph 12.6 ± 7.7c 
9 3.6g Piperazine 1-naphthyl 11.1 ± 5.3c 
10 3.6h Piperazine (2-MeO)Ph >25b 
11 3.6i HN N R  
(2-Me)Ph 18.4 ± 9.2c 
12 3.6j HN N R
 
(2-Me)Ph 11.1 ± 3.3b 
13 3.6k HN
N R  
(2-Me)Ph 3.1 ± 1.1b 
14 3.6l 
HN
N R
 
Ph 14.7 ± 4.4b 
15 3.6m 
HN
N R
 
(3-Me)Ph 16.6 ± 4.8c 
16 3.6o 
HN
R
H  
(2-Me)Ph 7.7 ± 1.6c 
17 3.6p 
HN
H
R  
(2-Me)Ph 7.9 ± 2.8b 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism and is the average ± stdev of at least two independent 
experiments using triplicate determinations at each concentration for each experiment; n = 
number of assay repeats: bn = 2, cn = 3, dn = 4, en = 6. 
 
For the investigation of zone 3, the piperazine and 2-Me-Ph substitution were retained for 
comparison. Interestingly, the amide was found to not be necessary for activity, as the reduced 
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analog 3.7b maintained activity (Table 3.2). The sulfonamide 3.7a was also as active as the 
initial hit 3.5 whereas the urea 3.7c and carbamate 3.7d were completely inactive. 
Table 3.2. Modifications to amide of zone 3. 
XS Y
O
N
N
 
Entry Compound Structure EC50 (µM)a X Y 
1 3.7a SO2 N 7.2 ± 2.7d 
2 3.7b CH2 N 10.8 ± 5.7c 
3 3.7c N
H
O
Y  
N >25b 
4 3.7d N
H
O
O Y  
CH >25d 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism and are the average ± stdev of at least two independent 
experiments using triplicate determinations at each concentration for each experiment; n = 
number of assay repeats: bn = 2, cn = 3, dn = 4. 
 
Finally zones 4 and 5 were investigated. The thioether linker was oxidized to sulfoxide 
3.8a and sulfone 3.8b resulting in analogs with very poor or decreased activity, confirming that 
the biological activity was not a result of S-oxidation (Table 3.3). Substitution of the thioether 
with oxygen and N-Me resulted in a complete loss in activity. It was found that a phenyl ring 
could be used in place of the 3,5-DMI (3.8d) with no significant decrease in activity. 
Additionally, activity was sustained when using an all-carbon linker in place of the thioether 
(3.8f).  Removing a carbon from the thioether linker 3.8g deleted all activity. The E-alkene 3.8h, 
trans-cyclopropane 3.8i, and alkyne 3.8j were also inactive. In contrast, the Z-alkene 3.8k was 
found to have similar activity to 3.6b (EC50 ~13 µM). Gratifyingly, the corresponding cis-
cyclopropane 3.8l had greatly improved activity over the initial hit 3.5 with an EC50 of 2.9 µM. 
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Table 3.3. Structural modifications in zones 4 and 5. 
X
O
N
N
Ar
 
Entry Compound Structure EC50 (µM)a X Ar 
1 3.5e S  3,5-DMI
f 7.3 ± 2.5d 
2 3.6b S  3,5-DMI
f 14.5 ± 3.2c 
3 3.8a S
O
 3,5-DMI
f >25c 
4 3.8b SO O  3,5-DMI
f 16.1 ± 3.3c 
5 3.8c O  3,5-DMI
f >25c 
6 3.8d S  Ph 13.7 ± 0.8
c 
7 3.8e MeN  Ph >25
c 
8 3.8f  Ph 14.4 ± 3.7
c 
9 3.8g S  Ph >25
b 
10 3.8h  Ph >25
b 
11 3.8i H
H  
Ph >25c 
12 3.8j  Ph 20.3 ± 11.6
b 
13 3.8k  Ph 12.7 ± 0.8
b 
14 3.8l H
H  
Ph 2.9 ± 1.0c 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism and are the average ± stdev of at least two independent 
experiments using triplicate determinations at each concentration for each experiment; n = 
number of assay repeats: bn = 2, cn = 3, dn = 4. epiperazine N-aryl group is 2,3-Me-Ph. f3,5-DMI, 
3,5-dimethylisoxazole.  
3.2 RESULTS AND DISCUSSION 
After identifying the cis-cyclopropane 3.8l as a key component of our pharmacophore, we sought 
to further develop the scaffold in order to increase its potency. We had previously discovered 
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that the N-aryl substitutions with 2-F and 5-Cl-2-Me showed a modest increase in biological 
activity. Our plan was to combine these substitutions with the cyclopropyl amide side chain to 
see if a similar trend in activity was observed. Initially, we attempted to generate the cis-
cyclopropane carboxylic acid 3.11 as building block for a convergent synthesis of new analogs 
(Scheme 3.1). The synthesis began with a hydrogenation of phenylpropiolic acid 3.9 using a 
Lindlar catalyst to afford the cis-alkene 3.10. A Simmons-Smith cyclopropanation afforded the 
cis-cyclopropane carboxylic acid 3.11 in poor yield after recrystallization.413 The carboxylic acid 
was then used in a HATU-mediated amide coupling with commercially available piperazines 
3.12a and 3.12b to afford amides 3.13a and 3.13b.  
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Scheme 3.1. Synthesis of cyclopropane analogs 3.13a and 3.13b. 
 To further improve these analogs, we decided to introduce a 4-fluoro substitution on the 
unsubstituted aryl ring to reduce the potential for metabolic oxidation (Figure 3.8).414  
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Figure 3.8. Proposed fluorine substitution for increased metabolic stability. 
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We first needed to synthesize 4-fluorophenylpropiolic acid (3.16a), as it wasn't readily 
available from commercial sources (Scheme 3.2). Initial attempts to directly couple propiolic 
acid with 4-bromofluorobenzene were messy, difficult to purify, and low yielding. Exploring an 
alternative stepwise approach previously described by Kondo et al., we first coupled TMS-
acetylene to the aryl bromide 3.14a. Concomitant desilylation and decarboxylation mediated by 
CsF under an atmosphere of CO2 provided the carboxylic acid 3.15a in excellent yields.415 A T3P 
mediated amide coupling gave amide 3.17a that was subsequently reduced under Lindlar 
hydrogenation conditions to the cis-alkene 3.18a in excellent yields. This reaction is typically 
stopped prematurely as the alkene is readily separated by chromatography from the alkyne 
starting material but not the over-reduced alkane, which can be observed with long reaction 
times. We have also found the Pd/BaSO4 quinoline catalyst system works well for the reduction 
of the alkyne to the cis-alkene.416 Finally, the cis-alkene 3.18 was subjected to chromium 
mediated Simmons-Smith cyclopropanation conditions to give the cyclopropane JJ450 in good 
yield. Other attempts to form the cyclopropane using samarium and diiodomethane were very 
low yielding with incomplete conversion of the starting material.417 This route has been 
optimized for multigram-scale synthesis of JJ450 and used to prepare more than 20 g of JJ450. 
Analysis of JJ450 by inductively coupled plasma optical emission spectroscopy (ICP-OES) and 
chromium levels were measured at 1.3 ppm (1.3 mg/L) with no detectable amount of lead. 
Chromium (II) is readily oxidized to chromium (III), which has been found to be an essential 
nutrient with low toxicity by oral administration by the EPA and FDA. According to USP<232> 
the permissible daily exposure (PDE) is 11,000 µg/day and 1,100 µg/day for oral and parenteral 
exposure respectively. The environmental protection agency (EPA) set the maximum 
contaminant level of chromium in drinking water to 100 µg/L (100 ppb).418  
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Scheme 3.2. Synthesis of JJ450. 
In order to determine if a specific binding site is being engaged by our analogs, we 
separated racemic JJ450 by semi-preparative chiral SFC using a Chiralpak IC column (25 x 1 
cm) and 20% methanol as the modifier. The absolute configuration of the enantiomers were 
initially assigned based on the specific rotation of similar compounds in the literature,419 and 
were later confirmed by single crystal X-ray diffraction of (1R,2S)-JJ450 (Figure 3.9).  
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Figure 3.9. Resolution of racemic JJ450 and crystal structure of (1R,2S)-JJ450. 
3.2.1 Biological Data 
Our therapeutic goal was to discover a potent, orally bioavailable modulator of AR with 
preclinical efficacy in CRPC in both in vitro and in vivo tumor models. Following the synthesis 
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of analogs 3.13a, 3.13b, and JJ450, the Wang lab characterized their biological activity in a PSA 
luciferase assay (Table 3.4). The assay utilizes a Dual-Glo luciferase system in the presence of 1 
nM of the synthetic androgen R1881 in C4-2-PSA-rl cells. In this Dual-Glo luciferase system, 
the relative luciferase activity is calculated as the quotient of androgen-induced PSA-
firefly/Renilla luciferase and as the PSA promoter activity correlates to AR transcriptional 
activity, inhibition of AR will result in decrease PSA-luciferase activity.349 The EC50’s were 
calculated using GraphPad Prism and are highly dependent on the type of curve fit used for 
analysis. The biological activities were compared to the cyclopropane 3.8l and enzalutamide 
(EC50 1.1 µM, Table 3.4, entry 7). The cyclopropane derivative 3.13a with a 2-F-Ph ring was 
found to be equipotent to the 2-Me-Ph analog 3.8l. Interestingly, compound 3.13b (R2=Cl) was 
three-fold more potent than 3.8l and JJ450 was equipotent to 3.8l. Gratifyingly, chiral resolution 
of JJ450 (EC50 2.7 µM, entry 4) provided a more potent enantiomer (1S,2R)-JJ450 (EC50 1.7 
µM, entry 5) and the ca. 10-fold less potent (1R,2S)-JJ450 (EC50 15.2 µM, entry 6), which 
supports a specific binding mode at a still to be defined AR binding site. 
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Table 3.4. Biological activity of cis-cyclopropane analogs. 
O
N
N
R1
R2
R
 
Entry Compound Structure EC50 (µM)a R R1 R2 
1 3.8l H Me H 2.9 ± 1.0c 
2 3.13a H F H 2.6 ± 1.6b 
3 3.13b H Me Cl 0.9 ± 0.9b 
4 JJ450 F Me Cl 2.7 ± 1.1d 
5 (1S,2R)-JJ450 F Me Cl 1.7 ± 0.2c 
6 (1R,2S)-JJ450 F Me Cl 15.2 ± 3.3c 
7 enzalutamide - - - 1.1 ± 0.5e 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of at least two independent 
assays using triplicate determinations at each concentration for each experiment; n = number of 
assay repeats: bn = 2, cn = 3, dn = 4, en = 5. 
 
An initial mouse PK panel of JJ450 proved promising as JJ450 showed some oral 
bioavailability (23%), t1/2 (IV) of 1.3 h, clearance of 68 mL/min/kg, and steady state volume of 
distribution (Vss) of 0.7 L/kg. The plasma concentrations were quantifiable until 8 h after dosing 
C57BL/6 mice with 10 mg/kg JJ450 by IV and OG method of administration (Table 3.5). 
Comparison of JJ450 with data for the FDA approved enzalutamide shows that there is room to 
improve the PK profile of JJ450.391  
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Table 3.5. PK data for JJ450. 
Entry Compounda Tmax [h] 
C0/Cmax 
[ng/mL] 
AUClast 
[h•ng/ 
mL] 
AUCinf 
[h•ng/ 
mL] 
t1/2 
[h] 
CL 
[mL/min 
/kg] 
VSS 
[L/kg] %F 
1 JJ450 (i.v)a - 6,822.2 2423 2430 1.26 68 2.79 - 
2 JJ450 (o.g)a 0.25 582.3 559.7 569.2 - - - 23.1 
3 
enzalutamide 
(o.g) (CD-1 
mice)b  
4.0 19,800 - 212,000 15.8 0.675* (IV) 
0.824* 
(IV) 94.3 
aPharmacokinetic Data was obtained from C57BL/6 mice administered with JJ450 at 10 mg/kg 
by o.g or i.v as denoted. bData for enzalutamide was obtained from ref391. 
 
The metabolic stability in mouse liver microsomes (MLM), rat liver microsomes (RLM), 
and human liver microsomes (HLM) was determined at 30 and 60 min (Table 3.6). It appears 
that mouse and rats have rapid metabolism of JJ450 (t1/2 = 10 min) while HLM metabolism is 
much slower. The microsome stability was also determined for both enantiomers. These are 
relatively similar with half-lives in MLM of 6.21 min and 7.48 min for the (1S,2R)-JJ450 and 
(1R,2S)-JJ450 enantiomers respectively. In comparison, for enzaluatamide (Table 3.6, entry 5) 
almost no metabolism is present in RLM after 30 min.420  
Table 3.6. Liver microsome data for JJ450 and enzalutamide. 
Entry Compounda MLMb RLMb HLMb 
1 JJ450 (30 min) 8% 1% 85% 
2 JJ450 (60 min) 3% 0% 59% 
3 (1S,2R)-JJ450 (60 min) 0.3% - 27% 
4 (1R,2S)-JJ450 (60 min) 0.4% - 8% 
5 enzalutamide (30 min)420 - 98% - 
aInitial compound concentrations were 1 µM. bLiver microsome data is reported as the % 
compound remaining a time point (X) and were measured in the presence of NADPH. MLM, 
mouse liver microsomes; RLM, rat liver microsomes, HLM, human liver microsomes. 
 
From these studies, JJ450 emerged as a potent lead analog from our SAR. Despite 
having decreased activity compared to 3.13b, we proposed that JJ450 would have an increased 
metabolic stability in vivo due to the presence of the 4-fluoro substitution and was taken forward 
as a promising lead for further biological testing. The initial xenograft studies were performed in 
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the Wang lab using racemic JJ450 (Figure 3.10). JJ450 was screened in three human tumor 
mouse xenograft models LNCaP, VCaP, and 22Rv1. Nude SCID mice bearing LNCaP 
xenografts were administered JJ450 once daily by oral gavage (o.g) or intraperitoneal (i.p) at 
two concentrations (10 mg/kg o.g, 10 mg/kg i.p, and 75 mg/kg o.g) (Figure 3.10, (A)). Lower 
concentrations (10 mg/kg) administered by o.g had begun to show increased tumor growth 
around 30 days while the i.p (10 mg/kg) had shown almost no tumor growth until day 40. 
Interestingly, the highest dose of JJ450 (75 mg/kg) o.g had no tumor growth until day 50 (Figure 
3.10, A). JJ450 was administered to nude SCID mice bearing the more aggressive 22Rv1 
tumors, which are resistant towards enzalutamide, at 10 mg/kg and 75 mg/kg i.p (Figure 3.10, 
B). Although JJ450 was able to slow the progression of the 22Rv1 tumor, the rapid tumor 
growth combined with the poor metabolism may have contributed to its ineffectiveness in this 
tumor model. Finally, a comparison study of JJ450 and enzalutamide (MDV3100) in a VCaP 
xenograft model shows JJ450 to be more effective than enzalutamide with only a small increase 
in tumor volume (Figure 3.10, C). In all of these xenograft models, mice administered JJ450 
showed no sign of weight loss indicating low cytotoxicity. Additionally, no adverse effects were 
observed in mice administered with a single dose of either 225 mg/kg or 375 mg/kg. 
Interestingly, a subsequent in vivo experiment using the separated enantiomers of JJ450 revealed 
that (1R,2S)-JJ450 was more efficacious, directly contrasting the in vitro result. We are still 
unsure as to the reason for this activity difference from the in vitro to in vivo. 
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Figure 3.10. Effect of JJ450 on LNCaP, 22Rv1, and VCaP s.c. tumor xenografts in nude SCID mice.421 
To further understand the metabolism of JJ450, HLM were incubated with JJ450 and 
LCMS analysis of the microsome fractions indicated two oxidation events were occurring. Our 
initial hypothesis was first N-oxidation of the aniline nitrogen to give N-oxide 3.20 (Scheme 3.3). 
We proposed that the second oxidation could occur in several other locations including the 
fluorinated aryl ring (A), next to the amide (B), the benzylic methyl group (C), and the 4-position 
of the aniline (D).  
O
N
N
Cl
F
T1/2 ~ 5 min (HLM)
[O]
O
N
N
Cl
F
[O]
JJ450 3.19a 3.20a
O
N
N
Cl
F
O
A
B
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O
 
Scheme 3.3. Proposed metabolic oxidation and hotspots on JJ450. 
 70 
3.2.2 Improving the Metabolic Stability of JJ450 
With JJ450 as our new starting point, we wanted to further improve its metabolic stability. Drug 
metabolism is an important factor to consider for further development of lead compounds as it 
plays a key role in toxicity, oral bioavailability, dosing. Several strategies have been developed 
to block or replace metabolically labile sites that include decreasing lipophilicity, introducing 
conformational constraint, introducing steric hindrance, tuning electronics, and altering 
stereochemistry.422 Cytochrome P450s (CYP’s) are responsible for most oxidative metabolism, 
which increases the polarity facilitating faster elimination. Liver microsomes serve as an in vitro 
model to predict CYP metabolism. Fluorine and fluorinated functional groups (CF3, and SF5) are 
commonly employed to block metabolically labile C-H bonds, decrease electron density of 
aromatic rings, increase lipophilicity, and lower the pKa of adjacent heteroatoms. In particular, 
we aimed to block several potentially metabolically labile sites on JJ450 that included the 
benzylic methyl and aniline nitrogen (zone 1), the cyclopropane (zone 2), and the aryl ring (zone 
3) (Figure 3.11). Additionally, as lipophilic compounds are more prone to CYP metabolism, we 
were also interested in decreasing the lipophilicity of JJ450 through incorporation of 
heterocycles in zones 1 and 3 (Figure 3.11).  
O
N
N
Cl
F
zone 1
zone 2
zone 3
JJ450  
Figure 3.11. Proposed zones of structural modification.  
 The synthesis of new analogs were carried out in a similar fashion to JJ450 and began 
with a Sonogashira coupling of commercially available aryl bromides 3.14a-3.14g with TMS 
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acetylene followed by treatment with CsF under an atmosphere of CO2 to give the corresponding 
carboxylic acids 3.16a-3.16g in good yields (Scheme 3.3). A subsequent T3P coupling of 
carboxylic acids 3.16b-3.16r with N-arylated piperazines 3.12b-3.12f afforded amides 3.17b-
3.17r. Hydrogenation was accomplished using either Lindlar catalyst or Pd/BaSO4 with 
quinoline to afford the cis-alkenes 3.18b-3.18r that were subjected to the chromium 
cyclopropanation conditions to afford cis-cyclopropanes 3.21a-3.21r.  
Ar Br
Pd(PPh3)2Cl2 (1 mol%)
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TMS
Et3N, 80 °C, 16-24 h Ar
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Ar
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O
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N
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Scheme 3.4. Synthetic route to analogs of JJ450. 
 In addition to analogs with varying aryl substitutions, we prepared an analog containing a 
deuterium substituted cyclopropane ring. If the metabolic oxidation is a result of oxidation on the 
cyclopropane we should see a decrease in metabolic rate due to the primary kinetic isotope 
effect. The synthesis began with a Lindlar reduction of 3.17a under an atmosphere of D2 to 
afford the deuterated-cis-alkene 3.22 in excellent yields that was subsequently subjected to the 
Simmons-Smith cyclopropanation conditions to afford the desired deutero-cyclopropane 3.23 
(Scheme 3.4). Interestingly, we had also attempted to form the deutero-cis-alkene using D2O and 
 72 
gold nanoparticle catalysis under a high pressure atmosphere of CO as previously described by 
Cao et al.,423 but, were unable to reproduce the reported pressures (400 psi) and therefore had 
low conversions and deuterium incorporation. 
O
N
N
Lindlar cat., D2
EtOAc, rt, 18 h
O
N
N
CrCl2, CH2ICl
THF, 80 °C, 24 h
O
N
N
F
Cl
D
DD
D
F
Cl Cl
F
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61% 70%3.17a 3.22 3.23
 
Scheme 3.5. Synthesis of deuterocyclopropane 3.23. 
In total 19 analogs of JJ450 were synthesized. Several of these racemic analogues were 
further resolved into their component enantiomers by semi-preparative chiral SFC 
chromatography. The absolute configurations of the separated enantiomers were assigned 
through a combination of circular dichroism (CD) and specific rotation analysis. Since the 
separated enantiomers retain the same cis-cyclopropane substitution pattern of the parent 
compound (1R,2S)-JJ450, the absolute configurations of the separated enantiomers were 
assigned by comparison to the specific rotation of (1R,2S)-JJ450, whose absolute configuration 
had been previously assigned by X-ray crystallography. Additionally, these analogs displayed 
consistent cotton effects in the circular dichroism (CD) spectra of enantiomers with matching 
specific rotation signs to (1S,2R)-JJ450 and (1R,2S)-JJ450 (See Appendix B). 
3.2.3 Biological Data of JJ450 Analogs: Cell Data and Metabolism 
Following the synthesis of the 43 analogs of JJ450, their biological activity was determined in a 
PSA luciferase assay using a Dual-Glo luciferase system in the presence of 1 nM of the synthetic 
androgen R1881 in C4-2-PSA-rl cells.349 The EC50’s were calculated using GraphPad Prism and 
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are preliminary. The biological activities were compared to JJ450 (EC50 2.7 µM, Table 3.7, 
entry 1). Deuteration of the cyclopropane did not have any significant effect on the activity or the 
metabolism, indicating that the oxidation is possibly not on the cyclopropane but on one of the 
aryl rings. Substituents on the piperazines with aryl groups replacing the benzylic methyl or 
chloro with a trifluoromethyl were met with slight loss in activity with no effect on the 
metabolism. Unfortunately, the pyrimidine aryl functionality was met with a complete loss in 
activity as it has one of the most promising cLogD values of 2.25. 
Table 3.7. Biological activity and liver microsome data for 4-fluoro substituted analogs. 
O
N
N Ar
F
 
Entry Compound Structure EC50 (µM)a cLogDe MLMf HLMf Ar 
1 JJ450 2-Me-5-Cl-Ph 2.7 ± 1.1d 4.6 - - 
2 (1S,2R)-JJ450 2-Me-5-Cl-Ph 1.7 ± 0.2c 4.6 0.3% 27% 
3 (1R,2S)-JJ450 2-Me-5-Cl-Ph 15.2 ± 3.3c 4.6 0.4% 8% 
4 3.23 2-Me-5-Cl-Ph 2.2 ± 0.3b 4.6 - - 
5 (1S,2R)-3.23 2-Me-5-Cl-Ph 1.9 ± 0.5b 4.6 0.2% 28% 
6 (1R,2S)-3.23 2-Me-5-Cl-Ph 14.3 ± 0.2b 4.6 0.5% 9% 
7 3.21ag 2-Me-5-CF3 6.3 ± 3.0b 4.9 - - 
8 (1S,2R)-3.21ag 2-Me-5-CF3 2.5 ± 1.9b 4.9 0.8% 31% 
9 (1R,2S)-3.21ag 2-Me-5-CF3-Ph 9.4 ± 1.4b 4.9 7% 26% 
10 3.21b 2-CF3-5-Cl-Ph 4.9 ± 0.9b 5.0 - - 
11 3.21c 
N
N
 
>25b 2.3 - - 
12 (1S,2R)-3.21c 
N
N
 
>25b 2.3 - - 
13 (1R,2S)-3.21c 
N
N
 
>25b 2.3 - - 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average of at least one independent assays 
using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 2, cn = 3, dn = 4. ecLogD were calculated using InstantJchem. 
fLiver microsome data is reported as the % compound remaining at 60 min and were measured in 
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the presence of NADPH. MLM, mouse liver microsomes; HLM, human liver microsomes. 
gCompound was synthesized by Dr. Keita Takubo. 
 
 The 4-trifluoromethyl substitution of the arylcyclopropane resulted in an overall 2 to 3-
fold decrease in activity and an overall increase in microsome stability, possibly due to an 
increased in steric bulk and decreased electron density on the aryl ring respectively. The parent 
3.21d (2-Me-5-Cl-Ph) appears to have poor metabolism (Table 3.8, entries 1-3) while the 
trifluormethyl substitutions afford a 20-fold increase in microsome stability over JJ450. In 
particular, analog (1S,2R)-3.21f (Table 3.8, entry 8) had a promising half-life of 1.5 h with and 
EC50 of ~12 µM. Interestingly, compound 3.21g with the 2-CN-5-Br-Ph substitution led to a 
significant decrease in activity contrary to what we had previously observed for compound 3.6e 
in our original SAR (Table 3.8, entries 10-12). Additionally, these trifluoromethyl substituted 
analogs also are significantly lipophilic (cLogD ~5-6), possibly limiting their utility in animal 
and human studies.  
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Table 3.8. Biological activity and liver microsome data for 4-trifluoromethyl substituted analogs. 
O
N
N Ar
CF3
 
Entry Compound Structure EC50 (µM)a cLogDd MLMe HLMe Ar 
1 3.21df 2-Me-5-Cl-Ph 6.6 ± 1.7c 5.4 - - 
2 (1S,2R)-3.21df 2-Me-5-Cl-Ph 8.4 ± 3.6c 5.4 11% 45% 
3 (1R,2S)-3.21df 2-Me-5-Cl-Ph 23.1 ± 2.6c 5.4 14% 5% 
4 3.21ef 2-Me-5-CF3-Ph 11.9 ± 2.1c 5.6 - - 
5 (1S,2R)-3.21ef 2-Me-5-CF3-Ph 12.1 ± 4.5c 5.6 49% 58% 
6 (1R,2S)-3.21ef 2-Me-5-CF3-Ph 15.5 ± 5.7c 5.6 48% 23% 
7 3.21f 2-CF3-5-Cl-Ph 9.1 ± 0.8c 5.7 - - 
8 (1S,2R)-3.21f 2-CF3-5-Cl-Ph 12.0b 5.7 
60%  
(t1/2 = 1.5 h) 
65% 
9 (1R,2S)-3.21f 2-CF3-5-Cl-Ph >25b 5.7 34% 51% 
10 3.21g 2-CN-5-Br-Ph >25c 4.9 - - 
11 (1S,2R)-3.21g 2-CN-5-Br-Ph 23.4 ± 3.5c 4.9 - - 
12 (1R,2S)-3.21g 2-CN-5-Br-Ph >25c 4.9 - - 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of at least one independent 
assay using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 1, cn = 2. dcLogD were calculated using InstantJchem. eLiver 
microsome data is reported as the % compound remaining at 60 min and were measured in the 
presence of NADPH. MLM, mouse liver microsomes; HLM, human liver microsomes.  
fCompound was synthesized by Dr. Keita Takubo. 
 
 Analogs containing the 3-trifluoromethyl substitution also showed a slight decrease in 
activity (ca. 2-fold) compared to the 4-F analogs, exhibiting a similar trend to analogs containing 
the 4-trifluoromethyl substitution (Table 3.9). In contrast, the 3-substituted analogs were not as 
metabolically stable as the 4-substituted analogs with a ca. 5-fold decrease in stability.  
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Table 3.9. Biological activity and liver microsome data for 3-trifluoromethyl substituted analogs. 
O
N
N Ar
F3C
 
Entry Compound Structure EC50 (µM)a cLogDd MLMe HLMe Ar 
1 3.21h 2-Me-5-Cl-Ph 3.3 ± 0.8c 5.4 - - 
2 (1S,2R)-3.21h 2-Me-5-Cl-Ph 3.6 ± 0.2b 5.4 0.2% 1% 
3 (1R,2S)-3.21h 2-Me-5-Cl-Ph 6.3 ± 1.8b 5.4 0.9% 4% 
4 3.21i 2-Me-5-CF3-Ph 7.7 ± 2.1b 5.6 - - 
5 3.21j 2-CF3-5-Cl-Ph 3.4 ± 2.3b 5.7 12% 34% 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of two independent assay 
using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 2, cn = 3. dcLogD were calculated using InstantJchem. MLM, 
mouse liver microsomes; HLM, human liver microsomes. eLiver microsome data is reported as 
the % compound remaining at 60 min and were measured in the presence of NADPH. 
 
 Similar to its trifluoromethyl counterpart, the 4-pentafluorosulfanyl substitution led to a 
global 3-fold decrease in activity but an overall increase in microsome stability (Table 3.10). In 
particular, analog (1S,2R)-3.21l (Table 3.10, entry 5) had a half-life in liver microsomes ~3 h 
with an EC50 of 11 µM. Unfortunately, these analogs are even more lipophilic than the 
trifluoromethyl analogs with cLogDs ~6-7 that could also limit their utility in animal and human 
studies.  
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Table 3.10. Biological activity and liver microsome data for 4-pentafluorosulfanyl substituted analogs. 
O
N
N Ar
SF5
 
Entry Compound Structure EC50 (µM)a cLogDd MLMe HLMe  Ar 
1 3.21k 2-Me-5-Cl-Ph 11.4 ± 1.6c 6.5 - - 
2 (1S,2R)-3.21k 2-Me-5-Cl-Ph 8.2 ± 4.0b 6.5 24% 3% 
3 (1R,2S)-3.21k 2-Me-5-Cl-Ph 18.9 ± 4.4b 6.5 40% 53% 
4 3.21l 2-Me-5-CF3-Ph 7.8 ± 4.3b 6.9 - - 
5 (1S,2R)-3.21l 2-Me-5-CF3-Ph 9.1 ± 2.7b 6.9 80% 
77%  
(t1/2 = 3 h) 
6 (1R,2S)-3.21l 2-Me-5-CF3-Ph 21.3 ± 2.8b 6.9 66% 30% 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of two independent assay 
using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 2, cn = 3. dcLogD were calculated using InstantJchem. eLiver 
microsome data is reported as the % compound remaining at 60 min and were measured in the 
presence of NADPH. MLM, mouse liver microsomes; HLM, human liver microsomes. 
 
 The 3-pentafluorosulfanyl analogs were ca. 2-fold more potent compared to the 4-
pentafluorosulfanyl analogs, but did not perform as well in the liver microsomes (Table 3.11). 
Even with the modest recovery of activity, the aqueous solubility will also be a concern for these 
analogs. 
 
 
 
 
 78 
Table 3.11. Biological activity and liver microsome data for 3-pentafluorosulfanyl substituted analogs. 
O
N
N Ar
F5S
 
Entry Compound Structure EC50 (µM)a cLogDc MLMd HLMd  Ar 
1 3.21m 2-Me-5-Cl-Ph 4.6 ± 0.8b 5.4 - - 
2 3.21n 2-Me-5-CF3-Ph 5.7 ± 0.3b 6.9 - - 
3 (1S,2R)-3.21n 2-Me-5-CF3-Ph 9.9 ± 1.4b 6.9 6% 4% 
4 (1R,2S)-3.21n 2-Me-5-CF3-Ph 7.1 ± 1.8b 6.9 35% 11% 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of at least two independent 
assays using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 2. ccLogD were calculated using InstantJchem. dLiver microsome 
data is reported as the % compound remaining at 60 min and were measured in the presence of 
NADPH. MLM, mouse liver microsomes; HLM, human liver microsomes. 
 
 Interestingly, the trifluoromethyl pyridine 3.21o (Table 3.12, entries 1-3) was found to be 
less active and less stable in microsomes. Additionally, it appears that (1R,2S)-3.21o is slightly 
more potent than the (1S,2R)-3.21o, which is opposite from what is observed with other JJ450 
analogs. In contrast, the thiophene 3.21p-3.21r was similar potency to JJ450 with all 
substitutions on the piperazine. This is promising as smaller 5-membered heterocycles seem to 
recover the activity lost with introduction of bulky para-substituents as previously observed with 
the SF5 and CF3 substitutions.  
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Table 3.12. Biological activity and liver microsome data for heteroaryl substituted analogs. 
O
N
N Ar1
Ar
 
Entry Compound Structure EC50 (µM)a cLogDd MLMe HLMe Ar Ar1 
1 3.21o 
N
F3C
 
2-Me-5-CF3-Ph 20.8 ± 6.0c 4.8 - - 
2 (1S,2R)- 3.21o N
F3C
 
2-Me-5-CF3-Ph 18.0 ± 1.7b 4.8 35% 39% 
3 (1R,2S)- 3.21o N
F3C
 
2-Me-5-CF3-Ph 13.6 ± 1.8b 4.8 24% 6% 
4 3.21p S
 
2-Me-5-Cl-Ph 2.2 ± 0.5c 5.0 - - 
5 3.21q S
 
2-Me-5-CF3-Ph 4.1 ± 0.3c 5.3 - - 
6 3.21r S
 
2-CF3-5-Cl-Ph 2.0 ± 0.1b 5.4 - - 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
was calculated using GraphPad Prism, and are the average ± stdev of at least two independent 
assays using triplicate determinations at each concentration for each experiment where noted; n = 
number of assay repeats: bn = 2, cn = 3. dcLogD were calculated using InstantJchem. eLiver 
microsome data is reported as the % compound remaining at 60 min and were measured in the 
presence of NADPH. 
  
In summary, 43 analogs were synthesized, and the SAR evaluated 3 zones of 
modifications of our lead compound JJ450 (Figure 3.12). We gained further understanding about 
the environment that these compounds bind. Zone 1 modifications showed that the 2,5-aryl 
substitutions with Cl or CF3 were well tolerated, while other modifications appeared to cause 
significant loss in activity. Limited substitutions were performed in zone 2 and deutero-JJ450 
was found to have similar activity to the parent compound. In zone 4, increasing the steric bulk 
of the para or meta-substituent reduced activity, and only the thiophene maintained activity 
comparable to JJ450. 
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Figure 3.12. Zones of structural modification on JJ450. 
Our primary aim of these 3 zones of structural modifications was to increase the stability 
of the parent compound JJ450 in liver microsomes, a predictive model for phase 1 metabolism 
(Scheme 3.6).  In zone 1, the 2-CF3-5-Cl and 2-Me-5-CF3 substitution only afforded modest 
increase in stability. The deuterium labeling in zone 2 resulted in no overall effect on the 
metabolism indicating that this is not a major or initial site of metabolism. Finally, modifications 
in zone 3 were shown to be the most influential in increasing the microsomal stability indicating 
that this is our primary site of metabolism. The most significant increase in microsomal stability 
was noted in compounds containing a para-CF3 or SF5. Gratifyingly, compound 3.21l was found 
to have a half-life of ~3 h in liver microsomes, a ~40-fold increase in stability from the parent 
JJ450. Additionally, given this data we must reconsider our initial hypothesis of the metabolic 
oxidation of JJ450. The major metabolic liability appears to be the fluorinated aryl ring (Scheme 
3.6). The second metabolic liability is found at the aniline ring where fluorinated substituents 
were found to slightly improve the microsomal stability.  
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Scheme 3.6. Revised sites of metabolism on JJ450. 
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3.2.4 Synthesis of Chemical Probes to Elucidate the Mechanism of Action 
In addition to developing new and more potent inhibitors of CRPC with increased metabolic 
stability, we also wanted to develop small molecules to probe the mechanism of action of our 
lead compounds. Several methods have been developed using small-molecule-based affinity 
reagents to identify cellular targets.424-425 They require an effective conjugation protocol as well 
as methods for affinity purification. There are three main methods for target pull-down using 
small molecules that include immobilization onto agarose beads, conjugation to biotin, or 
photoaffinity labeling. In particular, many agarose beads are commercially available or readily 
tuned to have a variety of functionalized surfaces (containing carboxylic acids, amines, alkynes, 
or azides). There are many methods used for the conjugation step such as peptide coupling of 
amines and carboxylic acids, reductive amination, or Cu-(I)-catalyzed [3+2] cycloaddition. 
Agarose beads conjugated to active compounds are incubated with whole cell lysates to capture 
potential target proteins. Schreiber and coworkers developed a method to conjugate alcohol-
containing small molecules to agarose beads that uses CDI to form an activated carbamate that 
can then undergo conjugation to an agarose bead functionalized with amine linkers (Scheme 
3.7).426  
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Scheme 3.7. Bead conjugation of alcohol-containing molecules. 
Previously, we identified 3.24 as a new analog that was slightly more potent than the 
original HTS hit 3.5 and contained a propargyl alcohol handle that could be coupled to an 
agarose bead to form a derivative for pull-down studies. The bridged bicyclic [3.2.1] analogs 
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such as 3.6p were of interest as both diastereomers were equipotent indicating that structural 
bulk could be tolerated around the piperazine as well as a 2-fold increase in potency from the 2-
MePh analog 3.6b. We proposed that a hybrid structure of 3.24 and the bridged bicyclic [3.2.1] 
analog 3.6p would yield a 2-fold increase in binding affinity compared to 3.24. This more potent 
analog 3.25 would be better suited for conjugation to agarose beads and a subsequent pull-down 
study (Scheme 3.8).  
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Scheme 3.8. Initial proposed analog 3.25 for affinity labeling. 
 Our retrosynthetic approach to 3.25 features a late stage coupling of amine 3.27 to 
commercially available carboxylic acid 3.26 (Scheme 3.9). We proposed hydrogenation of the 
styrene 3.28 followed by a Sonogashira coupling to install the key propargyl alcohol side chain. 
We envisioned that styrene 3.28 could be constructed from commercially available nortropinone 
hydrochloride 3.29 via a Boc-protection, enolization and vinyl triflate formation, and a Suzuki 
cross coupling.  
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Scheme 3.9. Retrosynthetic approach to analog 3.25. 
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 The synthesis of the styrene intermediate 3.28 began with Boc-protection of 
commercially available nortropinone hydrochloride (3.29) followed by enolization with 
NaHMDS and trapping of the enolate with Comins’ reagent to afford the vinyl triflate 3.31 
(Scheme 3.10). A Suzuki coupling of vinyl triflate 3.31 and boronic acid 3.32 afforded the 2-
bromostyrene 3.28 in good yields.  
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Scheme 3.10. Synthesis of styrene 3.28. 
 Our next focus was to reduce the alkene in the presence of the aryl bromide. We screened 
many reaction conditions for this reduction including PtO2, and diimide reductions; however, all 
attempts were unsuccessful due to overreduction of the alkene and aryl bromide or lack of 
reactivity.427-429 In the case of the diimide reductions, a large excess of reagents was required to 
see even trace reduction. Gratifyingly, we discovered that the hydrogen atom transfer 
hydrogenation conditions, previously developed by Shenvi, were successful on our substrate to 
afford the product 3.33 in modest yields as a 3:1 mixture of diastereomers 3.33a and 3.33b 
(Scheme 3.11).430-431 Using the mixture of diastereomers, we moved forward with the 
Sonogashira cross coupling. Using CuI, other sources of Pd, or a protected propargyl alcohol 
afforded only trace product. Ultimately, we found that we could use (iPr)CuCl293 (vide infra) to 
give a single diastereomer of propargyl alcohol 3.27 in manageable yields with only trace 
amounts (<5%) of the minor diastereomer as separable products by chromatography. 
Additionally, using the styrene for the Sonogashira coupling was also unsuccessful and 
protodemetalation was the major pathway observed. Finally, Boc-deprotection of 3.27 and 
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coupling to commercially available carboxylic acid 3.26 afforded amide 3.25 in modest yields.  
The poor yield in the coupling is the result of over acylation of the propargyl alcohol.  
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Scheme 3.11. Synthesis of 3.25. 
For the conjugation of 3.25 to the agarose beads, we had initially tried using CDI to form 
the activated carbamate but found it difficult to quantify by LCMS and IR. We modified our 
procedure for the use of 4-nitrophenylchloroformate to form the activated carbonate that releases 
the highly colored 4-nitrophenolate anion 3.35 upon amine conjugation in DMF at rt for 5 days 
with gentle inversion (Scheme 3.12).  
3.25
N
O
SO
N
H
OH
H2N
1) Et3N, CH2Cl2, rt, 4 h
2) DMF, rt, 5 d
Cl
O
O
NO2
O
NO2
3.34 3.35
N
O
SO
N
H
O
O
H
N
 
Scheme 3.12. Conjugation of 3.25 to agarose beads. 
After washing of the beads, we were able to see several characteristic IR shifts compared 
to a blank bead sample. In particular, we can see a small alkyne stretch around 2050 cm-1 and 
significant changes in the fingerprint region (Figure 3.13). 
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Figure 3.13. Comparison of the IR spectra of the unconjugated blank bead to the conjugated bead. 
In addition to 3.25, we also wanted to synthesize an analog 3.36 with a longer flexible 
linker to prevent any potential interference of the agarose bead with binding of the inhibitor and 
to avoid any nonspecific binding interactions (Figure 3.14). Initial attempts at the Sonogashira 
coupling with a PEG-alkyne were unsuccessful and instead we used a Heck coupling to install an 
ester as a more flexible handle for conjugation. We proposed that the benzyl ester could be 
selectively cleaved in the presence of the internal ester and the corresponding carboxylic acid can 
be used in an amide coupling for conjugation.  
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Figure 3.14. Proposed flexible linker modifications to 3.25. 
For a convergent approach we synthesized the acrylate PEG linker 3.29 for the Heck 
coupling (Scheme 3.13). The synthesis of 3.29 began from the monoalkylation of diethylene 
glycol (DEG, 3.37) to afford benzyl ester 3.38 in poor yields. The terminal alcohol of 3.38 was 
acylated with acryoyl chloride to afford acrylate 3.39 in poor yields.  
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Scheme 3.13. Synthesis of acrylate linker 3.39. 
The acrylate side chain was coupled to the previously prepared bromide diastereomers 
3.33 (enriched to a 10:1 mixture of 3.33a:3.33b by chromatography) via a Heck coupling 
(Scheme 3.14). In contrast to the Sonogashira coupling, both diastereomers participate in the 
Heck coupling to give the alkene 3.40 as a similar mixture of diastereomers. Selective reduction 
of the αβ-unsaturated ester 3.40 in the presence of the benzyl ether was accomplished using 
nickel mediated conjugate reduction. Other attempts using Pd/C also resulted in competitive 
cleavage of the OBn ester. Boc-deprotection and coupling to carboxylic acid 3.26 afforded 3.36 
as a mixture of diastereomers that could be separated by preparative HPLC to afford poor yields 
of 3.26 as a single diastereomer. In preparation for conjugation, we looked to selectively cleave 
the benzyl ester in the presence of the internal ester. Unfortunately, the benzyl ester could not 
readily cleaved by hydrogenation using Pd/C due to the presence of the thioether with no 
reactivity observed. Saponification in alcoholic solvents only afforded a mixture of 
transesterified products. We were delighted to find that tetrabutyl ammonium hydroxide (TBAH) 
selectively cleaved the benzyl ester in modest yields. Unfortunately, on large scale we 
encountered problems with the stability of these compounds during the conjugate reduction of 
3.40 to 3.41, where we observed reduction of the internal ester and loss of the PEG linker. As a 
result of this we wanted to modify the linker to have increased stability.  
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Scheme 3.14. Synthesis of 3.36. 
 We hypothesized that a major source of instability was the presence of the internal ester. 
Therefore, we proposed analog 3.42, which would contain an ether in place of the ester (Figure 
3.15). We anticipated that this analog could be synthesized using a late stage amide coupling of 
carboxylic acid 3.26 and an amine precursor that can presumably be constructed by a Heck 
coupling with ethyl acrylate and then reduced to the propyl alcohol that can be alkylated with a 
PEG linker. 
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Figure 3.15. Proposed structural modifications to improve chemical stability. 
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Given the difficulty encountered in separating the diastereomers at the final step, we 
optimized the chromatographic separation after the reduction of alkene 3.28 to yield pure 
diastereomer 3.33a, which, under Heck coupling conditions with ethyl acrylate, gave ester 3.43 
in excellent yields (Scheme 3.15). Hydrogenation of the alkene 3.43 followed by reduction of the 
ester afforded alcohol 3.45. Unfortunately, displacement of the activated mesylate and brosylate 
only afforded the transesterified product 3.48 with only trace amounts of the ether 3.47. 
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Scheme 3.15. Synthetic approach to ether intermediate 3.47. 
 To circumvent issues of reactivity we decided to synthesize an analog of 3.36 containing 
an amide in place of the internal ester (Figure 3.16). This more stable variant containing a readily 
saponified aromatic ester will reduce problems of chemical intractability encountered with 
previous substrates. We envisioned the synthesis of this analog could be through a late stage 
amide coupling of an amine linker and the carboxylic acid of 3.44.  
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Figure 3.16. Proposed amide bead precursor 3.49. 
The synthesis of the amine linker 3.53 began with an Appel bromination of DEG (3.37) 
and displacement of the bromide with methyl paraben (3.51) to afford ester 3.52 (Scheme 3.16). 
The terminal alcohol of 3.52 was activated as the mesylate, displaced with sodium azide, and 
reduced under Staudinger reduction conditions to afford amine 3.53.  
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Scheme 3.16. Synthesis of amine linker 3.53. 
 The previously synthesized ester 3.45 was hydrolyzed and coupled to the amine linker 
3.53 to afford the amide 3.54 (Scheme 3.17). Deprotection of the Boc group and coupling with 
the commercially available carboxylic acid 3.26 gave the amide 3.55 in modest yields. 
Saponification of the methyl ester of 3.55 gave the carboxylic acid that was activated as the N-
hydroxysuccinimide (NHS) ester and conjugated to the Carboxylink® agarose beads to afford 
the affinity labeled 3.57.  
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Scheme 3.17. Synthesis and conjugation of analog 3.55. 
In addition to the bridged bicyclic [3.2.1] analogs we also wanted to append a 
cyclopropane side chain in place of the thioether of 3.24 to test if we will see a similar increase 
in efficacy when attached to a piperazine containing a propargyl alcohol linker (Figure 3.17).  
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Figure 3.17. Proposed cyclopropane analog 3.58. 
The synthesis of the cyclopropane analog 3.58 began with a T3P coupling of 
cyclopropane carboxylic acid 3.11 and piperazine 3.59 that was previously prepared by Dr. 
Mustafa Kazancioglu to afford the amide 3.60 in poor yields (Scheme 3.18). The low yield in the 
coupling is possibly due to some decomposition of piperazine 3.59 after storage as the free base. 
A final TBS deprotection of 3.60 afforded the desired propargyl alcohol 3.58 in modest yields.  
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Scheme 3.18. Synthesis of cyclopropane analog affinity labeling precursor 3.58. 
3.2.5 Biological Activity of Analogs for Affinity Labeling 
Following the synthesis of the analogs for affinity labeling, their biological activity was 
determined using a PSA luciferase assay using a Dual-Glo luciferase system in the presence of 1 
nM of the synthetic androgen R1881 in C4-2-PSA-rl cells. The preliminary EC50’s were 
calculated using GraphPad Prism. Gratifyingly, analog 3.27 was 2-fold more active compared to 
the alkyne 3.24 further supporting our hypothesis that the bridged bicyclic [3.2.1] system results 
in a 2-fold increase in activity (Table 3.13). The analog with the longer linker 3.55 was 
significantly less active than hybrid 3.25. We are not sure if this is the result of a longer linker or 
the more flexible propyl side chain compared to the propargyl linker. Surprisingly, the 
cyclopropyl analog of 3.58 was 3-fold less active than 3.24 with the thioether side chain.  With 
the promising activity of 3.25, the conjugated beads were carried forward into whole cell pull-
down assay. 
Table 3.13. Biological activity of affinity precursors. 
Entry Compound EC50 (µM)a 
1 3.24 5.8 ± 2.9b 
2 3.25 2.8 ± 1.0 b 
3 3.55 11.1 ± 4.3b 
4 3.58 14.9 ± 9.1b 
aEC50’s were determined using a cell based luciferase assay as previously described.349 EC50 
refers to the concentration that results in 50% inhibition of PSA-luciferase activity. Each EC50 
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was calculated using GraphPad Prism, and are the average ± stdev of two independent assays 
using triplicate determinations at each concentration for each experiment. 
  
A subsequent pull-down experiment conducted in the Wang lab using C4-2 whole cell 
lysates. Cell lysates were precleared with acetylated control beads and incubated with or without 
50-fold 3.5. Levels of AR were detected using electrophoresis followed by western 
immunoblotting experiments with an anti-AR antibody.  Using the control beads in the presence 
or absence of 3.5 there is no observed pull-down of AR. In contrast, using 3.34 beads resulted in 
AR pull-down. Additionally, compound 3.5 was found to competitively block the AR pull-down 
of the 3.34 beads.   
 
Figure 3.18. Affinity purification of AR from C4-2 whole cell lysate using immobilized 3.34. 
3.3 CONCLUSIONS 
In conclusion, compound 3.5 was discovered in a HTS to reduce endogenous levels of AR in 
both the cytoplasm and the nucleus. An SAR of 3.5 was established using 5 zones of structural 
diversification that resulted in the synthesis of JJ450 a new, more potent analog than the initial 
HTS hit 3.5 that contained a cis-cyclopropane in place of the potentially metabolically labile 
thioether side chain. JJ450 was administered to nude mice bearing s.c. prostate cancer (LnCaP, 
VCaP, 22Rv1) xenografts via o.g and i.p to determine the in vivo efficacy. Gratifyingly, JJ450 
was found to have modest therapeutic efficacy with no toxicity in the xenograft models and was 
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even more efficacious than enzalutamide in a comparison study. A resolution of JJ450 afforded 
the separated enantiomers, which were unambiguously assigned by X-ray crystallography. A 
preliminary xenograft study using the separated enantiomers indicated that the (1R,2S)-JJ450 
was more efficacious in vivo, contrary to the trend observed with the in vitro data. It was 
determined that JJ450 had a poor metabolic half-life in liver microsomes and in a effort to 
improve metabolic stability 43 analogs were synthesized with varying substituents to decrease 
metabolism and increase half-life. Although increased potency was not achieved, we identified 
compound 3.21l that was 40-fold more stable in liver microsomes compared to the parent JJ450 
with only a 3-fold decrease in activity. A subsequent xenograft study is currently underway using 
the resolved enantiomers of 3.21l. 
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Figure 3.19. Structural improvements leading to compound 3.21l.  
Several analogs were synthesized as probes for the determination of mechanism of 
action. In particular, we discovered that 3.25, a structural hybrid of 3.6p and 3.24 had an EC50 of 
2.8 µM that was conjugated to an agarose bead through a carbamate linker. Additionally, an 
analog of 3.55 containing a longer linker was synthesized and was found to have a 3-fold 
reduction in activity, and was also conjugated to the agarose beads for comparison to 3.25. 
Interestingly, we found that the cyclopropyl side chain performed poorly on the analogs 
containing the propargyl alcohol linker when compared to those containing the thioether side 
chain. This indicated that the more flexible thioether allows for better binding with the more 
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rigid alkyne handle. A preliminary pull-down assay using bead conjugate 3.34 revealed that AR 
was retained by the affinity reagent 3.34 and was competitively blocked by 3.5. 
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4.0  EFFORTS TOWARDS THE TOTAL SYNTHESIS OF 9-
DESMETHYLPLEUROTIN 
4.1 INTRODUCTION 
The natural product pleurotin was first isolated from the fungus Pleurotus griseus in 1947. In 
preliminary biological evaluations it was found to inhibit Staphylococcus aureus along with 
several other gram-positive bacteria.432 Although the structure of pleurotin was unknown at the 
time of isolation, Kavanagh and coworkers were able to determine several structural 
characteristics by chemical degradation studies.432 The full structure was eventually elucidated in 
1974 by NMR and later confirmed in 1981 by X-Ray crystallography.433-434 Pleurotin has also 
been isolated from the fungus Hohenbuehelia geogenius and has demonstrated moderate 
antitumor activity against Ehrlich ascites carcinoma, L-1210 lymphoid leukemia and a 
spontaneous mammary tumor in mice.435-436 More recently, pleurotin has been shown to inhibit 
bacterial peptidoglycan biosynthesis, a potential target for resistant infections.437 Synthetically 
challenging structural features of the complex hexacyclic framework of pleurotin includes a 
redox labile para-quinone moiety with two adjacent β-leaving groups, and the presence of 8 
contiguous stereocenters (Figure 4.1).  
 96 
O
O O
O
H
HO
Me
H
Pleurotin
O
O
O
O
O H
 
Figure 4.1. Structure of pleurotin. 
Although pleurotin performed poorly in the National Cancer Institute (NCI) 60 cancer 
cell line panel having a GI50 of 20 µM and no selectivity toward tissue type, it has been a target 
of interest for many years as it is a potent irreversible inhibitor of the thioredoxin-thioreductase 
(Trx/TrxR) system (IC50 = 170 nM).438-440 The Trx/TrxR system is important for the regulation 
of reactive oxygen species (ROS) and various redox processes, synthesis of 
deoxyribonucleotides, growth factor signaling, cytokine function, and protein biosynthesis.441 
The TrxR’s contain a selenocysteine, which is essential for their redox activity.441 In hypoxic 
tumors, Trx-1 is over-expressed leading to increasing levels of hypoxia-inducible factor-
1α (HIF-1α). The hypoxia-activated transcription factor HIF-1 is the heterodimer of HIF-1α and 
HIF-1β and is responsible for the transcription of genes leading to angiogenesis, cell 
proliferation and survival, vasculogenisis, glucose metabolism, and iron homeostasis.442-443 The 
activity of the HIF-1 complex is directly correlated to levels of HIF-1α, and pleurotin has been 
shown to reduce levels of HIF-1α and decrease HIF-1 transactivation both in vitro and in vivo 
through inhibition of TrxR.439 Since hypoxia is a common feature that promotes the survival and 
metastasis of most cancerous tumors, a therapeutic treatment that targets hypoxic tumors is 
highly desirable.  
In 2006, the NCI expressed renewed interest in pleurotin as a cancer therapeutic; 
however, the short supply of pleurotin largely limited further development. Previous isolations 
from Hohenbuehelia atrocaerulea were extremely low yielding (1-2 mg/L) and took over 2 
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months. Shipley and coworkers optimized a fermentation process of H. atrocaerulea to afford 
~300 mg/L over 5 weeks resulting in the isolation of more than 10 g of pleurotin. Due to the long 
fermentation times, this optimization was accomplished over 5 years.440 
Like many of the redox active natural products, the proposed mechanism of action of 
pleurotin is through bioreductive alkylation444 and cross-linking of TrxR. In hypoxic cells, 
pleurotin can undergo a 2-electron reduction to the hydroquinone leukopleurotin 4.1 that can β-
eliminate to the intermediate quinone methide 4.2, a highly reactive Michael acceptor (Scheme 
4.1). Quinone methide 4.2 can either tautomerise to dihydropleurotin acid, a proposed 
intermediate in the biosynthetic pathway, or be trapped with a nucleophile to afford the 
intermediate hydroquinone 4.3. A subsequent β-elimination of the oxacycloheptane ether of 4.3 
unveils a second quinone methide 4.4 that can undergo nucleophilic trapping to afford the 
hydroquinone 4.5. Interestingly, bioreductive alkylating agents have been found to be selective 
for hypoxic tumor cells, and this is a mechanism of action observed with a number of FDA 
approved cancer treatments, including mitomycin C, which is used in combination therapies for 
the treatment of various solid tumors.445 
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Scheme 4.1. Proposed bioreductive alkylation mechanism of pleurotin. 
4.1.1 Previous Syntheses: Hart 
The first total synthesis of (±)-pleurotin was accomplished by Hart and coworkers in 1989 and 
was inspired by a novel radical cyclization methodology developed by their group to form 
perhydroindans (Scheme 4.2). In their initial report, the radical cyclization precursor 4.9 was 
prepared from a Birch reduction of m-toluic acid, alkylation with 4-bromo-1-butene (4.7), and a 
subsequent iodolactonization of intermediate 4.8.446-447 Treating intermediate 4.9 with 
azobisisobutyronitrile (AIBN) and tributyltin hydride delivered a mixture of products with 
perhydroindan 4.12 as the major component of the mixture.  
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Scheme 4.2. Hart's initial radical cyclization discovery. 
To showcase their chemistry, Hart and coworkers identified pleurotin as an appropriate 
synthetic target as its core contains the perhydroindan skeleton (Figure 4.2).   
OO
H
O
O
O
O
O H
Pleurotin4.12  
Figure 4.2. Perhydroindan scaffold 4.12 and pleurotin. 
The first portion of their synthesis focused on the preparation of the key radical 
cyclization precursor 4.21. The synthesis of 4.21 began with a Birch reduction of benzoic acid 
(4.14) and alkylation with bromide 4.15 (Scheme 4.3). Iodolactonization of carboxylic acid 4.16 
resulted in decomposition and, instead, this transformation was accomplished using the amide 
4.17. The acetal 4.18 was deprotected with aqueous formic acid and then subjected to a Wittig 
olefination with ylide 4.20 to deliver the radical cyclization precursor 4.21 in excellent yields as 
a single diastereomer.446-449 
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Scheme 4.3. Synthesis of radical cyclization precursor 4.21. 
 Gratifyingly, the radical cyclization of 4.21 proceeded with high diastereoselectivity 
giving almost complete conversion to 4.23 (Scheme 4.4). To test whether the olefin geometry 
was responsible for the observed selectivity, the olefin with opposite geometry 4.22 was 
synthesized and subjected to the same reaction conditions. Interestingly, a similar ratio of 4.23 to 
4.24 was obtained albeit in diminished yields. This indicated that while the alkene geometry 
influences the stereochemistry at C10, it is not responsible for the selectivity at C9. After 
conducting subsequent experiments where the alkene substituents were varied, they concluded 
that the stereochemistry at C9 is the result of a dipolar interaction between the two carbonyl 
groups.449 
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Scheme 4.4. Hart’s radical cyclization. 
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With ample amounts of the radical cyclization product in hand, they turned their attention 
to modifying the oxidation states at C8 and C12 (Scheme 4.5). As the lactone is also susceptible 
to reduction, the ester of 4.23 was reduced over 2 steps. First, 4.23 was hydrolyzed using 
aqueous lithium hydroxide to form the diacid. Subsequent treatment with acid regenerated the 
lactone in 4.30. The carboxylic acid was reduced by treatment with oxalyl chloride to form the 
acid chloride and then sodium borohydride to give an intermediate alcohol that was TBS 
protected to give 4.31 in excellent yields. Interestingly, the reduction of ester 4.23 to the alcohol 
can also be achieved in a single step using LAH in 95% yield, which is most likely due to the 
steric crowding of the lactone. Epoxidation of alkene 4.31 followed by lithium diethylamide 
mediated rearrangement of the epoxide gave the corresponding allylic alcohol 4.33. Birch 
reduction of the allylic ester 4.33 resulted in opening of the lactone and a subsequent methylation 
with diazomethane gave the methyl ester 4.34. Finally, Swern oxidation of the alcohol 4.34 
afforded the ketone 4.35 in good yields. It was also noted that starting from 4.31, the epoxide 
opening, reduction, and esterification could give 4.34 in a one-pot procedure with 59% overall 
yield. 
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Scheme 4.5. Synthesis of ketone 4.35. 
With the ketone 4.35 in hand, Hart then focused on the formation of the oxacycloheptane 
ring and the pentacyclic core. Transmetalation of 2,5-dimethoxybenzyl magnesium chloride 4.36 
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with cerium(III) followed by addition of the resulting organocerium reagent to ketone 4.35 
afforded the alcohol 4.37 as a single diastereomer (Scheme 4.6). Subsequent elimination of the 
tertiary alcohol 4.37 afforded alkene isomers as an inseparable 1:1 mixture. The isomers were 
directly subjected to LAH reduction to give the separable alcohols 4.38 and 4.39. Oxidation of 
alcohol 4.39 to aldehyde 4.40 followed by a mild acid catalyzed TBS deprotection of 4.40 using 
Dowex-50 in methanol provided acetal 4.41. Treatment of acetal 4.41 with boron trifluoride 
etherate at low temperature initiated an intramolecular electrophilic aromatic substitution 
reaction to yield pentacyclic 4.42 in modest yields. Hart noted that performing the cyclization in 
other solvents at room temperature resulted in the formation of several rearranged products. 
Furthermore, it was also noted that product 4.42 was susceptible to rearrangement after 
prolonged exposure to acid.  
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Scheme 4.6. Synthesis of pentacyclic core 4.42. 
 Following the synthesis of the pentacyclic core 4.42, Hart shifted his attention to the final 
installation of the lactone ring and the completion of the synthesis of pleurotin. A hydroboration 
of the alkene 4.42 followed by oxidation afforded an intermediate alcohol that was further 
oxidized to the ketone 4.43 using a Swern oxidation (Scheme 4.7). A Van Leusen reaction of 
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ketone 4.43 with tosylmethyl isocyanide (TosMIC) and KOtBu afforded the homologated nitrile 
4.44. While direct hydrolysis of the nitrile to the carboxylic acid proved problematic, they found 
that a two step protocol was effective whereby the nitrile was reduced to the corresponding 
aldehyde with DIBAL-H then oxidized to the carboxylic acid 4.45 with silver (I) oxide. 
Oxidation of 4.45 with ceric ammonium nitrate (CAN) in aqueous acetonitrile gave 
dihydropleurotin acid in excellent yields. Initial attempts to oxidize dihydropleurotin acid using 
amine bases in the presence or absence of oxygen were unsuccessful. Instead, the final oxidation 
was accomplished by treating dihydropleurotin with an excess of manganese dioxide over 2 days 
to give pleurotin in 32% yield along with 33% of recovered dihydropleurotin acid. Thus, the first 
total synthesis of pleurotin was completed in 26 steps and 0.3% overall yield.  
1) BH3•THF, THF 0°C
then EtOH, 6M NaOH
H2O2, 50°C
2) (COCl)2, DMSO,
Et3N, CH2Cl2, -78 °C
TosMIC, KOtBu
DME, 0 °C
1) DIBAL, PhMe
2) Ag2O, NaOH
H
H
O
OMe
MeO
4.42
H
H
O
OMe
MeO
O H
HO
OMe
MeO
O
O H
H
H
O
OMe
MeO
NC H
H
H
O
OMe
MeO
HOH
O
83% (2 steps)
75%
58% (2 steps)
4.43 4.44
4.45
4.45
CAN
MeCN/H2O
89%
HO
O
O
O
O H
Dihydropleurotin acid
O
O
O
O
O H
Pleurotin
MnO2
CH2Cl2
32%
 
Scheme 4.7. Completion of the synthesis of pleurotin. 
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4.1.2 Synthesis of a Pleurotin Analog: Kraus 
In 1993 Kraus and coworkers developed a photoenolization/Diels-Alder approach to an analog of 
pleurotin.450-451 The synthesis began with the formation of the dianion of 4.46, which underwent 
formylation with DMF followed by mild hydrolysis to afford lactol 4.47 (Scheme 4.8). 
Unfortunately, direct acylation of 4.47 with dihydrobenzoic acid (4.49) proved unsuccessful and 
an alternative approach was pursued where thioacetal 4.48 was prepared and readily acylated 
with dihydrobenzoic acid (4.49). Subsequent thioacetal deprotection using MeI in aqueous 
acetonitrile yielded aldehyde 4.50 in modest yields. With their photoenolization substrate 4.50 in 
hand, aldehyde 4.50 was subjected to their previously optimized photoenolization conditions to 
deliver intermediate 4.51.450-452 Gratifyingly, they found that heating the enolate intermediate 
4.51 neat at 165 °C promoted the key intramolecular Diels-Alder (IMDA) reaction to afford the 
tetracyclic core 4.52 as a single diastereomer in modest yield over two steps. The relative 
configuration of 4.52 was supported by 2D-NMR analysis and molecular mechanics calculations 
revealed that endo adduct 4.52 was favored over the exo adduct by 1.6 kcal/mol. Finally, 
oxidation of 4.52 to the quinone 4.53 was accomplished using silver (II) oxide and nitric acid in 
THF.451  
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Scheme 4.8. Synthesis of pleurotin analog 4.53. 
Biological testing revealed that quinone 4.53 was active against a SR leukemia cell line 
(GI50 = 4.67 µM) and most colon cancer cell lines (GI50 = 22.4 µM to 17.0 µM). These activities 
are comparable to pleurotin, which has a mean value of GI50 of 3.09 µM against SR leukemia 
and 6.76 µM against colon cancer cell lines.451 
4.1.3 Previous Synthetic Work: Wipf Group 
The Wipf group has ongoing interest in the synthesis and biological evaluation of pleurotin and 
other quinoid inhibitors of the Trx/TrxR system.453-457 Early synthetic efforts toward the total 
synthesis of pleurotin within the Wipf group were pioneered by Drs. Sonia Rodriguez, Shinya 
Immura, and Stephan Elzner. Retrosynthetically, the original approach to pleurotin featured a 
late stage reductive etherification to form pleurotin from intermediate 4.54 (Scheme 4.9). 
Intermediate 4.54 would then be formed by a key IMDA reaction of 4.55. Diels-Alder precursor 
4.55 could be constructed via a Horner Wadsworth Emmons reaction with aldehyde 4.56, which 
in turn cold be formed from an Ireland-Claisen rearrangement of 4.57. Lastly, it was envisaged 
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that intermediate 4.57 could be formed by a hydrozirconation-transmetalation-addition sequence 
of propargyl alcohol 4.58 to aldehyde 4.59. 
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Scheme 4.9. Initial retrosynthetic approach to pleurotin. 
 The initial synthetic route used the known bromo-naphthylene 4.60 prepared from 1,5-
naphthalenediol in 5 steps.458 Lithium-halogen exchange of bromide 4.60 followed by 
formylation with N,N’-dimethylformamide gave the aldehyde 4.59 (Scheme 4.10). Propargyl 
alcohol 4.61 was subjected to hydrozirconation with Cp2ZrHCl followed by transmetalation to 
the corresponding organozinc species. Addition of the resulting alkenylzinc reagent to aldehyde 
4.59 afforded the allylic alcohol 4.62 in excellent yields. Acylation of alcohol 4.62 and 
enolization set the stage for a subsequent Ireland-Claisen rearrangement to produce carboxylic 
acid 4.63. Hydrogenation of the alkene 4.63, followed by reduction of the carboxylic acid, 
benzylation of the corresponding alcohol, and removal of the TBDPS protecting group gave 
alcohol 4.64 in excellent yield over 4 steps. Alcohol 4.64 was oxidized to the corresponding 
aldehyde and treated with phosphonate 4.65 in a HWE reaction to install the diene fragment of 
4.66. The naphthalene was oxidized to the naphthoquinone 4.66 using CAN to deliver the IMDA 
precursor 4.66. Gratifyingly, treatment of 4.66 with boron trifluoride etherate yielded the IMDA 
adduct that was subsequently reduced using sodium borohydride with an acidic workup to give 
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lactone 4.67 with unknown configuration at C10. To elucidate the configuration at C10, 4.67 was 
hydrogenated giving both reduction of the alkene and debenzylation in a single step. 
Epimerization of the intermediate alcohol at C14 under basic conditions afforded the 
thermodynamically favored trans lactone. The free alcohol was then acylated with p-
bromobenzoyl chloride yielding the crystalline product 4.68 whose structure was confirmed by 
X-ray crystallographic analysis. Unfortunately, the configuration at C10 was the opposite of the 
natural product and thus, a route to invert this stereogenic center was pursued.  
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Scheme 4.10. Early synthetic studies towards pleurotin. 
The strategy to invert the configuration was to first oxidize the side chain to the α,β-
unsaturated aldehyde 4.70 (Scheme 4.11). Based on the caged nature of the structure, it was 
proposed that a reduction from the least hindered face would yield the desired stereochemistry at 
C10.  
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Scheme 4.11. Synthetic approach to side chain inversion. 
Unfortunately, direct one step oxidations of 4.69 to the α,β-unsaturated aldehyde 4.70 
were unsuccessful (Scheme 4.12). Instead a stepwise approach was developed beginning with 
Dess-Martin periodinane (DMP) oxidation to the aldehyde 4.72. α-Selenation of 4.72 and 
oxidative elimination afforded the undesired α,β-unsaturated aldehyde isomer 4.73. 
Unfortunately, attempts to isomerize 4.73 to 4.70 did not yield the desired product.  
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Scheme 4.12. Attempts to invert C10 stereochemistry.  
An alternative alcohol elimination/alkene isomerization approach was also investigated 
(Scheme 4.13). Unfortunately, while the elimination of the alcohol 4.69 proceeded smoothly to 
afford alkene 4.74 in 75% yield over two steps, all attempts to isomerize the alkene to form the 
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tetrasubstituted exocyclic olefin failed. Acid mediated conditions resulted in isomerization of the 
alkene into the ring to give 4.75 and no reaction was observed when 4.74 was subjected to an 
isomerization with Grubbs catalyst. Given the numerous difficulties encountered in attempts to 
invert the configuration of the C10 stereocenter, the first-generation route was deprioritized and a 
second-generation approach was developed. 
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Scheme 4.13. Attempted alkene isomerization.  
The second-generation retrosynthetic approach retains the late stage reductive 
etherification reaction to form pleurotin from intermediate 4.54 (Scheme 4.14). To circumvent 
the problematic inversion of the C10 stereocenter in the first approach, a key displacement of 
alcohol 4.76 could be implemented to install the inverted side chain. The tetracyclic core 4.76 
would be formed via an IMDA reaction in an analogous manner to the previous route. It was 
envisioned that the Diels-Alder precursor 4.77 could be formed via a 
hydrozirconation/transmetalation of alkyne 4.79 and addition to aldehyde 4.78.  
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Scheme 4.14. 2nd generation retrosynthetic approach to pleurotin. 
The 4-step synthesis of aldehyde 4.78 began with a Dötz benzannulation of 
triisopropylsilyl (TIPS) protected 1-pentynol 4.81 and the chromium Fischer carbene 4.80 
followed by methylation of the naphthol intermediate to produce 4.82 (Scheme 4.15). TBAF 
desilylation of 4.82 and Swern oxidation of the intermediate alcohol gave aldehyde 4.78 in 
excellent yields.  
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Scheme 4.15. Synthesis of naphthalene 4.78. 
 The synthesis of alkyne fragment 4.86 was accomplished in 4 steps and began with the 
silylation of propargyl alcohol (4.83). Hydrozirconation/iodination of alkyne 4.61 afforded the E-
vinyl iodide that was coupled to TMS-acetylene using Sonogashira coupling conditions to give 
alkyne 4.85. Desilylation of alkyne 4.85 afforded the desired enyne 4.86.  
 111 
OH
TBDPSCl
Im
DMF
OTBDPS
Cp2ZrHCl, CH2Cl2
I2, THF
OTBDPSI
TMS
Pd(PPh3)4, CuI
i-Pr2NH, 0 °C
quant. 90% quant.
OTBDPS
TMS
K2CO3
MeOH, rt
OTBDPS
quant.
4.83 4.61 4.84
4.85 4.86
 
Scheme 4.16. Synthesis of enyne fragment 4.86. 
 Hydrozirconation of alkyne 4.86 followed by transmetalation, and addition to aldehyde 
4.78 went smoothly in 89% to give the diene 4.87 (Scheme 4.17). Benzylation of the allylic 
alcohol 4.87 and oxidation using CAN gave key napthoquinone 4.88 setting the stage for pivotal 
IMDA reaction. In contrast to the IMDA of the previous route, the Lewis acid catalyzed reaction 
was unsuccessful. Instead, the IMDA was accomplished thermally by heating 4.88 at 200 °C for 
3 h to afford the product 4.90 as a single diastereomer in excellent yields. One-pot hydrogenation 
of the alkene and debenzylation gave alcohol 4.91. Acylation of 4.91 produced the crystalline 
ester 4.92 that was unambiguously assigned by X-ray analysis. 
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Scheme 4.17. Synthesis of alcohol 4.91. 
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 Unfortunately, all attempts to install the side chain on 4.76 or cyclize the 
oxacycloheptane ring were unsuccessful, forcing alteration of the synthetic strategy to install and 
invert the C10 side chain in a third generation approach (Scheme 4.18).  
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Scheme 4.18. Attempts at installation of the side chain at C10. 
4.2 RESULTS AND DISCUSSION 
4.2.1 Retrosynthetic analysis 
Given the difficulties encountered in inverting the C10 configuration in the presence of the C9 
methyl group, we envisioned that we could initially develop a synthetic route to 9-
desmethylpleurotin and subsequently develop a late stage introduction of the methyl group at C9 
(Figure 4.3).  
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Figure 4.3. Proposed model system of pleurotin, 9-desmethylpleurotin. 
Our third generation retrosynthesis of 9-desmethylpleurotin is outlined in Scheme 4.19. Our 
approach retains the late stage reductive etherification to close the oxacycloheptane ring. We 
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expect lactone epimerization will deliver the desired trans lactone from 4.93. Inversion of the 
C10 stereocenter leads retrosynthetically to Diels-Alder precursor 4.94. In the absence of the C9 
methyl group, we envisioned a more facile inversion of the C10 configuration in 4.94. 
Analogous to previous routes, we propose that 4.94 can be formed via an IMDA reaction from 
the diene naphthaquinone 4.95. The naphthalene 4.95 would be constructed using a Dötz 
benzannulation of the chromium Fischer carbene 4.80 and lactone 4.97. We envisioned that 
butyrolactone 4.97 would serve as an easy handle for the construction of the diene fragment in 
4.95. 
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Scheme 4.19. Retrosynthetic approach to 9-desmethylpleurotin. 
4.2.2 Approach 1: Synthesis of γ-Butyrolactone 4.97 
Our initial approach to synthesize lactone fragment 4.97 was based on a direct α-alkylation of 
the γ-butyrolactone (4.100) (Scheme 4.20). Synthesis of bromide 4.99 began with the TMS 
protection of the dianaion of 1-butynol (4.98), mild hydrolysis of the TMS ether, and a 
subsequent Appel bromination.459-461 Many reaction conditions (solvents, temperature, times, 
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bases, additives) were screened for the alkylation of 4.100 including the use of the iodide as the 
coupling partner. Unfortunately, all conditions resulted in little or no formation of the desired 
product. Enyne 4.102 was identified as the main byproduct in many cases. At best, the desired 
product 4.101 was formed in 20% yield along with elimination byproduct 4.102 using 
LDA/HMPA enolization conditions. However, attempts to scale up this reaction were met with 
even lower yields of 4.101.  
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Scheme 4.20. Initial synthetic route to alkyne 4.97. 
 Given the difficulty in obtaining meaningful quantities of lactone 4.101, we investigated 
alternate approaches to form lactone 4.97. Hoping to circumvent the issue of base mediated 
elimination that dominated the alkylation of 4.100, we designed a new approach using activated 
lactone 4.103 (Scheme 4.21). We reasoned that alkylation of 4.103 should be favored using a 
mild base, hopefully avoiding the undesired elimination pathway that predominated under 
strongly basic conditions. The activated lactone 4.103 was rapidly synthesized by acylation of 
4.100 with dimethyl carbonate.462 With facile access to 4.103 we began to investigate alkylation 
conditions. After screening a variety of alkylating agents, we determined that the tosylate 4.104 
was superior over the corresponding mesylate, bromide, or iodide in both synthetic tractability as 
well as performance in the reaction. Additionally, after screening a number of bases, solvents, 
and additives, it was determined that K2CO3, NaI in DMF at 60 °C proved optimal; however, on 
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scale the maximum yield was 30%. Even with a low yield we had enough of this material to test 
subsequent transformations in the synthesis. The alkylated product 4.105 was subjected to 
Krapcho decarboxylation conditions to give our desired lactone 4.97.  
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Scheme 4.21. Synthesis of alkyne 4.97. 
4.2.3 Approach 1: Investigation of the Key Dötz Benzannulation and IMDA Sequence 
Using Lactone 4.97 
The chromium Fischer carbene 4.80 was prepared using a one-pot literature protocol starting 
with lithium-halogen exchange of 2-bromoanisole (4.106), addition of the resulting anion to 
chromium hexacarbonyl, and methylation using Meerwein’s reagent (Scheme 4.22).463 
Subjecting lactone 4.97 to the Dötz benzannulation yielded naphthalene 4.96 in a modest yield of 
41%. Attempts to optimize this reaction were unsuccessful in increasing the overall yield past 
41% and the reaction profile was generally complex. Other methylating reagents such as 
dimethyl sulfate resulted in multiple methylations of the naphthalene substrate 4.96. Reduction 
of the lactone 4.96 to the corresponding lactol worked well using DIBAL-H;464 however, the 
subsequent HWE reaction with phosphonate 4.65 proved low yielding, forming diene 4.107 in 
30% over 2 steps.465  
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Scheme 4.22. Synthesis of diene 4.107. 
4.2.4 Approach 2: Synthesis of γ-Butyrolactone 4.110.  
We reasoned that the presence of the free primary alcohol could be interfering in the diene 
formation sequence, contributing to the low isolated yield of 4.107. Therefore, we decided to 
protect it prior to installation of the diene fragment. In order to introduce a protecting group, we 
needed to redesign the lactone precursor. In this second-generation approach, we envisioned that 
4.95 could be synthesized from the nitrile 4.108 (Scheme 4.23). We reasoned that using a smaller 
activating substituent on the γ-butyrolactone would increase yields by decreasing steric 
hindrance in the enolate formation and alkylation. The nitrile was an ideal choice since it is 
smaller in size compared to the methyl ester, electron-withdrawing, and can be converted to the 
necessary aldehyde by treatment with DIBAL-H. Analogous to the previous routes, naphthalene 
4.108 could be synthesized via a Dötz benzannulation of carbene 4.80 and alkyne 4.109. Alkyne 
4.109 can be prepared from the lactone 4.110.  
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Scheme 4.23. 2nd Generation retrosynthesis of 9-desmethylpleurotin. 
  An extensive search of the literature yielded only three methods for the synthesis of α-
cyanosubstituted γ-butyrolactones.466-468 Unfortunately, these literature protocols did not appear 
amenable to a scalable synthesis of this building block due to low yields or safety concerns. 
Instead, we discovered a method developed by Rao et al. for the rearrangement of cyclopropane-
1,1-dicarboxylic acid 4.111 with triethylammonium bromide to deliver 2-carboxy-γ-
butyrolactone 4.112 (Scheme 4.24).469 Encouraged by Rao’s work we wanted to see if this 
transformation could be applied to a cyano-substituted cyclopropane 4.113. 
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Scheme 4.24. Proposed synthesis of cyano-substituted lactone. 
 The synthesis of cyclopropane 4.113 began with alkylation of ethylcyanoacetate (4.114) 
with 1,2-dibromoethane to give cyclopropane ester 4.115 (Scheme 4.25). Saponification of ester 
4.115 afforded carboxylic acid 4.113 that, gratifyingly, rearranged upon treatment with 
triethylammonium bromide to give the desired lactone 4.110. This reaction sequence is highly 
scalable and has been carried out on upwards of 370 g scale with no incident. This sequence is 
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also appealing as it does not require any chromatography, and the only purification step is a 
distillation to purify lactone 4.110. Additionally, we demonstrated that the triethylammonium 
bromide can be recovered after lactonization and recycled up to 7 times with no detectable loss 
in yield. We were also interested in determining if this rearrangement could be carried out 
catalytically in the presence of a metal ion or Lewis acid. After screening numerous additives, it 
was found that 5 mol% of either sodium iodide or magnesium iodide effectively promoted the 
rearrangement. A 10 g scale test reaction with NaI gave 77% isolated yield of the desired lactone 
4.110. 
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Scheme 4.25. Synthesis of lactone 4.110. 
 With ample amounts of lactone 4.110 in hand, alkylation of 4.110 with tosylate 4.104 
proceeded smoothly (Scheme 4.26). On large scale (100 g), mechanical stirring in the lactone 
alkylation greatly improved the overall yield of the sequence. Lactone hydrolysis and 
decarboxylation were screened using a number of bases solvents and temperatures. When lithium 
or sodium hydroxide were used for the hydrolysis of lactone 4.116, the corresponding 
decarboxylation required high temperatures (~150 °C) and resulted in low yields and mixtures of 
products. We were delighted to find that when cesium hydroxide was used in the hydrolysis, the 
corresponding decarboxylation occurred under milder conditions in a mixture of THF and 
toluene to afford highly pure alcohol 4.118. Lastly, the benzylation of the primary alcohol 
afforded the desired intermediate 4.119, which was purified using the first chromatographic 
purification of the synthesis.  
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Scheme 4.26. Synthesis of alkyne 4.119. 
4.2.5 Approach 2: Investigation of the Key Dötz Benzannulation and IMDA Sequence 
Using Nitrile 4.119 
After successfully preparing the alkyne 4.119, we shifted our attention to the Dötz 
benzannulation and the IMDA (Scheme 4.27). Carbene 4.80 was combined with the previously 
prepared alkyne 4.119 and heated at 50 °C for 14 h to give a naphthol intermediate that was 
subsequently methylated with methyl iodide in DMF to give 4.120. Performing the methylation 
in THF or acetone led to incomplete conversion and lower yields of the methylation product. The 
DIBAL-H reduction of nitrile 4.120 to the corresponding aldehyde was sluggish at low 
temperatures and required warming to room temperature to give even modest conversion. 
Interestingly, the reduction proved highly sensitive to the solvent in the commercial DIBAL 
solution. A 1.2 M solution of DIBAL in toluene was far superior to a 1.0 M solution of DIBAL 
in hexanes. The intermediate aldehyde 4.121 was treated with phosphorus ylide 4.122 in a Wittig 
olefination to give diene 4.123 in modest yields.470 Additionally, this transformation has also 
been accomplished under HWE conditions using phosphonate 4.65 with LiOH in THF to give 
the diene product in comparable yields. Oxidation of the naphthalene 4.123 with CAN to the 
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naphthoquinone yielded the Diels-Alder precursor 4.124.471 Unfortunately, the yields for the 
CAN oxidation dropped significantly on scales larger than 1 g. Encouraged by the initial work on 
this transformation (vide infra), 4.124 was treated with boron trifluoride etherate at low 
temperature to yield Diels-Alder product 4.126 as a single diastereomer in modest yields. Using 
the TBS or TBDPS protected alcohol in the IMDA reaction resulted in low yields (~20%) of 
only the desilylated product. Additionally, the yields were much lower in other solvents such as 
THF or toluene.   
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Scheme 4.27. Dötz and IMDA reaction sequence. 
Given the stereochemical outcome of the Diels-Alder reaction to 4.126 we propose that 
the IMDA proceeds via the endo-transition state 4.125 with the side chain placed away from the 
plane of the dienophile, thus minimizing any destabilizing A1,3 interactions (Figure 4.4). This 
result is similar to previous results on related systems such as 4.67. The alternate endo-transition 
state 4.127 is destabilized by an A1,3 strain between the side chain R and the plane of the 
diene, resulting in  a 2-3 kcal/mol destabilization  versus 4.125.472   Houk and coworkers used
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DFT calculations to study the effect of BF3 on the rate and stereoselectivity of IMDA 
reactions of cycloalkenones, and have shown, in their system, that the endo pathway is 
favored over the exo pathway by ~2.8 kcal/mol.473 Furthermore, both exo-transition states 
4.128 and 4.129 contain a combination of destabilizing A1,3 interactions. Therefore, we 
propose that all alternative transition states are higher in energy than 4.125.  
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Figure 4.4. Diels-Alder transition state models. 
The Diels-Alder product 4.126 was subjected to one-pot hydrogenation conditions to 
reduce the alkene and cleave the benzyl ether to give the alcohol 4.130 (Scheme 4.28). A 
subsequent selective reduction of the ketone and acidic workup yielded lactone 4.131. The 
selectivity for cis-lactone formation is governed by hydride addition to the more accessible 
convex face. Interestingly, if this sequence is used in the reverse order, the alkene is prone to a 
base mediated conjugation with the ester. A conjugate reduction of the resulting α,β-unsaturated 
ester can be accomplished using NiBH4 and affords the thermodynamically favored trans-fused 
lactone.  
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Scheme 4.28. Synthesis of lactone 4.131. 
4.2.6 End Game: Progress Toward the C10 Inversion Sequence and Preliminary 
Investigation Into the Reductive Etherification to Deliver the Hexacyclic Core of 9-
Desmethylpleurotin  
With the tetracyclic core successfully synthesized, we turned our attention to the challenging 
C10 inversion sequence. We intended to employ the groups’ first-generation strategy to 
accomplish the inversion by converting the alcohol 4.132 to the enal 4.133 followed by a 
selective reduction to give 4.134 (Scheme 4.29).  
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Scheme 4.29. Proposed inversion of side chain configuration. 
 Our initial studies were performed on the undesired C14 epimer, which we reasoned 
could be epimerized at a later stage to the desired trans-configuration. The inversion of the C10 
side chain on the undesired C14 epimer began with a Dess-Martin oxidation of the alcohol 4.131 
to give the aldehyde 4.135 in excellent yields (Scheme 4.30). Selenation under standard 
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conditions using PhSeCl and acid resulted in a complex mixture of products. However, we 
discovered a mild enamine catalyzed selenation using L-prolinamide and N-
(phenylseleno)phthalimide (PhthSePh) to give selenide 4.136 in 72% yield as a 4:1 mixture of 
diastereomers.474 Using DL-proline affords the same mixture of diastereomers in similar yields 
indicating that this transformation is highly substrate controlled. Next, several oxidants were 
screened for the elimination of selenide 4.136, including sodium periodate, tetrabutyl ammonium 
periodate (TBAIO4), and manganese monoperphthalate (MMPP).475 The sodium periodate 
reaction proved optimal, proceeding with the cleanest reaction profile. The intermediate enal 
4.137 was highly prone to isomerization; therefore, this product was directly subjected to a 
Luche reduction to give allylic alcohol 4.138.  
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Scheme 4.30. Progress towards the inversion of the C10 configuration. 
 While attempts to reduce 4.138 using Pd/C resulted in a mixture of C16 benzylic 
cleavage products, we found that hydrogenation using Crabtree’s catalyst gave the desired 
saturated alcohol 4.140 by crude 1HNMR and LCMS. The crude alcohol products were directly 
subjected to reductive etherification conditions using TMSOTf and triethylsilane and a HRMS 
match by LCMS indicated formation of the desired product 4.141 (Scheme 4.31).476 
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Scheme 4.31. Reduction of allylic alcohol 4.139 and reductive etherification to 4.142. 
4.2.7 Future Directions  
Following the reductive etherification, we plan to epimerize at C14, demethylate the phenol, and 
oxidize to the quinone to give 9-desmethylpleurotin (Scheme 4.32).   
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Scheme 4.32. Proposed endgame for the synthesis of 9-desmethylpleurotin. 
After the completion of 9-desmethylpleurotin, we propose that we can perform a late 
stage methylation of aldehyde 4.144 (Scheme 4.33). Using the proposed reductive 
etherification/demethylation/oxidation sequence outlined in Scheme 4.32 we can arrive at the 
desired pleurotin. 
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Scheme 4.33. Proposed synthesis of pleurotin by late stage methylation. 
4.3 CONCLUSIONS 
We have developed a third generation approach to pleurotin and a first generation approach to 9-
desmethylpleurotin. This strategy utilizes a key IMDA reaction to afford the tetracyclic core of 
pleurotin and sets three of the required seven stereocenters. Progress has been made toward 
completing the challenging inversion sequence to correct the C10 side chain configuration that 
proved a significant synthetic challenge in previous routes. We have demonstrated that the 
saturated alcohol side chain with the incorrect C10 configuration can be oxidized to the enal and 
then subsequently reduced to the allylic alcohol. Synthetic investigations to reduce the allylic 
alcohol 4.138 to the saturated alcohol 4.140 and complete the inversion sequence were 
promising. Upon completion of 9-desmethylpleurotin, we can potentially access pleurotin via a 
late stage methylation.  
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5.0  EXPERIMENTAL PART 
5.1 GENERAL EXPERIMENTAL 
Moisture and air-sensitive reactions were performed under N2 or Ar atmosphere and glassware 
used for these reactions was flamed dried and cooled under N2 or Ar prior to use. All moisture 
sensitive reactions were performed using syringe-septum cap techniques under an atmosphere of 
dry N2 or Ar. Reactions carried out below 0 °C employed a dry ice/acetone bath or a cryocool 
and an isopropanol bath. THF and Et2O were distilled from sodium/benzophenone ketyl. DMF 
and CH2Cl2 were distilled from CaH2. Anhydrous 1,4-dioxane, dimethylsulfoxide, and 
dimethylformamide were purchased from Acros (Sure/Seal bottle) and used as received. Et3N 
was distilled from CaH2 and stored over KOH. Toluene was purified by passage through an 
activated alumina filtration system. Melting points were determined using a Mel-Temp II 
instrument and are not corrected. Infrared spectra were determined using a Smiths Detection 
IdentifyIR FT-IR spectrometer. High-resolution mass spectra were obtained on a Micromass UK 
Limited, Q-TOF Ultima API, Thermo Scientific Exactive Orbitrap LC-MS. 1H and 13C NMR 
spectra were obtained on Bruker Advance 300 MHz, 400 MHz, 500 MHz, 600 MHz, or 700 
MHz instruments. Chemical shifts (δ) were reported in parts per million with the residual solvent 
peak used as an internal standard, δ 1H/13C (Solvent): 7.26/77.00 (CDCl3); 2.05/29.84 (acetone-
d6); 2.50/39.52 (DMSO-d6), 3.31/49.00 (CD3OD); and are tabulated as follows: chemical shift, 
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multiplicity (s = singlet, bs = broad singlet, d = doublet, bd = broad doublet, t = triplet, app t = 
apparent triplet, q = quartet, m = multiplet), number of protons, and coupling constant(s). 13C 
NMR spectra were obtained at 75 MHz, 100 MHz, 125 MHz, 150 MHz, or 175 MHz using a 
proton-decoupled pulse sequence and are tabulated by observed peak. 19F NMR spectra were 
obtained at 376 MHz or 470 MHz using a proton-decoupled pulse sequence, are tabulated by 
observed peak, and are uncorrected. CDCl3 was filtered through dried basic alumina prior to use. 
Thin-layer chromatography was performed using pre-coated silica gel 60 F254 plates (EMD, 250 
µm thickness) and visualization was accomplished with a 254 nm UV light and by staining with 
a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 
g of (NH4)6Mo7O24•4H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution) or a 
KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH solution). 
Chromatography on SiO2 (Silicycle, Silia-P Flash Silica Gel or SiliaFlash® P60, 40-63 µm) was 
used to purify crude reaction mixtures. Automated column chromatography was done using an 
Isco Combiflash Rf. Concentrating under reduced pressure refers to the use of rotary evaporator 
connected to a PIAB Lab Vac H40 to remove solvent.  Final products were of >95% purity as 
analyzed by RP HPLC (Alltech Prevail C-18, 100 × 4.6 mm, 1 mL/min, CH3CN, H2O and 0.1% 
TFA) with UV (210, 220 and 254 nm), ELS (nebulizer 45 °C, evaporator 45 °C, N2 flow 1.25 
SLM), and MS detection using a Thermo Scientific Exactive Orbitrap LC-MS (ESI positive). All 
other materials were obtained from commercial sources and used as received.  
Safety Note: All organic azides and azide waste products should be considered toxic as 
well as potentially explosive and must be handled and stored with care. Avoid using halogenated 
solvents when performing reactions involving sodium azide, in addition to using halogenated 
solvents in reaction workup. Avoid quenching/manipulating/treating sodium azide reactions with 
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acid, as generation of trace amounts of hydrazoic acid (HN3) may result in an explosion. In 
general, a safety shield must be used when conducting reactions involving either sodium azide or 
organic azide derivatives. 
5.2 CHAPTER 1 EXPERIMENTAL PART 
N N
Cl
Cl Cl
O  
1.10 
2,4,6-Trichloropyrimidine-5-carbaldehyde (1.10).144 N,N-Dimethylformamide (4.85 
mL, 62.5 mmol) was added dropwise to phosphorus oxychloride (25.1 mL, 269 mmol) at 0 ºC. 
Barbituric acid (1.9, 5.00 g, 62.5 mmol) was then added portion-wise over 1 h, and the resulting 
suspension was stirred in a pre-equilibrated oil bath at 90 ºC for 2 d. The reaction mixture was 
concentrated under reduced pressure and a H2O-ice mixture (50 mL) was slowly added to the 
residue in an ice bath. The yellow precipitate that formed was filtered, washed with a H2O-ice 
mixture (3 x 10 mL), dissolved in CH2Cl2 (100 mL) and washed with brine (30 mL) and satd. 
aqueous NaHCO3 (30 mL). The organic extract was dried (MgSO4) and concentrated under 
reduced pressure to give 1.10 (4.70 g, 22.3 mmol, 57%) as a pale yellow solid: 1H NMR (400 
MHz, CDCl3) δ 10.40 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 184.6, 164.0, 161.5, 160.9, 159.9, 
122.9.  
N
N
Cl
Cl N
N
 
 129 
1.8a 
4,6-Dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (1.8a).144 A solution of 2,4,6-
trichloropyrimidine-5-carbaldehyde (1.10, 1.00 g, 4.73 mmol) in dry THF (10 mL) at -78 ºC was 
treated with a solution of methyl hydrazine (0.26 mL, 4.73 mmol) in dry THF (2 mL) dropwise 
followed by Et3N (2.0 mL, 14.2 mmol). The resulting mixture was stirred for 1.5 h at -78 ºC, 
warmed to rt, and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 8:2) to give 1.8a (0.570 g, 2.81 mmol, 59 %) as a 
colorless solid: Mp 88.9-90.9 °C; IR (neat) 3110, 1588, 1545, 1371, 1299, 1127 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.12 (s, 1 H), 4.10 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 156.5, 155.4, 
154.2, 132.3, 112.6, 34.6. 
N
N
Cl
N
N
Cl
 
1.8b 
1-(t-Butyl)-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.8b).144 A solution of 2,4,6-
trichloropyrimidine-5-carbaldehyde (1.10, 1.00 g, 4.73 mmol) in dry CH2Cl2 (20 mL) at -78 ºC 
under Ar was treated with a solution of t-butyl hydrazine hydrochloride (0.631 g, 4.73 mmol) 
and Et3N (2.0 mL, 14.2 mmol) in dry CH3CN (30 mL) dropwise. The mixture was stirred for 2 h 
at -78 °C where analysis by TLC (hexanes/EtOAc, 4:1) indicated the SM was consumed. SiO2 
was added and the reaction was concentrated under reduced pressure and was purified by 
chromatography on SiO2 (solid load, hexanes/EtOAc, 8:1) to give 1.8b (0.937 g, 3.82 mmol, 
81%) as a colorless solid: IR (neat) 3118, 2984, 2934, 1582, 1525, 1320, 1230, 1208, 1152 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1 H), 1.80 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.1, 
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155.0, 153.6, 130.8, 113.7, 61.9, 29.0; HRMS (ESI) m/z calcd for C9H10Cl2N4 ([M+H]+) 
245.0361, found 245.0357. 
N
N
NH
Cl N
N
 
1.11a 
6-Chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11a). To a solution 
of 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (1.8a, 0.300 g, 1.48 mmol) in dry THF 
(15 mL) was added methylamine hydrochloride (0.110 g, 1.55 mmol), followed by freshly 
distilled Et3N (1.0 mL, 7.38 mmol). The reaction mixture was stirred at rt for 2 d, concentrated 
under reduced pressure, and the residue was dissolved in EtOAc (100 mL), washed with H2O (3 
x 75 mL), dried (MgSO4) and concentrated under reduced pressure. The crude product was 
purified by chromatography on SiO2 (hexanes/EtOAc, 2:1) to give 1.11a (0.267 g, 1.35 mmol, 
91%) as a colorless solid: Mp 239.3-240.4 °C; IR (neat) 3230, 3105, 1614, 1579, 1316, 1128, 
930 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.70 (bs, 1 H), 8.03 (s, 1 H), 3.83 (s, 3 H), 2.95 (d, J 
= 4.4 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 157.4, 157.2, 153.3, 131.6, 99.3, 33.7, 27.1; 
HRMS (ESI) m/z calcd for C7H8ClN5 ([M+H]+) 198.0546, found 198.0551. 
N
N
NH2
Cl N
N
 
1.11b 
6-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11b). Ammonia gas was 
bubbled for 15 min through a suspension of 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-
d]pyrimidine (1.8a, 0.300 g, 1.48 mmol) in dry THF (48 mL). The mixture was stirred at rt for 8 
h, concentrated under reduced pressure, and the residue was dissolved in EtOAc (30 mL), 
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washed with H2O (3 x 15 mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude product was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 to EtOAc) to give 
1.11b (0.220 g, 1.20 mmol, 81%) as a colorless solid: Mp 265-275 °C; IR (neat) 3308, 3099, 
2920, 1657, 1599, 1561, 1187 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 8.24 (bs, 1 H), 8.11 (bs, 1 
H), 8.05 (s, 1 H), 3.83 (s, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 158.6, 157.3, 153.9, 132.1, 
98.9, 33.6; HRMS (ESI) m/z calcd for C6H6ClN5 ([M+H]+) 184.0390, found 184.0381. 
N
N
NH2
N
N
Cl
 
1.11c 
1-(t-Butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11c). Ammonia gas was 
bubbled through a suspension of 1-(t-butyl)-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.8b, 
0.800 g, 3.26 mmol) in THF (100 mL) for 20 min. A white precipitate started to form after 
several minutes and the resulting mixture was stirred at rt for 24 h, concentrated under reduced 
pressure, and the residue was dissolved in EtOAc (250 mL), washed with H2O (3 x 75 mL), dried 
(MgSO4) and concentrated under reduced pressure to give 1.11c (0.740 g, 3.19 mmol, 98%) as a 
colorless solid which was used in the next step without further purification: Mp 272-274 °C; IR 
(neat) 3297, 3135, 2971, 2932, 1644, 1592, 1469, 1366, 1236, 1171 cm-1; 1H NMR (400 MHz, 
DMSO-d6) δ 8.17 (bs, 1 H), 8.03 (s, 2 H), 1.65 (s, 9 H); 13C NMR (100 MHz, DMSO-d6) δ 
158.7, 156.0, 153.5, 130.6, 100.3, 59.6, 28.7; HRMS (ESI) m/z calcd for C9H12ClN5 ([M+H]+) 
226.0859, found 226.0882. 
N
N
NH
N
N
Cl
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1.11d 
1-(t-Butyl)-6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11d). A 
solution of 1-(t-butyl)-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.8b, 0.800 g, 3.26 mmol) in 
THF (24 mL) at rt under Ar was treated with methylamine hydrochloride (0.230 g, 3.43 mmol) 
and Et3N (2.30 mL, 16.3 mmol). The reaction mixture was stirred at rt for 24 h, concentrated 
under reduced pressure, dissolved in EtOAc (75 mL), washed with H2O (3 x 30 mL), dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified by chromatography 
on SiO2 (hexanes/EtOAc, 2:1) to give 1.11d (0.700 g, 2.93 mmol, 90%) as a colorless solid: Mp 
160.7-161.9 °C; IR (neat) 3236, 3133, 2947, 1579, 1428, 1361, 1310, 1282, 1124, 1075 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 8.63 (bd, J = 4.4 Hz, 1 H), 8.02 (s, 1 H), 2.93 (d, J = 4.4 Hz, 3 H), 
1.65 (s, 9 H); 13C NMR (100 MHz, DMSO-d6) δ 157.3, 156.1, 152.8, 130.0, 100.7, 59.7, 28.7, 
27.0; HRMS (ESI) m/z calcd for C10H14ClN5 ([M+H]+) 240.1016, found 240.1006. 
N
N
NH
Cl N
N
Br
 
1.7a 
3-Bromo-6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7a). A 
mixture of 6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11a, 0.260 g, 1.31 
mmol) and Br2 (0.21 mL, 3.92 mmol) in H2O (90 mL) was stirred at rt for 1 h and heated at 100 
°C for 2 h. The reaction mixture was cooled to rt and extracted with EtOAc (3 x 75 ml), washed 
with 5% aqueous NaHSO3 solution (100 mL) and brine (75 mL), dried (MgSO4) and 
concentrated under reduced pressure to give 1.7a (0.318 g, 1.15 mmol, 88%) as a colorless solid, 
which was used in the next step without further purification: Mp 246.9-248.0 °C; IR (neat) 3407, 
2939, 1606, 1567, 1325, 1200 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.14 (bs, 1 H), 3.94 (s, 3 H), 
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3.20 (d, J = 4.8 Hz, 3 H); 13C NMR δ 159.3, 157.4, 154.8, 116.8, 99.3, 34.4, 28.1; HRMS (ESI) 
m/z calcd for C7H7BrClN5 ([M+H]+) 275.9652, found 275.9652. 
 
N
N
NH2
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1.7b 
3-Bromo-6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7b). A mixture 
of 6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11b, 0.196 g, 1.07 mmol) and Br2 
(0.23 mL, 4.27 mmol) in H2O (5 mL) was stirred at rt for 1 h and at 100 °C for an additional 1 h. 
The reaction mixture was cooled to rt, extracted with EtOAc (3 x 15 mL), and washed with 5% 
aqueous NaHSO3 solution (10 mL) and brine (15 mL). The organic layer was dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:1) to give 1.7b (0.113 g, 0.431 mmol, 40%) as a colorless solid: Mp 285-295 
°C; IR (neat) 3451, 3282, 3125, 1586, 1552, 1248, 1189 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
8.53 (bs, 1 H), 7.28 (bs, 1 H), 3.81 (s, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 157.9 (2 C), 
154.8, 117.3, 98.5, 34.0; HRMS (ESI) m/z calcd for C6H6ClN5 ([M+H]+) 262.9573, found 
262.9593. 
N
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1.7c 
3-Bromo-1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7c). A mixture 
of 1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.11c, 0.100 g, 0.440 mmol) and 
Br2 (50 µL, 0.890 mmol) in H2O (5 mL) was stirred at rt for 1 h and then at 100 °C for 30 min. In 
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order to increase the solubilizing power of the reaction mixture, EtOAc (3 mL) was added, and 
the resulting solution was heated at reflux for an additional 15 min. The two layers were 
separated and the aqueous phase was extracted with EtOAc (3 x 7.5 mL). The combined organic 
extracts were washed with 5% aqueous NaHSO3 solution (10 mL), brine (15 mL), dried (MgSO4) 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (CH2Cl2 to CH2Cl2:EtOAc, 1:1) to give 1.7c (0.110 g, 0.371 mmol, 84%) as a light yellow 
solid: Mp 225-226°C; IR (neat) 3450, 3282, 2971, 2919, 2718, 1651, 1634, 1584, 1543, 1461, 
1234, 1174, 1131 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.05 (bs, 2 H), 1.74 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 157.6, 157.1, 154.7, 115.8, 100.1, 61.9, 29.1; HRMS (ESI+) m/z calcd for 
C9H11BrClN5 ([M+H]+) 303.9965, found 303.9983. 
N
N
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1.7d 
3-Bromo-1-(t-butyl)-6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.7d). A mixture of 1-(t-butyl)-6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.11d, 0.120 g, 0.500 mmol) and Br2 (50 µL, 1.00 mmol) in H2O (3 mL) was stirred at rt for 1 h, 
treated with EtOAc (1 mL), and heated at reflux for an additional 1 h.  Additional EtOAc (3 mL) 
was added and the reaction mixture was heated at reflux for 15 min. Analysis by TLC 
(hexanes/EtOAc, 2:1) indicated the SM was consumed, the layers were separated and the 
aqueous phase was extracted with EtOAc (3 x 8 mL). The combined organic layers were washed 
with 5% aqueous NaHSO3 solution (10 mL), brine (15 mL), dried (MgSO4) and concentrated 
under reduced pressure. The crude residue was purified by automated chromatography on SiO2 
(12 g column, liquid load CH2Cl2, stepwise gradient, 100% hexanes to 100% EtOAc over 15 
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min) to give 1.7d (0.130 g, 0.355 mmol, 71%) as a colorless solid: Mp 106.8-108.4 °C; IR (neat) 
3413, 2982, 2934, 1609, 1553, 1364, 1322, 1217, 1133 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.12 
(bs, 1 H), 3.18 (d, J = 4.8 Hz, 3 H), 1.73 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 157.3, 
154.2, 114.9, 100.2, 61.7, 29.1, 27.9; HRMS (ESI) m/z calcd for C10H13BrClN5 ([M+H]+) 
318.0121, found 318.0110. 
N
N
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N
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PP1 
1-(tert-Butyl)-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1).1,2,3 A 
solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II)-CH2Cl2 adduct (0.0182 
g, 0.0200 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was treated with 3-bromo-
1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7c, 0.0750 g, 0.250 mmol), 
Cs2CO3 (0.122 g, 0.370 mmol) and 1-naphthylboronic acid (0.0500 g, 0.300 mmol). The flask 
was sealed and the reaction mixture was stirred at 100 °C for 2 d, filtered through Celite, and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 6:1) to give a mixture of 1-(t-butyl)-6-chloro-3-(naphthalen-1-yl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine and starting material (3:1, 0.0436 g) as an off-white solid. 
A solution of this mixture (0.0400 g, 0.0825 mmol), 5% Pd/C (1.08 g, 0.460 mmol) and 
NH4HCO2 (0.0430 g, 0.680 mmol) in MeOH (8 mL) was stirred at rt for 10 min, purged with H2 
for 30 min and stirred under and atmosphere of H2 (balloon) for 26 h. The reaction mixture was 
filtered through Celite, washed (CH2Cl2 (10 mL)), and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 4:1) to give PP1 
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(0.00594 g, 0.0187 mmol, 7.6% (2 steps), 95% purity by LC-MS) as a colorless solid: 1H NMR 
(400 MHz, CDCl3) δ 8.39 (bs, 1 H), 7.98 (d, J = 8.0 Hz, 1 H), 7.94 (t, J = 6.6 Hz, 1 H), 7.67 (d, J 
= 6.6 Hz, 1 H), 7.61 (d, J = 8.0 Hz, 1 H), 7.85-7.49 (m, 2 H), 5.00 (bs, 2 H), 1.89 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 157.6, 154.7, 153.9, 134.0, 131.8, 130.6, 129.6, 128.4, 128.4, 127.1, 
126.5, 125.6, 125.5, 60.6, 29.3; HRMS (ESI) m/z calcd for C19H19N5 ([M+H]+) 318.1719, found 
318.1698. 
N
N
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1.13a 
1-(tert-Butyl)-N-methyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.13a).129 To a solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 
adduct (0.0174 g, 0.0200 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was added 
3-bromo-1-(t-butyl)-6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7d, 0.0750 g, 
0.240 mmol) and Cs2CO3 (0.116 g, 0.350 mmol) and the resulting mixture was stirred for 10 
min, and treated with 1-naphthylboronic acid (0.0500 g, 0.280 mmol). The flask was sealed, 
heated to 100 °C for 42 h, and the reaction mixture was filtered through Celite. The filtrate was 
concentrated under reduced pressure. The residue was purified by automated chromatography on 
SiO2 (12 g column, liquid load CH2Cl2, stepwise gradient, 100% hexanes to 100% EtOAc over 
15 min) to give a mixture of 1-(t-butyl)-6-chloro-N-methyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine and starting material (3:1, 0.0318 g) as an off-white solid. 
A solution of this mixture (0.0318 g, 0.0652 mmol), 10% Pd/C (0.0154 g, 0.130 mmol) 
and NH4HCO2 (0.0328 g, 0.521 mmol) in MeOH (5 mL) was stirred at rt for 30 min, purged with 
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H2 for 15 min and stirred under an atmosphere of H2 (balloon) for 22 h. The reaction mixture 
was filtered through Celite and the filtrate was concentrated under reduced pressure. The residue 
was purified by preparative TLC on SiO2 (hexanes/EtOAc, 5:1) to give 1.13a (0.00485 g, 0.0146 
mmol, 6.2% (2 steps), 100% purity by LC-MS) as a clear oil which crystallized upon standing at 
rt for ~1 h: Mp 152.4-156.3 °C; IR (neat) 3437, 3044, 2975, 2926, 1597, 1558, 1312, 1243, 1079, 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1 H), 7.97 (dd, J = 14.4, 8.0 Hz, 2 H), 7.90 (d, J = 
8.0 Hz, 1 H), 7.65-7.50 (m, 4 H), 4.71 (bs, 1 H), 2.86 (d, J = 4.8 Hz, 3 H), 1.88 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 157.6, 154.7, 153.3, 139.7, 134.1, 131.9, 129.5, 128.4, 128.3, 127.0, 
126.5, 125.7, 125.5, 101.7, 60.4, 29.3, 27.6; HRMS (ESI) m/z calcd for C20H21N5 ([M+H]+) 
332.1875, found 332.1863. 
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1.13b 
1-(t-Butyl)-3-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13b). A 
solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 adduct (0.0180 
g, 0.0200 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was treated with 3-bromo-
1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7c, 0.0750 g, 0.250 mmol) and 
Cs2CO3 (0.122 g, 0.370 mmol). The reaction mixture was stirred for 10 min and 4-
methoxybenzeneboronic acid (0.0450 g, 0.300 mmol) was added. The flask was sealed and the 
solution was stirred at 100 °C for 20 h, filtered through Celite and concentrated under reduced 
pressure. The residue was purified by automated chromatography on SiO2 (4 g column, liquid 
load CH2Cl2, stepwise gradient, 100% hexanes to 100% EtOAc over 15 min) to give a mixture of 
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1-(t-butyl)-6-chloro-3-(4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine and starting 
material (20:1, 0.0480 g) as an off-white solid. 
A solution of this mixture (0.0200 g, 0.0571 mmol), 10% Pd/C (0.0857 g, 0.0700 mmol) 
and NH4HCO2 (0.0228 g, 0.360 mmol) in MeOH (2 mL) was stirred at rt for 30 min, purged with 
H2 for 15 min and stirred under H2 for 28 h. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 6:1) to give 1.13b (0.0140 g, 0.0486 mmol, 48% (2 
steps), 96% purity by LC-MS) as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1 H), 
7.61 (d, J = 8.6 Hz, 1 H), 7.04 (d, J = 8.6 Hz, 1 H), 5.51 (bs, 2 H), 3.87 (s, 3 H), 1.83 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 160.1, 157.8, 154.4, 154.1, 141.9, 129.9, 126.1, 114.7, 99.7, 60.3, 
55.4, 29.2; HRMS (ESI) m/z calcd for C16H19N5O ([M+H]+) 298.1668, found 298.1649. 
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1.13c 
1-(t-Butyl)-3-(4-methoxyphenyl)-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.13c). A solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 
adduct (0.0016 g, 0.0157 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was treated 
with 3-bromo-1-(t-butyl)-6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7d, 
0.0500 g, 0.157 mmol), and Cs2CO3 (0.0774 g, 0.235 mmol). The resulting mixture was stirred 
for 10 min and 4-methoxybenzeneboronic acid (0.0286 g, 0.188 mmol) was added. The flask was 
sealed and heated at 80 °C for 11 h and at 100 °C for an additional 4 h. The reaction mixture was 
filtered through Celite and the filtrate was concentrated under reduced pressure. The residue was 
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purified by automated chromatography on SiO2 (4 g column, liquid load CH2Cl2, stepwise 
gradient, 100% hexanes to 100% EtOAc over 15 min) to give a mixture of 1-(t-butyl)-6-chloro-
3-(4-methoxyphenyl)-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine and starting material 
(20:1, 0.0275 g) as an off-white solid. 
A solution of this mixture (0.0145 g, 0.0381 mmol), 10% Pd/C (0.0074 g, 0.0629 mmol) 
and NH4HCO2 (0.0159 g, 0.250 mmol) in MeOH (5 mL) was stirred at rt for 30 min, purged with 
H2 for 15 min and stirred under H2 for 25 h. The reaction mixture was filtered through Celite, 
and the filtrate was concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 4:1) to give 1.13c (0.00760 g, 0.0245 mmol, 30% (2 
steps), 100% purity by LC-MS) as a clear oil which crystallized to a colorless solid after ~1 h: 
Mp 89.3-91.2 °C; IR (neat) 3439, 2977, 2930, 1596, 1560, 1517, 1314, 1245, 1033 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.43 (s, 1 H), 7.57 (d, J = 8.8 Hz, 2 H), 7.05 (d, J = 8.8 Hz, 2 H), 
5.29 (bd, J = 4.6 Hz, 1 H), 3.88 (s, 3 H), 3.21 (d, J = 4.6 Hz, 3 H), 1.82 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 160.0, 157.8, 154.5, 153.5, 141.3, 129.9, 126.4, 114.7, 100.0, 60.1, 55.4, 29.2, 
27.7; HRMS (ESI) m/z calcd for C20H21N5 ([M+H]+) 312.1824, found 312.1814. 
N
N
NH2
N
N
F
 
1.13d 
1-(tert-Butyl)-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13d). A 
solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 adduct (0.0182 
g, 0.0200 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was treated with 3-bromo-
1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7c, 0.0750 g, 0.250 mmol) and 
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Cs2CO3 (0.0122 g, 0.370 mmol). The resulting mixture was stirred for 10 min and 4-
fluorobenzeneboronic acid (0.0400 g, 0.290 mmol) was added. The reaction was heated at 100 
°C for 20 h, filtered through Celite and the filtrate was concentrated under reduced pressure. The 
crude residue was purified by automated chromatography on SiO2 (4 g column, liquid load 
CH2Cl2, stepwise gradient, 100% hexanes to 100% EtOAc over 15 min) to give a mixture of 1-(t-
butyl)-6-chloro-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine and starting material 
(10:1, 0.0540 g) as an off-white solid. 
A solution of this mixture (0.0180 g, 0.0512 mmol), 10% Pd/C (0.0800 g, 0.0700 mmol) 
and NH4HCO2 (0.0200 g, 0.340 mmol) in MeOH (2 mL) was stirred at rt for 15 min, purged with 
H2 for 15 min and stirred under H2 for 28 h. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 6:1) to give 1.13d (0.00410 g, 0.0144 mmol, 18% (2 
steps), 93% purity by LC-MS) as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1 H), 
7.68 (dd, J = 8.2, 5.2 Hz, 2 H), 7.23 (t, J = 8.2 Hz, 2 H), 5.37 (bs, 2 H), 1.83 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 163.1 (d, JCF = 247 Hz), 157.7, 154.6, 154.3, 141.0, 130.4 (d, JCF = 8.3 Hz), 
129.9 (d, JCF = 3.1 Hz), 129.2, 128.6, 116.3 (d, JCF = 22 Hz), 99.7, 60.5, 29.2; HRMS (ESI) m/z 
calcd for C15H16FN5 ([M+H]+) 286.1468, found 286.1452. 
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1.13e 
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3-([1,1'-Biphenyl]-4-yl)-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13e). 
To a solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 adduct 
(0.0182 g, 0.0200 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was added  3-
bromo-1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7c, 0.0750 g, 0.250 mmol), 
and Cs2CO3 (0.122 g, 0.370 mmol). The resulting mixture was stirred for 10 min and 4-
phenylbenzeneboronic acid (0.0585 g, 0.300 mmol) was added. The flask was sealed and heated 
to 100 °C for 21 h. The reaction mixture was filtered through Celite and concentrated under 
reduced pressure. The residue was purified by automated chromatography on SiO2 (4 g column, 
liquid load CH2Cl2, stepwise gradient, hexanes to EtOAc over 15 min) to give a mixture of 3-
([1,1'-biphenyl]-4-yl)-1-(t-butyl)-6-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-amine and starting 
material (9:1, 0.0350 g) as an off-white solid. 
A solution of this mixture (0.0200 g, 0.0477 mmol), 10% Pd/C (0.0752 g, 0.0600 mmol), 
and NH4CO2 (0.0200 g, 0.320 mmol) in MeOH (2 mL) was stirred at rt for 30 min, purged with 
H2 for 15 min and stirred under an atmosphere of H2 (balloon) for 28 h. The reaction mixture 
was filtered through Celite and the filtrate was concentrated under reduced pressure. The residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 4:1) to give 1.13e (0.00890 g, 0.0260 
mmol, 19% (2 steps), 94% purity by LC-MS) as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 
8.38 (s, 1 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.75 (d, J = 8.4 Hz, 2 H), 7.65 (d, J = 7.6 Hz, 2 H), 7.48 
(t, J = 7.6 Hz, 2 H), 7.39 (t, J = 7.6 Hz, 1 H), 5.84 (bs, 3 H), 1.86 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 157.7, 154.5, 154.3, 141.6 (2 C), 140.3, 132.6, 128.9, 128.9, 127.9, 127.7, 127.0, 99.7, 
60.5, 29.2; HRMS (ESI) m/z calcd for C21H21N5 ([M+H]+) 344.1875, found 344.1858. 
N
N
NH2
N
N
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1.13f 
1-Methyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13f). A 
solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 adduct (0.0098 
g, 0.0100 mmol) in freshly distilled and degassed 1,4-dioxane was treated with 3-bromo-6-
chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7b, 0.0500 g, 0.190 mmol) and 
Cs2CO3 (0.0900 g, 0.0300 mmol). The reaction mixture was stirred for 10 min and 1-
naphthylboronic acid (0.0393 g, 0.230 mmol) was added. The solution was continuously 
degassed by purging with N2 over the course of the addition of reagent. The vial was capped and 
the solution was stirred at 80 °C for 34 h and at 100 °C for an additional 12 h, and filtered 
through Celite. The filtrate was concentrated under reduced pressure and the residue was purified 
by chromatography on SiO2 (hexanes/EtOAc, 2:1) to give a mixture of 6-chloro-1-methyl-3-
(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine and starting material (6:1, 0.0180 g) as 
an off-white solid. 
A solution of this mixture (0.00420 g, 0.00857 mmol), 5% Pd/C (0.0819 g, 0.0300 mmol) 
and NH4HCO2 (0.0087 g, 0.140 mmol) in MeOH (1 mL) was stirred at rt for 10 min, purged with 
H2 for 30 min and stirred under H2 for 22 h. The reaction mixture was filtered through Celite, 
which was rinsed with CH2Cl2 (4 mL), and the combined filtrate was concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 6:1) to 
give 1.13f (0.00370 g, 0.0133 mmol, 17 % (2 steps), 96% purity by LC-MS) as a colorless solid: 
Mp 210-212 °C; IR (neat) 3465, 3299, 3220, 2937, 1631, 1565, 1513, 1312, 1269 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.43 (s, 1 H), 8.01-7.92 (m, 3 H), 7.67-7.52 (m, 4 H), 5.11 (bs, 2 H), 4.16 
(s, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.6, 156.2, 154.3, 142.4, 133.9, 131.5, 130.0, 129.8, 
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128.6, 128.4, 127.3, 126.6, 125.5, 125.3, 100.3, 34.0; HRMS (ESI) m/z calcd for C16H13N5 
([M+H]+) 276.1249, found 276.1242. 
N
N
NH
N
N
 
1.13g 
N,1-Dimethyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13g). A 
solution of Pd2(dba)3 (0.0176 g 0.0200 mmol) and PA-Ph (0.0087 g, 0.0300 mmol) in degassed 
1,4-dioxane (1.7 mL) was stirred at rt for 10 min, treated with 3-bromo-6-chloro-N,1-dimethyl-
1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7a, 0.0750 g, 0.270 mmol), Cs2CO3 (0.133 g, 0.410 
mmol) and 1-naphthylboronic acid (0.0560 g, 0.330 mmol) and stirred in a pre-equilibrated oil 
bath at 100 °C for 25 h. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 4:1) to give a mixture of 6-chloro-N,1-dimethyl-3-(naphthalen-1-yl)-1H-
pyrazolo[3,4-d]pyrimidin-4-amine and starting material (10:1, 0.0340 g) as an off-white solid. 
A solution of this mixture (0.0080 g, 0.0182 mmol), 10% Pd/C (0.0400 g, 0.0400 mmol) 
and NH4HCO2 (0.0093 g, 0.150 mmol) in MeOH (1 mL) was stirred at rt for 30 min, purged with 
H2 for 15 min and stirred under H2 for 27 h. The reaction mixture was filtered through Celite and 
the filtrate was concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 6:1) to give 1.13g (0.00330 g, 0.0113 mmol, 18% (2 
steps)) as a colorless solid: Mp 154.2-155.6 °C; IR (neat) 3438, 3045, 2939, 1599, 1569, 1312, 
1269 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.51 (s, 1 H), 7.99 (dd, J = 16.0, 8.0 Hz, 2 H), 7.90 (d, 
J = 8.0 Hz, 2 H), 7.70-7.50 (m, 4 H), 4.76 (bs, 1 H), 4.15 (s, 3 H), 2.89 (d, J = 4.8 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 157.5, 156.3, 153.7, 141.8, 134.0, 131.6, 130.3, 129.8, 128.5, 128.3, 
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127.2, 126.6, 125.5, 125.4, 100.5, 34.0, 27.7; HRMS (ESI) m/z calcd for C17H14ClN5 ([M+H]+) 
290.1406, found 290.1385. 
N
N
NH2
N
N
O
 
1.13h 
3-(4-Methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13h). A 
mixture of 6-chloro-3-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.12h, 0.0132 g, 0.0500 mmol), 5% Pd/C (0.162 g, 0.0700 mmol) and NH4HCO2 (0.0172 g, 
0.270 mmol) in MeOH (3 mL) was stirred at rt for 10 min, purged with H2 for 10 min and stirred 
under H2 for 22 h. The reaction mixture was filtered through Celite, which was washed with 
CH2Cl2 (4 mL), and the combined filtrate was concentrated under reduced pressure. The residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 6:1) to give 1.13h (0.00435 g, 0.0170 
mmol, 37 %, 100% purity by LC-MS) as a colorless solid: Mp 185-188 °C IR (neat) 3468, 3071, 
2926, 2851, 1647, 1581, 1568, 1322, 1288, 1249, 1172 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.40 
(s, 1 H), 7.62 (d, J = 8.8 Hz, 2 H), 7.06 (d, J = 8.8 Hz, 2 H), 5.48 (bs, 2 H), 4.07 (s, 3 H), 3.88 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 160.3, 157.8, 156.0, 154.5, 144.0, 129.7, 125.5, 114.8, 
98.4, 55.4, 33.8; HRMS (ESI) m/z calcd for C13H13N5O ([M+H]+) 256.1198, found 256.1181. 
N
N
NH
N
N
O
 
1.13i 
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3-(4-Methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13i). A 
mixture of 6-chloro-3-(4-methoxyphenyl)-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.12i, 0.0080 g, 0.0300 mmol), 10% Pd/C (0.0500 g, 0.100 mmol) and NH4HCO2 (0.0010 g, 
0.160 mmol) in MeOH (0.8 mL) was stirred at rt for 30 min, purged with H2 for 15 min and 
stirred under H2 for 24 h. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The residue was dissolved in EtOAc (1 mL), washed with 
H2O (2 x 1 mL), dried (MgSO4), and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 1:2) to give 1.13i (0.0053 g, 0.0196 
mmol, 74%) as a colorless solid: Mp 110.2-111.6 °C; IR (neat) 3442, 2935, 1591, 1567,1526, 
1496, 1246 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1 H) 7.56 (d, J = 8.4 Hz, 2 H), 7.06 (d, J 
= 8.4 Hz, 2 H), 5.37 (bs, 1 H), 4.05 (s, 3 H), 3.89 (s, 3 H), 3.09 (d, J = 4.8 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 160.2, 157.8, 156.0, 153.9, 143.5, 129.6, 125.8, 114.8, 98.6, 55.4, 33.7, 
27.8; HRMS (ESI) m/z calcd for C14H14ClN5O ([M+H]+) 270.1355, found 270.1351. 
N
N
NH2
N
N
O
Cl  
1.12h 
6-Chloro-3-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.12h). A solution of dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II)-CH2Cl2 
adduct (0.0099 g, 0.0100 mmol) in freshly distilled and degassed 1,4-dioxane (2 mL) was stirred 
for 10 min, treated with 3-bromo-6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.7b, 0.0500 g, 0.190 mmol), Cs2CO3 (0.0900 g, 0.290 mmol), and 4-methoxybenzeneboronic 
acid (0.0350 g, 0.230 mmol) and stirred at 80 °C for 20 h and at 100 °C for an additional 4 h. 
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The reaction mixture was filtered through Celite and the filtrate was concentrated under reduced 
pressure. The residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to give 
1.12h (0.0137 g, 0.0473 mmol, 25%) as a colorless solid: Mp >250 °C; IR (neat) 3465, 3288, 
3070, 3001, 2835, 1648, 1586, 1504, 1450, 1251, 1038 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.59 
(d, J = 8.4 Hz, 2 H), 7.06 (d, J = 8.4 Hz, 2 H), 5.72 (bs, 2 H), 4.03 (s, 3 H), 3.88 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 160.5, 158.2, 157.9, 155.6, 144.4, 129.5, 124.9, 114.9, 97.1, 55.4, 
34.1; HRMS (ESI) m/z calcd for C13H12ClN5O ([M+H]+) 290.0809, found 290.0799. 
N
N
NH
Cl N
N
O
 
1.12i 
6-Chloro-3-(4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.12i). A solution of Pd2(dba)3 (0.0176 g 0.0200 mmol) and PA-Ph (0.0079 g, 0.0300 mmol) in 
degassed 1,4-dioxane (1 mL) was stirred for 10 min, treated with 3-bromo-6-chloro-N,1-
dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7a, 0.0748 g, 0.270 mmol), Cs2CO3 (0.133 g, 
0.410 mmol) and 4-methoxybenzeneboronic acid (0.0390 g 0.270 mmol), and stirred at 50 °C for 
24 h. The reaction mixture was filtered through Celite and the filtrate was concentrated under 
reduced pressure. The crude residue was purified by preparative TLC on SiO2 (hexanes/EtOAc, 
3:7) to give 1.12i (0.0284 g, 0.0935 mmol, 35%, 100% purity by LC-MS) as a colorless solid: 
Mp 159.3-160.9 °C; IR (neat) 3349, 2957, 1601, 1569, 1496, 1246, 1209, 1172 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.54 (d, J = 8.8 Hz, 2 H), 7.06 (d, J = 8.8 Hz, 2 H), 5.51 (bs, 1 H), 4.01 (s, 3 
H), 3.89 (s, 3 H), 3.09 (d, J = 4.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 160.3, 158.2, 157.9, 
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154.8, 143.6, 129.4, 125.1, 114.8, 97.2, 55.3, 33.8, 27.9; HRMS (ESI) m/z calcd for 
C14H14ClN5O ([M+H]+) 304.0965, found 304.0974. 
N
N
NH
N
N
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1.13j 
N,1-Dimethyl-3-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1l). A solution of 6-chloro-N,1-dimethyl-3-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (1.12j, 0.0081 g, 0.0200 mmol), 5% Pd/C (0.0800 g, 0.0300 mmol) and 
NH4HCO2 (0.0085 g, 0.140 mmol) in MeOH (2 mL) was stirred at rt for 30 min, purged with H2 
for 15 min and stirred under H2 for 19 h. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc (1 mL), 
washed with H2O (2 x 1 mL), dried (MgSO4) and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 6:1) to give 1.13j 
(0.00651 g, 0.0201 mmol, 89%, 91% purity by LC-MS) as a colorless solid: Mp 101.5-103.3 °C; 
IR (neat) 3452, 2943, 1592, 1568, 1249, 1219, 1204, 1161, 1103 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.49 (s, 1 H), 7.69 (d, J = 8.4 Hz, 2 H), 7.39 (d, J = 8.4 Hz, 2 H), 5.25 (bd, J = 2.4 Hz, 
1 H), 4.10 (s, 3 H), 3.12 (d, J = 5.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.6, 156.1, 154.1, 
149.7, 142.1, 132.6, 129.9, 129.4, 128.4, 121.8, 120.4 (q, JCF = 257 Hz), 98.6, 33.9, 28.0; HRMS 
(ESI) m/z calcd for C14H11ClF3N5O ([M-H]-) 324.1072, found 324.1078. 
N
N
NH
Cl N
N
OCF3
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1.12j 
6-Chloro-N,1-dimethyl-3-(4-(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-
d]pyrimidin-4-amine (1.12j). A solution of Pd2(dba)3 (0.0176 g, 0.0200 mmol) and dppf 
(0.0090 g, 0.0160 mmol) in freshly distilled and degassed 1,4-dioxane (1.7 mL) was stirred for 
10 min, treated with 3-bromo-6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.7a, 0.0750 g, 0.270 mmol), Cs2CO3 (0.133 g, 0.410 mmol), and 4-
trifluoromethoxybenzeneboronic acid (0.0670 g, 0.330 mmol), and stirred at 100 °C for 2 d, 
filtered through Celite, and the filtrate was concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 4:1) to give 1.12j (0.0270 g, 
0.0753 mmol, 28%, 100% purity by LC-MS) as a colorless solid: Mp 115.3-119.1 °C; IR (neat) 
3444, 2944, 1593, 1567, 1246, 1202, 1155 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.4 
Hz, 2 H), 7.38 (d, J = 8.4 Hz, 2 H), 5.40 (bs, 1 H), 4.00 (s, 3 H), 3.11 (d, J = 4.8 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 158.5, 157.9, 155.2, 149.9, 142.4, 131.7, 129.8, 121.7, 120.4 (q, JCF 
= 257 Hz), 97.3, 34.1, 28.2; HRMS (ESI) m/z calcd for C14H11ClF3N5O ([M-H]-) 356.0526, 
found 356.0521. 
N
N
NH
N
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1.13k 
3-(4-Fluorophenyl)-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13k). A 
solution of 6-chloro-3-(4-fluorophenyl)-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.12k, 
0.0120 g, 0.0400 mmol), 10% Pd/C (0.0580 g, 0.0490 mmol) and NH4HCO2 (0.0053 g, 0.0800 
mmol) in MeOH (1 mL) was stirred at rt for 30 min, purged with H2 for 15 min and stirred under 
 149 
an atmosphere of H2 (balloon) for 24 h. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under reduced pressure. The residue was dissolved in EtOAc (1 mL), 
washed with H2O (2 x 1 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 to 1:4) to give 
1n (0.0080 g, 0.0311 mmol, 76%, 96% purity by LC-MS) as a colorless solid: Mp 111.8-114.5 
°C; IR (neat) 3446, 2941, 1588, 1567, 1522, 1494, 1312, 1265, 1220 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.47 (s, 1 H), 7.62 (dd, J = 8.4, 5.2 Hz, 2 H), 7.23 (t, J = 8.4 Hz, 2 H), 5.26 (bs, 1 H), 
4.06 (s, 3 H), 3.10 (d, J = 4.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 163.2 (d, JCF = 248 Hz), 
157.6, 156.1, 154.0, 142.6, 130.2 (d, JCF = 8.2 Hz), 129.2 (d, JCF = 3.2 Hz), 116.4 (d, JCF = 22 
Hz), 98.6, 33.8, 27.9; HRMS (ESI) m/z calcd for C13H12FN5 ([M+H]+) 258.1155, found 
258.1150. 
N
N
HN
Cl N
N
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1.12k 
6-Chloro-3-(4-fluorophenyl)-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(1.12k). A solution of Pd2(dba)3 (0.0176 g, 0.0200 mmol) and PA-Ph (0.0079 g, 0.0300 mmol) in 
1,4-dioxane (1 mL) was stirred for 10 min, treated with 3-bromo-6-chloro-N,1-dimethyl-1H-
pyrazolo[3,4-d]pyrimidin-4-amine (1.7a, 0.0748 g, 0.270 mmol), Cs2CO3 (0.133 g, 0.410 mmol) 
and 4-fluorobenzeneboronic acid (0.0420 g 0.300 mmol), and stirred at 60 °C for 22 h and at 100 
°C for an additional 4 h. The reaction mixture was filtered through Celite and the filtrate was 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 5:1) to give 1.12k (0.0210 g, 0.0734 mmol, 27%, 100% purity by LC-MS) as a 
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colorless solid: Mp 189.9-192.3 °C; IR (neat) 3438, 2943, 1597, 1569, 1526, 1493, 1347, 1260 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.60 (dd, J = 8.4, 5.6 Hz, 2 H), 7.20-7.30 (m, 2 H), 5.40 (bs, 
1 H), 4.02 (s, 3 H), 3.11 (d, J = 4.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 163.4 (d, JCF = 248 
Hz), 158.5, 158.0, 155.1, 142.9, 130.2 (d, JCF = 8.2 Hz), 129.2 (d, JCF = 3.4 Hz), 116.7 (d, JCF = 
21.4 Hz), 97.4, 34.1, 28.2; HRMS (ESI) m/z calcd for C13H11ClFN5 ([M+H]+) 292.0765, found 
292.0788. 
N
N
NH
N
N
 
1.13l 
3-([1,1'-Biphenyl]-4-yl)-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.13l). 
A solution of 3-([1,1'-biphenyl]-4-yl)-6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-
amine (1.12l, 0.0200 g, 0.0500 mmol), 10% Pd/C (0.0850 g, 0.0725 mmol) and NH4HCO2 
(0.0183 g, 0.290 mmol) in MeOH (2 mL) was stirred at rt for 30 min, purged with H2 for 30 min 
and stirred under H2 for 22 h. The reaction mixture was filtered through Celite and the filtrate 
was concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (hexanes/EtOAc, 6:1) to give 1.13l (0.0128 g, 0.0404 mmol, 84%, 100% purity by LC-MS) 
as a colorless solid: Mp 190.8-192.3 °C; IR (neat) 3439, 3027, 2937, 1590, 1566, 1487, 1264 cm-
1; 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1 H), 7.78-7.71 (m, 4 H), 7.66 (d, J = 7.6 Hz, 2 H), 7.49 
(t, J = 7.6 Hz, 2 H), 7.40 (t, J = 7.2 Hz, 1 H), 5.46 (bd, J = 4.0 Hz, 1 H), 4.08 (s, 3 H), 3.12 (d, J 
= 4.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 156.0, 154.0, 143.3, 141.8, 140.1, 132.4, 
128.9, 128.7, 128.0, 127.8, 127.1, 98.7, 33.8, 27.9; HRMS (ESI) m/z calcd for C6H6ClN5 
([M+H]+) 316.1562, found 316.1571. 
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1.12l 
3-([1,1'-Biphenyl]-4-yl)-6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-
amine (1.12l). A solution of Pd2(dba)3 (0.0176 mg, 0.0200 mmol) and dppf (0.0098 g, 0.0160 
mmol) in distilled and degassed 1,4-dioxane (1.7 mL) was stirred for 10 min, treated with 3-
bromo-6-chloro-N,1-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.7a, 0.0750 g, 0.270 
mmol), Cs2CO3 (0.133 g, 0.410 mmol) and 4-phenylbenzeneboronic acid (0.0640 g, 0.330 
mmol), and stirred at 100 °C for 21 h. The reaction mixture was filtered through Celite and the 
filtrate was concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 4:1) to give 1.12l (0.0470 g, 0.136 mmol, 50%) as a 
colorless solid: Mp 211.9-213.8 °C; IR (neat) 3435, 3058, 1593, 1569, 1485, 1347, 1260 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.77-7.66 (m, 4 H), 7.65 (d, J = 7.6 Hz, 2 H), 7.48 (t, J = 7.2 Hz, 
2 H), 7.40 (t, J = 7.2 Hz, 1 H), 5.61 (bs, 1 H), 4.02 (s, 3 H), 3.11 (d, J = 6.0 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 158.4, 158.0, 155.1, 143.6, 142.0, 139.9, 131.8, 128.9, 128.6, 128.1, 127.8, 
127.0, 97.3, 34.0, 28.1; HRMS (ESI) m/z calcd for C19H16ClN5 (M-H)- 350.1172, found 
350.1165. 
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5.3 CHAPTER 2 EXPERIMENTAL PART 
5.3.1 Synthesis of Thiazocine Inhibitor 2.15 
SH O
OMe
Br  
2.19 
Methyl 5-bromo-2-mercaptobenzoate (2.19).273-274 To a cooled (0-5 °C) stirring 
solution of 2-amino-5-bromobenzoic acid (2.18, 1.00 g, 4.49 mmol), NaOH (0.180 g, 4.49 
mmol), and NaNO2 (0.310 g, 4.49 mmol) in H2O (6 mL) was slowly treated with a solution of 
concentrated HCl (12.4 mL) in H2O (21.5 mL). The resulting mixture was stirred at 0 °C for 1 h, 
and then neutralized with potassium acetate (1.47 g). This solution was added to a solution of 
potassium O-ethylxanthate (2.23 g, 13.6 mmol) in H2O (6 mL) which was preheated to 90 °C. 
The mixture was stirred at the same temperature for 30 min, cooled to 0 °C and acidified with 
conc. HCl. The aqueous phase was decanted from the resulting semisolid sludge. This was 
dissolved in 10% aqueous NaOH (5 mL), and heated to 85 °C for 2 h. To this mixture was added 
portionwise NaHSO3 (0.42 g), and the mixture was heated to 85 °C for 10 min. The mixture was 
filtered, cooled to 0 °C, and acidified with conc. HCl. The precipitate was collected by filtration 
and washed with H2O. The moist cake was dissolved in THF/EtOAc, washed with brine, dried 
(Na2SO4), and concentrated under reduced pressure to give crude product as a yellow solid. This 
material was used for the next reaction without further purification. 
A mixture of crude 5-bromo-2-mercaptobenzoic acid (1.05 g, 4.49 mmol) and conc. 
H2SO4 (0.45 mL) in MeOH (10 mL) was heated to reflux for 16 h, concentrated under reduced 
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pressure, diluted with ice-H2O, and extracted with EtOAc. The combined organic layers were 
washed with brine, dried (Na2SO4), and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes:EtOAc, 10:1) to give 2.19 (0.338 g, 1.37 
mmol, 31%) as a yellow solid: 1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 2.1 Hz, 1 H), 7.41 (dd, 
J = 8.6, 2.1 Hz, 1 H), 7.18 (d, J = 8.6 Hz, 1 H), 4.80 (s, 1 H), 3.93 (s, 3 H); 13C NMR (75 MHz, 
CDCl3) δ 166.0, 137.5, 135.2, 134.3, 132.1, 127.2, 117.7, 52.5. 
F
CN
O
 
2.20 
4-Fluoro-3-formylbenzonitrile (2.20).477 A solution of 5-bromo-2-fluorobenzaldehyde 
(4.00 g, 19.3 mmol) in DMF (4 mL) was treated with CuCN (2.10 g, 23.2 mmol) and the mixture 
was heated at 100 °C for 2 h, and at 130 °C for 18 h. The mixture was cooled to rt, treated with a 
solution of FeCl3 (13.0 g) in conc. HCl (4 mL) and H2O (16 mL). The mixture was heated at 70-
80 °C for 20 min. The aqueous layer was extracted with CH2Cl2 (3 x 80 mL). The combined 
organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 9:1) to 
give 2.20 (1.52 g, 10.2 mmol, 53%) as a colorless solid: 1H NMR (400 MHz, CDCl3) δ 10.34 (s, 
1 H), 8.19 (d, J = 6.0 Hz, 1 H), 7.90 (m, 1 H), 7.35 (t, J = 9.0 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 184.7 (d, JCF = 6.0 Hz), 167.5 (d, JCF = 266.0 Hz), 139.4 (d, JCF = 11.0 Hz), 133.4 (d, 
JCF = 3.0 Hz), 124.8 (d, JCF = 9.0 Hz), 118.3 (d, JCF = 22.0 Hz), 116.7, 109.7 (d, JCF = 4.0 Hz). 
S
Br
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2.21 
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Methyl 5-bromo-2-((4-cyano-2-formylphenyl)thio)benzoate (2.21) A solution of 
methyl 5-bromo-2-mercaptobenzoate (2.19, 1.68 g, 6.80 mmol) and 5-cyano-2-
fluorobenzaldehyde (2.20, 0.940 g, 6.18 mmol) in DMF (24 mL) was treated with K2CO3 (1.28 
g, 9.27 mmol) and the reaction was heated to 90 °C for 3 d, cooled to rt, poured onto a mixture of 
EtOAc (150 mL) and H2O (150 mL) and the mixture was extracted with EtOAc (2 x 100 mL). 
The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 9:1 to hexanes/EtOAc, 4:1) to give 2.21 (1.51 g, 4.01 mmol, 65%) as a light 
yellow solid: Mp 108-110 °C; IR (neat) 3115, 3083, 3070, 3059, 2945, 2837, 2227, 1739, 1672, 
1596, 1569, 1534, 1458, 1430, 1282, 1221 cm-1; 1H NMR (300 MHz, CDCl3) δ 10.31 (s, 1 H), 
8.18 (d, J = 1.8 Hz, 1 H), 8.13 (d, J = 2.2 Hz, 1 H), 7.68 (dd, J = 8.4, 1.8 Hz, 1 H), 7.57 (dd, J = 
8.4, 2.1 Hz, 1 H), 7.27 (d, J = 8.4 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 1 H), 3.88 (s, 3 H); 13C NMR (75 
MHz, CDCl3) δ 189.2, 165.2, 145.6, 136.2, 135.9, 135.0, 134.9, 134.5, 134.3, 133.9, 133.5, 
132.8, 122.4, 111.4, 52.8; HRMS (ESI) m/z calcd for C16H11BrNO3S ([M+H]+) 375.9643, found 
375.9668. Note: characterization was taken from Dr. Igor Opsenica's final postdoctoral research 
report. 
S
Br
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2.22 
Methyl 5-bromo-2-((4-cyano-2-(hydroxymethyl)phenyl)thio)benzoate (2.22). To a 
stirred solution of methyl 5-bromo-2-((4-cyano-2-formylphenyl)thio)benzoate (2.21, 1.40 g, 3.72 
mmol) in dry MeOH (60 mL) was added NaBH4 (0.154 g, 4.09 mmol) and the mixture was 
stirred at rt for 30 min where analysis by TLC (hexanes/EtOAc, 7:3) indicated the starting 
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material had been consumed. The reaction was concentrated under reduced pressure, and the 
residue was diluted with EtOAc (80 mL) and 10% HCl aq. (15 mL), and the aqueous layer was 
extracted with EtOAc (80 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The residue was triturated with 
Et2O to give 2.22 (1.39 g, 3.67 mmol, 99%) as a colorless solid: Mp 76-77 °C; IR (neat) 3515, 
3088, 2945, 2235, 1711, 1456, 1446, 1301, 1236 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.18 (d, J 
= 2.2 Hz, 1 H), 7.94 (s, 1 H), 7.56 (dd, J = 8.0, 1.6 Hz, 1 H), 7.47 (d, J = 8.0 Hz, 1 H), 7.41 (dd, J 
= 8.6, 2.2 Hz, 1 H), 6.64 (d, J = 8.6 Hz, 1 H), 4.77 (s, 2 H), 3.92 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 165.4, 145.1, 138.0, 136.8, 135.6, 135.5, 134.2, 131.6, 131.3, 130.1, 129.8, 119.7, 
118.2, 113.1, 62.1, 52.7; HRMS (ESI) m/z calcd for C16H13BrNO3S ([M+H]+) 377.9800, found 
377.9820. Note: characterization was taken from Dr. Igor Opsenica's final postdoctoral research 
report. 
S
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2.23 
Methyl 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoate (2.23). To a 
solution of methyl 5-bromo-2-((4-cyano-2-(hydroxymethyl)phenyl)thio)benzoate (2.22, 1.00 g, 
2.64 mmol) in CH2Cl2 (30 mL) under Ar at 0 °C was added Et3N (0.56 mL, 3.97 mmol) and 
MsCl (0.23 mL, 2.91 mmol). The cooling bath was removed and the solution was stirred at rt for 
2 h. The reaction mixture was poured into CH2Cl2 (40 mL) washed with H2O (10 mL), dried 
(Na2SO4), and concentrated under reduced pressure to give the mesylate as a crude intermediate. 
A mixture of the above crude mesylate and sodium azide (0.868 g, 13.2 mmol) in DMF 
(10 mL) under an Ar atmosphere was stirred at rt for 3 h, poured onto EtOAc (100 mL), washed 
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with H2O (30 mL) and brine, dried (Na2SO4) and concentrated under reduced pressure to give 
2.23 (1.01 g, 2.51 mmol, 95%) as a tan solid: Mp 121-122 °C; IR (neat) 3096, 3070, 3001, 2950, 
2240, 2127, 2089, 1704, 1450, 1437, 1295, 1243 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J 
= 2.4 Hz, 1 H), 7.82 (s, 1 H), 7.61 (dd, J = 8.0, 2.0 Hz, 1 H), 7.53 (d, J = 8.0 Hz, 1 H), 7.44 (dd, J 
= 8.4, 2.4 Hz, 1 H), 6.64 (d, J = 8.4 Hz, 1 H), 4.58 (s, 2 H), 3.94 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 165.3, 140.1, 138.4, 137.5, 135.8, 135.7, 134.3, 132.4, 132.3, 130.2, 130.1, 120.0, 
117.8, 113.2, 52.7, 52.0; HRMS (ESI) m/z calcd for C16H12BrN4O2S ([M+H]+) 402.9864, found 
402.9897. Note: characterization was taken from Dr. Igor Opsenica's final postdoctoral research 
report. 
S
Br
CN
N3
OPfpO
 
2.24 
Perfluorophenyl 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoate (2.24) A 
solution of methyl 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoate (2.23, 0.800 g, 
1.98 mmol) in MeOH (20 mL) and THF (20 mL) was treated with 1 M aqueous NaOH (18 mL). 
The solution was stirred for 5 h at rt, concentrated under reduced pressure and acidified to pH 2 
with 1 M aqueous HCl, extracted with EtOAc (100 mL), dried (Na2SO4), and concentrated under 
reduced pressure to give crude 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoic  acid 
that was used in next reaction without purification.  
A solution of 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoic acid (0.700 g, 
1.80 mmol) in CH2Cl2 (60 mL) was treated with Pfp-OH (0.331 g, 1.80 mmol), EDCI (0.518 g, 
2.70 mmol) and DMAP (0.0220 g, 0.180 mmol) at 0 °C. The mixture was warmed at rt for 2.5 h, 
poured onto H2O (50 mL), and extracted with CH2Cl2 (2 x 100 mL). The combined organic 
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layers were washed with Brine, dried (Na2SO4), and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 9:1) to give 2.24 (0.619 
g, 1.12 mmol, 56% (2 steps)) as a colorless solid: Mp 160-163 °C; IR (neat) 3089, 2938, 2235, 
2103, 1750, 1517, 1454, 1214 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.41 (d, J = 2.0 Hz, 1 H), 
7.85 (s, 1 H), 7.66 (dd, J = 8.0, 2.0 Hz, 1 H), 7.59-7.56 (m, 2 H), 6.71 (d, J = 8.4 Hz, 1 H), 4.59 
(s, 2 H); 13C NMR (100 MHz, CDCl3) δ 160.5, 142.2 (m, C-F coupling), 140.9 (m, C-F 
coupling), 140.6, 140.2 (m, C-F coupling), 140.1, 139.0 (C-F coupling), 137.4, 137.2, 137.0 (m, 
C-F coupling), 136.2, 135.3, 132.6, 132.5, 130.3, 126.2, 124.7 (m, C-F coupling), 120.1, 117.6, 
113.9, 52.0; HRMS (ESI) m/z calcd for C21H9BrF5N4O2S  ([M+H]+) 554.9550, found 554.9534. 
Note: characterization was taken from Dr. Igor Opsenica's final postdoctoral research report. 
S
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2.17 
9-Bromo-7-oxo-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile (2.17). A 
solution of perfluorophenyl 2-((2-(azidomethyl)-4-cyanophenyl)thio)-5-bromobenzoate (2.24, 
0.500 g, 0.900 mmol) in MeCN (48 mL) and H2O (12 mL) was treated with PPh3 (0.286 g, 1.08 
mmol) at rt. The mixture was stirred at 50 °C for 20 h. During reaction a precipitate formed. The 
reaction mixture was concentrated under reduced pressure and filtered. The solid was washed 
with CH2Cl2 and acetone. The solid by NMR still contained trace PPh3 oxide and was sonicated 
in acetone and decanted several times to give 2.17 (0.212 g, 0.614 mmol, 68%) as a colorless 
solid: Mp >250 °C; IR (neat) 3309, 3227, 3102, 2228, 1661, 1469, 1447, 1404, 1342 cm-1; 1H 
NMR (400 MHz, DMSO-d6) δ 8.46 (t, J = 6.8 Hz, 1 H), 7.81-7.72 (m, 4 H), 7.68-7.63 (m, 2 H), 
4.20-4.10 (m, 2 H); 13C NMR (100 MHz, DMSO-d6) δ 169.7, 144.3, 139.4, 138.0, 137.2, 134.5, 
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134.1, 131.7, 130.7, 130.1, 125.3, 123.6, 118.2, 109.6, 45.0; HRMS (ESI) m/z calcd for 
C15H10BrN2OS ([M+H]+) 344.9697, found 344.9669. Note: characterization was taken from Dr. 
Igor Opsenica's final postdoctoral research report. 
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2.26 
Methyl 5-bromo-2-((4-cyano-2-((4-
nitrophenylsulfonamido)methyl)phenyl)thio)benzoate (2.26).  A solution of methyl 5-bromo-
2-((4-cyano-2-formylphenyl)thio)benzoate (2.21, 0.500 g, 1.33 mmol) in absolute EtOH (10 mL) 
was treated titanium(IV)isopropoxide (2.45 mL, 7.97 mmol), 4-nitrobenzenesulfonamide (0.537 
g, 2.66 mmol), Et3N (0.37 mL, 2.66 mmol) and stirred at rt for 13 h. NaBH4 (0.101 g, 2.66 
mmol) was added and the mixture stirred for additional 2 h at rt, diluted with aqueous 
ammonium hydroxide (5 mL). The resulting inorganic precipitate was removed by filtration, 
washed with EtOAc (50 mL) and H2O (10 mL). The organic layer was separated washed with 1 
M aqueous HCl, brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 2:1) to give 2.26 (0.455 
g, 0.808 mmol, 61%) as a colorless solid: Mp 138.7-141.5 °C; IR (neat) 3312, 3103, 2952, 2229, 
1709, 1527, 1340, 1303, 1247, 1171, 1159, 818, 734 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.29 
(dd, J = 2.2, 9.2 Hz, 2 H), 8.12 (d, J = 2.4 Hz, 1 H), 7.95 (dd, J = 2.2, 9.2 Hz, 2 H), 7.73 (d, J = 
1.8 Hz, 1 H), 7.52 (dd, J = 1.8, 8.4 Hz, 1 H), 7.49 (dd, J = 1.8, 8.4 Hz, 1 H), 7.34 (d, J = 7.8 Hz, 
1 H), 6.73 (d, J = 7.8 Hz, 1 H), 5.52 (bt, J = 6.2 Hz, 1 H), 4.28 (d, J = 6.2 Hz, 2 H), 3.91 (s, 3 H); 
13C NMR (100 MHz, CDCl3) δ 165.2, 150.1, 145.5, 139.4, 139.3, 136.2, 135.9, 134.8, 134.6, 
 159 
133.5, 132.5, 131.6, 130.4, 128.3, 124.3, 120.9, 117.5, 112.9, 52.9, 45.1; HRMS (ESI) m/z calcd 
for C22H16N3O6BrS2 ([M+Na]+) 583.9562, found 583.9558. 
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2.27 
N-(2-((4-Bromo-2-(hydroxymethyl)phenyl)thio)-5-cyanobenzyl)-4-
nitrobenzenesulfonamide (2.27) A solution of methyl 5-bromo-2-((4-cyano-2-((4-
nitrophenylsulfonamido)methyl)phenyl)thio)benzoate (2.26, 0.250 g, 0.445 mmol) in dry THF 
(16 mL) was treated with NaBH4 (0.168 g, 4.45 mmol) and the mixture was refluxed for 30 min 
followed by the addition of MeOH (8 mL) and the solution was refluxed for 25 h, cooled to rt, 
and concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and 
washed with 10% HCl aq. (10 mL). The aqueous layer was extracted with EtOAc (50 mL). The 
combined organic layers were washed with brine, dried (Na2SO4) and concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 
2:1) to give 2.27 (0.110 g, 0.207 mmol, 47%) as a colorless amorphous solid: IR (neat) 3525, 
3320, 3142, 2928, 2229, 1685, 1596, 1528, 1411, 1348, 1142, 1090, 1033, 736 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.31 (d, J = 8.8 Hz, 2 H), 8.01 (d, J = 8.8 Hz, 2 H), 7.74 (d, J = 1.8 Hz, 1 
H), 7.56 (d, J = 1.8 Hz, 1 H), 7.46 (dd, J = 1.8, 8.4 Hz, 1 H), 7.49 (dd, J = 1.8, 8.4 Hz, 1 H), 7.32 
(dd, J = 1.8, 8.4 Hz, 1 H), 7.19 (d, J = 8.2 Hz, 1 H), 6.77 (d, J = 8.2 Hz, 1 H), 5.30 (bt, J = 6.2 
Hz, 1 H), 4.60 (s, 2 H), 4.30 (d, J = 6.2 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 150.1, 145.5, 
145.4, 142.4, 136.9, 135.0, 132.7, 132.3 (2 C), 132.1, 128.5, 128.3, 127.0, 125.1, 124.4, 118.0, 
109.7, 62.5, 44.7; HRMS (ESI) m/z calcd for C21H16N3O5BrS2 ([M]+) 534.9694, found 534.9688. 
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2.29 
4-((4-Bromo-2-(hydroxymethyl)phenyl)thio)-3-(((4-
methoxybenzyl)amino)methyl)benzonitrile (2.29) A solution of methyl 5-bromo-2-((4-cyano-
2-formylphenyl)thio)benzoate (2.21, 0.300 g, 0.797 mmol) in absolute EtOH (8 mL) was treated 
with titanium(IV)isopropoxide (0.612 mL, 1.99 mmol), 4-methoxybenzylamine (0.219 g, 1.59 
mmol), Et3N (0.22 mL, 1.59 mmol) and stirred at rt for 2 h. Analysis by 1H NMR (300 MHz, 
CDCl3) indicated that the aldehyde had been consumed, NaBH4 (0.0603 g, 1.59 mmol) was 
added and the mixture stirred for 17 h where analysis by TLC (hexanes/EtOAc, 1:1) indicated 
the imine intermediate had been consumed. The reaction was diluted with aqueous ammonium 
hydroxide (5 mL). The resulting inorganic precipitate was filtered off washed with EtOAc (30 
mL) and H2O (10 mL), and the organic layer separated. The aqueous layer was extracted with 
EtOAc (2 x 20 mL) and the combined organic layers were washed with satd. aqueous NaHCO3, 
brine, and dried (Na2SO4). The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 2:1 to hexanes/EtOAc, 1:2 w/ 3% Et3N) to give 2.29 (0.196 g, 0.418 mmol, 
53%) as a colorless solid: Mp 125.7-128.6 °C; IR (neat) 3262, 3006, 2870, 2833, 2220, 1592, 
1510, 1454, 1238, 1174, 1070, 1031, 822, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1 H), 
7.66 (s, 1 H), 7.48 (d, J = 8.0 Hz, 1 H), 7.32 (d, J = 8.2 Hz, 2 H), 7.28-7.24 (m, 3 H), 6.90 (d, J = 
8.2 Hz, 2 H), 6.80 (d, J = 8.0 Hz, 1 H), 4.61(s, 2 H), 3.89 (s, 2 H), 3.82 (s, 3 H), 3.80 (s, 2 H); 
13C NMR (100 MHz, CDCl3) δ158.9, 146.1, 143.0, 139.1, 137.5, 132.2, 132.0, 131.8, 131.5, 
131.1, 129.4, 128.0, 127.9, 124.7, 118.6, 113.9, 113.8, 62.6, 55.3, 52.9, 50.2; HRMS (ESI) m/z 
calcd for C23H22N2O2Br ([M+H]+) 469.0580, found 469.0575. 
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9-Bromo-6-(4-methoxybenzyl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-
carbonitrile (2.30). A solution of 4-((4-bromo-2-(hydroxymethyl)phenyl)thio)-3-(((4-
methoxybenzyl)amino)methyl)benzonitrile (2.29, 0.100 g, 0.213 mmol) in dry THF (20 mL) at 0 
°C, was treated with phosphorus tribromide (13.5 µL, 0.142 mmol), stirred at 0 °C for 2 h, 
heated at reflux for 27 h, cooled to rt, diluted with H2O (5 mL), and made basic with solid 
K2CO3. The organic layer was separated and the aqueous layer was extracted with EtOAc (3 x 20 
mL). The combined organic layers were washed with brine, dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 3:1 w/ 5% Et3N) to give 2.30 (0.0624 g, 0.138 mmol, 65%) as a colorless solid: 
Mp 149.6-152.8 °C; IR (neat) 3064, 3003, 2949, 2833, 2803, 2227, 1614, 1514, 1463, 1253, 
1174, 1092, 1046, 815, 746 cm-1; 1H NMR (400 MHz, DMSO-d6, 100 °C) δ 7.75 (d, J = 8.0 Hz, 
1 H), 7.65 (d, J = 8.0 Hz, 1 H), 7.58 (d, J = 7.6 Hz, 1 H), 7.47 (d, J = 7.6 Hz, 1 H) 7.41 (s, 1 H), 
7.21 (d, J = 7.6 Hz, 1 H), 6.93 (d, J = 7.6 Hz, 1 H), 4.13 (s, 4 H), 4.79 (s, 3 H), 3.42 (s, 2 H); 13C 
NMR (100 MHz, DMSO-d6, 100 °C) δ 165.2, 150.1, 145.5, 139.4, 139.3, 136.2, 135.9, 134.8, 
134.6, 133.5, 132.5, 131.6, 130.4, 128.3, 124.3, 120.9, 117.5, 112.9, 52.9, 45.1; HRMS (ESI) m/z 
calcd for C23H20N2OBrS ([M+H]+) 451.0474, found 451.0482. 
 
1-(tert-Butoxycarbonyl)-1H-indole-6-carbonitrile478 A solution of 6-cyanoindole (4.00 
g, 28.1 mmol) and Boc-anhydride (7.68 g, 35.2 mmol) in anhydrous CH2Cl2 (45 mL) at rt was 
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treated with DMAP (0.0530 g, 0.422 mmol) stirred for 3 h, diluted with ice H2O (200 mL). The 
organic layer was separated and the aqueous layer was extracted with CH2Cl2 (200 mL). The 
combined organic layers were washed with 0.5M aqueous HCl (50 mL), brine (100 mL) and 
H2O (200 mL), and dried (MgSO4). The solution was filtered through a pad of SiO2 (CH2Cl2) 
and the combined filtrates were concentrated under reduced pressure. The product was 
crystallized from cold EtOH/hexanes (1:1) to give 1-(tert-butoxycarbonyl)-1H-indole-6-
carbonitrile (6.15 g, 25.4 mmol, 90%) as a colorless solid: 1H NMR (500 MHz, CDCl3) δ 8.51 
(bs, 1 H), 7.77 (bs, 1 H), 7.64 (d, J = 8.0 Hz, 1 H), 7.48 (d, J = 8.0 Hz, 1 H), 6.64 (d, J = 3.5 Hz, 
1 H), 1.70 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ 148.9, 134.2, 133.8, 129.2, 125.7, 121.7, 
119.7, 107.2, 107.1, 85.0, 28.1. 
NNC
SnMe3
Boc  
2.31 
1-(tert-Butoxycarbonyl)-2-(trimethylstannyl)-1H-indole-6-carbonitrile478  (2.31). A 
solution of distilled iPr2NH (2.21 mL, 15.5 mmol) in anhydrous THF (15 mL) at -78 °C was 
treated with n-BuLi (2.5 M in hexanes)(5.40 mL, 13.4 mmol) dropwise. The solution was 
allowed to warm to 0 °C briefly then cooled back down to -78 °C. The solution was then 
cannulated dropwise into a solution, cooled to -78 °C, of 1-(tert-butoxycarbonyl)-1H-indole-6-
carbonitrile (2.50 g, 10.3 mmol) and trimethyltin chloride (2.50 g, 12.4 mmol) in THF (30 mL) 
while keeping the temperature below -40 °C. The reaction mixture was stirred at -78 °C for 30 
min then warmed to rt and left to stir for 22 h. After quenching the reaction with H2O (5 mL), the 
reaction mixture was concentrated under reduced pressure. The crude residue was dissolved in 
Et2O (250 mL), washed with 10% KF solution (50 mL) and H2O, dried (Na2SO4), filtered, and 
concentrated under reduced pressure to give 2.31 (3.82 g, 9.43 mmol, 91%) as a colorless solid, 
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which was used immediately in the next reaction: 1H NMR (300 MHz, CDCl3) δ 8.25 (bs, 1 H), 
7.59 (d, J = 8.1 Hz, 1 H), 7.44 (dd, J = 8.1, 0.9 Hz, 1 H), 6.79 (t, J = 8.6 Hz, 1 H), 1.74 (s, 9 H), 
0.35 (t, JSn-H = 28.8 Hz, 9 H).  
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2.32 
tert-Butyl 6-cyano-2-(9-cyano-6-(4-methoxybenzyl)-6,7-dihydro-5H-
dibenzo[b,g][1,5]thiazocin-3-yl)-1H-indole-1-carboxylate (2.32) A solution of 9-bromo-6-(4-
methoxybenzyl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile (2.30, 0.500 g, 1.11 
mmol) and tert-butyl 6-cyano-2-(trimethylstannyl)-1H-indole-1-carboxylate (2.31, 0.769 g, 1.33 
mmol) in dry degassed DMF (10 mL) was treated with Pd(PPh3)2Cl2 (0.0778 g, 0.111 mmol) and 
(iPr)CuCl293 (0.0810 g, 0.166 mmol) at rt. The reaction mixture was heated to 80 °C for 21 h 
where analysis by LCMS indicated that the SM was consumed. The reaction mixture was poured 
onto H2O (20 mL) and extracted EtOAc (3 x 75 mL). The combined organic layers were washed 
with satd. aqueous NaHCO3 (10 mL), brine (10 mL), dried (Na2SO4), filtered, and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 (hexanes to 
hexanes/EtOAc, 3:1 w/ 5% Et3N). The product was sonicated with methanol and pelleted by 
centrifugation. The supernatant was removed and this process was repeated twice, and the 
product was dried under high vacuum to give 2.32 (0.312 g, 0.509 mmol, 46%) as a colorless 
solid. Due to the removal of the Boc group during high temperature NMR analysis this product 
was carried onto the Boc-deprotection: Characteristic 1H NMR peaks, 1H NMR (400 MHz, 
DMSO-d6, 82 °C) δ 8.44 (s, 1 H), 7.82 (t, J = 8.2 Hz, 2 H), 7.76 (d, J = 8.0 Hz, 1 H), 7.70 (d, J = 
8.0 Hz, 1 H), 7.64 (d, J = 8.2 Hz, 1 H), 7.45-7.43 (m, 2 H), 7.24-7.22 (m, 3 H), 6.92 (d, J = 8.2 
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Hz, 2 H), 6.88 (s, 1 H), 4.18 (s, 4 H), 3.77 (s, 3 H), 3.47 (s, 2 H), 1.30 (s, 9 H); HRMS (ESI) m/z 
calcd for C37H33N4O3S ([M+H]+) 613.2268, found 613.2267. 
S
HN CN
NH
NC
HCl
 
2.33 
9-(6-Cyano-1H-indol-2-yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-
carbonitrile hydrochloride (2.33). A solution of tert-butyl 6-cyano-2-(9-cyano-6-(4-
methoxybenzyl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocin-3-yl)-1H-indole-1-carboxylate 
(2.33, 0.150 g, 0.245 mmol) in dry 1,2-dichloroethane (4 mL) cooled to 0 °C was treated with α-
chloroethylchloroformate (54 uL, 0.201 mmol) and stirred for 30 min at 0 °C. The reaction was 
heated to 90 °C for 4 h at which point analysis by LCMS indicated the starting material had been 
consumed. The reaction was concentrated under reduced pressure, dissolved in dry MeOH (2 
mL), and heated to reflux for 1 h. The resulting precipitate was collected by vacuum filtration 
and washed with Et2O to give tert-butyl 6-cyano-2-(9-cyano-6,7-dihydro-5H-
dibenzo[b,g][1,5]thiazocin-3-yl)-1H-indole-1-carboxylate hydrochloride (0.106 g, 0.201 mmol) 
as a colorless solid. The product was taken on to the next deprotection with no further 
purification. 
A solution of tert-butyl 6-cyano-2-(9-cyano-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocin-
3-yl)-1H-indole-1-carboxylate hydrochloride (0.0200 g, 0.0378 mmol) in 4M HCl in dioxane (1 
mL) was stirred in a sealed tube at 0 °C for 20 min, warmed to rt for 4 h, and heated at 80 °C for 
20 h. The reaction had turned green and was diluted with Et2O (10 mL). The resulting precipitate 
was collected by vacuum filtration and washed with Et2O (20 mL), and dried under high vacuum 
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to give 2.33 (0.0130 g, 0.0331 mmol, 72% (2 steps)) as a green solid: Mp 290 °C (decomp.); IR 
(neat) 3541, 3458, 2937, 2729, 2608, 2216, 1735, 1596, 1458, 1314, 1254, 1221, 1117, 1055, 
870, 818 cm-1; 1H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.16 (s, 1 H), 8.20 (s, 1 H), 8.00 (m, 2 
H), 7.85-7.79 (m, 5 H), 7.72 (d, J = 8.0 Hz, 1 H), 7.31 (d, J = 8.0 Hz, 1 H), 7.09 (s, 1 H), 4.51 (s, 
2 H), 4.43 (s, 2 H); 13C NMR (100 MHz, DMSO-d6, 100 °C) δ 143.7, 139.6, 137.3, 135.8, 134.7, 
132.6, 132.0, 131.2, 130.9, 126.7, 121.7, 120.7, 119.6, 117.0, 115.5, 110.3, 103.0, 100.2; HRMS 
(ESI) m/z calcd for C24H17N4S ([M+H]+) 393.1168, found 393.1172. 
S
HN
NH
N
NH
N
H
N
 
2.15 
3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-
yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine (2.15). A solution of 9-(6-cyano-1H-indol-2-
yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine-3-carbonitrile (30, 0.0200 g, 0.0466 mmol) in 
ethylenediamine (1.0 mL) was treated with sulfur (0.0056 g, 0.0932 mmol). The reaction was 
irradiated in the microwave for 80 min at 110 °C, poured onto H2O, filtered, and the resulting 
solid was washed with H2O, Et2O, and dried under high vacuum to give 2.15 (0.0142 g, 0.0297 
mmol, 64%) as a brown orange solid: Mp 233 °C (decomp.); IR (neat) 3217, 2926, 2875, 1599, 
1551, 1445, 1396, 1370, 1342, 1281, 1113, 1090, 1034, 984, 784, 708 cm-1; 1H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 11.45 (bs, 1 H), 7.91 (s, 1 H), 7.78 (s, 1 H), 7.72-7.63 (m, 5 H), 7.55 (s, 2 
H), 6.92 (s, 1 H), 4.22 (s, 2 H), 4.18 (s, 2 H), 3.69 (s, 4 H), 3.63 (s, 4 H); 13C NMR (100 MHz, 
DMSO-d6, 100 °C) δ 164.4, 162.4, 143.5, 142.5, 138.6, 138.2, 136.3, 135.0, 132.3, 131.9, 131.3, 
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130.6, 130.0, 129.4, 127.5, 125.8, 124.1, 118.9, 118.5, 110.2, 99.1, 51.8, 49.2, 48.4; HRMS 
(ESI) m/z calcd for C28H27N6S ([M+H]+) 479.2012, found 479.2007. 
S
HN
NH
N
NH
N
H
N
2x TFA
 
2.15•TFA 
3-(4,5-Dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-2-
yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine bis(2,2,2-trifluoroacetate) (2.15•TFA). A 
suspension of 3-(4,5-dihydro-1H-imidazol-2-yl)-9-(6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indol-
2-yl)-6,7-dihydro-5H-dibenzo[b,g][1,5]thiazocine (2.15, 0.0400 g, 0.0836 mmol) in THF (0.5 
mL) was treated with a solution of TFA in THF (100 µL, 4 M) and the reaction mixture was 
vigorously stirred at rt for 18 h, concentrated under reduced pressure, and co-evaporated with 
hexanes. The resulting solid was suspended in Et2O and pelleted by centrifugation. The 
supernatant was removed and the solid was dried under high vacuum to give 2.15•TFA (0.0572 
g, 0.0809 mmol, 97%, 98.5% pure by ELSD) as a tan solid: Mp 272 °C (decomp.); IR (neat) 
3210, 3094, 2753, 1664, 1609, 1482, 1426, 1370, 1289, 1197, 1174, 1130, 1034, 824, 798, 719 
cm-1; 1H NMR (400 MHz, DMSO-d6, 100 °C) δ 12.06 (bs, 1 H), 10.14 (bs, 1 H), 8.05-8.03 (m, 2 
H), 7.96-7.79 (m, 6 H), 7.58 (dd, J = 8.4, 1.8 Hz, 1 H), 7.12 (d, J = 1.8 Hz, 1 H), 4.40 (s, 2 H), 
4.28 (s, 2 H), 4.07 (s, 4 H), 4.05 (s, 4 H); 13C NMR (100 MHz, DMSO-d6, 100 °C) δ 166.0, 
163.9, 158.3, 157.9, 150.3, 150.1, 147.8, 144.7, 140.7, 136.0, 134.7, 132.6, 132.1, 128.6, 126.6, 
121.2, 120.2, 118.7, 114.4, 112.2 100.3, 44.2, 43.9; HRMS (ESI) m/z calcd for C28H27N6S 
([M+H]+) 479.2012, found 479.2007. 
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5.3.2 Synthesis of 1,2,4-Triazines  
O
O
N N
H OH  
2.44 
(E)-Ethyl 2-(2-(2-hydroxyethyl)hydrazono)propanoate (2.44).303 A solution of ethyl 
pyruvate (2.42, 3.64 mL, 32.7 mmol) in THF (40 mL) was treated with a solution of 2-
hydroxyethylhydrazine (2.43, 3.00 mL, 44.7 mmol) in EtOH (0.5 mL). This mixture was heated 
at reflux for 7 h, concentrated under reduced pressure, diluted with H2O (30 mL) and EtOAc (30 
mL), partitioned, and the aqueous layer was extracted with EtOAc (3 x 40 mL). The combined 
organic layers were washed with brine, dried (Na2SO4), and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (100% EtOAc) to give 2.44 
(3.90 g, 22.4 mmol, 68%) as a pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 4.25 (q, J = 7.2 
Hz, 2 H), 3.84 (dd, J = 5.1, 4.5 Hz, 2 H), 3.56 (dd, J = 5.1, 4.5 Hz, 2 H), 1.93 (s, 3 H), 1.31 (t, J = 
7.2 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 164.9, 132.6, 62.3, 61.0, 52.1, 14.3, 10.0.  
O
O
N N
H N3  
2.45 
(E)-Ethyl 2-(2-(2-azidoethyl)hydrazono)propanoate (2.45).303 A solution of (E)-Ethyl 
2-(2-(2-hydroxyethyl)hydrazono)propanoate (2.44, 6.35 g, 36.5 mmol) and Et3N (7.87 mL, 56.0 
mmol) in THF (60 mL) was treated with MsCl (3.54 mL, 45.7 mmol). This mixture was stirred 
at rt for 20 min, diluted with satd. aqueous NaHCO3 (80 mL) and H2O (50 mL), and extracted 
with Et2O (3 x 125 mL). The combined organic layers were dried (Na2SO4), and concentrated 
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under reduced pressure to give the crude mesylate as a yellow oil that was used without further 
purification.  
The crude oil was dissolved in DMF (30 mL), treated with NaN3 (7.14 g, 110. mmol) and 
heated to 50 °C behind a blast shield for 10 h where analysis by TLC (hexanes/EtOAc, 1:1) 
indicated that the mesylate intermediate was completely consumed. The reaction was cooled to 
rt, diluted with H2O (60 mL) and brine (40 mL) and extracted with EtOAc (4 x 100 mL). The 
combined organic layers were washed with H2O (50 mL), brine (2 x 100 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes to hexanes/EtOAc, 2:1 gradient with 1% Et3N) to give 2.45 
(4.25 g, 21.4 mmol, 59% (2 steps)) as a yellow oil: 1H NMR (300 MHz, CDCl3) δ 5.83 (bs, 1 H), 
4.29 (q, J = 7.2 Hz, 2 H), 3.84 (dd, J = 9.9, 5.1 Hz, 2 H), 3.56 (dd, J = 9.9, 5.1 Hz, 2 H), 1.96 (s, 
3 H), 1.33 (t, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ 164.8, 113.7, 61.1, 51.2, 49.7, 14.3, 
10.3. 
O
O
N N
Bn N3  
2.46a 
Ethyl (E)-2-(2-(2-azidoethyl)-2-benzylhydrazineylidene)propanoate (2.46a).303 A 
solution of (E)-ethyl 2-(2-(2-azidoethyl)hydrazono)propanoate (2.45, 1.00 g, 5.02 mmol) in dry 
DMF (28 mL) was treated with K2CO3 (1.39 g, 10.0 mmol), NaI (0.752 g, 5.02 mmol), and 
benzyl bromide (1.80 mL, 15.1 mmol), heated at 70 °C behind a blast shield for 18 h, cooled to 
rt, diluted with H2O (15 mL), and extracted with EtOAc (3 x 20 mL). The combined organic 
layers were washed with H2O (20 mL), brine (20 mL), dried (Na2SO4), filtered and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 (hexanes to 
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hexanes/EtOAc, 1:1 with 1% NEt3) to give 2.46a (0.832 g, 2.88 mmol, 57%) as a golden oil: 1H 
NMR (300 MHz, CDCl3) δ 7.37-7.29 (m, 5 H), 4.33 (q, J = 7.2 Hz, 2 H), 4.08 (s, 3 H), 3.34 (t, J 
= 5.5 Hz, 2 H), 3.23 (t, J = 5.5 Hz, 2 H), 2.22 (s, 3 H), 1.36 (t, J = 7.2 Hz, 3 H); 
H2N N
Bn
N3
 
2.47a 
1-(2-azidoethyl)-1-benzylhydrazine (2.47a).303 A solution of (E)-ethyl 2-(2-(2-
azidoethyl)-2-benzylhydrazono)propanoate (2.46a, 1.30 g, 4.49 mmol) in THF (20 mL) and H2O 
(6 mL) at rt was treated with hydrazine dihydrochloride (1.41 g, 13.5 mmol). This mixture was 
stirred at rt for 5 h, treated with solid Na2CO3, filtered through a cotton plug, washed (EtOAc), 
and concentrated under reduced pressure. The resulting oil was immediately purified by 
chromatography on SiO2 (hexanes/EtOAc, 1:1 with 1% Et3N) to give 2.47a (0.634 g, 3.31 mmol, 
74%) as an unstable colorless oil: 1H NMR (300 MHz, CDCl3) δ 7.38-7.29 (m, 5 H), 3.76 (s, 2 
H), 3.49 (t, J = 5.7 Hz, 2 H), 2.77 (t, J = 5.7 Hz, 2 H). 
O
O
N N
PMB N3  
2.46b 
(E)-Ethyl 2-(2-(2-azidoethyl)-2-(4-methoxy benzyl)hydrazono)propanoate (2.46b).303 
A solution of (E)-ethyl 2-(2-(2-azidoethyl)hydrazono)propanoate (2.45, 4.20 g, 21.1 mmol) in 
DMF (50 mL) was treated with K2CO3 (5.83 g, 42.2 mmol), NaI (3.16 g, 21.1 mmol), and 
freshly prepared paramethoxybenzyl bromide (9.2 mL, 12.7 g, 63.3 mmol). The mixture was 
heated at 70 °C behind a blast shield for 22 h, cooled to rt, diluted with H2O (100 mL) and 
extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with H2O (100 
mL), brine (100 mL), dried (Na2SO4), and concentrated under reduced pressure. The crude 
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residue was purified by chromatography on SiO2 (hexanes to hexanes/EtOAc, 2:1 gradient with 
1% Et3N) to give 2.46b (3.49 g, 10.9 mmol, 52%) as a golden oil: 1H NMR (300 MHz, CDCl3) δ 
7.27 (d, J = 8.4 Hz, 2 H), 6.89 (d, J = 8.4 Hz, 2 H), 4.29 (q, J = 7.2 Hz, 2 H), 4.00 (s, 2 H), 3.79 
(s, 3 H), 3.31 (t, J = 5.5 Hz, 2 H), 3.20 (t, J = 5.5 Hz, 2 H), 2.22 (s, 3 H), 1.35 (t, J = 7.2 Hz, 3 
H); 13C NMR (75 MHz, CDCl3) δ 164.6, 158.9, 152.6, 129.4, 128.3, 113.8, 61.4, 60.0, 55.5, 
55.0, 49.4, 15.7, 14.0.  
H2N N
PMB
N3
 
2.47b 
1-(2-Azidoethyl)-1-(4-methoxybenzyl)hydrazine (2.47b).303 A solution of (E)-ethyl 2-
(2-(2-azidoethyl)-2-(4-methoxy benzyl)hydrazono)propanoate (2.46b, 0.150 g, 0.470 mmol) in 
THF (2 mL) and H2O (1 mL) at rt was treated with hydrazine dihydrochloride (0.148 g, 1.41 
mmol), stirred at rt for 2 h, treated with solid Na2CO3, and concentrated under reduced pressure. 
The crude residue was immediately purified by chromatography on SiO2 (hexanes/EtOAc, 1:2 
with 1% Et3N) to give 2.47b (0.0761 g, 0.344 mmol, 73%) as an unstable, colorless oil: 1H NMR 
(300 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2 H), 6.89 (d, J = 8.6 Hz, 2 H), 3.81 (s, 3 H), 3.67 (s, 2 
H), 3.48 (t, J = 5.6 Hz, 2 H), 2.74 (t, J = 5.6 Hz, 2 H); 13C NMR (75 MHz, CDCl3) δ 130.3, 
114.0, 66.9, 58.5, 55.3, 44.7. 
O
O
N N
N3
O
O  
2.46c 
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(E)-Ethyl 2-(2-(2-azidoethyl)-2-(3,4-dimethoxybenzyl)hydrazono)propanoate (2.46c). 
A solution of (E)-ethyl 2-(2-(2-azidoethyl)hydrazono)propanoate (2.45, 13.7 g, 68.8 mmol) in 
DMF (138 mL) was treated 4-(chloromethyl)-1,2-dimethoxybenzene (32.1 g, 138 mmol), KI 
(34.3 g, 206 mmol), and K2CO3 (28.5 g, 206 mmol). The reaction mixture was stirred at rt for 2 
d, diluted with H2O (500 mL) and extracted with EtOAc (3 x 250 mL). The combined organic 
layers were washed with H2O (300 mL), brine (300 mL), dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 5:1 with 1% Et3N) to give 2.46c (22.5 g, 57.9 mmol, 84%) as a yellow oil: IR 
(CHCl3) 2921, 2848, 2097, 1708, 1590, 1512, 1462, 1258, 1234, 1135, 1025, 803 cm-1; 1H NMR 
(300 MHz, CDCl3) δ 6.94-6.81 (m, 3 H), 4.31 (q, J = 7.2 Hz, 2 H), 3.99 (s, 2 H), 3.87 (m, 6 H), 
3.31 (t, J = 5.4 Hz, 2 H), 3.22 (t, J = 5.4 Hz, 2 H), 2.20 (s, 3 H), 1.34 (t, J = 7.2 Hz, 3 H); 13C 
NMR (75 MHz, CDCl3) δ 164.6, 152.9, 149.0, 148.4, 128.9, 120.4, 111.1, 110.8, 61.5, 60.4, 
55.7, 55.6, 49.4, 15.8, 14.0; HRMS (ESI) m/z calcd for C16H24N5O2 ([M+H]+) 350.1823, found 
350.1832.  
H2N N N3
O
O  
2.47c 
1-(2-Azidoethyl)-1-(3,4-dimethoxybenzyl)hydrazine (2.47c). A solution of (E)-ethyl 2-
(2-(2-azidoethyl)-2-((3,4-methoxy benzyl)hydrazono)propanoate (2.46c, 1.00 g, 2.86 mmol) in 
THF (40 mL) and H2O (2 mL) at 25 °C was treated with hydrazine dihydrochloride (0.901 g, 
8.59 mmol). The reaction mixture was stirred at rt for 24 h, treated with solid Na2CO3, filtered 
and washed with EtOAc, concentrated under reduced pressure. The crude residue was purified 
by chromatography on SiO2 (EtOAc/hexanes, 3:2 with 1% Et3N) to give 2.47c (0.515 g, 2.05 
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mmol, 72%) as yellow oil: IR (CH2Cl2) 3426, 2934, 2831, 2097, 1696, 1590, 1512, 1450, 1260, 
1232, 1135, 1025, 764 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.99 (s, 1 H), 6.82 (bd, J = 0.9 Hz, 2 
H), 3.90 (s, 3 H), 3.88 (s, 3 H), 3.72 (s, 2 H), 3.49 (t, J = 5.6 Hz, 2 H), 2.79 (t, J = 5.6 Hz, 2 H); 
13C NMR (75 MHz, CDCl3) δ 149.3, 148.6, 121.1, 111.8, 110.9, 67.1, 58.5, 55.9, 48.4; HRMS 
(ESI) m/z calcd for C11H18N5O2 ([M+H]+) 252.1455, found 252.1458.  
5.3.3 Synthesis of Triazine Analogs 2.51a-c 
O
H
N
O
N
PMB
N3
2.50a 
N'-(2-Azidoethyl)-4-methoxy-N'-(4-methoxybenzyl)benzohydrazide (2.50a). A 
solution of 4-methoxybenzoic acid (2.49a, 0.250 g, 1.64 mmol) in CH2Cl2 (10 mL) was cooled to 
0 °C and treated with oxalyl chloride (0.16 mL, 1.81 mmol) and DMF (2 drops). The reaction 
mixture was stirred at rt for 2 h, concentrated under reduced pressure and used without further 
purification.  
A solution of 4-methoxybenzoyl chloride, prepared above, in CH2Cl2 (8 mL) was cooled 
to 0 °C and treated with a solution of 1-(2-azidoethyl)-1-(4-methoxybenzyl)hydrazine (2.47b, 
0.400 g, 1.81 mmol) in CH2Cl2 (1.0 mL), and Et3N (0.69 mL, 4.93 mmol). The reaction mixture 
was allowed to warm to rt for 20 h, diluted with satd. aqueous NaHCO3 (2 mL), and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude residue was washed with hexanes and filtered to 
give 2.50a (0.436 g, 1.23 mmol, 75%) as a colorless solid that was used without further 
purification: Mp 90.4-91.8 °C; IR (neat) 3251, 2833, 2114, 2089, 1640, 1605, 1504, 1459, 1252, 
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1171, 1023, 820, 768 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.4 Hz, 2 H), 7.27 (d, J = 
8.4 Hz, 2 H), 7.01 (bs, 1 H), 6.88 (d, J = 6.8 Hz, 2 H), 6.85 (d, J = 6.8 Hz, 2 H), 4.22 (s, 2 H), 
3.83 (s, 3 H), 3.79 (s, 3 H), 3.42 (t, J = 5.6 Hz, 2 H); 3.34 (t, J = 5.6 Hz, 2 H); 13C NMR (100 
MHz, CDCl3) δ 166.9, 162.4, 159.2, 130.6, 128.6, 125.7, 113.9, 59.6, 55.4, 55.2, 54.3, 49.0; 
HRMS (ESI) m/z calcd for C18H22N5O3 ([M+H]+) 356.1717, found 356.1715. 
O
HN N
PMB
N
 
2.51a 
1-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-1,2,5,6-tetrahydro-1,2,4-triazine (2.51a). 
A flame-dried microwave vial containing a solution of N'-(2-azidoethyl)-4-methoxy-N'-(4-
methoxybenzyl)benzohydrazide (2.50a, 0.0500 g, 0.141 mmol) in dry o-1,2-dichlorobenzene (4 
mL) was treated with P(n-Bu)3 (0.139 mL, 0.563 mmol). The reaction mixture was irradiated in 
the microwave at 180 °C for 1 h, treated with Et3N (0.1 mL) and then applied directly to a 4g 
silica cartridge and purified by automated chromatography on SiO2 (gradient, 100% hexanes to 
100% EtOAc over 15 min) to give 2.51a (0.0206 g, 0.0662 mmol, 47%) as a tan solid: Mp 
115.5-119.8 °C; IR (hexanes) 3410, 1609, 1508, 1491, 1446, 1351, 1238, 1172, 1025, 988, 843, 
762 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 2 H), 7.37 (d, J = 8.8 Hz, 2 H), 6.87 
(dd, J = 8.8, 2.0 Hz, 4 H), 4.13 (s, 2 H), 3.81 (s, 6 H), 3.54 (bs, 2 H), 2.70 (t, J = 5.0 Hz, 2 H); 
13C NMR (100 MHz, CDCl3) δ 160.2, 158.8, 144.8, 130.6, 130.1, 128.1, 126.8, 113.7, 113.5, 
63.3, 55.3, 55.2, 45.0, 41.7; HRMS (ESI) m/z calcd for C18H21N3O2 ([M+H]+) 312.1707, found 
312.1695. 
O
Br N  
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2.57 
4-(4-Bromophenoxy)benzonitrile (2.57).479 A solution of 4-bromophenol (2.58, 4.00 g, 
22.7 mmol) and 4-fluorobenzonitrile (2.59, 3.05 g, 24.9 mmol) in DMF (22 mL) was treated with 
K2CO3 (3.46 g, 23.8 mmol) and the mixture was stirred for 10 min at rt, then heated at 150 °C 
under nitrogen for 24 h, cooled to rt, poured onto ice and stirred for 10 min. A tan solid formed 
and was collected by vacuum filtration and washed with H2O. The solid was dissolved in 
CH2Cl2, dried (Na2SO4), and concentrated. The residue was recrystallized with EtOH to give 
2.57 (5.41 g, 19.8 mmol, 87%) as a tan crystalline solid: 1H NMR (500 MHz, CDCl3) δ 7.61 (d, J 
= 8.0 Hz, 2 H), 7.52 (d, J = 8.0 Hz, 2 H), 7.01 (d, J = 8.5 Hz, 2 H), 6.95 (d, J = 8.5 Hz, 2 H); 13C 
NMR (125 MHz, CDCl3) δ 161.0, 154.0, 134.1, 133.2, 121.9, 118.5, 118.0, 117.8, 106.3.  
O
Br OH
O  
2.49b 
4-(4-Bromophenoxy)benzoic acid (2.49b). A solution of 4-(4-
bromophenoxy)benzonitrile (2.57, 0.300 g, 1.09 mmol) in EtOH (4 mL) and H2O (1 mL) was 
treated with anhydrous LiOH (0.786 g, 32.8 mmol). The reaction was heated to reflux for 3 d, 
cooled to rt, acidified to pH 2 with 1 M aqueous HCl and the resulting precipitate was collected 
by vacuum filtration and washed with H2O. The solid was then suspended in toluene and 
methanol and concentrated under reduced pressure to give 2.49b (0.297 g, 1.01 mmol, 93%) as a 
colorless solid: 1H NMR (500 MHz, DMSO-d6) δ 7.93 (d, J = 8.0 Hz, 2 H), 7.59 (d, J = 8.0 Hz, 2 
H), 7.05 (d, J = 7.8 Hz, 2 H), 7.00 (d, J = 7.8 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ 166.6, 
160.4, 154.6, 133.1, 131.7, 125.7, 122.0, 117.5, 116.4; HRMS (ESI) m/z calcd for C13H10O3Br 
([M+H]+) 292.9808, found 292.9806. 
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2.50b 
N'-(Azidoethyl)-4-(4-bromophenoxy)-N'-(4-methoxybenzyl)benzohydrazide (2.50b). 
According to the procedure used to prepare compound 2.50a, 2.49b was converted to crude 
2.50b, which was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to give pure 2.50b 
(0.328 g, 0.661 mmol, 55%) as a viscous oil that solidified in the freezer at -20 °C to a pale 
yellow solid: Mp 98.2-101.8 °C; IR (neat) 3310, 2958, 2101, 2076, 1653, 1603, 1512, 1495, 
1478, 1232, 1174, 1010, 943, 869, 777 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 8.4 Hz, 
2 H), 7.45 (d, J = 8.7 Hz, 2 H), 7.28 (d, J = 8.4 Hz, 1 H), 7.13 (bs, 1 H), 6.94-6.83 (m, 6 H), 4.21 
(s, 2 H), 3.78 (s, 3 H), 3.42 (bd, J = 5.3 Hz, 2 H), 3.35 (bd, J = 5.3 Hz, 2 H); 13C NMR (75 MHz, 
CDCl3) δ 166.6, 160.1, 159.2, 155.1, 132.9, 130.5, 128.9, 128.5, 128.3, 121.3, 117.9, 116.9, 
113.9, 59.6, 55.2, 54.3, 49.1; HRMS (ESI) m/z calcd for C23H23N5O3Br ([M+H]+) 496.0979, 
found 469.0969.  
Br
N
O
NPMB
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2.51b 
3-(4-(4-Bromophenoxy)phenyl)-1-(4-methoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-
triazine (2.51b). According to the procedure used to prepare compound 2.51a, 2.50b was 
converted to crude 2.51b, which was purified by chromatography on SiO2 (hexanes/EtOAc, 2:1 
with 1% Et3N) to give 2.51b (0.0288 g, 0.0637 mmol, 63%) as a tan solid: Mp 180.3-184.1 °C; 
IR (neat) 3450, 3040, 2939, 2814, 1610, 1579, 1510, 1482, 1247, 1238, 1167, 1033, 839, 818, 
733 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.8 Hz, 2 H), 7.43 (d, J = 8.8 Hz, 2 H), 7.37 
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(d, J = 8.8 Hz, 1 H), 6.97 (d, J = 8.4 Hz, 2 H), 6.89-6.86 (overlapping doublets, J = 8.8, 8.4 Hz, 4 
H), 4.14 (s, 2 H), 3.81 (s, 3 H), 3.56 (bd, J = 2.4 Hz, 2 H), 2.73 (t, J = 5.0 Hz, 2 H); 13C NMR 
(100 MHz, CDCl3) δ 158.8, 157.4, 156.2, 132.7, 130.6, 129.8, 127.2, 120.5, 118.7, 115.9, 113.6, 
63.2. 55.2, 44.9, 41.6; HRMS (ESI) m/z calcd for C23H23N3O2Br ([M+H]+) 452.0968, found 
452.0953.  
Br
N
O
NH
H
N
TFA
 
2.52•TFA 
3-(4-(4-Bromophenoxy)phenyl)-1,2,5,6-tetrahydro-1,2,4-triazine (2.52•TFA) A 
solution of 3-(4-(4-bromophenoxy)phenyl)-1-(4-methoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-
triazine (2.51b, 0.0080 g, 0.0177 mmol) in TFA (0.2 mL) was warmed to 55 °C for 30 min. The 
reaction was diluted with satd. aqueous NaHCO3 (2.0 mL) and extracted with EtOAc (3 x 5 mL). 
The combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure to give 2.52•TFA (0.00621 g, 0.0139 mmol, 79%) as a pale yellow amorphous solid: IR 
(CH2Cl2) 3290, 2923, 2848, 1609, 1495, 1478, 1336, 1236, 1109, 1081, 1033, 736 cm-1; 1H 
NMR (400 MHz, MeOD-d4) δ 7.60 (d, J = 8.8 Hz, 2 H), 7.50 (d, J = 8.8 Hz, 2 H), 7.00 (d, J = 
8.8 Hz, 1 H), 6.95 (d, J = 8.8 Hz, 2 H), 3.55 (t, J = 5.0 Hz, 2 H), 3.09 (t, J = 5.0 Hz, 2 H); 13C 
NMR (100 MHz, MeOD-d4) δ 159.6, 157.5, 150.7, 134.0, 131.3, 129.0, 122.0, 119.4, 117.2, 
42.1, 41.2; HRMS (ESI) m/z calcd for C15H15N3OBr ([M+H]+) 332.0393, found 332.0383.   
N
PMB
N
 
1-(4-Methoxybenzyl)-1H-indole-6-carbonitrile480 A solution of 6-cyanoindole (0.800 g, 
5.63 mmol) in THF (10 mL) at 0 °C was treated with NaH (60% dispersion in mineral oil) (0.472 
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g, 11.8 mmol) and stirred for 20 min at 0 °C followed by the addition of a solution of 4-
methoxybenzyl bromide (1.25 g, 6.19 mmol) in THF (2 mL) dropwise. The reaction was stirred 
at 0 °C for 1 h, rt for 1 h, cooled to 0 °C, diluted with H2O (1.0 mL), and concentrated under 
reduced pressure. The residue was dissolved in EtOAc (50 mL), washed with H2O (5 mL), brine, 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 2:1 w/ 2% Et3N) to give 1-(4-methoxybenzyl)-1H-
indole-6-carbonitrile (0.575 g, 2.19 mmol, 39%) as a colorless solid: Mp 94.1-96.6 °C; IR (neat) 
3128, 2958, 2932, 2218, 1610, 1510, 1465, 1446, 1349, 1314, 1247, 1174, 1025, 813, 738 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.0 Hz, 2 H), 7.62 (s, 1 H), 7.31 (bs, 2 H), 7.07 (d, J = 
7.8 Hz, 2 H), 6.86 (d, J = 7.8 Hz, 2 H), 6.60 (s, 1 H), 5.25 (s, 2 H), 3.78 (s, 3 H); 13C NMR (100 
MHz, CDCl3) δ 159.3, 134.8, 131.8, 128.1 (2 C), 122.2, 121.6, 120.6, 114.6, 114.2, 103.9, 102.3, 
55.2, 49.9; HRMS (ESI) m/z calcd for C17H15N2O ([M+H]+) 263.1179, found 263.1181. 
N
PMB
HO
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2.49c 
1-(4-Methoxybenzyl)-1H-indole-6-carboxylic acid (2.49c) A solution of 1-(4-
methoxybenzyl)-1H-indole-6-carbonitrile (0.100 g, 0.381 mmol) in EtOH (3.0 mL) and H2O (3.0 
mL) was treated with anhydrous LiOH (0.183 g, 7.62 mmol), and heated at reflux for 4 d, 
concentrated, suspended in H2O (5.0 mL), and acidified to pH 2 using conc. HCl. The resulting 
precipitate was collected by vacuum filtration and dried under high vacuum to give 2.49c 
(0.0980 g, 0.348 mmol, 91%) as an off-white solid: Mp 157.6-159.7 °C; IR (neat) 3107, 2962, 
2636, 1672, 1612, 1508, 1463, 1286, 1234, 1174, 1019, 826, 809, 768, 736 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.25 (s, 1 H), 7.93 (dd, J = 8.4, 1.2 Hz, 1 H), 7.72 (d, J = 8.4 Hz, 1 H), 7.32 (d, J 
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= 3.2 Hz, 1 H), 7.14 (d, J = 8.7 Hz, 2 H), 6.89 (d, J = 8.7 Hz, 2 H), 6.63 (d, J = 3.2 Hz, 1 H), 5.36 
(s, 2 H), 3.81 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 173.3, 159.2, 153.5, 133.0, 131.6, 128.8, 
128.3, 122.3, 121.0, 120.5, 114.2, 112.7, 102.1, 55.2 (2 C), 49.6; HRMS (ESI) m/z calcd for 
C17H15NO3 ([M+H]+) 282.1125, found 282.1126. 
N
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2.50c 
N'-(2-Azidoethyl)-N',1-bis(4-methoxybenzyl)-1H-indole-6-carbohydrazide (2.50c). A 
solution of 1-(4-methoxybenzyl)-1H-indole-6-carboxylic acid (2.49c, 0.0750 g, 0.267 mmol) in 
CH2Cl2 (1 mL) was treated with 1-(2-azidoethyl)-1-(4-methoxybenzyl)hydrazine (2.47b, 0.0590 
g, 0.267 mmol), DIPEA (0.14 mL, 0.800 mmol), hydroxybenzotriazole (0.0735 g, 0.533 mmol), 
and EDCI (0.0767 g, 0.400 mmol) and stirred at rt 2 d, diluted with CH2Cl2 (10 mL) and washed 
with a mixture of H2O (2.0 mL) and satd. aqueous NaHCO3 (5 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 w/ 2% Et3N) to give 2.50c 
(0.0692 g, 0.143 mmol, 54%) as a colorless solid: Mp 110.6-114.4 °C; IR (neat) 3174, 3061, 
2829, 2099, 1642, 1610, 1549, 1510, 1301, 1243, 1228, 1176, 1034, 822, 725 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.81 (s, 1 H), 7.64 (d, J = 8.4 Hz, 1 H), 7.36 (d, J = 7.6 Hz, 2 H), 7.28 (d, J 
= 11.6 Hz, 2 H), 7.11 (d, J = 7.6 Hz, 2 H), 6.90 (t, J = 7.6 Hz, 4 H), 6.59 (s, 1 H), 5.28 (s, 2 H), 
4.30 (s, 2 H), 3.81 (s, 6 H), 3.47 (bs, 2 H), 3.42 (bs, 2 H); 13C NMR (100 MHz, CDCl3) δ 168.3, 
159.2, 159.1, 137.7, 131.3, 130.6 (2 C), 128.8, 128.7, 128.3, 126.5, 120.7, 117.2, 114.2, 113.8, 
109.6, 101.8, 59.6, 55.2, 55.1, 54.3, 49.5, 49.0; HRMS (ESI) m/z calcd for C27H29N6O3 ([M+H]+) 
485.2296, found 485.2292. 
 179 
N
PMB
NHPMBN
N
 
2.51c 
1-(4-Methoxybenzyl)-6-(1-(4-methoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)-
1H-indole (2.51c). A solution of N'-(2-azidoethyl)-N',1-bis(4-methoxybenzyl)-1H-indole-6-
carbohydrazide (2.50c, 0.0400 g, 0.0826 mmol) in PhCl (4.0 mL) (sparged with Ar for 20 min) 
was treated with a solution of P(Me)3 (1 M solution in toluene, 0.25 mL, 0.248 mmol) and 
irradiated in the microwave at 180 °C for 1 h. The reaction was applied directly to a column 
prequilibrated with hexanes and purified by chromatography on SiO2 (hexanes/EtOAc, 1:3 w/ 
5% Et3N) to give 2.51c (0.0198 g, 0.0449 mmol, 55%) as a yellow oil: IR (neat) 3383, 2951, 
2833, 1609, 1510, 1461, 1355, 1241, 1174, 1023, 1007, 818, 759, 701 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.66 (s, 1 H), 7.59 (d, J = 8.0 Hz, 1 H), 7.39-7.36 (m, 3 H), 7.11 (d, J = 3.6 Hz, 1 H), 
7.06 (d, J = 8.8 Hz, 2 H), 6.87 (d, J = 8.6 Hz, 2 H), 6.83 (d, J = 8.6 Hz, 2 H), 6.50 (d, J = 3.6 Hz, 
1 H), 5.27 (s, 2 H), 4.16 (s, 2 H), 3.80 (s, 3 H), 3.77 (s, 3 H), 3.56 (bs, 2 H), 2.72 (t, J = 5.0 Hz, 2 
H); 13C NMR (100 MHz, CDCl3) δ 159.1, 158.8, 136.2, 130.6, 130.2, 129.4 (2 C), 129.1, 128.2, 
120.7, 117.3, 114.1, 113.5, 107.2, 101.6, 63.3, 55.2 (2 C), 49.4, 45.1, 41.9; HRMS (ESI) m/z 
calcd for C27H29N4O2 ([M+H]+) 441.2285, found 441.2283. 
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N'-(2-Azidoethyl)-4-(4-bromophenoxy)-N'-(3,4-dimethoxybenzyl)benzohydrazide. A 
solution of 4-(4-bromophenoxy)benzoic acid (2.49b, 0.600 g, 2.05 mmol),  HATU (1.17 g, 3.07 
mmol), and HOAt (0.418 g, 3.07 mmol) in DMF (18 mL) cooled to 0 °C was treated with 
DIPEA (1.4 mL, 8.19 mmol) and stirred at 0 °C for 1 h. The reaction was treated, at 0 °C, with a 
 180 
solution of 1-(2-azidoethyl)-1-(3,4-dimethoxybenzyl)hydrazine (2.47c, 0.955 g, 2.66 mmol) in 
DMF (2 mL). The reaction was allowed to warm to rt for 24 h, diluted with EtOAc (200 mL) and 
satd. aqueous NaHCO3 (200 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 150 mL). The combined organic layers were washed with brine (2 x 150 mL), 
dried (Na2SO4) and concentrated under reduced pressure. The residue was purified twice by 
automated chromatography on SiO2 (12 g column, liquid load with CH2Cl2, hexanes to 
hexanes/EtOAc, 1:1) to give N'-(2-azidoethyl)-4-(4-bromophenoxy)-N'-(3,4-
dimethoxybenzyl)benzohydrazide (1.01 g, 1.91 mmol, 93%) as a pale yellow oil: IR (CH2Cl2) 
3303, 2952, 2097, 1650, 1512, 1478, 1260, 1230, 1156, 1025, 837 cm-1; 1H NMR (400 MHz, 
Acetone-d6) δ  8.76 (s, 1 H), 7.78 (dt, J = 9.4, 2.4 Hz, 1 H), 7.57 (dt, J = 9.4, 2.8 Hz, 2 H), 7.16 
(d, J = 1.6 Hz, 1 H), 7.03-6.98 (m, 4 H), 6.87-6.81 (m, 2 H), 4.21 (s, 2 H), 3.76 (s, 3 H), 3.75 (s, 
3 H), 3.44 (dd, J = 6.5, 4.7 Hz, 2 H), 3.33 (dd, J = 6.5, 4.7 Hz, 2 H); 13C NMR (100 MHz, 
Acetone-d6) δ 166.4, 160.3, 156.6, 150.2, 149.6, 133.8, 131.4 (2 C), 130.2, 122.2, 121.8, 118.7, 
117.0, 113.6, 112.1, 60.9, 56.0 (2 C), 55.9, 49.5; HRMS (ESI) m/z calcd for C24H25BrN5O4 
([M+H]+) 526.1084, found 526.1085. 
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2.53 
3-(4-(4-Bromophenoxy)phenyl)-1-(3,4-dimethoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-
triazine (2.53). To two flame-dried 20 mL microwave vials each containing a solution of N'-(2-
azidoethyl)-4-(4-bromophenoxy)-N'-(3,4-dimethoxybenzyl)benzohydrazide (0.400 g, 0.760 
mmol) in freshly distilled and degassed PhCl (16 mL) was added PMe3 (1 M in THF) (1.5 mL, 
1.52 mmol). The mixture was first warmed in an oil bath (preheated to 60 °C) for 30 min until 
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the evolution of gas had ceased. The microwave vial was sealed and heated at 180 °C for 2 h in 
the microwave. TLC analysis (hexanes/EtOAc, 1:2) showed the starting material had been 
consumed. The reactions were combined and the pale yellow solution was loaded directly onto a 
SiO2 column preequilibrated with hexanes w/ 2 % Et3N followed by chromatography on SiO2 
(hexanes/EtOAc, 1:1) to give 2.53 (0.409 g, 0.848 mmol, 56%) as a colorless solid: Mp 88.3-
92.1 °C; IR (CH2Cl2) 3323, 2831, 1607, 1512, 1476, 1240, 1165, 1030, 834, 734 cm-1; 1H NMR 
(400 MHz, MeOD-d4) δ 7.65 (dt, J = 9.2, 2.5 Hz, 2 H), 7.50 (dt, J = 9.6, 2.8 Hz, 2 H), 7.08 (d, J 
= 1.8 Hz, 1 H), 7.00 (dt, J = 9.2, 2.5 Hz, 2 H), 6.97-6.90 (m, 4 H), 4.05 (s, 2 H), 3.84 (s, 3 H), 
3.82 (s, 3 H), 3.49 (t, J = 5.0 Hz, 2 H), 2.69 (t, J = 5.0 Hz, 2 H); 13C NMR (100 MHz, MeOD-d4) 
δ 159.3, 157.6, 150.3, 149.9, 149.4, 134.0, 131.8, 131.2, 129.1, 123.2, 122.0, 119.4, 117.1, 114.3, 
112.6, 64.0, 56.5, 56.4, 46.4, 42.0; HRMS (ESI) m/z calcd for C24H25BrN3O3 ([M+H]+) 
482.1074, found 482.1071. 
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2.52 
3-(4-(4-Bromophenoxy)phenyl)-1,2,5,6-tetrahydro-1,2,4-triazine (2.52). (deprotection 
of 3,4-dimethoxybenzyl protected triazine) A solution of 3-(4-(4-bromophenoxy)phenyl)-1-(3,4-
dimethoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-triazine (2.53, 0.0500 g, 0.104 mmol) in 4 M HCl in 
dioxane (2.5 mL) was heated at 50 °C for 2.5 d, diluted with Et2O (20 mL) and the resulting 
precipitate was pelleted in the centrifuge and the supernatant removed and repeated 2 times. The 
resulting pellet was suspended in EtOAc (20 mL) and basified with 1 M NaOH (3 mL). The 
layers were separated and the aqueous layer was further extracted with EtOAc (2 x 10 mL). The 
combined organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure. 
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The crude residue was purified by automated chromatography on SiO2 (4 g column, liquid load 
CH2Cl2, gradient 100% CH2Cl2 to 10% MeOH/CH2Cl2; product eluted at 10% MeOH:CH2Cl2) 
to give 2.52 (0.0217 g, 0.0653 mmol, 63%) as a tan/orange waxy solid: IR (CH2Cl2) 3293, 2951, 
1622, 1579, 1478, 1336, 1234, 1165, 1068, 749 cm-1; 1H NMR (400 MHz, CDCl3) δ  7.55 (dt, J 
= 9.2, 2.4 Hz, 2 H), 7.43 (dt, J = 9.4, 2.7 Hz, 2 H), 6.96 (dt, J = 9.2, 2.4 Hz, 2 H), 6.88 (dt, J = 
9.4, 2.7 Hz, 2 H), 4.53 (bs, 1 H), 3.64 (t, J = 4.9 Hz, 2 H), 3.17 (t, J = 4.9 Hz, 2 H); 13C NMR 
(100 MHz, CDCl3) δ 157.6, 156.0, 145.3, 132.7, 130.6, 127.0, 120.7, 118.6, 116.0, 41.9, 40.4; 
HRMS (ESI) m/z calcd for C15H15BrN3O ([M+H]+) 332.0393, found 332.0388. 
5.3.4 Synthesis of 6-(1,2,5,6-Tetrahydro-1,2,4-triazin-3-yl)-2-(4-(4-(1,2,5,6-tetrahydro-
1,2,4-triazin-3-yl)phenoxy)phenyl)-1H-indole 
O
N
N
Boc
N
2.60 
tert-Butyl 6-cyano-2-(4-(4-cyanophenoxy)phenyl)-1H-indole-1-carboxylate (2.60). A 
solution of 4-(4-bromophenoxy)benzonitrile (2.57, 0.750 g, 2.74 mmol) and tert-butyl 6-cyano-
2-(trimethylstannyl)-1H-indole-1-carboxylate (2.31, 1.77 g, 3.28 mmol) in dry degassed DMF 
(15 mL) was treated with Pd(PPh3)2Cl2 (0.192 g, 0.274 mmol) and (iPr)CuCl293 (0.200 g, 0.410 
mmol) at rt,  heated to 80 °C for 18 h, cooled to rt, poured into H2O (30 mL) and extracted with 
Et2O (3 x 80 mL). The combined organic layers were washed with H2O, brine, dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The residue was purified by chromatography 
SiO2 (gradient hexanes to hexanes/EtOAc, 5:1). The product was triturated/sonicated with 
methanol then decanted to give 2.60 (0.694 g, 1.59 mmol, 58%) as a colorless solid: 1H NMR 
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(300 MHz, DMSO-d6) δ 8.44 (bs, 1 H), 7.89 (d, J = 8.4 Hz, 2 H), 7.82 (d, J = 8.3 Hz, 1 H), 7.67 
(d, J = 8.3 Hz, 1 H), 7.61 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.4 Hz, 2 H), 
6.90 (s, 1 H), 1.33 (s, 9 H); 13C NMR (75 MHz, DMSO-d6) δ 160.6, 154.7, 148.8, 142.8, 135.7, 
134.6, 132.2, 130.8, 129.8, 126.1, 121.8, 119.7, 119.6, 118.8, 118.5, 118.3, 109.7, 105.9, 105.5, 
84.8, 27.0; HRMS (ESI) m/z calcd for C23H14N3O3 ([M-tBu+H]+) 380.1030, found 380.1024. 
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2.56 
2-(4-(4-Carboxyphenoxy)phenyl)-1H-indole-6-carboxylic acid (2.56). A solution of 
tert-butyl 6-cyano-2-(4-(4-cyanophenoxy)phenyl)-1H-indole-1-carboxylate (2.60, 0.500 g, 1.15 
mmol) in a mixture of EtOH (125 mL) and H2O (125 mL) was treated with LiOH monohydrate 
(1.45 g, 34.5 mmol). The reaction was mixture was heated to reflux for 11 d, cooled to rt and 
filtered. The filtrate was acidified with 1 M HCl to pH 2 and the resulting precipitate was 
collected by vacuum filtration, and washed with a small amount of H2O. Toluene was added to 
the solid and concentrated under reduced pressure to give 2.56 (0.298 g, 0.799 mmol, 70%) as an 
off-white solid: Mp >350 °C; IR (MeOH) 3437, 3070, 2665, 1681, 1599, 1491, 1417, 1291, 
1260, 1230, 1200, 837, 790, 771 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 12.72 (bs, 2 H), 11.89 
(s, 1 H), 8.02-7.96 (m, 5 H), 7.60 (dd, J = 10.4, 76.0 Hz, 2 H), 7.25 (d, J = 6.6 Hz, 2 H), 7.10 (d, 
J = 6.6 Hz, 2 H), 6.99 (s, 1 H); 13C NMR (100 MHz, DMSO-d6) δ 168.1, 166.6, 160.6, 155.1, 
140.3, 136.3, 132.0, 131.7, 128.0, 127.3, 123.4, 120.3, 119.4, 117.5, 113.1, 98.9; HRMS (ESI) 
m/z calcd for C22H16NO5 ([M+H]+) 374.1023, found 374.1008. 
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2.61a 
N'-(2-Azidoethyl)-2-(4-(4-(2-(2-azidoethyl)-2-
benzylhydrazinecarbonyl)phenoxy)phenyl)-N'-benzyl-1H-indole-6-carbohydrazide (2.61a). 
A solution of 2-(4-(4-carboxyphenoxy)phenyl)-1H-indole-6-carboxylic acid (2.56, 0.200 g, 
0.536 mmol), HATU (0.713 g, 1.87 mmol), and HOAt (0.219 g, 1.61 mmol) in DMF (4.0 mL) 
cooled to 0 °C was treated with DIPEA (0.60 mL, 3.21 mmol) and stirred at 0 °C for 2 h where 
the color had changed from a brown yellow to a brown orange. The reaction mixture was treated 
with a solution of 1-(2-azidoethyl)-1-benzylhydrazine (2.47a, 0.615 g, 3.21 mmol) in DMF (1.5 
mL), warmed to rt, and stirred for 2 d, diluted with EtOAc (75 mL) and satd. aqueous NaHCO3 
(100 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2 x 75 
mL). The combined organic layers were washed with satd. aqueous NaHCO3 (50 mL), brine (2 x 
50 mL), dried (Na2SO4) and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (hexanes/EtOAc, 1:4 w/ 2% Et3N) followed by filtration 
through basic alumina (hexanes/EtOAc, 1:2 to hexanes/EtOAc, 1:4) to give 2.61a (0.158 g, 
0.220 mmol, 41%) as a pale yellow foam: IR (CH2Cl2) 3259, 2925, 2854, 2096, 1644, 1599, 
1489, 1458, 1238, 1171, 752 cm-1; 1H NMR (500 MHz, Acetone-d6) δ 10.92 (bs, 1 H), 8.81 (bs, 
1 H), 8.71 (bs, 1 H), 7.93-7.90 (m, 2 H), 7.87 (s, 1 H), 7.80-7.78 (m, 2 H), 7.53 (d, J = 8.0 Hz, 1 
H), 7.47-7.43 (m, 5 H), 7.29 (td, J = 7.4, 2.0 Hz, 5 H), 7.25-7.21 (m, 2 H), 7.16-7.13 (m, 2 H), 
7.05-7.02 (m, 2 H), 6.91 (dd, J = 2.0, 0.7 Hz, 1 H), 4.34 (s, 2 H), 4.30 (s, 2 H), 3.50-3.46 (m, 4 
H), 3.37 (td, J = 10.4, 4.4 Hz, 4 H) ; 13C NMR (125 MHz, Acetone-d6) δ 168.1, 166.4, 163.3, 
160.7, 157.1, 140.8, 139.3, 139.1, 137.7, 132.5, 130.2, 129.9 (2 C), 129.2, 129.0, 128.7, 128.0, 
120.8, 120.4, 119.5, 118.7, 111.9, 99.9 (2 C), 61.2, 61.1, 55.8 (2 C), 49.8, 49.7; HRMS (ESI) m/z 
calcd for C40H38N11O3 ([M+H]+) 720.3154, found 720.3151.  
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2.62a 
6-(1-Benzyl-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)-2-(4-(4-(1-benzyl-1,2,5,6-
tetrahydro-1,2,4-triazin-3-yl)phenoxy)phenyl)-1H-indole (2.62a). A solution of 2.61a (0.130 
g, 0.181 mmol) in degassed PhCl (14 mL) and THF (1 mL) was treated with a solution of PMe3 
(1 M solution in THF, 1.08 mL, 1.08 mmol) and the reaction was warmed to 50 °C for 2 h under 
an atmosphere of nitrogen. The reaction vessel was sealed and heated to 180 °C for 2 h. The 
resulting yellow solution was applied directly to a column of SiO2 (equilibrated with hexanes w/ 
3% Et3N) and purified by chromatography on SiO2 (hexanes to 4:1 EtOAc/Acetone w/ 3% 
Et3N), and chromatographed on basic Al2O3 (EtOAc/Acetone, 2:1) to give 2.62a (0.0239 g, 
0.0378 mmol, 21%) as a pale yellow foam: IR (Acetone) 3657, 2990, 2889, 1611, 1489, 1382, 
1242, 1153, 1072, 956, 821 cm-1; 1H NMR (400 MHz, Acetone-d6) δ 10.71 (bs, 1 H), 7.88-7.85 
(m, 2 H), 7.81 (s, 1 H), 7.78-7.74 (m, 2 H), 7.50-7.44 (m, 6 H), 7.32 (t, J = 7.6 Hz, 4 H), 7.26-
7.23 (m, 2 H), 7.11-7.08 (m, 2 H), 7.04-7.00 (m, 2 H), 6.83 (bs, 1 H), 5.78 (bs, 1 H), 5.72 (bs, 1 
H), 4.14 (s, 2 H), 4.13 (s, 2 H), 3.58-3.53 (m, 4 H), 2.73-2.70 (m, 4 H); 13C NMR (100 MHz, 
Acetone-d6) δ 158.1, 157.6, 145.5, 143.7, 139.8, 139.6, 139.4, 138.1, 132.1, 130.6, 130.5, 130.0 
(2 C), 128.9, 128.8, 127.7, 127.6, 127.5, 120.2, 120.0, 119.1, 118.4, 108.9, 99.6, 64.3, 64.2, 46.4, 
46.2, 42.4, 42.3; HRMS (ESI) m/z calcd for C40H38N7O ([M+H]+) 632.3132, found 632.3136. 
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2.61b 
N'-(2-azidoethyl)-2-(4-(4-(2-(2-azidoethyl)-2-(4-
methoxybenzyl)hydrazinecarbonyl)phenoxy)phenyl)-N'-(4-methoxybenzyl)-1H-indole-6-
carbohydrazide (2.61b). A solution of 2-(4-(4-carboxyphenoxy)phenyl)-1H-indole-6-carboxylic 
acid (2.56, 0.100 g, 0.268 mmol) in CH2Cl2 (5 mL) was treated with PyBrOP (0.375 g, 0.804 
mmol), 1-(2-azidoethyl)-1-(4-methoxybenzyl)hydrazine (2.47b, 0.148 g, 0.670 mmol) and 
DIPEA (0.37 mL, 2.14 mmol). The solution was stirred at rt for 17 h, poured onto H2O (5 mL), 
and extracted with EtOAc (3 x 5 mL). The combined organic layers were and washed with 5% 
NaHCO3, brine, dried (Na2SO4) and concentrated under reduced pressure. The crude residue was 
purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 with 5% Et3N) to give 2.61b (0.0512 
g, 0.0657 mmol, 25%) as a light yellow solid: Mp 73.6-77.9 °C; IR (neat) 3241, 2930, 2093, 
1642, 1610, 1510, 1487, 1454, 1301, 1234, 1171, 1031, 822 cm-1; 1H NMR (400 MHz, CDCl3) δ 
9.96 (bs, 1 H), 8.00 (s, 1 H), 7.77 (d, J = 8.4 Hz, 2 H), 7.57-7.53 (overlapping doublets, J = 8.4, 
7.6 Hz, 3 H), 7.30-7.20 (m, 6 H), 7.02 (d, J = 8.8 Hz, 2 H), 6.95 (d, J = 8.8 Hz, 2 H), 6.84-6.77 
(m, 5 H), 4.20 (s, 2 H), 4.18 (s, 2 H), 3.76 (s, 3 H), 3.73 (s, 3 H), 3.44-3.35 (m, 4 H), 3.32 (dd, J 
= 6.0, 5.2 Hz, 2 H), 3.27 (dd, J = 6.0, 5.2 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 168.3, 166.7, 
160.2, 159.1 (2 C), 155.8, 140.4, 136.6, 132.0, 130.6, 130.5, 128.9, 128.4, 128.3, 128.1 (2 C), 
127.3, 126.4, 120.1, 120.0, 118.0, 117.7, 113.8, 111.4, 99.4, 59.9, 59.7, 55.2 (2 C), 54.4, 49.0 (2 
C); HRMS (ESI) m/z calcd for C42H42N11O5 ([M+H]+) 780.3365, found 780.3350. 
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2.61c 
N’-(2-Azidoethyl)-2-(4-(4-(2-(2-azidoethyl)-2-(3,4-
dimethoxybenzyl)hydrazinecarbonyl)phenoxy)phenyl)-N’-(3,4-dimethoxybenzyl)-1H-
indole-6-carbohydrazide (2.61c). A solution of 2-(4-(4-carboxyphenoxy)phenyl)-1H-indole-6-
carboxylic acid (2.56, 0.0500 g, 0.134 mmol) in DMF (1.5 mL) was treated with HATU (0.204 
g, 0.536 mmol), 1-(2-azidoethyl)-1-(3,4-dimethoxybenzyl)hydrazine (2.47c, 0.135 g, 0.536 
mmol) and DIPEA (0.240 mL, 1.34 mmol). The reaction mixture was stirred at rt for 17 h, 
diluted with H2O, and stirred at rt for 5 min, extracted with EtOAc (3 x 10 mL). The combined 
organic layers were washed with H2O, satd. aqueous NaHCO3, brine, dried (Na2SO4), filtered, 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (hexanes/EtOAc, 1:6 to EtOAc with 2% Et3N) to give 2.61c (0.0429 g, 0.0511 mmol, 38%) 
as an off-white foam: IR (neat) 3277, 2930, 2833, 2095, 1646, 1596, 1512, 1487, 1452, 1232, 
1156, 1025, 727 cm-1; 1H NMR (300 MHz, CDCl3) δ 9.86 (s, 1 H), 7.93 (s, 1 H), 7.75 (d, J = 8.4 
Hz, 2 H), 7.57-7.50 (m, 3 H), 7.37 (s, 1 H), 7.27 (s, 1 H), 7.20 (d, J = 8.1 Hz, 1 H), 7.03-6.93 (m, 
6 H), 6.86-6.71 (m, 5 H), 4.21 (bd, J = 4.2 Hz, 4 H), 3.82 (s, 3 H), 3.79 (s, 6 H), 3.74 (s, 3 H), 
3.42-3.34 (m, 8 H); 13C NMR (75 MHz, CDCl3) δ 168.4, 166.8, 160.2, 155.9, 149.0, 148.5, 
140.4, 136.6, 132.0, 129.2, 128.9, 128.2, 128.0, 127.3, 126.5, 121.6, 121.4, 120.0, 118.1, 117.8, 
112.4, 112.3, 111.3, 111.0, 99.4, 60.0, 55.8, 54.6, 48.9; HRMS (ESI) m/z calcd for C44H46N11O7 
([M+H]+) 840.3576, found 840.3574. 
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2.62c 
6-(1-(3,4-Dimethoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)-2-(4-(4-(1-(3,4-
dimethoxybenzyl)-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)phenoxy)phenyl)-1H-indole (2.62c). 
Two flame-dried microwave vials each containing a solution of N’-(2-azidoethyl)-2-(4-(4-(2-(2-
azidoethyl)-2-(3,4-dimethoxybenzyl)hydrazinecarbonyl)phenoxy)phenyl)-N’-(3,4-
dimethoxybenzyl)-1H-indole-6-carbohydrazide (2.61c, 0.200 g, 0.238 mmol) in THF (6 mL) and 
chlorobenzene (12 mL) were sparged with Ar for 20 min, treated with PMe3 (1 M solution in 
THF, 1.43 mL, 1.43 mmol) and heated at 180 °C in the microwave for 1 h. The two solutions 
were combined and concentrated under reduced pressure. The residue was dissolved in CH2Cl2 
(100 mL) and washed with H2O, brine, dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (100% hexanes to 
MeOH/EtOAc, 1:9 with 2% Et3N) to give 2.62c (0.0947 g, 0.126 mmol, 27%) as a pale yellow 
foam: IR (CH2Cl2) 3419, 3268, 2992, 2947, 2880, 1668, 1603, 1512, 1488, 1462, 1352, 1236, 
1156, 1025, 843, 735 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.50 (s, 1 H), 7.89 (s, 1 H), 7.61 (d, J 
= 8.5 Hz, 2 H), 7.56 (d, J = 8.5 Hz, 2 H), 7.49 (d, J = 8.5 Hz, 1 H), 7.30 (dd, J = 8.0, 1.0 Hz, 1 
H), 7.04 (d, J = 1.5 Hz, 1 H), 6.98 (dd, J = 9.0, 2.0 Hz, 4 H), 6.94-6.89 (m, 2 H), 6.82 (d, J = 8.0 
Hz, 1 H), 6.77 (d, J = 8.0 Hz, 1 H), 6.66 (d, J = 1.0 Hz, 1 H), 4.70 (bs, 1 H), 4.47 (s, 1 H), 4.14 
(s, 4 H), 3.87 (s, 6 H), 3.83 (s, 3 H), 3.77 (s, 3 H), 3.56-3.52 (m, 4 H), 2.77 (t, J = 4.8 Hz, 2 H), 
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2.73 (t, J = 4.8 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ 157.6, 156.7, 148.8, 148.3, 148.2, 
147.0, 144.5, 138.9, 136.9, 130.8, 130.6 (2 C), 130.1, 128.8, 127.7, 127.1, 126.9, 121.6 (2 C), 
120.0, 119.1, 118.7, 117.4, 112.5, 112.4, 110.8, 109.1, 99.1, 63.8, 63.7, 55.9, 55.8, 45.5, 45.1, 
41.7, 46.6; HRMS (ESI) m/z calcd for C44H46N7O5 ([M+H]+) 752.3555, found 752.3537. 
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Figure 5.1. DSC thermogram for 2.47b. 
Table 5.1. DSC data for hydrazines 2.47b and 2.47c. 
Compound Onset (°C) Peak (°C) Energy J/g Energy kJ/mol 
2.47b 154.8 209.9 564.4 124.8 
2.47c 185.3 238.5 490.7 123.7 
Trityl azide 167.9 198.0 612.5 174.6 
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3.11 
(1RS,2SR)-2-Phenylcyclopropanecarboxylic acid (3.11).413 A solution of 3-
phenylpropiolic acid (3.9, 1.60 g, 10.9 mmol) and quinoline (4.1 mL, 34.1 mmol) in EtOH (80 
mL) at rt was treated with Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 1.17 g, equivalent 
to 5 mol% Pd). The flask was evacuated and back-filled with H2 (3x) using a balloon. The 
resulting suspension was stirred for 20 h, filtered through a short pad of Celite, washed (EtOAc), 
and concentrated under reduced pressure. The residue was dissolved in ether and washed with 1 
M aqueous HCl. The organic phase was dried (Na2SO4), filtered, and concentrated under reduced 
pressure to give a mixture of cis-cinnamic acid (3.10) and trans-cinnamic acid (ratio 5:1, 0.527 
g, 3.56 mmol) as a brown liquid. 
A solution of Et2Zn (1 M in CH2Cl2, 1.1 mL Et2Zn in 10.5 mL CH2Cl2, 10.5 mmol) was 
diluted with CH2Cl2 (8.0 mL) and treated with a solution of TFA (0.78 mL, 10.5 mmol) in 
CH2Cl2 (6.0 mL) at 0 °C under an Ar atmosphere, stirred for 20 min, treated with a solution of 
CH2I2 (0.85 mL, 10.5 mmol) in CH2Cl2 (6.0 mL) stirred for 20 min and treated with a solution of 
cis/trans-cinamic acid (0.520 g, 3.51 mmol) in CH2Cl2 (10 mL) was added to the mixture. The 
reaction was stirred at rt for 16 h, diluted with satd. aqueous NH4Cl, extracted with Et2O, dried 
(MgSO4), filtered, and concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (12 g column, liquid load CH2Cl2, gradient 100% hexanes to 
30% EtOAc/hexanes) and, following recrystallization (toluene), to give 3.11 (0.0690 g, 0.591 
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mmol, 6% (2 steps)) as colorless needles: 1H NMR (500 MHz, CDCl3) δ 11.35 (bs, 1 H), 7.23-
7.16 (m, 5 H), 2.58 (q, J = 8.3 Hz, 1 H), 1.99 (dd, J = 8.3, 6.3 Hz, 1 H), 1.62 (q, J = 6.3 Hz, 1 H), 
1.34-1.29 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 177.4, 135.9, 129.2, 127.9, 126.7, 26.6, 21.4, 
12.0. 
N
N
O
F
3.13a 
(4-(2-fluorophenyl)piperazin-1-yl)((1SR,2RS)-2-phenylcyclopropyl)methanone 
(3.13a). A solution of (1SR,2RS)-2-phenylcyclopropanecarboxylic acid (3.11, 0.0260 g, 0.160 
mmol) and HATU (0.0914 g, 0.240 mmol) in CH2Cl2 (1 mL) was cooled to 0 °C and treated with 
DIPEA (83 µL, 0.481 mmol) warmed to rt over 45 min, cooled to 0 °C and treated with a 
solution of 1-2-fluorophenyl piperazine (3.12a, 0.0318 g, 0.176 mmol) in CH2Cl2 (0.5 mL) and 
stirred at rt for 17 h, diluted with H2O and washed with EtOAc (2 × 10 mL). The combined 
organic layers were washed with 1 M aqueous NaHSO4, satd. aqueous NaHCO3, dried (Na2SO4), 
and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 100% 
EtOAc) to give 3.13a (0.0463 g, 0.0143 mmol, 89%) a light orange oil: IR (CH2Cl2) 3005, 2895, 
1635, 1489, 1458, 1431, 1223, 1206, 1033, 749, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26-
7.22 (m, 2 H), 7.15-7.12 (m, 3 H), 7.04-6.98 (m, 2 H), 6.97-6.92 (m, 1 H), 6.70 (dt, J = 8.8, 1.6 
Hz, 1 H), 3.88 (app dt, J = 13.2, 3.6 Hz, 1 H), 3.72 (app dt, J = 13.2, 4.0 Hz, 1 H), 3.60 (ddd, J = 
12.0, 8.8, 3.2 Hz, 1 H), 3.32 (ddd, J = 12.0, 8.4, 2.8 Hz, 1 H), 2.97-2.94 (m, 2 H), 2.48-2.36 (m, 2 
H), 2.21-2.12 (m, 2 H), 1.86 (dd, J = 12.8, 5.6 Hz, 1 H), 1.34 (ddd, J = 8.4, 8.4, 5.2 Hz, 1 H); 13C 
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NMR (100 MHz, CDCl3) δ 167.1, 155.6 (d, JCF = 244.0 Hz), 139.6 (d, JCF = 9.0 Hz), 137.5, 
128.1, 127.3, 126.3, 124.4 (d, JCF = 4.0 Hz), 122.9 (d, JCF = 32.0 Hz), 119.0 (d, JCF = 3.0 Hz), 
116.1 (d, JCF = 21 Hz), 50.7, 50.3, 45.2, 41.8, 24.3, 24.0, 10.5; HRMS (ESI) m/z calcd for 
C20H22FN2O ([M+H]+) 325.1711, found 325.1711. 
N
N
O
Cl  
3.13b 
(4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1SR,2RS)-2-
phenylcyclopropyl)methanone (3.13b). A solution of (1SR,2RS)-2-
phenylcyclopropanecarboxylic acid (3.11, 0.0260 g, 0.160 mmol) and HATU (0.0914 g, 0.240 
mmol) in CH2Cl2 (1 mL) was cooled to 0 °C and treated with DIPEA (83 µL, 0.481 mmol) and 
warmed to rt over 45 min. The solution was cooled to 0 °C again and added a solution of 1-(5-
chloro-2-methylphenyl)piperazine (3.12b, 0.0372 g, 0.176 mmol) in CH2Cl2 (0.5 mL) and stirred 
at rt for 17 h, diluted with H2O and washed with EtOAc (2 × 10 mL). The combined organic 
layers were washed with 1 M aqueous NaHSO4, satd. aqueous NaHCO3, dried (Na2SO4), and 
concentrated. The crude residue was purified by automated chromatography on SiO2 (4g column, 
liquid load CH2Cl2, gradient 100% hexanes to 100% EtOAc) to give the 3.13b (0.0169 g, 0.0476 
mmol, 30%) a light orange oil: IR (CH2Cl2) 3018, 2913, 1635, 1487, 1458, 1431, 1223, 1206, 
1033, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.31-7.28 (m, 2 H), 7.22 (tt, J = 7.2, 1.6 Hz, 1 H), 
7.18-7.15 (m, 2 H), 7.05 (d, J = 8.2 Hz, 1 H), 6.94 (dd, J = 8.2, 2.0 Hz, 1 H), 6.63 (d, J = 2.0 Hz, 
1 H), 3.96 (app d, J = 12.8 Hz, 1 H), 3.76 (app d, J = 12.8 Hz, 1 H), 3.54-3.48 (m, 1 H), 3.22-
3.16 (m, 1 H), 2.70-2.66 (m, 2 H), 2.45 (ddd, J = 9.2, 9.2, 7.2 Hz, 1 H), 2.21-2.13 (m, 5 H), 1.95-
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1.89 (m, 1 H), 1.86 (dd, J = 12.8, 6.0 Hz, 1 H), 1.36 (ddd, J = 8.4, 8.4, 5.6 Hz, 1 H); 13C NMR 
(100 MHz, CDCl3) δ 167.3, 152.0, 137.7, 131.9, 131.7, 131.1, 128.3, 127.4, 126.6, 123.5, 119.9, 
51.6, 45.6, 42.2, 24.6, 24.1, 17.3, 10.7; HRMS (ESI) m/z calcd for C21H24ClN2O ([M+H]+) 
355.1572, found 355.1570. 
F
TMS
3.15a 
((4-Fluorophenyl)ethynyl)trimethylsilane (3.15a).415,481 A solution of Pd(PPh3)2Cl2 
(0.361 g, 0.514 mmol), CuI (0.0979 g, 0.514 mmol), and 4-fluorobromobenzene (3.14a, 5.66 
mL, 51.4 mmol) in Et3N (110 mL) was sparged with Ar for 15 min and treated with 
(trimethylsilyl)acetylene (10.9 mL, 77.1 mmol) and the solution was sparged with Ar for 5 min. 
The reaction mixture was heated to 80 °C for 16 h, cooled to rt, filtered through Celite, washed 
(Et2O) until the washes appeared colorless, and the combined filtrates were concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (hexanes) to give 
3.15a (9.03 g, 47.0 mmol, 91%) as a pale orange oil: 1H NMR (300 MHz, CDCl3) δ 7.47-7.42 
(m, 2 H), 6.99 (t, J = 8.7 Hz, 2 H), 0.25 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ 162.6 (d, JCF = 
244.5 Hz), 133.9 (d, JCF = 8.3 Hz), 119.3 (d, JCF = 4.0 Hz), 115.5 (d, J CF = 21.8 Hz), 104.0, 93.8, 
-0.07.
F
OH
O
3.16a 
3-(4-Fluorophenyl)propiolic acid (3.16a).415 CsF (4.74 g, 31.2 mmol) was loaded into 
an oven-dried 250-mL round bottom flask in a glovebox. The flask was removed from the 
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glovebox, attached to a CO2 balloon, equipped with a magnetic stirrer and a septum, and filled 
with anhydrous DMSO (60 mL). Neat ((4-fluorophenyl)ethynyl)trimethylsilane (3.15a, 5.00 g, 
26.0 mmol) was added dropwise. The reaction mixture was stirred under and atmosphere of CO2 
at rt for 17 h, diluted with H2O (600 mL) and washed with CH2Cl2 (2 × 150 mL). The aqueous 
layer was acidified at 0 °C to pH 1 with 6 M aqueous HCl and then extracted with Et2O (3 × 200 
mL). The combined organic layers were dried (MgSO4), filtered, and concentrated under reduced 
pressure to give 3.16a (3.02 g, 18.4 mmol, 71%) as an orange solid: 1H NMR (400 MHz, 
Acetone-d6) δ 11.74 (bs, 1 H), 7.71 (dd, J = 8.6, 5.6 Hz, 2 H), 7.26 (t, J = 8.6 Hz, 2 H); 13C NMR 
(100 MHz, Acetone-d6) δ 164.8 (d, JCF = 249.0 Hz), 154.7, 136.1 (d, JCF = 9.0 Hz), 117.1 (d, JCF 
= 22.5 Hz), 84.6, 81.8. 
O
N
N
F
Cl  
3.17a 
1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(4-fluorophenyl)prop-2-yn-1-one 
(3.17a). A solution of 3-(4-fluorophenyl)propiolic acid (3.16a, 3.00 g, 18.3 mmol) and 1-(5-
chloro-2-methylphenyl)piperazine (3.12b, 4.62 g, 21.9 mmol) in anhydrous CH2Cl2 (180 mL) at 
0 °C was treated with Et3N (6.35 mL, 45.7 mmol), followed by dropwise addition of T3P (50 
wt.% solution in EtOAc, 19.4 mL, 27.4 mmol). The reaction mixture was stirred at 0 °C for 30 
min, warmed to rt for 24 h, diluted with CH2Cl2 (200 mL), washed with 1 M aqueous HCl (150 
mL), dried (MgSO4), filtered, and concentrated under reduced pressure. The residue was purified 
by chromatography on SiO2 (hexanes/EtOAc, 2:1) to give 3.17a (5.22 g, 14.6 mmol, 80%) as an 
off white solid: Mp 138.7-140.4 °C; IR (neat) 2924, 2216, 1625, 1596, 1504, 1443, 1431, 1219, 
195 
1038, 837 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.55 (dd, J = 7.5, 5.4 Hz, 2 H), 7.12-6.94 (m, 5 
H), 3.96 (app t, J = 4.8 Hz, 2 H), 3.82 (app t, J = 4.8 Hz, 2 H), 2.95 (app t, J = 4.8 Hz, 2 H), 2.87 
(app t, J = 4.8 Hz, 2 H,), 2.28 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 163.5 (d, JCF = 250.5 Hz), 
153.0, 151.7, 134.5 (d, JCF = 9.0 Hz), 132.1, 131.8, 130.9, 123.7, 119.8, 116.4 (d, JCF = 3.8 Hz), 
116.0 (d, JCF = 22.5 Hz), 89.9, 80.9, 51.9, 51.3, 47.4, 41.8, 17.3; HRMS (ESI) m/z calcd for 
C20H19ClFON2 ([M+H]+) 357.1164, found 357.1165. 
O
N
N
F
Cl
3.18a 
(Z)-1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(4-fluorophenyl)prop-2-en-1-
one (3.18a). A solution of 1-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)-3-(4-
fluorophenyl)prop-2-yn-1-one (5.00 g, 14.0 mmol) in dry EtOAc (140 mL) was treated with 
Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 0.298 g, equivalent to 1 mol% Pd) and 
quinoline (0.83 mL, 7.01 mmol). The reaction vessel was placed under vacuum, backfilled with 
H2 (balloon, 2x) and allowed to stir under and atmosphere of H2 for 6 h. Analysis by TLC (2:1, 
hexanes/EtOAc) indicated that 3.17a had been mostly consumed. The reaction mixture was 
filtered through Celite, washed (EtOAc), and the combined filtrates were washed with 1 M 
aqueous HCl, dried (MgSO4), filtered, and concentrated under reduced pressure. The crude 
residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to give 3.18a (3.15 g, 
8.78 mmol, 63%, 87% brsm) as a colorless solid: IR (neat) 2913, 2239, 1616, 1506, 1437, 1223, 
837, 725 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.41-7.36 (m, 2 H), 7.08-7.02 (m, 3 H), 6.96 (dd, J
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= 8.1, 2.1 Hz, 1 H), 6.80 (d, J = 2.1 Hz, 1 H), 6.66 (d, J = 12.5 Hz, 1 H), 6.05 (d, J = 12.5 Hz, 1 
H), 3.80 (t, J = 5.0 Hz, 2 H), 3.49 (t, J = 5.0 Hz, 2 H), 2.80 (t, J = 5.0 Hz, 2 H), 2.53 (t, J = 5.0 
Hz, 2 H), 2.21 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 167.3, 162.7 (d, JCF = 247.0 Hz), 151.7, 
132.6, 132.0, 131.8, 131.5 (d, JCF = 4.0 Hz), 132.1, 131.8, 130.9, 130.2 (d, JCF = 9.0 Hz), 123.6, 
122.7, 119.6, 115.6 (d, JCF = 22 Hz), 51.4, 51.2, 46.5, 41.5, 17.3; HRMS (ESI) m/z calcd for 
C20H21ClFON2 ([M+H]+) 359.1321, found 359.1329. 
N
N
O
F
Cl  
JJ450 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
fluorophenyl)cyclopropyl)methanone (JJ450).  THF (90 mL) was degassed by sparging with 
Ar for 60 min and treated at rt under Ar atmosphere with anhydrous CrCl2 (6.43 g, 51.8 mmol) 
followed by (Z)-1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(4-fluorophenyl)prop-2-en-1-
one (3.18a, 3.10 g, 8.64 mmol) and CH2ICl (3.36 mL, 43.2 mmol). The reaction mixture was 
stirred for 20 h at 80 °C, cooled to rt, diluted with 1 M aqueous HCl (300 mL) and extracted with 
EtOAc (3 x 300 mL). The combined organic layers were filtered through a plug of basic Al2O3, 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (1:1, hexanes/EtOAc) to give an oil that was further purified twice by chromatography on 
basic Al2O3 (hexanes/EtOAc, 1:1) to give JJ450 (2.76 g, 7.41 mmol, 86%) as a clear oil that 
solidified after storage on high vacuum: Mp 78.2-80.4 °C (hexanes); IR (CH2Cl2) 2936, 1637, 
1592, 1510, 1487, 1435, 1223, 1033, 837, 815 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.16-7.11 (m, 
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2 H), 7.07 (dd, J = 8.1, 0.5 Hz, 1 H), 7.00-6.94 (m, 3 H), 6.73 (d, J = 2.1 Hz, 1 H), 3.81-3.76 (m,
1 H), 3.71-3.60 (m, 2 H), 3.36 (ddd, J = 12.4, 8.8, 3.1 Hz, 1 H), 2.79-2.71 (m, 2 H), 2.45 (td, J = 
8.8, 7.0 Hz, 1 H), 2.35-2.29 (m, 1 H), 2.26-2.16 (m, 5 H), 1.83 (dt, J = 7.0, 5.6 Hz, 1 H), 1.35 (td, 
J = 8.8, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 167.2, 161.7 (d, JCF = 244.0 Hz), 151.9, 
133.1 (d, JCF = 3.0 Hz), 132.0, 131.8, 130.9, 129.1 (d, JCF = 8.0 Hz), 123.6, 119.7, 115.0 (d, JCF = 
21.0 Hz), 51.8, 51.6, 45.6, 42.2, 23.8, 23.5, 17.3, 10.7; HRMS (ESI) m/z calcd for C21H23ClFON2 
([M+H]+) 373.1477, found 373.1478. 
N
N
O
F
(1S,2R)-JJ450 (1R,2S)-JJ450
Cl
N
N
O
F
Cl
Racemic (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
fluorophenyl)cyclopropyl)methanone (JJ450) was separated on a SFC Chiralpak-IC semiprep 
(250 x 10 mm) column (20% MeOH, 6 mL/min, 220 nM, P=100) to give (4-(5-chloro-2-
methylphenyl)piperazin-1-yl)((1S,2R)-2-(4-fluorophenyl)cyclopropyl)methanone ((1S,2R)-
JJ450) (retention time 13.1 min) as a colorless viscous oil (100% purity by ELSD): [α]20D  -
164.3 (c 1.34, MeOH); 1H NMR (300 MHz, CDCl3) δ 7.17-7.10 (m, 2 H), 7.07 (d, J = 8.1 Hz, 1
H), 7.02-6.94 (m, 3 H), 6.72 (d, J = 2.1 Hz, 1 H), 3.83-3.75 (m, 1 H), 3.72-3.58 (m, 2 H), 3.39-
3.31 (m, 1 H), 2.81-2.69 (m, 2 H), 2.45 (td, J = 8.6, 6.9 Hz, 1 H), 2.36-2.25 (m, 1 H), 2.25-2.15 
(m, 5 H), 1.83 (dt, J = 6.9, 5.6 Hz, 1 H), 1.35 (td, J = 8.6, 5.6 Hz, 1 H); HRMS (ESI) m/z calcd 
for C21H23ClFON2 ([M+H]+) 373.1477, found 373.1476. The enantiomeric excess was >99.9% 
ee (SFC Chiralpak-IC (250 x 4.6 mm); 20% MeOH, 220 nM, 2 mL/min; retention time: 9.8 
min). 
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(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1R,2S)-2-(4-
fluorophenyl)cyclopropyl)methanone ((1S,2R)-JJ450) (retention time 16.5 min) was obtained as 
a colorless viscous oil (100% purity by ELSD): [α]20D  +167.1 (c 1.27, MeOH); 1H NMR (300 
MHz, CDCl3) δ 7.17-7.10 (m, 2 H), 7.07 (d, J = 8.1 Hz, 1 H), 7.01-6.94 (m, 3 H), 6.72 (d, J = 2.1 
Hz, 1 H), 3.82-3.74 (m, 1 H), 3.71-3.60 (m, 2 H), 3.39-3.30 (m, 1 H), 2.81-2.68 (m, 2 H), 2.45 
(td, J = 8.6, 7.0 Hz, 1 H), 2.35-2.26 (m, 1 H), 2.25-2.15 (m, 5 H), 1.83 (dt, J = 7.0, 5.6 Hz, 1 H), 
1.35 (td, J = 8.6, 5.6 Hz, 1 H); HRMS (ESI) m/z calcd for C21H23ClFON2 ([M+H]+) 373.1477, 
found 373.1476. The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 4.6 mm); 
20% MeOH, 220 nM, 2 mL/min; retention time: 12 min). 
JJ450	Chiralpak-IC,	20%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-JJ450,	(-)-rota@on,	Chiralpak-IC,	20%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-JJ450,	(+)-rota@on,	Chiralpak-IC,	20%	
MeOH,	7	mL/min,	220	nm	
 
Figure 5.2. SFC chromatograms for JJ450 and separated enantiomers. 
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5.4.1 Synthesis of JJ450 Analogs 
CF3
CO2H
3.16b 
3-(3-(Trifluoromethyl)phenyl)propiolic acid (3.16b).415,482-483 A solution of 
Pd(PPh3)2Cl2 (0.0306 g, 0.0436 mmol), CuI (0.00829 g, 0.0436 mmol), and 3-
bromobenzotriflouride 3.14b (0.62 mL, 4.36 mmol) in Et3N (8.7 mL) was sparged with Ar for 15 
min and treated with (trimethylsilyl)acetylene (0.93 mL, 6.53 mmol) and sparged for an 
additional 2 min, heated to 80 °C for 16 h, cooled to rt, filtered through Celite, washed (Et2O) 
until the washes appeared colorless and the filtrate was concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (hexanes) to give the trimethyl((3-
(trifluoromethyl)phenyl)ethynyl)silane (3.15b, 1.03 g, 4.24 mmol) as a pale yellow oil. 
A solution of CsF (0.775 g, 5.10 mmol) in dry DMSO (6.5 mL) under an atmosphere of 
CO2 (balloon) at rt was treated with a solution of trimethyl((3-
(trifluoromethyl)phenyl)ethynyl)silane (3.15b, 1.03 g, 4.25 mmol) dropwise and the reaction was 
stirred under CO2 at rt for 17 h. The reaction mixture was diluted with H2O (80 mL) and 
extracted with CH2Cl2 (2 × 25 mL). The aqueous layer was acidified (> pH 1) with 6 M aqueous 
HCl at 0 °C and extracted with Et2O (3 × 25 mL). The combined organic layers were dried 
(MgSO4), concentrated under reduced pressure, and dried under high vacuum to give 3.16b 
(0.774 g, 3.62 mmol, 83% (2 steps)) as an pale tan orange waxy solid: 1H NMR (400 MHz, 
Acetone-d6) δ 11.85 (bs, 1 H), 7.95-7.87 (m, 3 H), 7.36 (t, J = 7.4 Hz, 1 H); 13C NMR (100 MHz, 
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Acetone-d6) δ 154.3, 137.1, 131.7 (q, JCF = 33.0 Hz), 130.0 (q, JCF = 3.8 Hz), 128.1 (q, JCF = 3.4 
Hz), 124.5 (q, JCF = 272.0 Hz), 121.7, 83.6, 82.9. 
CO2H
F5S  
3.16c 
3-(4-(Pentafluoro-λ6-sulfaneyl)phenyl)propiolic acid (3.16c). A solution of 
Pd(PPh3)2Cl2 (0.0365 g, 0.0519 mmol), CuI (0.0100 g, 0.0519 mmol), and (4-
bromophenyl)pentafluoro-λ6-sulfane (3.14c, 1.50 g, 5.19 mmol) in Et3N (11 mL) was sparged 
with Ar for 10 min, treated with (trimethylsilyl)acetylene (1.10 mL, 7.79 mmol), sparged with Ar 
for 5 min, heated to 80 °C for 22 h, cooled to rt, filtered through Celite, washed (Et2O) until the 
washes appeared colorless, and the combined filtrates were concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (hexanes) to give 3.15c (1.32 g, 4.40 
mmol) as a pale yellow oil. 
A solution of CsF (0.801 g, 5.27 mmol) in dry DMSO (3 mL) under CO2 (balloon) at rt 
was treated with a solution of trimethyl((4-(pentafluoro-λ6-sulfaneyl)phenyl)ethynyl)silane 
(3.15c, 1.32 g, 4.40 mmol) in DMSO (5.8 mL) dropwise and the reaction was stirred under CO2 
at rt for 25 h, diluted with H2O (90 mL) and extracted with CH2Cl2 (2 × 50 mL). The aqueous 
layer was acidified (> pH 1) with 6 M aqueous HCl at 0 °C and extracted with Et2O (3 × 50 mL). 
The combined organic layers were washed with H2O (50 mL), dried (MgSO4), concentrated 
under reduced pressure, and dried under high vacuum to give 3.16c (0.338 g, 1.24 mmol, 24% (2 
steps)) as light brown solid: Mp 156.5–159.6 °C; IR (CHCl3) 2979, 2876, 2577, 2235, 1677, 
1416, 1298, 1217, 886, 829, 751 cm-1; 1H NMR (400 MHz, CDCl3) δ 10.00 (bs, 1 H), 7.82 (dt, J 
= 9.0, 2.0 Hz, 2 H), 7.73 (d, J = 9.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 155.2 (quint, 
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JCF = 19.0 Hz), 133.3, 126.5 (quint, JCF = 4.0 Hz), 122.7, 85.9, 81.7; 19F NMR (376 MHz, 
CDCl3) δ 82.6 (quint, J = 150.5 Hz, 1 F), 62.3 (d, J = 150.3 Hz, 4 F); HRMS (ESI) m/z calcd for 
C9H4O2F5S ([M-H]-) 270.9858, found 270.9858. 
SF5
CO2H
3.16d 
3-(3-(Pentafluoro-λ6-sulfaneyl)phenyl)propiolic acid (3.16d). A solution of 
Pd(PPh3)2Cl2 (0.0365 g, 0.0519 mmol), CuI (0.0100 g, 0.0519 mmol), and (3-
bromophenyl)pentafluoro-λ6-sulfane (3.14d, 1.50 g, 5.19 mmol) in Et3N (11 mL) was sparged 
with Ar for 10 min, treated with (trimethylsilyl)acetylene (1.10 mL, 7.79 mmol), sparged with Ar 
for 5 min heated to 80 °C for 22 h, cooled to rt, filtered through Celite, washed (Et2O) until the 
washes appeared colorless. The combined filtrates were concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (hexanes) to give 3.15d (1.29 g, 4.29 
mmol) as a yellow oil. 
A solution of CsF (0.783 g, 5.15 mmol) in dry DMSO (3 mL) under CO2 (balloon) at rt 
was treated a solution of trimethyl((3-(pentafluoro-λ6-sulfaneyl)phenyl)ethynyl)silane (3.15d, 
1.29 g, 4.30 mmol) in DMSO (5.6 mL) dropwise and the reaction was stirred under CO2 at rt for 
25 h. The reaction mixture was diluted with H2O (90 mL) and extracted with CH2Cl2 (2 × 50 
mL). The aqueous layer was acidified (> pH 1) with 6 M aqueous HCl at 0 °C and then extracted 
with Et2O (3 × 50 mL). The combined organic layers were washed with H2O (50 mL), dried 
(MgSO4), concentrated under reduced pressure, and further dried under high vacuum to give 
3.16d (0.935 g, 3.43 mmol, 66% (2 steps)) as tan solid: Mp 121.1-124.4 °C; IR (CHCl3) 2831, 
2218, 1688, 1479, 1426, 1214, 831, 791, 768, 680 cm-1; 1H NMR (400 MHz, CDCl3) δ 10.92 (s, 
 202 
1 H), 8.01 (t, J = 2.0 Hz, 1 H), 7.87 (ddd, J = 8.0, 2.0, 0.9 Hz, 1 H), 7.75 (d, J = 8.0 Hz, 1 H), 
7.54 (t, J = 8.0 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 158.1, 153.8 (quint, JCF = 19.0 Hz), 
135.9, 130.7 (quint, JCF = 5.0 Hz), 129.3, 128.4 (quint, JCF = 4.0 Hz), 120.2, 86.2, 81.0; 19F 
NMR (376 MHz, CDCl3) δ 82.5 (quint, J = 150.4 Hz, 1 F), 62.5 (d, J = 150.4 Hz, 4 F); HRMS 
(ESI) m/z calcd for C9H4O2F5S ([M-H]-) 270.9858, found 270.9856. 
CO2H
S
 
3.16e 
3-(5-Methylthiophen-2-yl)propiolic acid (3.16e).484-485 486 A solution of Pd(PPh3)2Cl2 
(0.0615 g, 0.0877 mmol), CuI (0.0167 g, 0.0877 mmol), and 2-bromo-5-methyl thiophene 
(3.14e, 1.00 mL, 8.77 mmol) in Et3N (17.5 mL) sparged with Ar for 15 min and treated with 
(trimethylsilyl)acetylene (1.9 mL, 13.2 mmol) and the mixture was further sparged for 2 min, 
heated to 80 °C for 17 h, cooled to rt, filtered through Celite, washed (Et2O) until the washes 
appeared colorless and the filtrate was concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes) to give the 3.15e (1.06 g, 5.47 mmol) as a 
pale yellow oil. 
To solution of CsF (0.994 g, 6.54 mmol) in dry DMSO (8 mL) under an atmosphere of 
CO2 (balloon) at rt was added a solution of trimethyl((5-methylthiophen-2-yl)ethynyl)silane 
(3.15e, 1.06 g, 5.45 mmol) dropwise and the reaction was stirred under CO2 at rt for 17 h. The 
reaction mixture was diluted with H2O (100 mL) and extracted with CH2Cl2 (2 × 25 mL). The 
aqueous layer was acidified (> pH 1) with 6 M aqueous HCl at 0 °C and extracted with Et2O (3 × 
25 mL). The combined organic layers were washed with brine (50 mL), dried (MgSO4), filtered, 
and concentrated under reduced pressure to give 3.16e (0.571 g, 3.44 mmol, 39% (2 steps)) as a 
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brown solid:  1H NMR (300 MHz, CDCl3) δ 10.14 (bs, 1 H), 7.36 (d, J = 3.3 Hz, 1 H), 6.73 (dd, J 
= 3.3 Hz, 1 H), 2.52 (s, 3 H). 
N
CO2Me
F3C
Methyl 3-(6-(trifluoromethyl)pyridin-3-yl)propiolate. To two flasks each containing a 
solution of Pd(PPh3)2Cl2 (0.0466 g, 0.0664 mmol), CuI (0.0126 g, 0.0664 mmol), and 5-bromo-
2-trifluoromethyl pyridine (3.14f, 1.50 g, 6.64 mmol) in Et3N (13 mL) sparged with Ar for 10
min followed by addition of (trimethylsilyl)acetylene (1.4 mL, 9.96 mmol) and sparged with Ar 
for 2 min. The resulting mixtures were heated to 80 °C for 16 h where analysis by TLC 
(hexanes/EtOAc, 4:1) indicated that the SM had been consumed. After cooling the reaction to rt, 
the reactions were combined, the solution was filtered through Celite, which was washed with 
Et2O (100 mL) until the washes appeared colorless. The filtrate was concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 9:1) to
give 3.15f (3.37 g, 13.9 mmol) as orange/brown waxy solid. 
A solution of CsF (2.52 g, 16.6 mmol) in DMSO (20 mL) under CO2 at rt was treated 
with a solution of 2-(trifluoromethyl)-5-((trimethylsilyl)ethynyl)pyridine (3.15f, 3.37 g, 13.9 
mmol) in DMSO (7 mL) dropwise and the reaction was stirred under CO2 (balloon) at rt for 5 h, 
treated with MeI (0.95 mL, 15.2 mmol) was added and the solution was stirred for 1 h at rt. The 
reaction mixture was diluted with H2O (200 mL), brine (100 mL) and extracted with Et2O (3 ×
150 mL). The combined organic layers were washed with H2O (100 mL), dried (MgSO4), and
concentrated under reduced pressure. The crude product was purified by chromatography on 
SiO2 (hexanes/EtOAc, 4:1) to give methyl 3-(6-(trifluoromethyl)pyridin-3-yl)propiolate (1.87 g, 
8.17 mmol, 59% (2 steps)) as tan solid: Mp 98.2-99.7 °C; IR (neat) 2962, 2233, 1712, 1433, 
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1337, 1242, 1127, 1085, 864, 745 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.87 (s, 1 H), 8.04 (ddd, J 
= 8.0, 1.2, 0.6 Hz, 1 H), 7.71 (d, J = 8.0 Hz, 1 H), 3.86 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
153.4, 153.1, 148.6 (q, JCF = 35.5 Hz), 141.2, 121.0 (q, JCF = 274.4 Hz), 120.1 (q, JCF = 2.8 Hz), 
120.0, 84.7, 80.7, 53.2; 19F NMR (376 MHz, CDCl3) δ -68.3 (s, 3 F); HRMS (ESI) m/z calcd for 
C10H7F3NO2 ([M+H]+) 230.0423, found 230.0422. 
O
N
N
F
CF3
Cl  
3.21b 
(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
fluorophenyl)cyclopropyl)methanone (3.21b). A solution of 3-(4-fluorophenyl)propiolic acid 
(3.16a, 0.0800 g, 0.487 mmol) and 1-(5-chloro-2-
(trifluoromethyl)phenyl)piperazinehydrochloride (3.12b, 0.142 g, 0.536 mmol) in CH2Cl2 (4.9 
mL) at 0 °C was treated Et3N (0.27 mL, 1.95 mmol). The cooled solution was treated with T3P 
(50% solution in EtOAc) (0.52 mL, 0.73 mmol) dropwise and the reaction was stirred at 0 °C for 
30 min, warmed to rt for 24 h, diluted with CH2Cl2 (30 mL), washed with H2O (20 mL), satd. 
aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude material was purified by automated chromatography on SiO2 (4g column, liquid load 
CH2Cl2, gradient 100% hexanes to 30% EtOAc/hexanes) to give 3.17b (0.140 g, 0.341 mmol) as 
a colorless solid.  
A solution of 1-(4-(5-chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-
fluorophenyl)prop-2-yn-1-one (3.17b, 0.140 g, 0.341 mmol) in EtOAc (3.4 mL) was treated with 
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Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 0.0363 g, equivalent to 5 mol% Pd). The
reaction was placed under a balloon of H2 (3 vacuum/backfill cycles) and stirred at rt for 2 d. 
TLC (hexanes/EtOAc, 2:1) indicated that the SM had been mostly consumed. The reaction was 
filtered through Celite (eluting with EtOAc (10 mL)) and the combined filtrates were 
concentrated under reduced pressure. The crude residue was purified by automated
chromatography on SiO2 (4g column, 100% hexanes to 40% EtOAc/hexanes, product eluted at 
20% EtOAc/hexanes) to give 3.18b (0.0510 g, 0.124 mmol) as a colorless solid. 
A solution of CrCl2 (0.0911 g, 0.741 mmol) and (Z)-1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-fluorophenyl)prop-2-en-1-one (3.18b, 0.0510 g, 
0.124 mmol) in dry degassed THF (1.2 mL) was sparged with Ar for 5 min and treated with 
CH2ICl (0.071 mL, 0.618 mmol) at rt, stirred for 2 d at 80 °C, cooled to rt, diluted with EtOAc 
(50 mL) and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by automated
chromatography on SiO2 (4g column, liquid load CH2Cl2, 100% hexanes to 30% EtOAc/hexanes, 
product eluted at 20% EtOAc/hexanes), filtered through basic Al2O3 (CH2Cl2/EtOAc, 1:1) and 
concentrated under reduced pressure. The resulting oil was recrystallized from a mixture of
hexanes/cyclohexane (1:1), the crystals were washed with hexanes and dried under high vacuum 
to give 3.21b  (0.0238 g, 0.0558 mmol, 11% (3 steps) (100% purity by ELSD)) as a colorless 
solid: Mp 101.0-103.2 °C; IR (CH2Cl2) 2917, 1639, 1513, 1418, 1308, 1225, 1126, 1085, 1031, 
838 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.45 (dd, J = 8.4, 0.6 Hz, 1 H), 7.25-7.22 (m, 1 H), 
7.16-7.11 (m, 2 H), 7.00 (d, J = 1.8 Hz, 1 H), 6.99-6.93 (m, 2 H), 3.92-3.86 (m, 1 H), 3.79-3.73 
(m, 1 H), 3.67 (ddd, J = 12.6, 8.6, 3.2 Hz, 1 H), 3.37 (ddd, J = 12.6, 9.0, 3.2 Hz, 1 H), 3.01-2.95 
(m, 2 H), 2.49-2.39 (m, 2 H), 2.31-2.25 (m, 1 H), 2.19 (ddd, J = 9.0, 8.6, 5.8 Hz, 1 H), 1.83 (dt, J 
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= 6.8, 5.8 Hz, 1 H), 1.36 (td, J = 8.6, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 167.2, 161.6 
(d, JCF = 245.1 Hz), 149.1, 132.5, 131.1, 130.1 (q, JCF = 32.7 Hz), 129.1, 129.0, 123.6 (q, JCF = 
272.2 Hz), 120.8 (q, JCF = 3.8 Hz), 117.2 (q, JCF = 3.8 Hz), 115.0 (d, JCF = 21.3 Hz), 51.3, 51.0, 
45.3, 41.9, 23.9, 23.5 10.7; 19F NMR (376 MHz, CDCl3) δ -62.6 (s, 3 F), -116.4 (s, 1 F); HRMS 
(ESI) m/z calcd for C21H20ClF4N2O ([M+H]+) 427.1195, found 427.1192. 
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3.17c 
3-(4-Fluorophenyl)-1-(4-(pyrimidin-2-yl)piperazin-1-yl)prop-2-yn-1-one (3.17c). A 
solution of 3-(4-fluorolphenyl)propionic acid (3.16a, 0.150 g, 0.914 mmol) and 2-(1-
piperazinyl)pyrimidine (3.12f, 0.188 g, 0.841 mmol) in CH2Cl2 (9.1 mL) at 0 °C was treated 
Et3N (0.51 mL, 3.66 mmol). The cooled solution was treated with T3P (50% solution in EtOAc) 
(1.0 mL, 1.37 mmol) dropwise and the reaction was stirred at 0 °C for 30 min, warmed to rt for 
16 h, diluted with CH2Cl2 (30 mL), washed with H2O (20 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude material was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 100% 
EtOAc) to give 3.17c (0.223 g, 0.719 mmol, 79%) as a colorless solid: Mp 168.4-170.8 °C; IR 
(CH2Cl2) 2859, 2217, 1618, 1585, 1506, 1435, 1355, 1261, 1227, 980, 838, 732 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.34 (d, J = 4.6 Hz, 2 H), 7.56 (dd, J = 8.8, 5.3 Hz, 2 H), 7.08 (t, J = 8.8 
Hz, 2 H), 6.56 (t, J = 4.6 Hz, 1 H), 3.95-3.93 (m, 2 H), 3.88 (app dd, J = 6.6, 3.4 Hz, 4 H), 3.76 
(app dd, J = 6.6, 4.1 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 163.6 (d, JCF = 253.0 Hz), 161.4, 
157.8, 153.1, 134.6 (d, JCF = 8.7 Hz), 116.4 (d, JCF = 3.6 Hz), 116.1 (d, JCF = 22.1 Hz), 110.6,  
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90.0, 80.8, 46.8, 44.0, 43.3, 41.5; 19F NMR (376 MHz, CDCl3) δ -107.3 (s, 1 F); HRMS (ESI) 
m/z calcd for C17H16FN4O ([M+H]+) 311.1303, found 311.1301. 
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3.21c 
((1RS,2SR)-2-(4-Fluorophenyl)cyclopropyl)(4-(pyrimidin-2-yl)piperazin-1-
yl)methanone (3.21c). A solution of 3-(4-fluorophenyl)-1-(4-(pyrimidin-2-yl)piperazin-1-
yl)prop-2-yn-1-one (3.17c, 0.200 g, 0.644 mmol) in EtOAc (6.4 mL) was treated with Lindlar 
catalyst (5% Pd on CaCO3, lead poisoned, 0.0685 g, equivalent to 5 mol% Pd). The reaction
vessel was placed under vacuum and backfilled with H2 (balloon, 4x) and stirred for 18 h at rt, 
filtered through Celite, washed (EtOAc), and the combined filtrates were concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
column, gradient 100% hexanes to 40% EtOAc/hexanes) to give 3.18c (0.211 g, 0.676 mmol) as 
a colorless solid. 
A solution of CrCl2 (0.472 g, 3.84 mmol) and (Z)-3-(4-fluorophenyl)-1-(4-(pyrimidin-2-
yl)piperazin-1-yl)prop-2-en-1-one (3.18c, 0.200 g, 0.640 mmol) in dry degassed THF (6.4 mL) 
(previously sparged with Ar for 15 min) was treated with CH2ICl (0.37 mL, 3.20 mmol) and 
further sparged with Ar for 2 min. The reaction mixture was stirred for 20 h at 80 °C, cooled to 
rt, diluted with EtOAc (10 mL), filtered through a plug of basic Al2O3 (EtOAc), and concentrated 
under reduced pressure. The crude material was purified by automated chromatography on SiO2
(4g column, liquid load CH2Cl2, gradient 100% hexanes to 60% EtOAc/hexanes) to give 3.21c 
(0.128 g, 0.392 mmol, 61% (2 steps) (100% purity by ELSD)) as a colorless solid: Mp 141.9-
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145.3 °C; IR (CH2Cl2) 2922, 1636, 1583, 1510, 1432, 1359, 1224, 1027, 981, 837, 797 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.28 (d, J = 4.6 Hz, 2 H), 7.12 (dd, J = 8.7, 5.3 Hz, 2 H), 6.92 (t, J = 
8.7 Hz, 2 H), 6.50 (t, J = 4.6 Hz, 1 H), 4.00 (dt, J = 13.3, 4.4 Hz, 1 H), 3.93 (dt, J = 13.0, 4.4 Hz, 
1 H), 3.76 (ddd, J = 13.0, 5.1, 3.6 Hz, 1 H), 3.66 (dt, J = 13.0, 4.4 Hz, 1 H), 3.53 (ddd, J = 13.0, 
8.8, 3.6 Hz, 1 H), 3.26 (ddd, J = 13.0, 8.8, 3.4 Hz, 1 H), 3.13 (ddd, J = 13.0, 8.8, 3.6 Hz, 1 H), 
3.00 (ddd, J = 13.0, 8.8, 3.6 Hz, 1 H), 2.49-2.43 (m, 1 H), 2.18 (ddd, J = 9.2, 8.4, 5.8 Hz, 1 H), 
1.83 (q, J = 5.8 Hz, 1 H), 1.34 (td, J = 8.4, 5.8 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 167.3, 
161.7 (d, JCF = 244.9 Hz), 161.3, 157.7, 133.0, 129.0 (d, JCF = 8.0 Hz), 115.0 (d, JCF = 21.3 Hz), 
110.3, 45.0, 43.8, 43.4, 41.6, 23.9, 23.5, 10.6; 19F NMR (470 MHz, CDCl3) δ -116.4 (s, 1 F); 
HRMS (ESI) m/z calcd for C18H20FN4O ([M+H]+) 327.1616, found 327.1616. 
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(1R,2S)-3.21c(1S,2R)-3.21c  
Racemic ((1RS,2SR)-2-(4-fluorophenyl)cyclopropyl)(4-(pyrimidin-2-yl)piperazin-1-
yl)methanone (3.21c) was separated on a SFC Chiralpak-IC semiprep (250 x 10 mm) column 
(30% Methanol/CO2, 7 mL/min, p = 100 bar, 90µL injection, 20 mg/mL in MeOH) to give 
((1S,2R)-2-(4-fluorophenyl)cyclopropyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone ((1S,2R)-
3.21c)  (retention time 7.63 min) as a colorless solid (100% purity by ELSD): [a]17D  -207.0 (c 
0.53, MeOH); 1H NMR (300 MHz, CDCl3) δ 8.28 (d, J = 4.6 Hz, 1 H), 7.12 (dd, J = 8.6, 5.3 Hz, 
1 H), 6.92 (t, J = 8.6 Hz, 1 H), 6.50 (t, J = 4.6 Hz, 1 H), 4.02-3.91 (m, 2 H), 3.79-3.73 (m, 1 H), 
3.69-3.64 (m, 1 H), 3.56-3.48 (m, 2 H), 3.29-3.21 (m, 1 H), 3.16-3.08 (m, 1 H), 2.98 (ddd, J = 
12.6, 9.0, 3.7 Hz, 1 H), 2.51-2.42 (m, 1 H), 2.18 (ddd, J = 9.0, 8.4, 6.0, 1 H), 1.83 (q, J = 5.6 Hz, 
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1 H), 1.35 (td, J = 8.4, 5.6 Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC 
(250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; retention time: 8.0 min). 
((1R,2S)-2-(4-Fluorophenyl)cyclopropyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone 
((1R,2S)-3.21c) (retention time 8.61 min) was obtained as a colorless solid (100% purity by 
ELSD): [a]17D  +213.2 (c 0.54, MeOH); 1H NMR (300 MHz, CDCl3) δ 8.28 (d, J = 4.6 Hz, 2 H), 
7.12 (dd, J = 8.6, 5.3 Hz, 2 H), 6.92 (t, J = 8.6 Hz, 2 H), 6.50 (t, J = 4.6 Hz, 1 H), 4.02-3.90 (m, 2 
H), 3.79-3.73 (m, 1 H), 3.69-3.62 (m, 1 H), 3.57-3.48 (m, 2 H), 3.30-3.21 (m, 1 H), 3.16-3.08 
(m, 1 H), 2.98 (ddd, J = 13.0, 9.0, 3.5 Hz, 1 H), 2.47 (td, J = 9.0, 6.0 Hz, 1 H), 2.18 (ddd, J = 9.0, 
8.4, 6.0 Hz, 1 H), 1.83 (q, J = 5.6 Hz, 1 H), 1.35 (td, J = 8.4, 5.6 Hz, 1 H). The enantiomeric 
excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 
100 bar, 220 nm; retention time: 9.0 min). 
(1S,2R)-3.21c,	(-)-rota/on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21c,	(+)-rota/on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
3.21c	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
Figure 5.3. SFC chromatograms for 3.21c and separated enantiomers.
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3.22 
(Z)-1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(4-fluorophenyl)prop-2-en-1-
one-2,3-d2 (3.22). A solution of 1-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)-3-(4-
fluorophenyl)prop-2-yn-1-one (3.17a, 0.150 g, 0.140 mmol) in anhydrous EtOAc (4.2 mL) was 
treated with Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 0.0447 g, 0.0210 mmol, 
equivalent to 5 mol% Pd). The reaction was placed under a balloon of D2 (3 vacuum/backfill 
cycles) and stirred vigorously at rt for 24 h, filtered through Celite, washed (EtOAc), and 
concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4 g column, liquid load with CH2Cl2, gradient 100% hexanes to 30% 
EtOAc:hexanes, product eluted at 25% EtOAc:hexanes) to give 3.22 (0.0919 g, 0.255 mmol, 
61%, 97% deuterium incorporation) as a colorless solid: Mp 122.1-124.8 °C; IR (CH2Cl2) 2918, 
2819, 1628, 1595, 1505, 1432, 1222, 1022, 852, 817, 735 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.39 (dd, J = 8.6, 5.4 Hz, 2 H), 7.07-7.01 (m, 3 H), 6.95 (dd, J = 8.2, 2.0 Hz, 1 H), 6.79 (d, J = 
2.0 Hz, 1 H), 3.79 (bs, 2 H), 3.48 (t, J = 5.0 Hz, 2 H), 2.80 (t, J = 5.0 Hz, 2 H), 2.52 (t, J = 5.0 
Hz, 2 H), 2.20 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 167.2, 162.6 (d, J = 249.3 Hz), 151.7, 
132.1 (t, JCD = 23.6 Hz), 132.0, 131.7, 131.4 (d, JCF = 3.2 Hz), 130.8, 130.2 (d, JCF = 8.1 Hz), 
123.6, 122.2 (t, JCD = 24.2 Hz), 119.5, 115.6 (d, JCF = 21.4 Hz), 51.4, 51.1, 46.5, 41.4 17.3; 19F 
NMR (376 MHz, CDCl3) δ -112.0 (s, 1 F); HRMS (ESI) m/z calcd for C20H19D2ClFN2O 
([M+H]+) 361.1446, found 361.1446 
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3.23 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
fluorophenyl)cyclopropyl-1,2-d2)methanone (3.23). A solution of CrCl2 (0.225 g, 1.83 mmol) 
and (4-(5-chloro-2-methylphenyl)piperazin-1-yl)(2-(4-fluorophenyl)cyclopropyl-1,2-
d2)methadone (3.22, 0.110 g, 0.305 mmol) in dry degassed THF (3 mL) was treated with CH2ICl 
(0.18 mL, 1.52 mmol) and sparged with Ar for 2 min. The reaction mixture was stirred for 24 h 
at 80 °C, cooled to rt, diluted with EtOAc (50 mL), and washed with 1 M HCl (3 x 20 mL). The 
organic layer was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
residue was purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, 
gradient 100% hexanes to 40% EtOAc/hexanes) to give a yellow oil that was filtered through 
basic Al2O3 (CH2Cl2/EtOAc, 1:1) concentrated under reduced pressure to a clear oil that was 
triturated in minimal cyclohexane to give a colorless solid that was dried under high vacuum to 
give 3.23 (0.0799 g, 0.213 mmol, 70% (100% purity by ELSD)) as a colorless solid: Mp 100.2-
102.7 °C; IR (CH2Cl2) 2917, 1632, 1512, 1431, 1221, 1032, 818, 729 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.16-7.11 (m, 2 H), 7.06 (d, J = 8.2 Hz, 1 H), 7.00-6.94 (m, 3 H), 6.71 (d, J = 2.0 Hz, 1 
H), 3.81-3.77 (m, 1 H), 3.72-3.59 (m, 2 H), 3.37-3.31 (m, 1 H), 2.79-2.69 (m, 2 H), 2.33-2.28 
(m, 1 H), 2.24-2.20 (m, 4 H), 1.81 (d, J = 5.4 Hz, 1 H), 1.32 (d, J = 5.4 Hz, 1 H); 13C NMR (100 
MHz, CDCl3) δ 167.2, 161.5 (d, JCF = 244.7 Hz), 151.8, 133.0 (d, JCF = 3.1 Hz), 131.9, 131.7, 
130.9, 129.0 (d, JCF = 7.7 Hz), 123.5, 119.6, 114.9 (d, JCF = 21.3 Hz), 51.7, 51.5, 45.5, 42.1, 23.4 
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(t, JCD = 25.4 Hz), 23.0 (t, JCD = 24.6 Hz) 17.3, 10.4; 19F NMR (376 MHz, CDCl3) δ -116.3 (s, 1 
F); HRMS (ESI) m/z calcd for C21H21D2ClFN2O ([M+H]+) 375.1603, found 375.1602.  
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(1R,2S)-3.23(1S,2R)-3.23
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Racemic (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
fluorophenyl)cyclopropyl-1,2-d2)methanone (3.23) was separated on a SFC Chiralpak-IC 
semiprep (250 x 10 mm) column (30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm) injection 
volume 90 µL, 20 mg/mL) to give (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1S,2R)-2-(4-
fluorophenyl)cyclopropyl-1,2-d2)methanone ((1S,2R)-3.23) (retention time 7.58 min) as a 
colorless viscous oil (100% purity by ELSD): [a]18D  -152.0 (c 0.70, MeOH); 1H NMR (300 MHz, 
CDCl3) δ 7.16-7.12 (m, 2 H), 7.07 (d, J = 8.1 Hz, 1 H), 7.01-6.94 (m, 3 H), 6.72 (d, J = 1.8 Hz, 1 
H), 3.82-3.76 (m, 1 H), 3.74-3.58 (m, 2 H), 3.39-3.31 (m, 1 H), 2.80-2.69 (m, 2 H), 2.80-2.69 
(m, 2 H), 2.35-2.17 (m, 5 H), 1.82 (d, J = 5.4 Hz, 1 H), 1.33 (d, J = 5.4 Hz, 1 H). The 
enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 
mL/min, p = 100 bar, 220 nm; retention time: 7.8 min). 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1R,2S)-2-(4-fluorophenyl)cyclopropyl-
1,2-d2)methanone ((1S,2R)-3.23) (retention time 9.28 min) was obtained as a colorless viscous 
oil (100% purity by ELSD): [a]19D  +154.0 (c 0.66, MeOH); 1H NMR (300 MHz, CDCl3) δ 7.17-
7.10 (m, 2 H), 7.07 (d, J = 8.2 Hz, 1 H), 7.02-6.94 (m, 3 H), 6.72 (d, J = 2.0 Hz, 1 H), 3.83-3.74 
(m, 1 H), 3.73-3.58 (m, 2 H), 3.39-3.31 (m, 1 H), 2.80-2.69 (m, 2 H), 2.36-2.18 (m, 5 H), 1.82 
(d, J = 5.4 Hz, 1 H), 1.33 (d, J = 5.4 Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC 
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Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; retention 
time: 9.6 min). 
3.23	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.23,	(-)-rota?on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.23,	(+)-rota?on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
Figure 5.4. SFC chromatograms for 3.23 and separated enantiomers.
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3.17d 
1-(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-
(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17d). A solution of 3-(4-
(trifluoromethyl)phenyl)propiolic acid (3.16h, 0.100 g, 0.467 mmol) and 1-(5-chloro-2-
(trifluoromethyl)phenyl)piperazinehydrochloride (3.12b, 0.155 g, 0.514 mmol) in CH2Cl2 (4.7 
mL) cooled to 0 °C was treated with Et3N (0.26 mL, 1.87 mmol). The cooled solution was 
treated with T3P (50 wt. % solution in EtOAc, 0.49 mL, 0.701 mmol) dropwise and the reaction 
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was stirred at 0 °C for 30 min and allowed to warm to rt for 16 h, diluted with CH2Cl2 (30 mL) 
and washed with H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude material was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, hexanes to 30% EtOAc/hexanes), to 
give 3.17d (0.161 g, 0.350 mmol, 75%) as a colorless solid: Mp 145.8-148.8 °C; IR (CH2Cl2) 
2928, 2827, 2223, 1634, 1596, 1432, 1322, 1310, 1122, 1107, 1033, 844 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.65 (app q, J = 7.3 Hz, 4 H), 7.58 (d, J = 8.4 Hz, 1 H), 7.28-7.24 (m, 2 H), 3.96 
(app t, J = 5.0 Hz, 2 H), 3.84 (app t, J = 5.0 Hz, 2 H), 3.00 (app t, J = 5.0 Hz, 2 H), 2.94 (app t, J 
= 5.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 152.5, 138.8, 132.5, 131.6 (q, JCF = 33.0 Hz), 
128.5 (q, JCF = 5.4 Hz), 125.7 (q, JCF = 29.4 Hz), 125.7, 125.4 (q, JCF = 3.7 Hz), 124.7, 124.1, 
123.5 (q, JCF = 270.8 Hz, 2 C), 89.0, 82.7, 53.6, 52.7, 47.3, 41.8; 19F NMR (376 MHz, CDCl3) δ  
-60.3 (s, 3 F), -63.1 (s, 3 F); HRMS (ESI) m/z calcd for C21H16ClF6N2O ([M+H]+) 461.0850, 
found 461.0847. 
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3.21f 
(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21f). A solution of 1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17d, 
0.127 g, 0.276 mmol) in EtOAc (2.8 mL) was treated with quinoline (0.16 mL, 1.38 mmol) and 
5% Pd/BaSO4 (0.0059 g, equivalent to 1 mol% Pd). The reaction was placed under and 
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atmosphere of H2 (balloon) (3 vacuum/backfill cycles) and stirred at rt for 1.5 h, filtered through 
Celite, washed (EtOAc), and the combined filtrates were washed with 1 M aqueous HCl (10 
mL), dried (MgSO4), filtered, and concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4 g column, liquid load CH2Cl2, gradient 100% 
hexanes to 30% EtOAc/hexanes; product eluted at 20% EtOAc) to give 3.18d (0.114 g, 0.246 
mmol) as a colorless solid.  
A solution of CrCl2 (0.182 g, 0.148 mmol) and (Z)-1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (3.18d, 
0.114 g, 0.246 mmol) in dry degassed THF (2.5 mL) was sparged with Ar for 15 min, treated 
with CH2ICl (0.14 mL, 1.23 mmol), heated for 2 d at 80 °C. The reaction was cooled to rt, 
diluted with EtOAc (50 mL) and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer 
was dried (MgSO4), filtered and concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% 
hexanes to 30% EtOAc/hexanes, product eluted at 20% EtOAc/hexanes), filtered through basic 
Al2O3 (CH2Cl2/EtOAc, 1:1), concentrated, and dried under high vacuum to give 3.21f (0.0681 g, 
0.143 mmol, 52% (2 steps) (100% purity by ELSD)) as a colorless solid: Mp 138.0-139.9 °C; IR 
(CH2Cl2) 3014, 2825, 1641, 1596, 1326, 1309, 1116, 1031, 844 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.56 (d, J = 8.2 Hz, 2 H), 7.51 (d, J = 8.5 Hz, 1 H), 7.29 (d, J = 8.2 Hz, 2 H), 7.19 (dd, 
J = 8.5, 1.4 Hz, 1 H), 6.89 (d, J = 1.4 Hz, 1 H), 3.95 (bd, J = 12.4 Hz, 1 H), 3.73 (bd, J = 12.4 
Hz, 1 H), 3.54 (bt, J = 10.0 Hz, 1 H), 3.21 (bt, J = 10.0 Hz, 1 H), 2.74 (bt, J = 10.0 Hz, 2 H), 2.50 
(td, J = 8.9, 7.1 Hz, 1 H), 2.29-2.19 (m, 2 H), 1.98 (bt, J = 8.9 Hz, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 
1.43 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.5, 152.7, 142.1, 138.9, 128.8 
(q, JCF = 32.6 Hz), 128.4 (q, JCF = 5.8 Hz), 127.9, 125.7 (q, JCF = 30.2 Hz), 125.6, 125.0 (q, JCF = 
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3.7 Hz), 124.6 (q, JCF = 273.0 Hz), 124.4, 123.6 (q, JCF = 272.9 Hz), 53.7, 52.9, 45.5, 42.1, 24.7, 
23.9, 11.2; 19F NMR (376 MHz, CDCl3) δ -60.4 (s, 3 F), -62.2 (s, 3 F); HRMS (ESI) m/z calcd 
for C22H20ClF6N2O ([M+H]+) 477.1163, found 477.1160. 
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Racemic (4-(5-chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21f) was separated on a SFC Chiralpak-IC 
semiprep (250 x 10 mm) column (25% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm) injection 
volume 90 µL, 20 mg/mL) to give (4-(5-chloro-2-(trifluoromethyl)phenyl)piperazin-1-
yl)((1S,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21f) (retention time 
3.57 min) as a colorless viscous oil (100% purity by ELSD): [a]19D  -106.6 (c 0.68, MeOH); 1H 
NMR (300 MHz, CDCl3) δ 7.57 (d, J = 8.1 Hz, 2 H), 7.52 (d, J = 8.4 Hz, 1 H), 7.29 (d, J = 8.1 
Hz, 2 H), 7.20 (d, J = 8.4 Hz, 1 H), 6.88 (d, J = 0.9 Hz, 1 H), 3.98-3.93 (m, 1 H), 3.76-3.70 (m, 1 
H), 3.54 (ddd, J = 12.3, 9.3, 3.0 Hz, 2 H), 3.21 (ddd, J = 12.3, 9.3, 3.0 Hz, 2 H), 2.76-2.71 (m, 2 
H), 2.51 (td, J = 9.3, 7.2 Hz, 1 H), 2.30-2.18 (m, 2 H), 2.00-1.89 (m, 2 H), 1.44 (td, J = 8.4, 5.7 
Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 25% 
Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; retention time: 3.8 min). 
(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1R,2S)-2-(4-
(trifluoromethyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21f)  (retention time 4.20 min) was 
obtained as a colorless viscous oil (100% purity by ELSD): [a]19D  +111.1 (c 0.71, MeOH); 1H 
NMR (300 MHz, CDCl3) δ 7.57 (d, J = 8.1 Hz, 2 H), 7.52 (d, J = 8.4 Hz, 1 H), 7.29 (d, J = 8.1 
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Hz, 2 H), 7.20 (d, J = 8.4 Hz, 1 H), 6.88 (s, 1 H), 3.99-3.93 (m, 1 H), 3.76-3.70 (m, 1 H), 3.58-
3.49 (m, 1 H), 3.25-3.16 (m, 1 H), 2.76-2.71 (m, 2 H), 2.51 (q, J = 9.6 Hz, 1 H), 2.30-2.18 (m, 2 
H), 2.00-1.89 (m, 2 H), 1.44 (td, J = 8.4, 5.6 Hz, 1 H). The enantiomeric excess was >99.9% ee 
(SFC Chiralpak-IC (250 x 10 mm); 25% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; 
retention time: 4.1 min). 
3.21f	Chiralpak-IC,	25%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21f,	(-)-rotaBon,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21f,	(+)-rotaBon,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
 
Figure 5.5. SFC chromatograms for 3.21f and separated enantiomers. 
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3.17e 
4-Bromo-2-(4-(3-(4-(trifluoromethyl)phenyl)propioloyl)piperazin-1-yl)benzonitrile 
(3.17e). A solution of 3-(4-trifluoromethylphenyl)propiolic acid (3.16h, 0.400 g, 1.87 mmol) and 
4-bromo-2-(piperazin-1-yl)benzonitrile hydrochloride (3.12e, 0.735 g, 2.43 mmol) in CH2Cl2 (19 
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mL) at 0 °C was treated Et3N (1.0 mL, 7.47 mmol). The cooled solution was treated with T3P 
(50% solution in EtOAc) (2.0 mL, 2.80 mmol) dropwise and the reaction was stirred at 0 °C for 
30 min, warmed to rt for 16 h, diluted with EtOAc (80 mL) and washed with H2O (20 mL), satd. 
aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1), to give 3.17e 
(0.784 g, 1.70 mmol, 91%) as a pale yellow solid: Mp 176.3-179.1 °C; IR (CH2Cl2) 2824, 2222, 
1626, 1583, 1432, 1324, 1163, 1129, 1107, 1035, 949, 928, 846, 816 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.66 (dd, J = 7.8 Hz, 4 H), 7.45 (d, J = 8.0 Hz, 1 H), 7.22 (dd, J = 8.0, 1.6 Hz, 1 H), 
7.15 (d, J = 1.6 Hz, 1 H), 4.05 (t, J = 5.0 Hz, 2 H), 3.91 (t, J = 5.0 Hz, 2 H), 3.31 (t, J = 5.0 Hz, 2 
H), 3.22 (t, J = 5.0 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ 155.6, 152.6, 135.1, 132.6, 131.8 (q, 
JCF = 32.8 Hz), 128.8, 125.9, 125.5 (q, JCF = 3.8 Hz), 124.0, 123.5 (q, JCF = 272.5 Hz), 122.7, 
117.4, 105.1, 89.3, 82.5, 52.0, 50.7, 47.0, 41.5; 19F NMR (470 MHz, CDCl3) δ -63.1 (s, 3 F); 
HRMS (ESI) m/z calcd for C21H16BrF3N3O ([M+H]+) 462.0423, found 462.0423. 
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3.21g 
4-Bromo-2-(4-((1RS,2SR)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-
carbonyl)piperazin-1-yl)benzonitrile (3.21g). A solution of 4-bromo-2-(4-(3-(4-
(trifluoromethyl)phenyl)propioloyl)piperazin-1-yl)benzonitrile (3.17e, 0.750 g, 1.62 mmol) in 
EtOAc (16 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 0.691 g, 
equivalent to 20 mol% Pd). The reaction was placed under a balloon of H2 (3 vacuum/backfill 
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cycles) and stirred at rt for 3 d, filtered through Celite, washed (EtOAc), and the combined 
filtrates were concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 1:4) to give 3.18e (0.318 g, 0.685 mmol) as a tan 
foam.  
A solution of CrCl2 (0.477 g, 0.899 mmol) and (Z)-4-bromo-2-(4-(3-(4-
(trifluoromethyl)phenyl)acryloyl)piperazin-1-yl)benzonitrile (3.18e, 0.300 g, 0.646 mmol) in dry 
degassed THF (6.5 mL) was sparged with Ar for 5 min and treated with CH2ICl (0.37 mL, 3.23 
mmol) at rt, stirred for 2 d at 80 °C, cooled to rt, diluted with EtOAc (150 mL) and washed with 
1 M aqueous HCl (3 x 50 mL). The organic layer was dried (MgSO4), filtered and concentrated 
under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:9) to give a colorless oil that was filtered through basic Al2O3 (EtOAc) 
concentrated and further dried under high vacuum to give 3.21g (0.148 g, 0.309 mmol, 20% (2 
steps) (100% purity by ELSD)) as a colorless oil: IR (CH2Cl2) 2833, 2222, 1642, 1583, 1484, 
1436, 1326, 1228, 1116, 1069, 844 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.5 Hz, 2 H), 
7.38 (d, J = 8.0 Hz, 1 H), 7.27 (d, J = 8.5 Hz, 2 H), 7.17 (dd, J = 8.0, 1.5 Hz, 1 H), 6.90 (d, J = 
1.5 Hz, 1 H), 3.93 (dt, J = 13.0, 3.5 Hz, 1 H), 3.78 (dt, J = 13.0, 3.5 Hz, 1 H), 3.67 (ddd, J = 13.0, 
9.0, 3.0 Hz, 1 H), 3.35 (ddd, J = 13.0, 9.0, 3.0 Hz, 1 H), 3.18-3.15 (m, 1 H), 3.08-3.06 (m, 1 H), 
2.55-2.45 (m, 2 H), 2.29-2.24 (m, 2 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.43 (td, J = 8.0, 6.0 Hz, 1 H); 
13C NMR (125 MHz, CDCl3) δ 166.8, 155.7, 141.8, 135.0, 128.8, 128.8 (q, JCF = 32.6 Hz), 
127.9, 125.7, 125.1 (q, JCF = 3.6 Hz), 124.1 (q, JCF = 271.8 Hz), 122.4, 117.5, 105.0, 52.1, 50.8, 
45.2, 41.7, 24.5, 24.1, 11.2; 19F NMR (376 MHz, CDCl3) δ -62.3 (s, 3 F); HRMS (ESI) m/z calcd 
for C22H20BrF3N3O ([M+H]+) 478.0736, found 478.0734.  
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Racemic 4-bromo-2-(4-((1RS,2SR)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-
carbonyl)piperazin-1-yl)benzonitrile (3.21g) was separated on a SFC Chiralpak-IC semiprep 
(250 x 10 mm) column (25% Methanol/CO2, 7 mL/min, 220nm, p =100 bar, 20 mg/mL in 
MeOH) to give 4-bromo-2-(4-((1S,2R)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-
carbonyl)piperazin-1-yl)benzonitrile ((1S,2R)-3.21g) (retention time 10.5 min) as a colorless 
solid (100% purity by ELSD): [a]19D  -144.1 (c 1.31, MeOH); 1H NMR (300 MHz, CDCl3) δ 7.52 
(d, J = 8.1 Hz, 2 H), 7.39 (d, J = 8.1 Hz, 1 H), 7.27 (d, J = 8.1 Hz, 2 H), 7.17 (dd, J = 8.1, 1.5 Hz, 
1 H), 6.90 (d, J = 1.5 Hz, 1 H), 3.95-3.89 (m, 1 H), 3.76-3.67 (m, 2 H), 3.38-3.33 (m, 1 H), 3.16-
3.04 (m, 2 H), 2.56-2.45 (m, 2 H), 2.27 (td, J = 8.7, 6.0 Hz, 2 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.44 
(td, J = 8.4, 5.5 Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 
mm); 25% MeOH, 7 mL/min, 220nm, p = 100 bar; retention time: 10.8 min). 
4-Bromo-2-(4-((1R,2S)-2-(4-(trifluoromethyl)phenyl)cyclopropane-1-carbonyl)piperazin-
1-yl)benzonitrile ((1R,2S)-3.21g) (retention time 11.6 min) was obtained as a colorless solid 
(100% purity by ELSD): [a]19D  +135.8 (c 1.43, MeOH); 1H NMR (300 MHz, CDCl3) δ 7.52 (d, J 
= 8.1 Hz, 2 H), 7.39 (d, J = 8.1 Hz, 1 H), 7.29 (s, 2 H), 7.17 (dd, J = 8.1, 1.5 Hz, 1 H), 6.90 (d, J 
= 1.5 Hz, 1 H), 3.93-3.90 (m, 1 H), 3.78-3.67 (m, 2 H), 3.38-3.33 (m, 1 H), 3.17-3.04 (m, 2 H), 
2.56-2.43 (m, 2 H), 2.27 (td, J = 8.7, 6.0 Hz, 2 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.44 (td, J = 8.4, 5.6 
Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 25% 
MeOH, 7 mL/min, 220nm, p = 100 bar; retention time: 11.8 min). 
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3.21g	Chiralpak-IC,	25%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21g,	(-)-rotaBon,	Chiralpak-IC,25%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21g,	(+)-rotaBon,	Chiralpak-IC,	25%	
MeOH,	7	mL/min,	220	nm	
Figure 5.6. SFC chromatograms for 3.21g and separated enantiomers.
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3.17f 
1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-
yn-1-one (3.17f). A solution of 3-(3-(trifluoromethyl)phenyl)propionic acid (3.16b, 0.0750 g, 
0.350 mmol) and 1-(5-chloro-2-methylphenyl)piperazine hydrochloride (3.12b, 0.104 g, 0.420 
mmol) in CH2Cl2 (3.5 mL) cooled to 0 °C was treated with Et3N (0.15 mL, 1.05 mmol). The 
cooled solution was treated with T3P (50 wt. % solution in EtOAc 0.37 mL, 0.525 mmol) 
dropwise and the reaction was stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with 
CH2Cl2 (30 mL), washed with 1 M aqueous HCl (20 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude material was purified by automated 
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chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 40% 
EtOAc/hexanes) to give 3.17f  (0.106 g, 0.261 mmol, 75%) as a colorless solid: Mp 130.3-132.8 
°C; IR (CH2Cl2) 2820, 2218, 2161, 1631, 1489, 1435, 1201, 1128, 1041, 805, 695 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.81 (s, 1 H), 7.74 (d, J = 7.8 Hz, 1 H), 7.68 (d, J = 7.8 Hz, 1 H), 7.52 (t, J 
= 7.8 Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1 H), 7.00 (dd, J = 8.1, 2.1 Hz, 1 H), 6.96 (d, J = 2.1 Hz, 1 
H), 3.98 (app t, J = 5.0 Hz, 2 H), 3.84 (app t, J = 5.0 Hz, 2 H), 2.98 (app t, J = 5.0 Hz, 2 H), 2.90 
(app t, J = 5.0 Hz, 2 H), 2.29 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 152.6, 151.6, 135.4, 132.1, 
131.8, 131.2 (q, JCF = 33.0 Hz), 130.9, 129.17, 129.0 (q, JCF = 4.1 Hz), 126.6 (q, JCF = 3.6 Hz), 
123.8, 123.5 (q, JCF = 272.5 Hz), 121.4, 119.8, 88.9, 82.1, 51.9, 51.3, 47.4, 41.9; HRMS (ESI) 
m/z calcd for C21H19ClF3N2O ([M+H]+) 407.1133, found 407.1130. 
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3.21h 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21h). A solution of 1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17f, 0.100 g, 
0.246 mmol) in EtOAc (2.5 mL) was added Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 
0.0105 g, equivalent to 2 mol% Pd) and quinoline (0.015 mL, 0.123 mmol). The reaction vessel 
was placed under vacuum and backfilled with H2 (balloon, 4x) stirred for 3.5 h at rt, filtered 
through Celite, washed (EtOAc), and the combined filtrates were washed with 1 M aqueous HCl, 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, 10% 
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EtOAc/hexanes to 40% EtOAc/hexanes) to give 3.18f (0.0932 g, 0.228 mmol, 93%) as a 
colorless solid. 
A solution of CrCl2 (0.105 g, 0.851 mmol) and (Z)-1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-en-1-one (3.18f, 0.0580 g, 
0.142 mmol) in dry degassed THF (1.4 mL) was treated with CH2ICl (82 uL, 0.709 mmol) and 
the mixture was sparged with Ar for 2 min, heated for 20 h at 80 °C, cooled to rt, diluted with 
Et2O (50 mL) and washed with 1 M HCl (3 x 20 mL). The organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude material was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, 100% hexanes to 40% 
EtOAc/hexanes) to give a clear oil that filtered through basic Al2O3 (CH2Cl2/EtOAc, 1:1), 
recrystallized from hot cyclohexane the mother liquor was decanted and the crystals were 
washed with hexanes (2 x 1 mL) and dried under high vacuum to give 3.21h (0.0356 g, 0.0842 
mmol, 55% (2 steps) (100% purity by ELSD)) as colorless needles: Mp 115.6-117.4 °C; IR 
(CH2Cl2) 2914, 2820, 1639, 1593, 1490, 1437, 1225, 1161, 1123, 1074, 806 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.49-7.48 (m, 2 H), 7.40 (t, J = 8.0 Hz, 1 H), 7.32 (d, J = 8.0 Hz, 1 H), 7.06 (d, J 
= 8.0 Hz, 1 H), 6.95 (dd, J = 8.0, 2.1 Hz, 1 H), 6.67 (d, J = 2.1 Hz, 1 H), 3.86 (dt, J = 13.0, 2.9 
Hz, 1 H), 3.74 (dt, J = 13.0, 3.2 Hz, 1 H), 3.62-3.56 (m, 1 H), 3.26 (ddd, J = 12.4, 9.0, 3.2 Hz, 1 
H), 2.79-2.70 (m, 2 H), 2.53 (td, J = 9.0, 6.9 Hz, 1 H), 2.26 (ddd, J = 9.0, 8.4, 5.9 Hz, 1 H), 2.20 
(s, 3 H), 2.10 (ddd, J = 11.2, 9.0, 2.4 Hz, 1 H), 1.91 (app q, J = 5.8 Hz, 1 H), 1.41 (td, J = 8.4, 5.8 
Hz, 1 H);  13C NMR (100 MHz, CDCl3) δ 166.7, 151.7, 138.7, 131.9, 131.8, 130.9, 130.5, 130.5 
(d, JCF = 32.2 Hz) 128.7, 125.1 (d, JCF = 4.0 Hz), 124.2 (d, JCF = 272.2 Hz), 123.6, 123.3 (d, JCF 
= 3.7 Hz), 119.6, 51.7, 51.6, 45.5, 42.2, 24.1, 23.9, 17.3, 10.8; 19F NMR (376 MHz, CDCl3) δ  -
62.4 (s, 3 F); HRMS (ESI) m/z calcd for C22H23ClF3N2O ([M+H]+) 423.1446, found 423.1443.  
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Racemic (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21h) was separated on a SFC Chiralpak-IC 
semiprep (250 x 10 mm) column (30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm) injection 
volume 90 µL, 20 mg/mL) to give (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1S,2R)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21h) (retention time 4.82 min) as a 
colorless viscous oil (100% purity by ELSD): [a]19D -133.5 (c 0.70, MeOH); 1H NMR (300 MHz, 
CDCl3) δ 7.48 (bs, 2 H), 7.41 (t, J = 8.0 Hz, 1 H), 7.33 (d, J = 7.4 Hz, 1 H), 7.06 (d, J = 8.1 Hz, 1 
H), 6.95 (dd, J = 8.1, 2.0 Hz, 1 H), 6.67 (d, J = 2.0 Hz, 1 H), 3.89-3.82 (m, 1 H), 3.78-3.71 (m, 1 
H), 3.63-3.55 (m, 1 H), 3.31-3.23 (m, 1 H), 2.79-2.69 (m, 2 H), 2.53 (td, J = 8.4, 7.2 Hz, 1 H), 
2.30-2.07 (m, 6 H), 1.92 (q, J = 5.4 Hz, 1 H), 1.41 (td, J = 8.4, 5.4 Hz, 1 H). The enantiomeric 
excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 
100 bar, 220 nm; retention time: 5.0 min). 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1R,2S)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone ((1R,2S)-3.21h) (retention time 5.57 min) was 
obtained as a colorless viscous oil (100% purity by ELSD): [a]19D  +133.1 (c 0.65, MeOH); 1H 
NMR (300 MHz, CDCl3) δ 7.48 (bs, 2 H), 7.41 (t, J = 8.0 Hz, 1 H), 7.33 (d, J = 8.0 Hz, 1 H), 
7.06 (d, J = 8.0 Hz, 1 H), 6.95 (dd, J = 8.0, 2.0 Hz, 1 H), 6.67 (d, J = 2.0 Hz, 1 H), 3.90-3.82 (m, 
1 H), 3.78-3.70 (m, 1 H), 3.64-3.55 (m, 1 H), 3.31-3.23 (m, 1 H), 2.80-2.69 (m, 2 H), 2.53 (td, J 
= 8.4, 6.8 Hz, 1 H), 2.30-2.07 (m, 6 H), 1.92 (q, J = 5.4 Hz, 1 H), 1.41 (td, J = 8.4, 5.4 Hz, 1 H). 
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The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 
7 mL/min, p = 100 bar, 220 nm; retention time: 5.7 min). 
3.21h	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21h,	(-)-rota@on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21h,	(+)-rota@on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
 
Figure 5.7. SFC chromatograms for 3.21h and separated enantiomers. 
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3.17g 
1-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(3-
(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17g). A solution of 3-(3-
(trifluoromethyl)phenyl)propionic acid (3.16b, 0.0763 g, 0.356 mmol) and 1-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine hydrochloride (3.12c, 0.100 g, 0.356 mmol) in CH2Cl2 (3.6 
mL) cooled to 0 °C was treated with Et3N (0.20 mL, 1.42 mmol). The cooled solution was 
treated with T3P (50 wt. % solution in EtOAc, 0.38 mL, 0.534 mmol) dropwise and the reaction 
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was stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with CH2Cl2 (30 mL), washed with 
1 M aqueous HCl (20 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude residue was purified by automated chromatography on SiO2 (4g column, liquid load 
CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes), to give 3.17g (0.0819 g, 0.186 mmol, 
52%) as a pink solid: Mp 121.8-125.2 °C; IR (CH2Cl2) 2924, 2217, 1633, 1436, 1333, 1310, 
1166, 1076, 1042, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 1 H), 7.74 (d, J = 7.8 Hz, 1 
H), 7.67 (d, J = 7.8 Hz, 1 H), 7.52 (t, J = 7.8 Hz, 1 H), 7.30 (d, J = 8.1 Hz, 1 H), 7.26 (d, J = 8.1 
Hz, 1 H), 7.22 (s, 1 H), 4.00 (app t, J = 5.0 Hz, 2 H), 3.86 (app t, J = 4.8 Hz, 2 H), 3.03 (app t, J 
= 5.0 Hz, 2 H), 2.93 (app t, J = 5.0 Hz, 2 H), 2.39 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 152.6, 
150.9, 136.8, 135.4, 135.4, 131.5, 131.2 (q, JCF = 33.0 Hz), 129.2 (s), 129.0 (q, JCF = 32.2 Hz), 
129.0 (q, JCF = 3.9 Hz), 126.6 (q, JCF = 3.7 Hz), 124.0 (q, JCF = 272.0 Hz), 123.4 (q, JCF = 272.3 
Hz), 121.3, 120.5 (q, JCF = 3.8 Hz), 88.9, 82.0, 51.8, 51.3, 47.4, 41.9, 17.9; 19F NMR (376 MHz, 
CDCl3) δ -62.3 (s, 3 F), -63.0 (s, 3 F); HRMS (ESI) m/z calcd for C22H19F6N2O ([M+H]+) 
441.1396, found 441.1391. 
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3.21i 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21i). A solution of 1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17g, 
0.0800 g, 0.182 mmol) in EtOAc (1.8 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, 
lead poisoned, 0.0193 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of 
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H2 (3 vacuum/backfill cycles) and stirred at rt for 2 d, filtered through Celite, washed (EtOAc), 
and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 40% 
EtOAc/hexanes, product eluted at 10% EtOAc/hexanes) to give the 3.18g (0.0572 g, 0.129 
mmol) as clear/tan viscous oil. 
A solution of CrCl2 (0.0955 g, 0.777 mmol) and (Z)-1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-en-1-one (3.18g, 
0.0573 g, 0.130 mmol) in dry degassed THF (1.3 mL) was sparged with Ar for 5 min and treated 
with CH2ICl (75 uL, 0.648 mmol) at rt and under Ar atmosphere, heated for 20 h at 80 °C, 
cooled to rt, diluted with Et2O (50 mL), and washed with 1 M aqueous HCl (3 x 20 mL). The 
organic layer was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
material was purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, 
gradient 100% hexanes to 40% EtOAc/hexanes) to give a clear oil that was filtered through basic 
Al2O3 (CH2Cl2/EtOAc, 1:1), recrystallized from CH2Cl2/hexanes (ca. 1:5) the mother liquor was 
decanted and the clear colorless cubes were washed with hexanes (2 x 1 mL) and dried under 
high vacuum to give 3.21i (0.0115 g, 0.0252 mmol, 14% (2 steps) (100% purity by ELSD)) as a 
colorless solid: Mp 113.4-116.8 °C; IR (CH2Cl2) 2914, 2824, 1641, 1418, 1328, 1309, 1163, 
1121, 1073 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.47 (bd, J = 7.1 Hz, 2 H), 7.41 (t, J = 7.8 Hz, 1 
H), 7.33 (d, J = 7.8 Hz, 1 H), 7.24 (s, 2 H), 6.92 (s, 1 H), 3.94 (d, J = 12.2 Hz, 1 H), 3.79 (d, J = 
12.2 Hz, 1 H), 3.58 (ddd, J = 12.2, 9.2, 3.0 Hz, 1 H), 3.24 (ddd, J = 12.2, 9.2, 2.6 Hz, 1 H), 2.77 
(td, J = 12.2, 3.7 Hz, 2 H), 2.53 (td, J = 9.2, 7.0 Hz, 1 H), 2.29 (s, 3 H), 2.28-2.18 (m, 2 H), 2.11-
2.05 (m, 1 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.42 (td, J = 8.5, 6.0 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 166.7, 151.1, 138.8, 136.9, 131.4, 130.6 (q, JCF = 31.2 Hz), 130.5, 129.1 (q, JCF = 32.1 
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Hz), 128.7, 125.1 (q, JCF = 3.7 Hz), 124.2 (q, JCF = 272.3 Hz, 2 C), 123.2 (q, JCF = 3.8 Hz), 120.4 
(q, JCF = 3.8 Hz), 116.1 (q, JCF = 3.7 Hz), 51.7 (2 C), 45.6, 42.2, 24.2, 24.0, 17.8, 10.9; 19F NMR 
(376 MHz, CDCl3) δ  -62.4 (s, 3 H), -62.6 (s, 3 H);  HRMS (ESI) m/z calcd for C22H23F6N2O 
([M+H]+) 457.1709, found 457.1704. 
CF3
O
N
N
CF3
Cl  
3.17h 
1-(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(3-
(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17h). A solution of 3-(3-
(trifluoromethyl)phenyl)propiolic acid (3.16b, 0.100 g, 0.467 mmol) and 1-(5-chloro-2-
(trifluoromethyl)phenyl)piperazinehydrochloride (3.12d, 0.155 g, 0.514 mmol) in CH2Cl2 (4.7 
mL) cooled to 0 °C was treated with Et3N (0.26 mL, 1.87 mmol). The cooled solution was 
treated with T3P (50 wt. % solution in EtOAc, 0.49 mL, 0.701 mmol) dropwise and the reaction 
was stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with CH2Cl2 (30 mL), washed with 
H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
column, liquid load CH2Cl2, gradient 100% hexanes to 30% EtOAc/hexanes) to give the crude 
product that was recrystallized from hot EtOH. The supernatant was removed and the crystals 
were washed with hexanes and then dried under high vacuum to give 3.17h (0.168 g, 0.365 
mmol, 78%) as a colorless solid: Mp 87.6-91.2 °C; IR (CH2Cl2) 2921, 2827, 2222, 1633, 1596, 
1436, 1332, 1309, 1121, 1034, 695 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1 H), 7.71 (d, J 
= 7.8 Hz, 1 H), 7.65 (d, J = 8.5 Hz, 1 H), 7.56 (d, J = 8.5 Hz, 1 H), 7.50 (t, J = 7.8 Hz, 1 H), 
 229 
7.26-7.22 (m, 2 H), 3.95 (app t, J = 5.0 Hz, 2 H), 3.81 (app t, J = 5.0 Hz, 2 H), 2.99 (app t, J = 
5.0 Hz, 2 H), 2.92 (app t, J = 5.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 152.6, 138.8, 135.4, 
131.2 (q, JCF = 33.0 Hz), 129.2, 129.0 (q, JCF = 3.7 Hz), 128.6 (q, JCF = 5.4 Hz), 126.6 (q, JCF = 
3.7 Hz), 125.8 (q, JCF = 29.5 Hz), 125.7, 124.7, 123.5 (q, JCF = 273.0 Hz), 123.2 (q, JCF = 272.5 
Hz), 121.3, 88.9, 82.0, 53.6, 52.7, 47.4, 41.8; 19F NMR (376 MHz, CDCl3) δ -60.3 (s, 3 F), -63.0 
(s, 3 F); HRMS (ESI) m/z calcd for C21H16ClF6N2O ([M+H]+) 461.0850, found 461.0849. 
O
N
N
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(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazine-1-yl)(2-(3-
(trifluoromethyl)phenyl)cyclopropyl)methanone (3.21j). A solution of 1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazine-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-yn-1-one (3.17h 
0.0684 g, 0.148 mmol) in EtOAc (1.5 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, 
lead poisoned, 0.0158 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of 
H2 (3 vacuum/backfill cycles) and stirred at rt for 3 d, filtered through Celite, washed (EtOAc), 
and the combined filtrates were concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% 
hexanes to 40% EtOAc/hexanes) to give 3.18h (0.0512 g, 0.111 mmol) as a colorless solid. 
A solution of CrCl2 (0.816 g, 0.940 mmol) and (Z)-1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazine-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-en-1-one (3.18h, 
0.0512 g, 0.111 mmol) in dry degassed THF (1.6 mL) was sparged with Ar for 5 min and treated 
with CH2Icl (0.064 mL, 0.553 mmol) at rt, heated for 2 d at 80 °C, cooled to rt, diluted with 
EtOAc (50 mL), and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried 
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(MgSO4), filtered and concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 
30% EtOAc/hexanes, product eluted at 20% EtOAc/hexanes) to give a clear oil that was filtered 
through basic Al2O3 (eluting with 1:1 CH2Cl2/EtOAc), concentrated under reduced pressure, and 
dried under high vacuum to give 3.21j (0.0409 g, 0.0858 mmol, 59% (2 steps) (100% purity by 
ELSD)) as a clear colorless oil: IR (CH2Cl2) 2918, 1641, 1596, 1437, 1327, 1120, 1032, 809, 702 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54-7.50 (m, 3 H), 7.44 (t, J = 8.0 Hz, 1 H), 7.34 (d, J = 8.0 
Hz, 1 H), 7.20 (dd, J = 8.5, 1.4 Hz, 1 H), 6.87 (d, J = 1.6 Hz, 1 H), 4.02 (d, J = 13.0 Hz, 1 H), 
3.80 (d, J = 13.0 Hz, 1 H), 3.51 (ddd, J = 12.8, 9.8, 3.0 Hz, 1 H), 3.13 (ddd, J = 12.5, 9.8, 2.7 Hz, 
1 H), 2.73 (td, J = 7.7, 3.6 Hz, 2 H), 2.52 (td, J = 9.0, 7.0 Hz, 1 H), 2.25 (ddd, J = 9.0, 8.4, 6.0 
Hz, 1 H), 2.21-2.15 (m, 1 H), 1.97-1.90 (m, 2 H), 1.42 (td, J = 8.4, 6.0 Hz, 1 H); 13C NMR (100 
MHz, CDCl3) δ 166.6, 152.7, 138.9, 138.7, 130.6 (q, JCF = 32.1 Hz), 130.5, 128.7, 128.3 (q, JCF 
= 5.4 Hz), 125.8 (q, JCF = 29.4 Hz), 125.6, 125.1 (q, JCF = 3.8 Hz), 124.6, 124.2 (q, JCF = 272.4 
Hz), 123.5 (q, JCF = 272.9 Hz), 123.2 (q, JCF = 3.7 Hz), 53.5, 53.0, 45.5, 42.1, 24.3, 23.9, 10.9; 
19F NMR (376 MHz, CDCl3) δ  -60.4 (s, 3 F), -62.4 (s, 3 F); HRMS (ESI) m/z calcd for 
C22H20ClF6N2O ([M+H]+) 477.1163, found 477.1166. 
O
N
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1-(4-(5-Chloro-2-methylphenyl)piperazine-1-yl)-3-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)prop-2-yn-1-one (3.17i). A solution of 3-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)propiolic acid (3.16c, 0.100 g, 0.367 mmol) and 1-(1-(5-chloro-2-
methylphenyl)piperazine hydrochloride (3.12b, 0.0999 g, 0.404 mmol) in CH2Cl2 (3.7 mL) 
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cooled to 0 °C was treated with Et3N (0.20 mL, 1.47 mmol). The cooled solution was treated 
with T3P (50 wt. % solution in EtOAc, 0.39 mL, 0.551 mmol) dropwise and the reaction was 
stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with EtOAc (30 mL), washed with H2O 
(20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
column, liquid load CH2Cl2, gradient 100% hexanes to 30% EtOAc/hexanes), to give 3.17i 
(0.127 g, 0.272 mmol, 74%) as a pale yellow foam: IR (CHCl3) 2981, 2222, 1627, 1490, 1432, 
1275, 832, 792, 727 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.8 Hz, 2 H), 7.64 (d, J = 
8.8 Hz, 2 H), 7.11 (d, J = 8.1 Hz, 1 H), 6.99 (dd, J = 8.1, 2.1 Hz, 1 H), 6.95 (d, J = 2.1 Hz, 1 H), 
3.96 (app t, J = 5.0 Hz, 2 H), 3.84 (app t, J = 5.0 Hz, 2 H), 2.97 (app t, J = 5.0 Hz, 2 H), 2.89 
(app t, J = 5.0 Hz, 2 H), 2.29 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 154.4 (quint, JCF = 18.3 
Hz), 152.4, 151.6, 132.4, 132.1, 131.9, 131.0, 126.2 (quint, JCF = 4.6 Hz), 124.1, 123.8, 119.8, 
88.2, 83.2, 51.9, 51.3, 47.4, 42.0, 17.3; 19F NMR (376 MHz, CDCl3) δ 83.0 (quint, J = 150.3 Hz, 
1 F), 62.4 (d, J = 150.3 Hz, 4 F); HRMS (ESI) m/z calcd for C20H19ClF5N2OS ([M+H]+) 
465.0821, found 465.0819. 
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3.21k 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone (3.21k). A solution of 1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(4-(pentafluoro-λ6-sulfaneyl)phenyl)prop-2-yn-1-one (3.17i, 
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0.0850 g, 0.183 mmol) in EtOAc (1.8 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, 
lead poisoned, 0.0195 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of 
H2 (3 vacuum/backfill cycles) and stirred at rt for 2 d, filtered through Celite, washed (EtOAc), 
and the combined filtrates were concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% 
hexanes to 40% EtOAc/hexanes, product eluted at 35% EtOAc/hexanes) to give 3.18i (0.0811 g, 
0.174 mmol) as a colorless solid. 
A solution of CrCl2 (0.126 g, 1.03 mmol) and (Z)-1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(4-(pentafluoro-λ6-sulfaneyl)phenyl)prop-2-en-1-one (3.18i, 
0.0800 g, 0.171 mmol) in dry degassed THF (1.7 mL) was sparged with Ar for 5 min and added 
CH2ICl (0.10 mL, 0.857 mmol) at rt, heated for 2 d at 80 °C, cooled to rt, diluted with EtOAc 
(50 mL) and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 30% 
EtOAc/hexanes, product eluted at 30% EtOAc/hexanes) to give a clear oil that was filtered 
through basic Al2O3 (CH2Cl2/EtOAc, 1:1), concentrated under reduced pressure, and dried under 
high vacuum to give 3.21k (0.0451 g, 0.0938 mmol, 52% (2 steps) (100% purity by ELSD)) as a 
colorless solid: Mp 169.8-172.0 °C; IR (CH2Cl2) 2919, 1639, 1490, 1466, 1438, 1225, 1035, 
835, 750 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.6 Hz, 2 H), 7.25 (d, J = 8.6 Hz, 2 H), 
7.06 (dd, J = 8.1, 0.4 Hz, 1 H), 6.95 (dd, J = 8.1, 2.1 Hz, 1 H), 6.69 (d, J = 2.1 Hz, 1 H), 3.82 
(bd, J = 14.0 Hz, 1 H), 3.70-3.58 (m, 2 H), 3.33 (ddd, J = 12.4, 8.9, 3.0 Hz, 1 H), 2.75 (tdd, J = 
14.0, 7.7, 3.4 Hz, 2 H), 2.50 (td, J = 8.9, 7.0 Hz, 1 H), 2.32-2.23 (m, 2 H), 2.20 (s, 3 H), 2.10 
(ddd, J = 11.1, 8.2, 3.0 Hz, 1 H), 1.91 (q, J = 6.3 Hz, 1 H), 1.44 (td, J = 8.4, 5.6 Hz, 1 H); 13C 
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NMR (100 MHz, CDCl3) δ 166.5, 152.1 (quint, JCF = 17.3 Hz), 151.6, 141.9, 131.9 (2 C), 130.9, 
127.7, 125.7 (quint, JCF = 4.6 Hz), 123.7, 119.5, 51.9, 51.5, 45.5, 42.2, 24.6, 23.7, 17.3, 11.3; 19F 
NMR (376 MHz, CDCl3) δ 84.8 (quint, J = 150.4 Hz, 1 F), 63.2 (d, J = 150.4 Hz, 4 F); HRMS 
(ESI) m/z calcd for C21H23ClF5N2OS ([M+H]+) 481.1134, found 481.1134. 
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Racemic (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone (3.21k) was separated on a SFC Chiralpak-IC 
semiprep (250 x 10 mm) column (30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm) injection 
volume 90 µL, 20 mg/mL) to give (4-(5-chloro-2-methylphenyl)piperazin-1-yl)((1S,2R)-2-(4-
(pentafluoro-λ6-sulfaneyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21k)) (retention time 5.14 
min) as a colorless viscous oil (100% purity by ELSD): [a]17D  -134.2 (c 0.60, MeOH); 1H NMR 
(300 MHz, CDCl3) δ 7.66 (d, J = 8.7 Hz, 2 H), 7.26 (overlap, 2 H), 7.06 (d, J = 8.1 Hz, 1 H), 
6.96 (dd, J = 8.1, 1.8 Hz, 1 H), 6.70 (d, J = 1.8 Hz, 1 H), 3.87-3.79 (m, 1 H), 3.73-3.58 (m, 3 H), 
3.38-3.31 (m, 1 H), 2.81-2.70 (m, 2 H), 2.50 (q, J = 8.7 Hz, 1 H), 2.33-2.24 (m, 2 H), 2.20 (s, 3 
H), 2.16-2.08 (m, 1 H), 1.91 (q, J = 5.7 Hz, 1 H), 1.44 (td, J = 8.1, 5.7 Hz, 1 H). The 
enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 
mL/min, p = 100 bar, 220 nm; retention time: 5.1 min). 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1R,2S)-2-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone ((1R,2S)-3.21k)) (retention time 6.57 min) was 
obtained as a colorless viscous oil (100% purity by ELSD): [a]17D  +136.3 (c 0.59, MeOH); 1H 
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NMR (300 MHz, CDCl3) δ 7.66 (d, J = 8.7 Hz, 2 H), 7.26-7.24 (m, 2 H), 7.06 (d, J = 8.4 Hz, 1 
H), 6.96 (dd, J = 8.4, 1.8 Hz, 1 H), 6.70 (d, J = 1.8 Hz, 1 H), 3.85-3.78 (m, 1 H), 3.67-3.61 (m, 2 
H), 3.39-3.30 (m, 1 H), 2.81-2.70 (m, 2 H), 2.50 (q, J = 8.7 Hz, 1 H), 2.33-2.24 (m, 2 H), 2.20 (s, 
3 H), 2.16-2.10 (m, 1 H), 1.91 (q, J = 5.7 Hz, 1 H), 1.44 (td, J = 8.4, 5.7 Hz, 2 H). The 
enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 
mL/min, p = 100 bar, 220 nm; retention time: 6.5 min). 
3.21k	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21k,	(-)-rota@on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21k,	(+)-rota@on,	Chiralpak-IC,	30%	
MeOH,	7	mL/min,	220	nm	
 
Figure 5.8. SFC chromatograms for 3.21k and separated enantiomers. 
O
N
N
CF3
F5S
 
3.17j 
1-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)prop-2-yn-1-one (3.17j). A solution of 3-(4-(pentafluoro-λ6-
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sulfaneyl)phenyl)propiolic acid (3.16c, 0.100 g, 0.367 mmol) and 1-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine hydrochloride (3.12b, 0.113 g, 0.404 mmol) in CH2Cl2 (3.7 
mL) cooled to 0 °C was treated with Et3N (0.20 mL, 1.47 mmol). The cooled solution was 
treated with T3P (50 wt. % solution in EtOAc, 0.39 mL, 0.551 mmol) dropwise and the reaction 
was stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with EtOAc (30 mL), washed with 
H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
column, liquid load CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes), to give 3.17j 
(0.139 g, 0.278 mmol, 76%) as a tan foam: IR (CH2Cl2) 2920, 2222, 1632, 1418, 1340, 1310, 
1279, 1122, 839, 793 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.8 Hz, 2 H), 7.63 (d, J = 
8.8 Hz, 2 H), 7.31-7.25 (m, 2 H), 7.21 (s, 1 H), 3.98 (t, J = 5.0 Hz, 2 H), 3.85 (app t, J = 5.0 Hz, 
2 H), 3.02 (app t, J = 5.0 Hz, 2 H), 2.92 (app t, J = 5.0 Hz, 2 H), 2.38 (s, 3 H); 13C NMR (100 
MHz, CDCl3) δ 154.3 (quint, JCF = 18.1 Hz), 152.4, 150.9, 136.8, 132.4, 131.5, 129.0 (q, JCF = 
32.1 Hz), 126.2 (quint, JCF = 4.6 Hz), 124.1 (q, JCF = 272.1 Hz), 124.0, 120.5 (q, JCF = 3.8 Hz), 
116.0 (q, JCF = 3.6 Hz), 88.2, 83.1, 51.8, 51.3, 47.4, 41.9, 17.8; 19F NMR (376 MHz, CDCl3) δ 
83.0 (quint, J = 150.4 Hz, 1 F), 62.4 (d, J = 150.2 Hz, 4 F), -62.3 (s, 3 F); HRMS (ESI) m/z calcd 
for C21H19F8N2OS ([M+H]+) 499.1085, found 499.1086. 
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3.21l 
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(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
(pentafluoro-λ6-sulfaneyl)phenyl)cyclopropyl)methanone (3.21l). A solution of 1-(4-(2-
methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(pentafluorosulfanyl)phenyl)prop-2-yn-1-
one (3.17j, 0.100 g, 0.201 mmol) in EtOAc (2 mL) was treated with Lindlar catalyst (5% Pd on 
CaCO3, lead poisoned, 0.0214 g, equivalent to 5 mol% Pd). The reaction was placed under a 
balloon of H2 (3 vacuum/backfill cycles) and stirred at rt for 2 d, filtered through Celite, washed 
(EtOAc), and the combined filtrates were concentrated under reduced pressure. The crude 
residue was purified by automated chromatography on SiO2 (4g column, gradient 100% hexanes 
to 40% EtOAc/hexanes, product eluted at 30% EtOAc/hexanes) to give 3.18j (0.0765 g, 0.153 
mmol) as a colorless foam. 
A solution of CrCl2 (0.111 g, 0.899 mmol) and (Z)-1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(4-(pentafluoro-λ6-sulfaneyl)phenyl)prop-2-en-1-one 
(3.18j, 0.0750 g, 0.150 mmol) in dry degassed THF (1.5 mL) was sparged with Ar for 5 min, 
treated with CH2ICl (0.087 mL, 0.749 mmol) sparged with Ar for 2 min, heated for 2 d at 80 °C, 
cooled to rt, diluted with EtOAc (50 mL), washed with 1 M aqueous HCl (3 x 20 mL). The 
organic layer was dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
residue was purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, 
gradient 100% hexanes to 30% EtOAc/hexanes, product eluted at 30% EtOAc/hexanes) to give 
the product as a clear oil that was filtered through basic Al2O3 (CH2Cl2/EtOAc, 1:1) concentrated 
to a colorless solid. The solid was recrystallized from hot cyclohexane (2x). The supernatant was 
removed and the crystals were washed with cyclohexane (2 x 1 mL) and hexanes (2 x 1 mL) and 
dried under high vacuum to give 3.21l (0.0176 g, 0.0342 mmol, 18% (2 steps) (100% purity by 
ELSD)) as a colorless solid: Mp 122.1-125.8 °C; IR (CH2Cl2) 2919, 1638, 1417, 1338, 1308, 
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1120, 824, 749 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.8 Hz, 2 H), 7.26-7.24 (m, 5 
H), 6.96 (s, 1 H), 3.85 (bd, J = 13.0 Hz, 1 H), 3.72-3.60 (m, 2 H), 3.38-3.32 (m, 1 H), 2.86-2.75 
(m, 2 H), 2.51 (td, J = 8.9, 7.0 Hz, 1 H), 2.32-2.26 (m, 5 H), 2.14 (ddd, J = 11.0, 8.6, 2.6 Hz, 1 
H), 1.92 (q, J = 6.2 Hz, 1 H), 1.45 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 
166.5, 152.2 (quint, JCF = 17.4 Hz), 150.9, 141.8, 136.7, 131.4, 129.1 (q, JCF = 32.1 Hz), 127.7, 
125.7, 125.7 (quint, JCF = 4.6 Hz), 124.0 (q, JCF = 271.9 Hz), 120.4 (q, JCF = 3.9 Hz), 115.7 (q, 
JCF = 3.8 Hz), 51.9, 51.4, 45.5, 42.2, 24.6, 23.7, 17.9, 11.3; 19F NMR (376 MHz, CDCl3) δ 84.6 
(quint, J = 149.9 Hz, 1 F), 63.0 (d, J = 149.8 Hz, 4 F), -62.4 (s, 3 F); HRMS (ESI) m/z calcd for 
C22H23F8N2OS ([M+H]+) 515.1398, found 515.1378. 
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(1R,2S)-3.21l(1S,2R)-3.21l
SF5 SF5
 
Racemic (4-(2-methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(4-
(pentafluoro-λ6-sulfaneyl)phenyl)cyclopropyl)methanone (3.21l) was separated on a SFC 
Chiralpak-IC semiprep (250 x 10 mm) column (30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 
nm) injection volume (90 µL, 20 mg/mL) to give (4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine-1-yl)((1S,2R)-2-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21l) (retention time 3.40 min) as a colorless 
viscous oil (100% purity by ELSD): [a]17D  -119.1 (c 0.79, MeOH); 1H NMR (300 MHz, CDCl3) 
δ 7.66 (d, J = 8.7 Hz, 2 H), 7.25 (d, J = 8.7 Hz, 3 H), 6.97 (s, 1 H), 3.89-3.80 (m, 1 H), 3.72-3.60 
(m, 2 H), 3.40-3.31 (m, 1 H), 2.86-2.74 (m, 2 H), 2.50 (q, J = 8.4 Hz, 1 H), 2.33-2.25 (m, 5 H), 
2.18-2.12 (m, 1 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.44 (td, J = 8.4, 6.0 Hz, 1 H). The enantiomeric 
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excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 
100 bar, 220 nm; retention time: 3.3 min). 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazine-1-yl)((1R,2S)-2-(4-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone ((1R,2S)-3.21l) (retention time 3.65 min) was obtained 
as a colorless viscous oil (100% purity by ELSD): [a]17D  +117.0 (c 0.87, MeOH); 1H NMR (300 
MHz, CDCl3) δ 7.66 (d, J = 8.7 Hz, 2 H), 7.26 (d, J = 8.7 Hz, 3 H), 6.97 (s, 1 H), 3.88-3.82 (m, 2 
H), 3.69-3.63 (m, 3 H), 3.40-3.31 (m, 2 H), 2.89-2.70 (m, 3 H), 2.50 (q, J = 8.4 Hz, 2 H), 2.34-
2.25 (m, 5 H), 2.20-2.12 (m, 1 H), 1.92 (q, J = 6.0 Hz, 1 H), 1.44 (td, J = 8.4, 6.0 Hz, 1 H). The 
enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 
mL/min, p = 100 bar, 220 nm; retention time: 3.7 min). 
3.21l	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21l,	(-)-rota@on,	Chiralpak-IC,	
30%	MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21l,	(+)-rota@on,	Chiralpak-IC,	
30%	MeOH,	7	mL/min,	220	nm	
 
Figure 5.9. SFC chromatograms for 3.21l and separated enantiomers. 
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1-(4-(5-Chloro-2-methylphenyl)piperazine-1-yl)-3-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)prop-2-yn-1-one (3.17k). A solution of 3-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)propiolic acid (3.16d, 0.100 g, 0.367 mmol) and 1-(1-(5-chloro-2-
methylphenyl)piperazine hydrochloride (3.12b, 0.0999 g, 0.404 mmol) in CH2Cl2 (3.7 mL) 
cooled to 0 °C was treated with Et3N (0.20 mL, 1.47 mmol). The cooled solution was treated 
with T3P (50 wt. % solution in EtOAc, 0.39 mL, 0.551 mmol) dropwise and the reaction was 
stirred at 0 °C for 30 min and allowed to warm to rt for 16 h. The reaction was diluted with 
EtOAc (30 mL) and washed with H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 30% 
EtOAc/hexanes), to give 3.17k (0.113 g, 0.244 mmol, 66%) as a pale yellow solid: Mp 127.9-
133.0 °C; IR (CHCl3) 2921, 2219, 1627, 1432, 1288, 1223, 1041, 838, 797, 728 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.94 (t, J = 2.0 Hz, 1 H), 7.80 (ddd, J = 8.4, 2.0, 0.8 Hz, 1 H), 7.69 (d, J = 
7.7 Hz, 1 H), 7.49 (t, J = 8.1 Hz, 1 H), 7.11 (d, J = 8.1 Hz, 1 H), 6.99 (dd, J = 8.1, 2.1 Hz, 1 H), 
6.96 (d, J = 2.1 Hz, 1 H), 3.97 (app t, J = 5.0 Hz, 2 H), 3.84 (app t, J = 5.0 Hz, 2 H), 2.98 (app t, 
J = 5.0 Hz, 2 H), 2.89 (app t, J = 5.0 Hz, 2 H), 2.29 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
153.8 (quint, JCF = 18.5 Hz), 152.4, 151.6, 135.1, 132.1, 131.9, 131.0, 129.7 (quint, JCF = 7.1 
Hz), 129.0, 127.3 (quint, JCF = 4.5 Hz), 123.8, 121.6, 119.8, 88.4, 82.3, 51.9, 51.3, 47.4, 42.0, 
17.3; 19F NMR (376 MHz, CDCl3) δ 82.9 (quint, J = 150.6 Hz, 1 F), 62.6 (d, J = 150.5 Hz, 4 F); 
HRMS (ESI) m/z calcd for C20H19ClF5N2OS ([M+H]+) 465.0821, found 465.0821. 
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(4-(5-Chloro-2-methylphenyl)piperazine-1-yl)((1RS,2SR)-2-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone (3.21m). A solution of 1-(4-(5-chloro-2-
methylphenyl)piperazine-1-yl)-3-(4-(pentafluorosulfanyl)phenyl)prop-2-yn-1-one (3.17k, 0.0930 
g, 0.200 mmol) in EtOAc (2 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, lead 
poisoned, 0.0213 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of H2 (3 
vacuum/backfill cycles) and stirred at rt for 3 d, filtered through Celite, washed (EtOAc) and the 
combined filtrates were concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 
30% EtOAc/hexanes, product eluted at 20% EtOAc/hexanes) to give 3.18k (0.0470 g, 0.101 
mmol) as a colorless solid.  
A solution of CrCl2 (0.0742 g, 0.604 mmol) and (Z)-1-(4-(5-chloro-2-
methylphenyl)piperazine-1-yl)-3-(3-(pentafluoro-λ6-sulfaneyl)phenyl)prop-2-en-1-one (3.18k, 
0.0470 g, 0.101 mmol) in dry degassed THF (1 mL) was treated with CH2Icl (0.058 mL, 0.503 
mmol) at rt, heated for 2 d at 80 °C. The reaction was cooled to rt, diluted with EtOAc (50 mL) 
and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), filtered 
and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 30% 
EtOAc/hexanes, product eluted at 20% EtOAc/hexanes), filtered through basic Al2O3 
(CH2Cl2/EtOAc, 1:1) concentrated and dried under high vacuum to give 3.21m (0.0182 g, 0.0378 
mmol, 19% (2 steps) (100% purity by ELSD)) as a colorless solid: Mp 112.9-116.1 °C; IR 
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(CH2Cl2) 2854, 1640, 1490, 1439, 1225, 1036, 841 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.62-
7.59 (m, 2 H), 7.38 (t, J = 8.1 Hz, 1 H), 7.29 (d, J = 7.8 Hz, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 6.95 
(dd, J = 8.1, 2.1 Hz, 1 H), 6.70 (d, J = 2.1 Hz, 1 H), 3.84 (bd, J = 12.8 Hz, 1 H), 3.76-3.71 (m, 1 
H), 3.61 (ddd, J = 12.8, 8.9, 3.2 Hz, 1 H), 3.29 (ddd, J = 12.8, 9.0, 3.1 Hz, 1 H), 2.80-2.71 (m, 2 
H), 2.53 (td, J = 8.9, 6.9 Hz, 1 H), 2.31-2.23 (m, 2 H), 2.20 (s, 3 H), 2.15-2.09 (m, 1 H), 1.91 (q, 
J = 6.2 Hz, 1 H), 1.43 (td, J = 8.4, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.6, 153.9 
(quint, JCF = 16.8 Hz), 151.8, 139.0, 132.0, 131.8, 131.0, 130.2, 128.6, 125.9 (quint, JCF = 4.5 
Hz), 124.0 (quint, JCF = 4.6 Hz), 123.7, 119.7, 51.8, 51.6, 45.6, 42.2, 24.1, 24.0, 17.3, 11.0; 19F 
NMR (376 MHz, CDCl3) δ 84.7 (quint, J = 150.1 Hz, 1 F), 62.9 (d, J = 149.9 Hz, 4 F); HRMS 
(ESI) m/z calcd for C21H23ClF5N2OS ([M+H]+) 481.1134, found 481.1133. 
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3.17l 
1-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazine-1-yl)-3-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)prop-2-yn-1-one (3.17l). A solution of 3-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)propiolic acid (3.16d, 0.100 g, 0.367 mmol) and 1-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine hydrochloride (3.12c, 0.113 g, 0.404 mmol) in CH2Cl2 (3.7 
mL) cooled to 0 °C was treated with Et3N (0.20 mL, 1.47 mmol). The cooled solution was 
treated with T3P (50 wt. % solution in EtOAc, 0.39 mL, 0.551 mmol) dropwise and the reaction 
was stirred at 0 °C for 30 min, warmed to rt for 18 h, diluted with EtOAc (30 mL), washed with 
H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
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column, liquid load CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes) to give 3.17l (0.150 
g, 0.300 mmol, 82%) as a tan foam: IR (CH2Cl2) 2919, 2825, 2219, 1629, 1418, 1309, 1152, 
1119, 840, 797, 730 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.94 (t, J = 1.8 Hz, 1 H), 7.81 (dt, J = 
8.2, 1.1 Hz, 1 H), 7.70 (d, J = 7.8 Hz, 1 H), 7.50 (t, J = 8.2 Hz, 1 H), 7.29 (q, J = 7.8 Hz, 2 H), 
7.22 (s, 1 H), 4.00 (app t, J = 5.0 Hz, 2 H), 3.87 (app t, J = 5.0 Hz, 2 H), 3.04 (app t, J = 5.0 Hz, 
2 H), 2.94 (app t, J = 5.0 Hz, 2 H), 2.39 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 153.8 (quint, 
JCF = 18.2 Hz), 152.5, 150.9, 136.8, 135.1, 131.6, 129.7 (quint, JCF = 4.7 Hz), 129.1 (q, JCF = 
32.3 Hz), 129.1, 127.4 (quint, JCF = 4.7 Hz), 124.1 (q, JCF = 271.8 Hz), 121.5, 120.6 (q, JCF = 3.9 
Hz), 116.1 (q, JCF = 3.6 Hz), 88.4, 82.3, 51.9, 51.3, 47.4, 42.0, 17.9; 19F NMR (376 MHz, 
CDCl3) δ 82.9 (quint, J = 150.6 Hz, 1 F), 62.6 (d, J = 150.4 Hz, 4 F), -62.3 (s, 3 F);  HRMS 
(ESI) m/z calcd for C21H19F8N2OS ([M+H]+) 499.1085, found 499.1086. 
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3.21n 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazine-1-yl)((1RS,2SR)-2-(3-
(pentafluoro-λ6-sulfaneyl)phenyl)cyclopropyl)methanone (3.21n). A solution of 1-(4-(2-
methyl-5-(trifluoromethyl)phenyl)piperazine-1-yl)-3-(3-(pentafluoro-λ6-sulfaneyl)phenyl)prop-
2-yn-1-one (3.17l, 0.100 g, 0.201 mmol) in EtOAc (2 mL) was treated with Lindlar catalyst (5% 
Pd on CaCO3, lead poisoned, 0.0214 g, equivalent to 5 mol% Pd). The reaction was placed under 
a balloon of H2 (3 vacuum/backfill cycles) and stirred at rt for 2 d, filtered through Celite, 
washed (EtOAc), and the combined filtrates were concentrated under reduced pressure. The 
crude residue was purified by automated chromatography on SiO2 (4g column, liquid load 
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CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes, product eluted at 30% EtOAc/hexanes) 
to give 3.18l (0.0938 g, 0.187 mmol) as a colorless foam.  
A solution of CrCl2 (0.138 g, 1.12 mmol) and (Z)-1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazine-1-yl)-3-(3-(pentafluoro-λ6-sulfaneyl)phenyl)prop-2-en-1-one 
(3.18l, 0.0938 g, 0.187 mmol) in dry degassed THF (1.9 mL) was treated with CH2ICl (0.11 mL, 
0.937 mmol) at rt, sparged for 2 min, heated for 2 d at 80 °C, cooled to rt, diluted with EtOAc 
(50 mL), and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 40% 
EtOAc/hexanes, product eluted at 30% EtOAc/hexanes), filtered through basic Al2O3 
(CH2Cl2/EtOAc, 1:1), concentrated under reduced pressure, and dried under high vacuum to give 
3.21n (0.0641 g, 0.125 mmol, 62% (2 steps) (100% purity by ELSD)) as a pale yellow oil: IR 
(CH2Cl2) 2917, 1638, 1438, 1417, 1337, 1307, 1120, 835, 758 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 7.62-7.58 (m, 2 H), 7.38 (t, J = 7.8 Hz, 1 H), 7.30 (d, J = 7.8 Hz, 1 H), 7.24-7.21 (m, 2 H), 6.96 
(s, 1 H), 3.93 (d, J = 13.0 Hz, 1 H), 3.79 (dt, J = 13.0, 3.8 Hz, 1 H), 3.60 (ddd, J = 12.6, 9.2, 3.1 
Hz, 1 H), 3.25 (ddd, J = 12.6, 9.2, 3.0 Hz, 1 H), 2.79 (ddt, J = 12.7, 11.9, 3.8 Hz, 2 H), 2.53 (td, J 
= 8.9, 6.9 Hz, 1 H), 2.31-2.20 (m, 5 H), 2.16-2.10 (m, 1 H), 1.92 (q, J = 6.2 Hz, 1 H), 1.43 (td, J 
= 8.4, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.5, 153.9 (quint, JCF = 16.9 Hz), 151.0, 
139.0, 136.8, 131.3, 130.3, 129.0 (q, JCF = 33.1 Hz), 128.5, 125.7 (quint, JCF = 4.6 Hz), 124.2 (q, 
JCF = 272.0 Hz), 123.9 (quint, JCF = 4.6 Hz), 120.3 (q, JCF = 3.9 Hz), 115.9 (q, JCF = 3.6 Hz), 
51.7, 51.6, 45.5, 42.2, 24.0 (2 C), 24.0, 17.8, 10.9; 19F NMR (376 MHz, CDCl3) δ 84.5 (quint, J 
= 150.0 Hz, 1 F), 62.7 (d, J = 149.8 Hz, 4 F), -62.4 (s, 3 F); HRMS (ESI) m/z calcd for 
C22H23F8N2OS ([M+H]+) 515.1398, found 515.1380. 
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Racemic (4-(2-methyl-5-(trifluoromethyl)phenyl)piperazine-1-yl)((1RS,2SR)-2-(3-
(pentafluoro-λ6-sulfaneyl)phenyl)cyclopropyl)methanone (3.21n) was separated on a SFC 
Chiralpak-IC semiprep (250 x 10 mm) column (30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 
nm) injection volume 90 µL, 20 mg/mL) to give (4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)((1S,2R)-2-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone ((1S,2R)-3.21n) (retention time 3.25 min) as a 
colorless viscous oil (100% purity by ELSD): [a]18D  -104.7 (c 0.84, MeOH); 1H NMR (300 
MHz, CDCl3) δ 7.62-7.58 (m, 2 H), 7.38 (t, J = 7.7 Hz, 1 H), 7.31-7.24 (m, 3 H), 6.96 (s, 1 H), 
3.94-3.89 (m, 1 H), 3.81-3.75 (m, 1 H), 3.65-3.56 (m, 1 H), 3.31-3.22 (m, 1 H), 2.84-2.74 (m, 2 
H), 2.53 (td, J = 9.3, 6.9 Hz, 1 H), 2.32-2.21 (m, 5 H), 2.19-2.11 (m, 1 H), 1.93 (q, J = 5.7 Hz, 1 
H), 1.43 (td, J = 8.4, 5.7 Hz, 1 H). The enantiomeric excess was >99.9% ee (SFC Chiralpak-IC 
(250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; retention time: 3.3 min). 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1R,2S)-2-(3-(pentafluoro-λ6-
sulfaneyl)phenyl)cyclopropyl)methanone ((1R,2S)-3.21n) (retention time 3.60 min) was obtained 
as a colorless viscous oil (100% purity by ELSD): [a]18D  +103.4 (c 0.87, MeOH); 1H NMR (300 
MHz, CDCl3) δ 8.54-7.81 (m, 2 H), 7.62-7.59 (m, 2 H), 7.38 (t, J = 7.8 Hz, 1 H), 7.31-7.24 (m, 3 
H), 6.96 (s, 1 H), 3.94-3.88 (m, 1 H), 3.81-3.75 (m, 1 H), 3.65-3.56 (m, 1 H), 3.31-3.22 (m, 1 H), 
2.84-2.74 (m, 2 H), 2.53 (td, J = 9.0, 7.2 Hz, 1 H), 2.32-2.22 (m, 5 H), 2.18-2.11 (m, 1 H), 1.93 
(q, J = 5.7 Hz, 1 H), 1.43 (td, J = 8.4, 5.7 Hz, 1 H); The enantiomeric excess was >99.9% ee 
 245 
(SFC Chiralpak-IC (250 x 10 mm); 30% Methanol:CO2, 7 mL/min, p = 100 bar, 220 nm; 
retention time: 3.6 min). 
3.21n	Chiralpak-IC,	30%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21n,	(-)-rota@on,	Chiralpak-IC,	
30%	MeOH,	7	mL/min,	220	nm	
(1R,2S)-3.21n,	(+)-rota@on,	Chiralpak-IC,	
30%	MeOH,	7	mL/min,	220	nm	
 
Figure 5.10. SFC chromatograms for 3.21n and separated enantiomers. 
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3.17m 
1-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(6-
(trifluoromethyl)pyridin-3-yl)prop-2-yn-1-one (3.17m). A solution of methyl 3-(5-
chloropyridin-2-yl)propionate (0.500 g, 2.18 mmol) in THF (4 mL) was treated with 2 M NaOH 
(1.2 mL, 2.40 mmol) and the mixture was stirred at rt for 3 h, acidified with 1 M aqueous HCl, 
and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried (MgSO4), 
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filtered and concentrated under reduced pressure to give 3.16f (0.422 g, 1.96 mmol) as a 
colorless solid. This solid was taken on to the coupling reaction with no further purification. 
A solution of 3-(6-(trifluoromethyl)pyridin-3-yl)propionic acid (3.16f, 0.422 g, 1.96 
mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine hydrochloride (3.12c, 0.661 g, 2.35 
mmol) in CH2Cl2 (19 mL) cooled to 0 °C was treated Et3N (0.83 mL, 5.88 mmol). The cooled 
solution was treated with T3P (50% solution in EtOAc) (2.1 mL, 2.94 mmol) dropwise and the 
reaction was stirred at 0 °C for 30 min, warmed to rt for 18 h, diluted with EtOAc (50 mL), 
washed with H2O (20 mL), satd. aqueous NaHCO3 (20 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. The crude material was purified by chromatography on 
SiO2 (hexanes/EtOAc, 1:1) to give 3.17m (0.781 g, 1.77 mmol, 81% (2 steps)) as a pale yellow 
solid: Mp 110.7-113.5 °C; IR (CH2Cl2) 3652, 2981, 2890, 1635, 1382, 1337, 1240, 1150, 1087, 
956 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.85 (dd, J = 1.6, 0.6 Hz, 1 H), 8.04 (ddd, J = 8.2, 1.6, 
0.6 Hz, 1 H), 7.72 (dd, J = 8.2, 0.6 Hz, 1 H), 7.32-7.26 (m, 2 H), 7.21 (s, 1 H), 3.99 (t, J = 5.0 
Hz, 2 H), 3.87 (t, J = 5.0 Hz, 2 H), 3.04 (t, J = 5.0 Hz, 2 H), 2.95 (t, J = 5.0 Hz, 2 H), 2.39 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 152.5, 152.0, 150.8, 148.2 (q, JCF = 35.3 Hz), 140.7, 136.8, 
131.6, 129.1 (q, JCF = 32.3 Hz), 124.1 (q, JCF = 272.1 Hz), 121.0 (q, JCF = 274.4 Hz), 120.7, 
120.6 (q, JCF = 3.9 Hz), 120.0 (q, JCF = 2.8 Hz), 116.1 (q, JCF = 3.6 Hz), 85.6, 51.8, 51.3, 47.4, 
42.0, 17.9; 19F NMR (376 MHz, CDCl3) δ -62.3 (s, 3 F). -68.2 (s, 3 F); HRMS (ESI) m/z calcd 
for C21H18F6N3O ([M+H]+) 442.1349, found 442.1345. 
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3.21o 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(6-
(trifluoromethyl)pyridin-3-yl)cyclopropyl)methanone (3.21o).  A solution of 1-(4-(2-methyl-
5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(6-(trifluoromethyl)pyridin-3-yl)prop-2-yn-1-one 
(3.17m, 0.720 g, 1.63 mmol) in EtOAc (16 mL) at rt was treated with quinoline (1.0 mL, 8.16 
mmol) and 5% Pd/BaSO4 (0.0347 g, 0.0163 mmol, equivalent to 1 mol% Pd) and the reaction 
was stirred under an atmosphere of H2 (3 x backfill cycles) for 4 h. Analysis by TLC 
(hexanes/EtOAc, 1:1) indicated that the starting material had been mostly consumed. The 
reaction was filtered (eluting with EtOAc), and the filtrate was washed with 1 M aqueous HCl (3 
x 30 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1 to EtOAc) to give 3.18m (0.640 
g, 1.44 mmol) as a yellow/orange oil.  
A solution of CrCl2 (1.06 g, 8.66 mmol) and (Z)-1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(6-(trifluoromethyl)pyridin-3-yl)prop-2-en-1-one 
(3.18m, 0.640 g, 1.44 mmol) in dry degassed THF (14 mL) was sparged with Ar for 5 min and 
treated with CH2ICl (0.83 mL, 7.22 mmol) at rt and under Ar atmosphere. The reaction mixture 
was stirred for 2 d at 80 °C, cooled to rt, diluted with EtOAc (50 mL), and washed with 1 M 
aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), filtered and concentrated under 
reduced pressure. The crude material was purified by chromatography on SiO2 (4:1, 
EtOAc:hexanes), filtered through basic Al2O3 (eluting with EtOAc) concentrated under reduced 
pressure, and dried under high vacuum to give 3.21o (0.280 g, 0.612 mmol, 37% (2 steps) (100% 
purity by ELSD)) as an orange oil: IR (CH2Cl2) 2981, 1640, 1418, 1339, 1309, 1166, 1126, 1035, 
828 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1 H), 7.60 (t, J = 2.0 Hz, 2 H), 7.24 (t, J = 2.0 
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Hz, 2 H), 7.02 (s, 1 H), 3.78-3.65 (m, 3 H), 3.53-3.46 (m, 1 H), 2.92-2.87 (m, 1 H), 2.80-2.75 (m, 
1 H), 2.59-2.53 (m, 1 H), 2.47-2.35 (m, 4 H), 2.30 (s, 3 H), 1.95 (q, J = 5.6 Hz, 1 H), 1.49 (td, J 
= 8.4, 5.6 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.4, 150.8, 150.5, 146.3 (q, JCF = 34.8 Hz), 
136.9, 136.7, 135.5, 131.4, 129.1 (q, JCF = 32.2 Hz), 124.1 (q, JCF = 272.1 Hz), 121.6 (q, JCF = 
273.7 Hz), 120.4 (q, JCF = 3.9 Hz), 119.8 (q, JCF = 2.6 Hz), 115.9 (q, JCF = 3.7 Hz), 52.0, 51.5, 
45.6, 42.3, 23.7, 21.5, 17.9, 11.0; 19F NMR (376 MHz, CDCl3) δ -62.4 (s, 3 F), -67.8 (s, 3 F); 
HRMS (ESI) m/z calcd for C22H22F6N3O ([M+H]+) 458.1662, found 458.1660. 
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Racemic (4-(2-methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(6-
(trifluoromethyl)pyridin-3-yl)cyclopropyl)methanone (3.21o) was separated on a SFC Chiralpak-
IC semiprep (250 x 10 mm) column (15% Methanol/CO2, 7 mL/min, 220nm, p = 100 bar, 20 
mg/mL in MeOH) to give (4-(2-methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1S,2R)-2-(6-
(trifluoromethyl)pyridin-3-yl)cyclopropyl)methanone ((1S,2R)-3.21o) (retention time 7.65 min) 
as a colorless solid (100% purity by ELSD): [a]19D  -134.8 (c 0.90, MeOH); 1H NMR (300 MHz, 
CDCl3) δ 8.64 (s, 1 H), 7.60 (s, 2 H), 7.26 (s, 4 H), 7.04 (s, 1 H), 3.75-3.64 (m, 3 H), 3.55-3.47 
(m, 1 H), 2.94-2.87 (m, 1 H), 2.82-2.74 (m, 1 H), 2.56 (q, J = 8.4 Hz, 1 H), 2.49-2.34 (m, 3 H), 
2.31 (s, 3 H), 1.96 (q, J = 5.8 Hz, 1 H), 1.50 (td, J = 8.4, 5.8 Hz, 1 H). The enantiomeric excess 
was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 15% Methanol:CO2, 7 mL/min, p = 100 bar, 
220 nm; retention time: 7.8 min). 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1R,2S)-2-(6-
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(trifluoromethyl)pyridin-3-yl)cyclopropyl)methanone ((1R,2S)-3.21o)  (retention time 8.38 min) 
was obtained as a colorless solid (100% purity by ELSD): [a]19D  +128.2 (c 1.08, MeOH); 1H 
NMR (300 MHz, CDCl3) δ 8.64 (s, 1 H), 7.60 (s, 2 H), 7.26 (s, 2 H), 7.04 (s, 1 H), 3.77-3.63 (m, 
3 H), 3.55-3.47 (m, 1 H), 2.93-2.87 (m, 1 H), 2.81-2.75 (m, 1 H), 2.61-2.52 (m, 1 H), 2.50-2.35 
(m, 2 H), 2.31 (s, 3 H), 1.96 (q, J = 5.8 Hz, 1 H), 1.50 (td, J = 8.4, 5.8 Hz, 1 H). The 
enantiomeric excess was >99.9% ee (SFC Chiralpak-IC (250 x 10 mm); 15% Methanol:CO2, 7 
mL/min, p = 100 bar, 220 nm; retention time:  8.4 min). 
3.21o	Chiralpak-IC,	15%	MeOH,	7	mL/min,	220	nm	
(1S,2R)-3.21o,	(-)-rotaAon,	Chiralpak-IC,	15%	MeOH,	
7	mL/min,	220	nm	
(1R,2S)-3.21o,	(+)-rotaAon,	Chiralpak-IC,	15%	
MeOH,	7	mL/min,	220	nm	
 
Figure 5.11. SFC chromatograms for 3.21o and separated enantiomers. 
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3.17n 
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1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-3-(5-methylthiophen-2-yl)prop-2-yn-
1-one (3.17n). A solution of 3-(5-methylthiophen-2-yl)propiolic acid (3.16e, 0.0750 g, 0.451 
mmol) and 1-(5-chloro-2-methylphenyl)piperazine hydrochloride (3.12b, 0.134 g, 0.542 mmol) 
in CH2Cl2 (4.5 mL) cooled to 0 °C was treated with Et3N (0.19 mL, 1.35 mmol). The cooled 
solution was treated with T3P (50 wt. % solution in EtOAc, 0.48 mL, 0.677 mmol) dropwise and 
the reaction was stirred at 0 °C for 30 min, warmed to rt for 16 h, diluted with CH2Cl2 (30 mL), 
washed with 1 M aqueous HCl (20 mL), dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude residue was purified by automated chromatography on SiO2 (4g 
column, liquid load CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes), to give 3.17n 
(0.0620 g, 0.173 mmol, 38%) as a colorless solid: Mp 114.4-116.0 °C; IR (CH2Cl2) 2919, 2197, 
1643, 1593, 1489, 1426, 1224, 1025, 806 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.24 (d, J = 3.6 
Hz, 1 H), 7.10 (d, J = 8.1 Hz, 1 H), 6.98 (dd, J = 8.1, 1.9 Hz, 1 H), 6.94 (d, J = 1.9 Hz, 1 H), 6.69 
(dd, J = 3.6, 0.8 Hz, 1 H), 3.91 (app t, J = 5.0 Hz, 2 H), 3.81 (app t, J = 5.0 Hz, 2 H), 2.94 (app t, 
J = 5.0 Hz, 2 H), 2.86 (app t, J = 5.0 Hz, 2 H), 2.49 (s, 3 H), 2.28 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 153.1, 151.7, 145.5, 135.7, 132.0, 131.8, 130.9, 125.8, 123.6, 119.7, 117.4, 85.4, 84.5, 
51.8, 51.3, 47.2, 41.8, 17.4, 15.5; HRMS (ESI) m/z calcd for C19H20ClN2OS ([M+H]+) 359.0979, 
found 359.0978. 
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3.21p 
(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)((1RS,2SR)-2-(5-methylthiophen-2-
yl)cyclopropyl)methanone (3.21p). A solution of 1-(4-(5-chloro-2-methylphenyl)piperazin-1-
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yl)-3-(5-methylthiophen-2-yl)prop-2-yn-1-one (3.17n, 0.0620 g, 0.173 mmol) in EtOAc (1.7 
mL) was treated with Lindlar catalyst (5% Pd on CaCO3, lead poisoned, 0.00735 g, equivalent to 
2 mol% Pd) and quinoline (10 µL, 0.172 mmol). The reaction was placed under a balloon of H2 
(4 vacuum/backfill cycles) and stirred at rt for 6 h, filtered through Celite, washed (EtOAc), and 
the combined filtrates were washed with 1 M aqueous HCl, dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 10% EtOAc/hexanes to 40% 
EtOAc/hexanes) to give 3.18n (0.0263 g, 0.0729 mmol) as a colorless solid. 
A solution of CrCl2 (0.0511 g, 0.416 mmol) and (Z)-1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(5-methylthiophen-2-yl)prop-2-en-1-one (3.18n, 0.0250 g, 
0.0693 mmol) in dry degassed THF (0.7 mL) was sparged with Ar for 5 min and treated with 
CH2ICl (40 uL, 0.346 mmol) at rt, heated for 20 h at 80 °C, cooled to rt, combined, diluted with 
Et2O (50 mL), and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried 
(MgSO4), filtered and concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 
40% EtOAc/hexanes), filtered through basic Al2O3 (CH2Cl2/EtOAc, 1:1), concentrated under 
reduced pressure and dried under high vacuum to give 3.21p (0.0154 g, 0.0411 mmol, 25% (2 
steps) (100% purity by ELSD)) as a pale yellow oil: IR (CH2Cl2) 2918, 1643, 1593, 1490, 1462, 
1436, 1226, 1029, 802 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.08 (dd, J = 8.1, 0.4 Hz, 1 H), 6.97 
(dd, J = 8.1, 2.1 Hz, 1 H), 6.79 (d, J = 2.1 Hz, 1 H), 6.57-6.55 (m, 2 H), 3.96 (d, J = 13.0 Hz, 1 
H), 3.85 (dt, J = 13.0, 3.5 Hz, 1 H), 3.63 (ddd, J = 13.0, 8.9, 3.5 Hz, 1 H), 3.34 (ddd, J = 13.0, 
9.0, 3.2 Hz, 1 H), 2.79 (ddt, J = 19.3, 11.2, 4.1 Hz, 2 H), 2.52 (td, J = 8.9, 6.8 Hz, 1 H), 2.45-2.36 
(m, 5 H), 2.24 (s, 3 H), 2.16 (ddd, J = 8.9, 8.2, 6.3 Hz, 1 H), 1.77 (td, J = 6.3, 5.6 Hz, 1 H), 1.38 
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(ddd, J = 8.9, 8.2, 5.6 Hz, 1 H).13C NMR (100 MHz, CDCl3) δ 167.2, 152.1, 138.2, 137.5, 131.9, 
131.7, 131.1, 125.0, 124.1, 123.5, 119.7, 51.8, 51.7, 45.7, 42.4, 24.1, 19.3, 17.3, 15.3, 12.2; 
HRMS (ESI) m/z calcd for C19H24ClN2OS ([M+H]+) 375.1292, found 375.1292. 
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3.17o 
1-(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(5-methylthiophen-2-
yl)prop-2-yn-1-one  (3.17o). A solution of 3-(5-methylthiophen-2-yl)propiolic acid (3.15e, 
0.0592 g, 0.356 mmol) and 1-(2-methyl-5-(trifluoromethyl)phenyl)piperazine hydrochloride 
(3.12c, 0.100 g, 0.356 mmol) in CH2Cl2 (3.6 mL) cooled to 0 °C was treated with Et3N (0.20 
mL, 1.42 mmol). The cooled solution was treated with T3P (50 wt. % solution in EtOAc, 0.38 
mL, 0.534 mmol) dropwise and the reaction was stirred at 0 °C for 30 min, warmed to rt for 18h, 
diluted with CH2Cl2 (30 mL), washed with 1 M aqueous HCl (20 mL), dried (MgSO4), filtered, 
and concentrated under reduced pressure. The crude material was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 40% 
EtOAc/hexanes), to give 3.17o (0.0685, 0.175 mmol, 49%) as a yellow solid. Mp 145.7-149.3 
°C; IR (CH2Cl2) 2919, 2199, 1635, 1420, 1340, 1309, 1120, 1029, 955, 732 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.31-7.24 (m, 3 H), 7.21 (s, 1 H), 6.69 (dd, J = 3.6, 0.8 Hz, 1 H), 3.94 (app t, J = 
5.0 Hz, 2 H), 3.83 (app t, J = 5.0 Hz, 2 H), 3.01 (app t, J = 5.0 Hz, 2 H), 2.91 (app t, J = 5.0 Hz, 
2 H), 2.49 (d, J = 0.8 Hz, 3 H), 2.38 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 153.2, 151.0, 145.5, 
136.8, 135.7, 131.5, 129.0 (q, JCF = 32.2 Hz), 125.9, 124.1 (q, JCF = 272.1 Hz), 120.4 (q, JCF = 
3.8 Hz), 117.4, 116.0 (q, JCF = 3.6 Hz), 85.4, 84.5, 51.8, 51.3, 47.3, 41.8, 17.9, 15.5; 19F NMR 
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(376 MHz, CDCl3) δ  -62.2 (s, 3 F);  HRMS (ESI) m/z calcd for C20H20F3N2OS ([M+H]+) 
393.1243, found 393.1241. 
O
N
N
CF3
S
 
3.21q 
(4-(2-Methyl-5-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(5-
methylthiophen-2-yl)cyclopropyl)methanone (3.21q). A solution of 1-(4-(2-methyl-5-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(5-methylthiophen-2-yl)prop-2-yn-1-one (3.17o, 
0.0650 g, 0.166 mmol) in EtOAc (1.7 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, 
lead poisoned, 0.0176 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of 
H2 (3 vacuum/backfill cycles) and stirred at rt for 3 d, filtered through Celite, washed (EtOAc), 
and the combined filtrates were concentrated under reduced pressure. The crude residue was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% 
hexanes to 40% EtOAc/hexanes, product eluted at 20% EtOAc/hexanes) to give 3.18o (0.0443 g, 
0.112 mmol) as a colorless solid. 
A solution of CrCl2 (0.105 g, 0.851 mmol) and (Z)-1-(4-(5-chloro-2-
methylphenyl)piperazin-1-yl)-3-(3-(trifluoromethyl)phenyl)prop-2-en-1-one (3.18o, 0.0420 g, 
0.142 mmol) in dry degassed THF (1.1 mL) was sparged with Ar for 5 min and treated with 
CH2ICl (62uL, 0.532 mmol) at rt, heated for 22 h at 80 °C, cooled to rt, diluted with Et2O (50 
mL), and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by automated 
chromatography on SiO2 (4g column, liquid load CH2Cl2, 100% hexanes to 40% 
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EtOAc/hexanes), filtered through basic Al2O3 (CH2Cl2/EtOAc, 1:1), concentrated under reduced 
pressure, and dried under high vacuum to 3.21q (0.0187 g, 0.0458 mmol, 29% (2 steps) (100% 
purity by ELSD)) as pale yellow viscous oil: IR (CH2Cl2) 2921, 2822, 1639, 1464, 1434, 1417, 
1337, 1306, 1116, 1079, 1031, 801 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.4 Hz, 1 
H), 7.24 (dd, J = 8.4, 1.4 Hz, 1 H), 7.04 (s, 1 H), 6.58 (t, J = 4.7 Hz, 1 H), 6.55 (dt, J = 3.5, 1.0 
Hz, 1 H), 4.00 (bd, J = 13.0 Hz, 1 H), 3.88 (dt, J = 13.0, 3.5 Hz, 1 H), 3.64 (ddd, J = 12.4, 9.0, 
3.2 Hz, 1 H), 3.34 (ddd, J = 13.0, 9.2, 2.9 Hz, 1 H), 2.82 (ddt, J = 19.4, 11.6, 3.7 Hz, 2 H), 2.53 
(td, J = 8.6, 6.6 Hz, 1 H), 2.48-2.40 (m, 1 H), 2.38 (d, J = 1.0 Hz, 3 H), 2.34 (s, 3 H), 2.17 (td, J 
= 8.6, 6.6 Hz, 1 H), 1.77 (q, J = 6.0 Hz, 1 H), 1.38 (td, J = 8.6, 5.3 Hz, 1 H); 13C NMR (100 
MHz, CDCl3) δ 167.2, 151.4, 138.3, 137.6, 136.9, 131.4, 128.9 (q, JCF = 32.0 Hz), 124.9, 124.3 
(q, JCF = 272.1 Hz), 124.2, 120.3 (q, JCF = 4.0 Hz), 116.0 (q, JCF = 3.7 Hz), 51.8, 51.7, 45.7, 
42.3, 24.1, 19.4 , 17.9, 15.1, 12.3; 19F NMR (376 MHz, CDCl3) δ  -62.2 (s, 3 F); HRMS (ESI) 
m/z calcd for C21H24F3N2OS ([M+H]+) 409.1556, found 409.1555. 
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3.17p 
1-(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)-3-(5-methylthiophen-2-
yl)prop-2-yn-1-one (3.17p). A solution of 3-(5-methylthiophen-2-yl)propiolic acid (3.16e, 
0.0770 g, 0.463 mmol) and 1-(5-chloro-2-(trifluoromethyl)phenyl)piperazine hydrochloride 
(3.12d, 0.153 g, 0.510 mmol) in CH2Cl2 (4.6 mL) cooled to 0 °C was treated with Et3N (0.26 
mL, 1.85 mmol). The cooled solution was treated with T3P (50 wt. % solution in EtOAc, 0.49 
mL, 0.695 mmol) dropwise and the reaction was stirred at 0 °C for 30 min, warmed to rt for 18 
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h, diluted with CH2Cl2 (30 mL), washed with H2O (20 mL), satd. aqueous NaHCO3 (20 mL), 
dried (MgSO4), filtered, and concentrated under reduced pressure. The crude material was 
purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, hexanes to 40% 
EtOAc/hexanes), to give 3.17p (0.135 g, 0.326 mmol, 70%) as a light orange waxy solid: IR 
(CH2Cl2) 2918, 2200, 1629, 1596, 1425, 1309, 1224, 1144, 1120, 1027, 809 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.58 (d, J = 8.4 Hz, 1 H), 7.27-7.23 (m, 3 H), 6.69 (dd, J = 3.6, 0.8 Hz, 1 H), 
3.91 (app t, J = 4.9 Hz, 2 H), 3.81 (app t, J = 5.0 Hz, 2 H), 2.98 (app t, J = 5.0 Hz, 2 H), 2.91 
(app t, J = 5.0 Hz, 2 H), 2.49 (d, J = 0.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 153.2, 152.7, 
152.6, 145.5, 138.8, 135.7, 128.5 (q, JCF = 5.4 Hz), 125.9, 125.8 (q, JCF = 29.3 Hz), 125.6, 124.7, 
123.6 (q, JCF = 273.0 Hz), 117.4, 85.4, 84.5, 53.6, 52.8, 47.3, 41.7, 15.5; 19F NMR (376 MHz, 
CDCl3) δ  -60.3 (s, 3 F); HRMS (ESI) m/z calcd for C19H17ClF3N2OS ([M+H]+) 413.0697, found 
413.0693. 
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3.21r 
(4-(5-Chloro-2-(trifluoromethyl)phenyl)piperazin-1-yl)((1RS,2SR)-2-(5-
methylthiophen-2-yl)cyclopropyl)methanone (3.21r). A solution of 1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(5-methylthiophen-2-yl)prop-2-yn-1-one (3.17p, 0.112 
g, 0.271 mmol) in EtOAc (2.7 mL) was treated with Lindlar catalyst (5% Pd on CaCO3, lead 
poisoned, 0.0289 g, equivalent to 5 mol% Pd). The reaction was placed under a balloon of H2 (3 
vacuum/backfill cycles) and stirred at rt for 3 d, filtered through Celite, washed (EtOAc), and the 
combined filtrates were concentrated under reduced pressure. The crude residue was purified by 
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automated chromatography on SiO2 (4g column, liquid load CH2Cl2, hexanes to 40% 
EtOAc/hexanes, product eluted at 20% EtOAc/hexanes) to give 3.18p (0.0655 g, 0.158 mmol) as 
a colorless foam.  
A solution of CrCl2 (0.116 g, 0.947 mmol) and (Z)-1-(4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazin-1-yl)-3-(5-methylthiophen-2-yl)prop-2-en-1-one (3.18p, 
0.0655 g, 0.158 mmol) in dry degassed THF (1.6 mL) was sparged with Ar for 5 min and treated 
with CH2ICl (0.091 mL, 0.789 mmol) at rt, heated for 2 days at 80 °C, cooled to rt, diluted with 
EtOAc (50 mL), and washed with 1 M aqueous HCl (3 x 20 mL). The organic layer was dried 
(MgSO4), filtered and concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% hexanes to 
30% EtOAc/hexanes, product eluted at 20% EtOAc/hexanes), filtered through basic Al2O3 
(CH2Cl2/EtOAc, 1:1), and concentrated under reduced pressure. The resulting oil was crystalized 
from cyclohexane (~0.5 mL at rt), the crystals were washed with hexanes and dried under high 
vacuum to give 3.21r (0.0313 g, 0.0730 mmol, 27% (2 steps) (100% purity by ELSD)) as a 
colorless solid: Mp 84.5-86.8 °C; IR (CH2Cl2) 3007, 2920, 1642, 1595, 1464, 1435, 1405, 1308, 
1144, 1120, 1031, 825, 803 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 1 H), 7.21 
(dd, J = 8.5, 1.5 Hz, 1 H), 7.03 (d, J = 1.5 Hz, 1 H), 6.61 (dd, J = 3.4, 1.0 Hz, 1 H), 6.59 (d, J = 
3.4 Hz, 1 H), 4.08 (d, J = 13.0 Hz, 1 H), 3.87 (d, J = 13.0 Hz, 1 H), 3.57 (ddd, J = 13.0, 9.4, 3.0 
Hz, 1 H), 3.23 (ddd, J = 13.0, 9.6, 3.0 Hz, 1 H), 2.78 (tt, J = 9.6, 4.7 Hz, 2 H), 2.52 (td, J = 8.8, 
6.8 Hz, 1 H), 2.46-2.40 (m, 4 H), 2.31-2.25 (m, 1 H), 2.16 (ddd, J = 8.8, 8.2, 6.0 Hz, 1 H), 1.77 
(q, J = 6.0 Hz, 1 H), 1.39 (td, J = 8.6, 6.0 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 167.1, 153.2, 
138.6, 138.5, 137.4, 128.4 (q, JCF = 5.4 Hz), 126.0 (q, JCF = 28.2 Hz), 125.5, 125.1, 124.8, 124.0, 
123.6 (q, JCF = 273.0 Hz), 53.6, 53.2, 45.7, 42.4, 24.4, 19.4, 15.3, 12.4; 19F NMR (376 MHz, 
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CDCl3) δ  -60.4 (s, 3 F);  HRMS (ESI) m/z calcd for C20H21ClF3N2OS ([M+H]+) 429.1010, found 
429.1006. 
HN
N
CF3
•HCl
 
3.12c 
1-(2-Methyl-5-(trifluoromethyl)phenyl)piperazine hydrochloride (3.12c). A solution 
of Boc-piperazine (2.14 g, 11.5 mmol), KOtBu (2.35 g, 20.9 mmol), (racemic)-BINAP (0.671 g, 
1.05 mmol), Pd2(dba)3 (0.194 g, 0.209 mmol) in dry toluene (105 mL) was sparged with Ar for 
20 min, treated with 2-bromo-1-methyl-4-(trifluoromethyl)benzene (2.50 g, 10.5 mmol), and the 
mixture was heated under Ar at 100 °C for 24 h, cooled to rt, diluted with Et2O (125 mL), 
filtered through Celite, washed (Et2O), and the combined filtrates were concentrated under 
reduced pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 
9:1) to give tert-butyl 4-(2-methyl-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate (2.49 g, 
7.23 mmol) as a orange oil.  
A solution of tert-butyl 4-(2-methyl-5-(trifluoromethyl)phenyl)piperazine-1-carboxylate 
(2.49 g, 7.23 mmol) in THF (3.5 mL) was cooled to 0 °C and treated with 4M HCl in dioxane 
(9.0 mL, 36.2 mmol) was added and the reaction was stirred at 0 °C for 30 min and then rt for 4 
h. The solution was concentrated under reduced pressure and the tan solid was precipitated in 
Et2O, filtered off from the solution, washed with Et2O, dried under vacuum to give the crude 
product. The crude material was recrystallized from EtOH/hexanes (1:1) to give 3.12c (1.71 g, 
6.10 mmol, 58% (2 steps)) as colorless needles: Mp 296 °C (decomp); IR (CH2Cl2) 2939, 2799, 
2498, 1610, 1418, 1338, 1307, 1153, 1076, 950, 827 cm-1; 1H NMR (400 MHz, DMSO-d6) δ 
9.44 (bs, 2 H), 7.42 (d, J = 7.9 Hz, 1 H), 7.35 (dd, J = 7.9, 1.0 Hz, 1 H), 7.25 (d, J = 1.0 Hz, 1 H), 
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3.22 (dd, J = 6.2, 3.6 Hz, 4 H), 3.12 (dd, J = 6.2, 3.6 Hz, 4 H), 2.33 (s, 3 H); 13C NMR (100 
MHz, DMSO-d6) δ 150.8, 137.2, 131.9, 127.5 (q, JCF = 31.6 Hz), 124.2 (q, JCF = 272.1 Hz), 
120.1 (q, JCF = 3.9 Hz), 115.3 (q, JCF = 3.8 Hz), 47.9, 43.1, 17.7; 19F NMR (376 MHz, CDCl3) δ 
-60.7 (s, 3 F); HRMS (ESI) m/z calcd for C12H16F3N2 ([M+H]+) 245.1260, found 245.1261. 
CF3
Cl
N
HN
HCl
 
3.12d 
1-(5-Chloro-2-(trifluoromethyl)phenyl)piperazine hydrochloride (3.12d). Two flasks 
each containing a solution Boc-piperazine (1.58 g, 8.48 mmol), KOtBu (1.73 g, 15.4 mmol), 
(racemic)-BINAP (0.480 g, 0.771 mmol), Pd2dba3 (0.142 g, 0.154 mmol) in toluene (8 mL) was 
sparged with argon for 15 min and treated with 2-bromo-4-chloro-1-(trifluoromethyl)benzene 
(2.00 g, 7.71 mmol), heated under N2 at 80 °C for 24 h, cooled to rt, combined, diluted with Et2O 
(100 mL) and added Celite and filtered through Celite, washed (Et2O), and the combined organic 
layers were concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 9:1) to give 4-(5-chloro-2-
(trifluoromethyl)phenyl)piperazine-1-carboxylate (3.12 g, 8.55 mmol) as a orange oil. 
A solution of tert-butyl 4-(5-chloro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate 
(3.12 g, 8.55 mmol) in THF (8 mL) was treated with 4M HCl in dioxane (10.7 mL, 42.8 mmol), 
stirred at rt for 18 h, diluted with hexanes (100 mL), and the resulting precipitate was filtered and 
washed with additional hexanes and Et2O. The crude material was recrystallized at rt 
(EtOH/hexanes), crystals were collected by vacuum filtration, washed (hexanes) and dried under 
high vacuum to give 3.12d (1.88 g, 6.24 mmol, 41% (2 steps)) as tan solid: Mp 272 °C 
(decomp); IR (neat) 2947, 2726, 2480, 1599, 1576, 1307, 1118, 1037, 946, 819 cm-1; 1H NMR 
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(400 MHz, DMSO-d6) δ 9.58 (s, 2 H), 7.72 (d, J = 8.8 Hz, 1 H), 7.57 (d, J = 1.6 Hz, 1 H), 7.46 
(dd, J = 8.8, 1.6 Hz, 1 H), 3.13 (bs, 8 H); 13C NMR (100 MHz, DMSO-d6) δ 152.2, 138.3, 129.0 
(q, J = 5.4 Hz), 125.9, 124.7, 124.2 (q, J = 29.7 Hz), 123.7 (q, J = 273.0 Hz), 49.6, 43.1; 19F 
NMR (376 MHz, CDCl3) δ -59.0 (s, 3 F);  HRMS (ESI) m/z calcd for C11H13N2ClF3 ([M+H]+) 
265.0714, found 265.0712. 
CN
Br
N
HN
HCl
 
3.12e 
4-Bromo-2-(piperazin-1-yl)benzonitrile hydrochloride (3.12e). A suspension of 4-
bromo-2-fluorobenzonitrile (2.00 g, 10.0 mmol), 1-boc-piperazine (1.86 g, 10.0 mmol), and Et3N 
(1.4 mL, 10.0 mmol) in anhydrous MeCN (5.0 mL) was heated to 110 °C for 21 h, cooled to rt, 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (hexanes/EtOAc, 9:1) to give tert-butyl 4-(5-bromo-2-cyanophenyl)piperazine-1-
carboxylate (3.03 g, 8.27 mmol) as a yellow oil. 
A solution of tert-butyl 4-(5-bromo-2-cyanophenyl)piperazine-1-carboxylate (3.03 g, 
8.27 mmol) in THF (4 mL) was cooled to 0 °C and treated with 4M HCl in dioxane (10.3 mL, 
41.4 mmol), stirred at 0 °C for 30 min, rt for 16 h, diluted with hexanes (200 mL), and the 
resulting precipitate was collected by vacuum filtration, washed with hexanes, Et2O, and dried 
under high vacuum to give 3.12e (3.82 g, 13.6 mmol, 79% (2 steps)) as a colorless solid: Mp 288 
°C (decomp); IR (neat) 2901, 2748, 1459, 1129, 1581, 1411, 1241, 1118, 949, 874 cm-1; 1H 
NMR (400 MHz, MeOD-d4) δ 7.59 (d, J = 8.0 Hz, 1 H), 7.44 (d, J = 1.6 Hz, 1 H), 7.37 (dd, J = 
8.0, 1.6 Hz, 1 H), 3.49 (td, J = 4.0, 1.2 Hz, 4 H), 3.44 (td, J = 4.0, 1.2 Hz, 4 H); 13C NMR (100 
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MHz, MeOD-d4) δ 156.5, 136.4, 129.9, 127.8, 124.2, 118.2, 106.7, 49.6, 44.9; HRMS (ESI) m/z 
calcd for C11H13N3Br ([M+H]+) 266.0287, found 266.0286. 
5.4.2 Synthesis of Analogs for Affinity Labeling 
BocN
O
 
3.30 
(tert-Butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (3.30).349 A solution of 
nortropinone•HCl (3.29, 2.00 g, 12.4 mmol) in a minimum amount of H2O (6.0 mL) was cooled 
to 0 °C, treated dropwise with 1 M NaOH (14.8 mL, 14.8 mmol), warmed to rt over 20 min, 
extracted with CH2Cl2 (3 x 40 mL), dried (MgSO4), filtered, and concentrated under reduced 
pressure (bath at 23 °C) to give nortropinone 3.29 as the free base (1.54 g, quant.). The colorless 
oil was used without further purification. 
A solution of nortropinone (3.29, 1.54 g, 12.3 mmol) in CH2Cl2 (50 mL) cooled to 0 °C 
was treated with Boc anhydride (4.26 mL, 18.6 mmol), DMAP (0.302 g, 2.47 mmol), and Et3N 
(7.0 mL, 50.2 mmol). The reaction mixture was allowed to warm to rt and stirred for 19 h, 
concentrated under reduced pressure, and the residue was diluted with H2O, extracted with 
EtOAc (3x), washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (CH2Cl2) to give 21a (2.18 
g, 9.68 mmol, 78% (2 steps)) as a pale yellow oil that solidified to an off-white solid upon 
standing at rt: 1H NMR (300 MHz, DMSO-d6) δ 4.34-4.30 (m, 2 H), 2.55 (dt, J = 15.6, 4.2 Hz, 2 
H), 2.23 (d, J = 15.6 Hz, 2 H), 2.20 (app s, 1 H), 2.03-1.94 (m, 2 H), 1.60-1.52 (m, 2 H), 1.44 (s, 
9 H); 13C NMR (75 MHz, DMSO-d6) δ 207.4, 152.6, 79.2, 52.7, 48.1, 28.0 (2 C). 
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BocN
OTf
 
3.31 
tert-Butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-
carboxylate (3.31).349 A solution of NaHMDS (0.895 g, 4.88 mmol) in THF (12 mL) was added 
dropwise (over 10 min) at -78 °C to a solution of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-
carboxylate (3.30, 1.00 g, 4.44 mmol) in THF (12 mL). The reaction mixture was stirred at -78 
°C for 2 h, treated dropwise (over 20 min) with a solution of PhN(Tf)2 (1.90 g, 5.33 mmol) in 
THF (12 mL), stirred for an additional 30 min at -78 °C and then allowed to warm to rt and 
stirred for 2 h, diluted with 10% aqueous Na2CO3 (50 mL), and extracted with Et2O (2 x 75 mL). 
The combined organic layers were washed with 10% aqueous Na2CO3 solution, dried (MgSO4), 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (1:19, EtOAc/hexanes w/ 1% Et3N) to give 3.31 (1.24 g, 3.47 mmol, 78%) as a clear oil that 
solidified to a wax upon storage at -20 °C: 1H NMR (400 MHz, CDCl3) δ 6.09 (bs, 1 H), 4.54-
4.38 (m, 2 H), 3.07-3.02 (m, 1 H), 2.30-2.20 (m, 1 H), 2.11-1.99 (m, 3 H), 2.00-1.97 (m, 2 H), 
1.79-1.70 (m, 1 H), 1.45 (s, 9 H). 
BocN Br  
3.28 
(1SR,5RS)-tert-Butyl 3-(2-bromophenyl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate 
(3.28). A solution of Na2CO3 (0.860 g, 8.11 mmol), lithium chloride (0.156 g, 3.69 mmol), 
(1SR,5RS)-tert-butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-
carboxylate (3.31, 1.20 g, 3.69 mmol), and 2-bromobenzeneboronic acid (3.32, 0.794 g, 3.87 
mmol) in DME (36 mL) and H2O (7 mL) was sparged with Ar for 20 min and treated with 
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Pd(PPh3)4 (0.128 g, 0.111 mmol), sparged with Ar for 2 min, heated to 60 °C for 6 h, cooled to 
rt, diluted with brine, and extracted with Et2O (3x). The combined organic layers were dried 
(Na2SO4), and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 9:1 w/ 1% Et3N) to give 3.28 (1.08 g, 2.97 mmol, 
81%) as a clear oil that solidified to a colorless solid upon storage at -20 °C: Mp 50.2-52.6 °C, 
IR (neat) 3280, 2971, 1685, 1379, 1327, 1169, 1092, 755 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.53 (dd, J = 7.8, 1.2 Hz, 1 H), 7.09 (dt, J = 7.8, 1.2 Hz, 1 H), 7.12-7.06 (m, 2 H), 5.94-5.92 (m, 
1 H), 4.45 (t, J = 5.0 Hz, 1 H), 4.38 (dd, J = 7.6, 4.4 Hz, 1 H), 2.95 (dt, J = 17.2, 2.0 Hz, 1 H), 
2.26-2.19 (m, 1 H), 2.14 (s, 1 H), 2.10-1.91 (m, 3 H), 1.49 (s, 9 H); 13C NMR (100 MHz, CDCl3) 
δ 154.2, 142.5, 136.3, 132.7, 132.0, 129.8, 128.5, 127.2, 122.6, 79.3, 53.1, 52.3, 37.8, 34.5, 29.7, 
28.4; HRMS (ESI) m/z calcd for C15H17BrNO2 ([M+H]+) 364.0915, found 364.0907. 
BocN
HO
H
 
3.27 
(1SR,3RS,5RS)-tert-Butyl 3-(2-(3-hydroxyprop-1-yn-1-yl)phenyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (3.27). To four separate flasks each containing a 
solution of (1SR,5RS)-tert-butyl 3-(2-bromophenyl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate 
(3.28, 0.150 g, 0.412 mmol) in anhydrous iPrOH (2 mL, 0.5 M) under argon and treated with 
phenylsilane (304 µL, 2.47 mmol) and TBHP (5.5 M solution in decane, 150 uL, 0.824 mmol) 
and the resulting mixture was sparged with Ar for 10 minutes. Mn(dpm)3 (0.0249 g, 0.0412 
mmol) was then added in one portion and the reaction was then degassed for an additional 30 
seconds. The reaction was stirred for 2 h where analysis by LCMS indicated that the SM was 
completely consumed. The reactions were combined, concentrated under reduced pressure and 
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purified by automated chromatography on SiO2 (12 g column, liquid load CH2Cl2, isocratic 10% 
EtOAc/hexanes) to give 3.33 (0.309 g, 0.844 mmol) as a 3:1 mixture of diastereomers as a 
colorless oil. 
A solution of tert-butyl (1SR,5RS)-3-(2-bromophenyl)-8-azabicyclo[3.2.1]octane-8-
carboxylate (0.300 g, 0.803 mmol) in dry toluene (6.0 mL) was sparged with Ar for 60 min and 
treated with propargyl alcohol (0.72 mL, 12.0 mmol), Et3N (1.70 mL, 12.0 mmol), (iPr)CuCl293 
(0.0587 g, 0.0587 mmol), and Pd(PPh3)2Cl2 (0.0287 g, 0.0040 mmol) further degassed for 5 min 
and the mixture was stirred 24 h at 90 °C. The reaction was diluted with EtOAc (30 mL) and 
washed with H2O (3 x 5 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. 
The crude residue was purified by automated chromatography on SiO2 (12g column, liquid load 
CH2Cl2, gradient 100% hexanes to 40% EtOAc/hexanes) to give a yellow brown oil that was 
contaminated with Cu. The oil was then dissolved in hexanes and decanted leaving behind solid 
Cu. This was repeated 3 times to give 3.27 (0.0695 g, 0.205 mmol, 12% (2 steps)) as a dark 
yellow oil as a single diastereomer: IR (neat) 3413, 2971, 2865, 1661, 1404, 1364, 1161, 1105, 
1029, 757 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.36 (dd, J = 7.5, 0.9 Hz, 1 H), 7.29-7.24 (m, 1 
H), 7.18-7.11 (m, 2 H), 4.47 (t, J = 4.5 Hz, 2 H), 4.31-4.21 (m, 3 H), 3.00 (app quint, J = 6.3 Hz, 
1 H), 2.91-2.82 (m, 1 H), 2.38 (app pent, J = 4.5 Hz, 1 H), 2.25-2.14 (m, 1 H), 2.07-1.96 (m, 1 
H), 1.76-1.54 (m, 4 H), 1.50 (s, 9 H), 1.01 (t, J = 12.9 Hz, 1 H); 13C NMR (75 MHz, CDCl3) δ 
155.6, 145.7, 131.4, 128.3, 125.9, 125.6, 122.9, 93.2, 83.1, 79.7, 51.7, 51.3, 51.0, 38.6, 35.6, 
32.5, 31.9, 28.5; HRMS (ESI) m/z calcd for C21H27NaNO3 ([M+Na]+) 364.1881, found 
364.1883. 
S
O
O
N
N
OH
H
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3.25 
2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-1-((1SR,3RS,5RS)-3-(2-(3-hydroxyprop-
1-yn-1-yl)phenyl)-8-azabicyclo[3.2.1]octan-8-yl)ethan-1-one (3.25). A solution of 
(1SR,3RS,5RS)-tert-butyl 3-(2-(3-hydroxyprop-1-yn-1-yl)phenyl)-8-azabicyclo[3.2.1]octane-8-
carboxylate (3.27 0.0450 g, 0.0132 mmol) in CH2Cl2 (2.5 mL) was treated with TFA (0.2 mL, 
2.64 mmol) at 0 °C. After 6 h, the solution was concentrated. The residual oil was dissolved in 
CH2Cl2 and satd. aqueous NaHCO3, and the aqueous layer was extracted with CH2Cl2 (3 x 20 
mL). The combined organic layers were dried (Na2SO4), filtered and concentrated under reduced 
pressure to give 3-(2-((1SR,3RS,5RS)-8-azabicyclo[3.2.1]octan-3-yl)phenyl)prop-2-yn-1-ol 
(0.0368 g, 0.152 mmol) as a dark red oil that was used without further purification. 
A solution of 2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)acetic acid (3.26, 0.0584 g, 
0.290 mmol), HATU (0.0121 g, 0.319 mmol) and DIPEA (101 µL, 0.580 mmol) in CH2Cl2 (1 
mL) was stirred for 30 min at 0 °C and treated with a solution of 3-(2-((1SR,3RS,5RS)-8-
azabicyclo[3.2.1]octan-3-yl)phenyl)prop-2-yn-1-ol (0.0350 g, 0.145 mmol) and DIPEA (50 µL, 
0.260 mmol) in CH2Cl2 (1 mL). The mixture is stirred at rt for 3 h, treated with 1 M NaOH (0.2 
mL) and stirred at rt for 2 h. The reaction was diluted with EtOAc, and the layers separated. The 
organic layer was washed with 1 M aqueous NaHSO4, satd. aqueous NaHCO3, dried (Na2SO4), 
and concentrated. The residue was purified by automated chromatography SiO2 (4g column, 
liquid load CH2Cl2, gradient 50% EtOAc/hexanes to 100% EtOAc) to give 3.25 (0.0182 g, 
0.0429 mmol, 30% (2 steps)) as a yellow oil that partially solidified to a waxy off white solid: IR 
(CH2Cl2) 3387, 2924, 2865, 1616, 1448, 1031, 759 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.35 (dd, 
J = 8.4, 1.6 Hz, 1 H), 7.26 (dt, J = 7.6, 1.2 Hz, 1 H), 7.16-7.13 (m, 2 H), 4.64 (t, J = 8.4 Hz, 1 H), 
4.47 (ddd, J = 16.4, 16.4, 6.0 Hz, 2 H), 4.25 (t, J = 8.0 Hz, 1 H), 4.10 (app t, J = 5.6 Hz, 1 H), 
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3.70 (dd, J = 20.0, 13.6 Hz, 2 H), 3.23 (dd, J = 20.0, 14.0 Hz, 2 H), 3.09 (app quint, J = 6.0 Hz, 1 
H), 2.91-2.83 (m, 1 H), 2.51-2.44 (m, 1 H), 2.37 (s, 3 H), 2.24 (s, 3 H), 2.23-2.17 (m, 1 H), 2.09-
2.00 (m, 1 H), 1.83 (ddd, J = 9.2, 9.2, 4.4 Hz, 1 H), 1.74-1.65 (m, 2 H), 1.15 (dt, J = 13.2, 1.2 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 168.1, 166.9, 159.7, 145.0, 132.0, 131.4, 128.5, 126.1, 
125.6, 122.7, 109.7, 93.4, 83.1, 53.5, 51.2, 50.2, 38.6, 36.6, 33.1, 32.7, 31.0, 24.2, 10.9, 10.0; 
HRMS (ESI) m/z calcd for C24H29N2O3S ([M+H]+) 425.1893, found 425.1894. 
Bead conjugation Conjugation of 3.25 to the Carboxylink Agarose beads 
Activation of the alcohol with p-nitrophenylchloroformate: A solution of 2-(((3,5-
dimethylisoxazol-4-yl)methyl)thio)-1-((1R,3s,5S)-3-(2-(3-hydroxyprop-1-yn-1-yl)phenyl)-8-
azabicyclo[3.2.1]octan-8-yl)ethanone (3.25, 0.00566 g, 0.0133 mmol) in CH2Cl2 (200 uL) was 
added p-nitrophenylchloroformate (0.00403 g, 0.0199 mmol) and Et3N (3.7 uL, 0.0266 mmol) 
and the reaction was stirred at rt for 4 hours, diluted with H2O (50 µL) and stirred for another 10 
min where a deep yellow color was noted. The reaction was diluted with CH2Cl2 (1 mL) filtered 
through a small column of Na2SO4 and washed (CH2Cl2 (1 mL)). The solution was concentrated 
under reduced pressure to give the product as a clear yellow oil that was dissolved in DMF (400 
µL) to give the "activated alcohol solution". 
Conjugation reaction: A suspension of Carboxylink Coupling Gel (1.0 mL) was washed 
with DMF (1.0 mL). The tube was capped and the gel resuspended by inverting with gentle 
shaking. The beads were pelleted in the centrifuge (2 min), the supernatent was removed (pipet). 
This washing was repeated 3 times and the resulting pellet was treated with the activated 
alcohol solution in DMF, the eppendorf tube was capped and rotated for 5 d at 20 °C then added 
5% MES buffer and warmed to 30 °C for 3 d. The gel was pelleted and washed with DMF (3 x 
1.0 mL), PBS buffer (3 x 1.0 mL), and (HPLC grade) H2O (3 x 1.0 mL). Similar to the initial 
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suspension/pelleting/and pipetting. Finally the gel was suspended with 1.0 mL of 0.05% azide 
solution to give 3.34 conjugated beads. 
Quantification: The DMF, phosphate buffer and HPLC H2O washes were combined and 
concentrated by centrifugal evaporation in the HT4 (24h@40 °C). The resulting solid was 
suspended in CH2Cl2 and filtered through a plug of cotton. The combined filtrates were 
concentrated under reduced pressure to give (4.74 mg of a 1:0.5:0.2:0.5 mixture of p-nitrophenol 
(M=139), activated carbonate (M=589): unknown pdt (M=508): unknown elimination pdt 
(M=443)). By mass the recovered material was 0.87 mg of p-nitrophenol with the rest comprised 
of 571 containing material (3.86 mg) was remaining resulting in 1.80 mg (4.24 µmol) of 571 
conjugated to bead. (Mass component X/Mass p-nitrophenol)*number of equivalents in 1HNMR. 
giving us the ratio by weight of the products as 1:2.1:0.73:1.6 respectively. Adding the values 
gives us 5.43 and 1/5.43 is the amount of 4.74 mg that contains pnitrophenol. Subtracting that 
from the mass and then an overall subtraction from the SM gives us 1.80 mg of SM consumed. 
Control beads: 
AcHN N
Ac
N
H  
Carboxylink Coupling Gel was washed with DMF (1.0 mL). The eppendorf tube was 
capped and the gel resuspended by inverting with gentle shaking. The beads were pelleted in the 
centrifuge tube (2 min), the supernatent was removed (pipet). This washing was repeated 3 
times. The pelleted beads were treated with a solution of N-acetoxysuccinimide (1 M in DMF, 
400 µL) and the eppendorf tube was placed on the rotator for 4 h at rt. After 4 h the gel was 
washed with DMF (3 x 1 mL), phosphate buffer (pH 7.0) (3 x 1 mL), and H2O (3 x 1.0 mL 
(HPLC grade)). The gel was suspended with 1.0 mL of 0.05% azide solution. 
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3.38 
Benzyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate (3.38).487 A suspension of tBuOK (2.96 
g, 26.4 mmol) in dry THF (70 mL) at 0 °C was treated with di(ethylene)glycol (3.37, 4.81 mL, 
50.3 mmol) warmed to rt and stirred for 1 h, treated dropwise with a solution of 
bromobenzoacetate (6.00 g, 4.15 mL, 25.1 mmol) in dry THF (14 mL). The resulting mixture 
was allowed to stir at rt for 24 h. The mixture was diluted with THF (200 mL) and filtered 
through Celite, washed (THF), and the filtrate was concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (100% EtOAc) to give 3.38 (1.49 g, 5.86 
mmol, 23%) as a pale yellow liquid: 1H NMR (300 MHz, CDCl3) δ 7.35 (bs, 5 H), 5.19 (s, 2 H), 
4.35-4.28 (m, 2 H), 4.18 (s, 2 H), 3.74-3.70 (m, 10 H), 3.63-3.56 (m, 2 H) 2.09 (bs, 1 H). 
O O O OBn
O
O  
3.39 
2-(2-(2-(Benzyloxy)-2-oxoethoxy)ethoxy)ethyl acrylate (3.39). A solution of benzyl 2-
(2-(2-hydroxyethoxy)ethoxy)acetate (3.38, 1.49 g, 5.86 mmol) in dry THF (30 mL) cooled to 0 
°C and treated with acryloyl chloride (0.5 mL, 6.15 mmol) and Et3N (0.91 mL, 6.45 mmol) and 
stirred at rt for 24 h. The reaction was concentrated under reduced pressure and was dissolved in 
CH2Cl2, successively washed with 5% aqueous HCl, 5% aqueous NaHCO3, and brine, dried 
(MgSO4), and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 2:1) to give the 3.39 (0.589 g, 1.91 mmol, 33%) as a 
clear oil: 1H NMR (400 MHz, CDCl3) δ 7.37-7.35 (m, 5 H), 6.46 (m, 2 H), 6.39-6.10 (m, 1 H), 
5.87-5.79 (m, 1 H), 5.19 (s, 2 H), 4.35-4.29 (m, 4 H), 4.20 (s, 2 H), 3.76-3.69 (m, 8 H); 13C NMR 
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(100 MHz, CDCl3) δ 170.3, 166.1, 135.4, 131.1, 131.0, 128.6, 128.5, 128.4 (2 C), 128.2, 128.1 
(2 C), 73.3, 70.9, 70.7, 69.1, 69.0, 68.9, 68.7, 67.0, 66.5, 63.7, 63.6, 63.5.  
BocN
OO
O
O
OBn
O
 
3.40 
tert-Butyl (1SR,5RS)-3-(2-((E)-3,12-dioxo-1-phenyl-2,5,8,11-tetraoxatetradec-13-en-
14-yl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.40).  A solution of a 10:1 mixture of 
3.33a and 3.33b (1SR,5RS)-tert-butyl 3-(2-bromophenyl)-8-azabicyclo[3.2.1]octane-8-
carboxylate (3.33, 0.215 g, 0.587 mmol) in dry degassed MeCN (3.0 mL) was treated with 
Pd(OAc)2 (0.0132 g, 0.0587 mmol), tri(o-tolyl)phosphine (0.0295 g, 0.0939 mmol) and Et3N 
(215 µL, 1.53 mmol), followed by 2-(2-(2-(benzyloxy)-2-oxoethoxy)ethoxy)ethyl acrylate (3.39, 
0.181 g, 0.587 mmol). The reaction mixture was heated at 85 °C for 24 h, cooled to rt, 
concentrated under reduced pressure, diluted with EtOAc (50 mL), filtered through Celite and 
the filtrate was concentrated under reduced pressure. The crude residue was purified by 
automated chromatography on SiO2 (12 g column, liquid load CH2Cl2, gradient, 100% hexanes 
to 70% EtOAc/hexanes product eluted at 50% EtOAc/hexanes) to give the 3.40 as a 10:1 mixture 
of diastereomers (0.183 g, 0.308 mmol, 53%) as a light brown/orange oil: IR (CH2Cl2) 2962, 
2872, 1752, 1711, 1687, 1390, 1310, 1165, 1122, 980, 751 cm-1; Characteristic NMR for the 
major diastereomer 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 15.7 Hz, 1 H), 7.47 (d, J = 7.7 
Hz, 1 H), 7.34-7.17 (m, 9 H), 6.34 (d, J = 15.7 Hz, 1 H), 5.17 (s, 1 H), 4.62 (s, 1 H), 4.35 (t, J = 
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4.5 Hz, 4 H), 4.26 (s, 1 H), 4.21 (s, 2 H), 4.13 (s, 1 H), 3.75 (t, J = 4.8 Hz, 6 H), 2.99-2.89 (m, 1 
H), 2.50-2.45 (m, 3 H), 2.07 (s, 2 H), 1.70-1.63 (m, 2 H), 1.53 (s, 9 H), 1.46-1.43 (m, 3 H); 13C 
NMR (75 MHz, CDCl3) δ 170.1, 166.2, 154.5, 143.8, 142.4, 135.3, 133.4, 129.8, 128.4, 128.2, 
127.9, 127.5, 127.1, 126.3, 120.2, 79.2, 73.2, 70.8, 70.5, 69.0, 68.8, 68.5, 66.9, 66.3, 63.6, 63.4, 
63.3, 51.3, 50.5, 38.6, 37.7, 32.1, 31.4, 30.4, 28.3; HRMS (ESI) m/z calcd for C34H44NO8 
([M+H]+) 594.3061, found 594.3060. 
BocN
OO
O
O
OBn
O
 
3.41 
tert-Butyl (1SR,5RS)-3-(2-(3,12-dioxo-1-phenyl-2,5,8,11-tetraoxatetradecan-14-
yl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.41). A 10:1 diastereomer mixture of 
(1SR,5RS)-tert-butyl 3-(2-((E)-3,12-dioxo-1-phenyl-2,5,8,11-tetraoxatetradec-13-en-14-
yl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.40, 0.400 g, 0.674 mmol) and NiCl2-
6H2O (0.320 g, 1.35 mmol) in THF (6.7 mL) was treated with NaBH4 (0.153 g, 4.04 mmol) in 
portions at 0 °C. Within 5 min gas evolution started and the solution turned black. The reaction 
was stirred for 6 h where by LCMS it appeared that a small amount of the SM remained so an 
additional NiCl2•6H2O (1eq) and NaBH4 (2 eq) was added and the reaction was left to stir for 12 
h. The reaction was diluted with Et2O (20 mL) and 1 M aqueous HCl (50 mL), extracted with 
EtOAc (3 × 50 mL), and the combined organic layers were washed with satd. aqueous NaHCO3 
(3 × 30 mL), dried (MgSO4), and concentrated under reduced pressure. The crude residue was 
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purified by automated chromatography on SiO2 (4g column, liquid load CH2Cl2, gradient 100% 
hexanes to 30% hexanes/EtOAc) to give the product as a 10:1 mixture of diastereomers (0.233 g, 
0.391 mmol, 58%) as a clear colorless oil: IR (CH2Cl2) 2958, 2895, 1733, 1685, 1390, 1163, 
1120, 753 cm-1; Characteristic NMR for the major diasteromer 1H NMR (400 MHz, CDCl3) δ 
7.37-7.33 (m, 6 H), 7.20-7.07 (m, 4 H), 5.18 (s, 1 H), 4.62 (s, 1 H), 4.30 (dd, J = 5.4, 4.2 Hz, 2 
H), 4.19 (t, J = 4.9 Hz, 4 H), 4.13 (s, 1 H), 3.73-3.63 (m, 7 H), 2.95 (t, J = 7.8 Hz, 2 H), 2.81-
2.74 (m, 1 H), 2.58 (t, J = 7.8 Hz, 2 H), 2.46-2.39 (m, 2 H), 2.07 (dd, J = 6.4, 4.2 Hz, 2 H), 1.69-
1.64 (m, 2 H), 1.49 (s, 9 H), 1.37 (t, J = 13.0 Hz, 2 H); 13C NMR (100 MHz, CDCl3) δ 172.4, 
170.2, 154.7, 142.5, 137.9, 137.0, 135.3, 129.3, 128.5, 128.4, 128.0, 126.0, 79.1, 73.2, 70.8, 70.5, 
69.2, 68.6, 66.9, 66.5, 63.6, 63.5, 63.3, 35.5, 29.4, 28.4, 27.8; HRMS (ESI) m/z calcd for 
C34H46NO8 ([M+H]+) 596.3218, found 596.3220. 
N
OO
S
O
O
N
H
O
O OBn
O
 
3.36 
2-(2-(2-(Benzyloxy)-2-oxoethoxy)ethoxy)ethyl 3-(2-((1SR,3RS,5RS)-8-(2-(((3,5-
dimethylisoxazol-4-yl)methyl)thio)acetyl)-8-azabicyclo[3.2.1]octan-3-yl)phenyl)propanoate 
(3.36). A solution of (1SR,5RS)-tert-butyl 3-(2-(3,12-dioxo-1-phenyl-2,5,8,11-
tetraoxatetradecan-14-yl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.41, 0.122 g, 0.205 
mmol) in THF (2 mL) was cooled to 0 ºC, treated with 4M HCl in dioxane (1.5 mL, 30 eq) and 
stirred at 0 ºC for 8 h. The solution was concentrated under reduced pressure and the residue was 
sonnicated with Et2O and hexanes and decanted (3x) leaving behind the product. The product 
was dried under high vacuum to give 2-(2-(2-(benzyloxy)-2-oxoethoxy)ethoxy)ethyl 3-(2-
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((1SR,3RS,5RS)-8-azabicyclo[3.2.1]octan-3-yl)phenyl)propanoate hydrochloride (0.115 g, 0.216 
mmol, quant) as a viscous oil that was taken onto the T3P coupling with no further purification. 
A solution of 2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)acetic acid (3.26, 0.0495 g, 
0.246 mmol) and 2-(2-(2-(benzyloxy)-2-oxoethoxy)ethoxy)ethyl 3-(2-((1SR,3RS,5RS)-8-
azabicyclo[3.2.1]octan-3-yl)phenyl)propanoate hydrochloride (0.109 g, 0.205 mmol) in CH2Cl2 
(2 mL), was cooled to 0 °C and treated with Et3N (86 µL, 0.0622 mmol). The cooled mixture 
was treated with T3P (50 wt. % solution in EtOAc, 217 µL, 0.307 mmol) and the reaction was 
warmed to rt, stirred for 12 h, diluted with CH2Cl2, and washed with satd. aqueous NH4Cl, satd. 
aqueous NaHCO3, brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
crude material was purified by automated chromatography on SiO2 (4g column, liquid load 
CH2Cl2, gradient 100% CH2Cl2 to 60% CH2Cl2/EtOAc, pdt eluted at 15% EtOAc CH2Cl2) to 
give the product as a 3:2 mixture of product:impurity. This mixture was then purified by 
preparative HPLC (isocratic 16% iPrOH/hexanes (Varian Dynamax 250 X 21.4 microsorb 60 - 8 
Si 20 mL/ min)) and filtered through a short plug of SiO2 (2:1, CH2Cl2/EtOAc) to give 3.36 as a 
single diastereomer (0.00850 g, 0.0125 mmol, 6%) as a clear oil: IR (CHCl3) 2951, 1733, 1629, 
1448, 1193, 1144 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.37-7.32 (m, 5 H), 7.22-7.18 (m, 2 H), 
7.14-7.10 (m, 2 H), 5.17 (s, 2 H), 4.75 (t, J = 7.9 Hz, 1 H), 4.18 (t, J = 4.7 Hz, 4 H), 3.82 (d, J = 
14.4 Hz, 1 H), 3.71 (dd, J = 5.6, 3.3 Hz, 2 H), 3.64 (dd, J = 4.8, 4.2 Hz, 4 H), 3.62 (d, J = 14.4 
Hz, 1 H), 3.17 (d, J = 13.8 Hz, 1 H), 3.03 (d, J = 13.8 Hz, 1 H), 2.99-2.95 (m, 3 H), 2.58 (t, J = 
8.0 Hz, 2 H), 2.54-2.47 (m, 5 H), 2.31 (s, 3 H), 2.17-2.05 (m, 2 H), 1.82-1.73 (m, 2 H), 1.51 (t, J 
= 12.8 Hz, 1 H), 1.46 (t, J = 12.8 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 172.6, 170.2, 167.0, 
166.4, 159.9, 141.9, 138.2, 135.4, 129.3, 128.6, 128.4 (2 C), 127.5, 126.7, 126.3, 110.0, 70.9, 
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70.5, 69.1, 68.6, 66.5, 63.5, 53.2, 49.2, 40.1, 38.8, 35.7, 32.9, 31.4, 31.1, 29.5, 27.7, 23.6, 11.1, 
10.2; HRMS (ESI) m/z calcd for C37H47O8N2S ([M+H]+) 679.3048, found 679.3045. 
BocN
H Br
 
3.33a 
tert-Butyl (1SR,3RS,5RS)-3-(2-bromophenyl)-8-azabicyclo[3.2.1]octane-8-
carboxylate (3.33a). A solution of (1R,5S)-tert-butyl 3-(2-bromophenyl)-8-azabicyclo[3.2.1]oct-
2-ene-8-carboxylate (1.75 g, 4.80 mmol) in anhydrous iPrOH (20 mL, 0.25 M) under argon was 
treated with phenylsilane (3.6 mL, 28.8 mmol) and TBHP (5.5 M in decane) (1.31 mL, 7.20 
mmol) and the resulting mixture was degassed by bubbling argon through the solution for 10 
minutes. Mn(dpm)3431 (0.290 g, 0.480 mmol) was added in one portion and the reaction was then 
degassed for an additional 30 seconds. After 1 h another portion of Mn(dpm)3 (0.290 g, 0.480 
mmol) was added and the solution was stirred for another hour. After 1 h another portion 
Mn(dpm)3 (0.290 g, 0.480 mmol) was added and the solution was stirred for another hour. After 
stirring for 1 h another portion of Mn(dpm)3 (0.290 g, 0.480 mmol) and the reaction was stirred 
for 16 at rt, quenched by SLOW ADDITION of 1 M NaOH (100 mL) at 0 °C and stirred for 15 
min, filtered, washed (EtOAc) the layers separated and the aqueous layer was extracted with 
EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered, and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 9:1) to give the major diastereomer 3.33a (0.470 g, 
1.28 mmol, 27%) as a clear colorless oil. Additionally, a 1:1 mixture of diastereromers was also 
recovered as mixed fractions (0.327 g, 0.892 mmol, 19%) as a clear colorless oil: 
Characterization for 3.33a: IR (CH2Cl2) 3280, 2971, 1685, 1379, 1327, 1169, 1092, 755 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.55 (dd, J = 7.8, 1.2 Hz, 1 H), 7.45 (dd, J = 7.8, 1.2 Hz, 1 H), 7.35 
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(td, J = 7.8, 1.2 Hz, 1 H), 7.13 (td, J = 7.8, 1.2 Hz, 1 H), 4.17-4.13 (m, 2 H), 2.90 (tt, J = 12.0, 
6.6 Hz, 1 H), 2.33-2.32 (m, 2 H), 2.01-1.98 (m, 1 H), 1.96-1.92 (m, 1 H), 1.71-1.67 (m, 2 H), 
1.45 (s, 9 H), 1.36 (t, J = 12.0 Hz, 2 H); 13C NMR (150 MHz, CDCl3) δ 153.7, 143.0, 132.5, 
129.3, 128.1, 128.1, 123.8, 78.4, 50.8, 50.1, 37.1, 36.4, 33.1, 31.7, 31.1, 28.2; HRMS (ESI) m/z 
calcd for C18H24BrNNaO2 ([M+Na]+) 388.0883, found 388.0880. 
BocN
OEtO
H
 
3.43 
tert-Butyl (1SR,3RS,5RS)-3-(2-((E)-3-ethoxy-3-oxoprop-1-en-1-yl)phenyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (3.43). A solution of (1SR,3RS,5RS)-tert-butyl 3-(2-
bromophenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.33a, 0.469 g, 1.28 mmol) in dry 
degassed MeCN (6.4 mL) was treated with Pd(OAc)2 (0.0287 g, 0.128 mmol), tri(o-
tolyl)phosphine (0.0643 g, 0.205 mmol), Et3N (467 µL, 3.33 mmol), and ethyl acrylate (181 µL, 
1.66 mmol) and heated 18 h at 85 °C, concentrated under reduced pressure. The residue was 
diluted with EtOAc (20 mL), filtered through Celite, washed (EtOAc) and the combined filtrates 
were concentrated under reduced pressure. The crude residue was purified by chromatography 
on SiO2 (hexanes/EtOAc, 3:1) to give 3.43 (0.432 g, 1.12 mmol, 87%) as a clear colorless oil: IR 
(CH2Cl2) 2973, 1701, 1691, 1392, 1310, 1172, 1102, 764 cm-1; 1H NMR (400 MHz, CDCl3) δ 
8.00 (d, J = 15.7 Hz, 1 H), 7.47 (dd, J = 7.7, 0.9 Hz, 1 H), 7.33 (td, J = 7.4, 1.2 Hz, 1 H), 7.28-
7.26 (m, 1 H), 7.20 (td, J = 7.4, 1.2 Hz, 1 H), 6.28 (d, J = 15.7 Hz, 1 H), 4.37 (bs, 1 H), 4.25 (q, J 
= 7.1 Hz, 3 H), 2.94 (tt, J = 11.4, 7.3 Hz, 1 H), 2.53-2.39 (m, 2 H), 2.10-2.05 (m, 2 H), 1.67 (q, J 
= 7.3 Hz, 2 H), 1.52 (s, 9 H), 1.48-1.39 (m, 2 H), 1.34 (t, J = 7.1 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 166.5, 154.6, 143.8, 142.0, 133.6, 129.8, 127.7, 127.3, 126.4, 120.9, 79.3, 60.4, 51.4, 
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50.6, 38.7, 37.8, 32.3, 31.6, 30.6, 28.4, 14.3; HRMS (ESI) m/z calcd for C23H32O4N ([M+H]+) 
386.2326, found 386.2327. 
BocN
OEtO
H
 
3.44 
tert-Butyl (1SR,3RS,5RS)-3-(2-(3-ethoxy-3-oxopropyl)phenyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (3.44). A solution of (1SR,3RS,5RS)-tert-butyl 3-(2-((E)-
3-ethoxy-3-oxoprop-1-en-1-yl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.43, 0.0500 g, 
0.130 mmol) in absolute EtOH (1.3 mL) was treated with 10% Pd/C (0.0138 g, 0.0130 mmol, 
equivalent to 10 mol% Pd) and stirred under a balloon of H2 for 1.5 h where analysis by 1H NMR 
indicated that the alkene had been consumed. The reaction was filtered through basic Al2O3 
(eluting with EtOAc) to give 3.44 (0.0517 g, 0.133 mmol, quant.) as a clear colorless oil: IR 
(CH2Cl2) 2971, 1732, 1687, 1390, 1564, 1163, 1100, 755 cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.22-7.16 (m, 2 H), 7.14-7.08 (m, 2 H), 4.35 (bs, 1 H), 4.24 (bs, 1 H), 4.10 (q, J = 7.1 Hz, 2 H), 
2.95 (t, J = 7.9 Hz, 2 H), 2.79 (tt, J = 11.9, 7.1 Hz, 1 H), 2.56-2.51 (m, 2 H), 2.09-2.07 (m, 2 H), 
1.67 (q, J = 7.4 Hz, 2 H), 1.50 (s, 9 H), 1.41-1.34 (m, 2 H), 1.22 (t, J = 7.1 Hz, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 172.5, 154.7, 142.5, 138.0, 129.3, 127.6, 126.6, 126.0, 79.1, 60.3, 51.3, 
50.6, 39.5 (2 C), 38.6, 35.8, 32.5, 31.8, 29.4, 28.4, 27.9, 14.1; HRMS (ESI) m/z calcd for 
C23H34O4N ([M+H]+) 388.2482, found 388.2479. 
BocN
OH
H
 
3.45 
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tert-Butyl (1SR,3RS,5RS)-3-(2-(3-hydroxypropyl)phenyl)-8-azabicyclo[3.2.1]octane-
8-carboxylate (3.45). A solution of (1SR,3RS,5RS)-tert-butyl 3-(2-(3-ethoxy-3-
oxopropyl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.44, 0.400 g, 1.03 mmol) in THF 
(8 mL) was treated with NaBH4 (0.390 g, 10.3 mmol) and stirred for 15 min at rt, treated with 
absolute ethanol (2 mL) and stirred at rt for 16 h where analysis by TLC (hexanes/EtOAc, 1:1) 
indicated there was still SM remaining. An additional 2 equiv. of NaBH4 was added and the 
reaction was stirred for another 1.5 h where analysis by TLC (hexanes/EtOAc, 1:1) indicated the 
SM had been consumed. The reaction was cooled to 0 °C and diluted with 1 M aqueous HCl (40 
mL), extracted with EtOAc (3 x 30 mL). The combined organic layers were dried (MgSO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 1:1) to give 3.45 (0.266 g, 0.771 mmol, 75%) as 
colorless solid: Mp 99.3-101.7 °C; IR (CH2Cl2) 3485, 2971, 1670, 1689, 1407, 1163, 1107, 753 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.21-7.08 (m, 4 H), 4.33 (bt, J = 7.4 Hz, 1 H), 4.24 (bt, J = 
7.4 Hz, 1 H), 3.66 (t, J = 6.5 Hz, 2 H), 2.83 (tt, J = 12.5, 6.5 Hz, 1 H), 2.76-2.67 (m, 2 H), 2.49-
2.36 (m, 2 H), 2.17-2.01 (m, 2 H), 1.98-1.86 (m, 1 H), 1.81 (quint, J = 7.1 Hz, 2 H), 1.51 (s, 9 
H), 1.43-1.32 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 154.9, 142.3, 139.5, 129.6, 127.5, 126.3, 
125.9, 79.2, 62.1, 51.4, 50.7, 39.4, 38.9, 34.6, 32.4 (2 C), 32.0, 29.4, 29.3, 28.5; HRMS (ESI) 
m/z calcd for C21H32O3N ([M+H]+) 346.2377, found 346.2373. 
Br O OH  
3.50 
2-(2-Bromoethoxy)ethanol (3.50).488 A solution of diethylene glycol (3.37, 1.79 mL, 
18.9 mmol) in MeCN (30.0 mL) at rt was treated with carbon tetrabromide (6.88 g, 20.7 mmol), 
and triphenylphosphine (4.95 g, 18.9 mmol) and the resulting mixture was stirred at rt for 16 h, 
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diluted with 1 M aqueous NaOH (25 mL) and MeCN, and the mixture was concentrated under 
reduced pressure. The aqueous residue was extracted with EtOAc (3 × 30 mL), dried (Na2SO4), 
filtered, and concentrated. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 1:1) to give 3.50 (2.16 g, 10.7 mmol, 57%) as yellow oil contaminated with 
16% PPh3O. This material was carried on with no further purification: 1H NMR (300 MHz, 
CDCl3) δ 3.83 (t, J = 6.0 Hz, 2 H), 3.76 (dd, J = 5.3, 3.7 Hz, 2 H), 3.63 (dd, J = 5.3, 3.7 Hz, 2 H), 
3.49 (t, J = 6.0 Hz, 2 H), 1.97 (s, 1 H). 
O O OH
O
O  
Methyl 4-(2-(2-hydroxyethoxy)ethoxy)benzoate (3.52).488 A solution of methyl 4-
hydroxybenzoate (3.51, 2.33 g, 15.3 mmol) in MeCN (80 mL) was treated with K2CO3 (4.41 g, 
31.9 mmol), NaI (1.91 g, 12.8 mmol), and 2-(2-bromoethoxy)ethanol (3.50, 2.16 g, 12.8 mmol) 
and the resultant mixture was heated to 60 °C 15 h. Then the mixture was diluted with H2O, 
extracted with EtOAc. The combined organic layers were dried (Na2SO4), filtered, and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(hexanes/EtOAc, 2:3) to give 3.52 that was contaminated with PPh3O (15%) (1.62 g, 5.73 mmol, 
45%) as a clear/pale-yellow oil: 1H NMR (300 MHz, CDCl3) δ 8.01-7.96 (m, 2 H), 6.96-6.91 (m, 
2 H), 4.20 (t, J = 4.7 Hz, 2 H), 3.91-3.87 (m, 5 H), 3.79-3.75 (m, 2 H), 3.70-3.66 (m, 2 H), 1.80 
(s, 1 H). 
O O NH2
O
O  
3.53 
 277 
Methyl 4-(2-(2-aminoethoxy)ethoxy)benzoate (3.53). A solution of methyl 4-(2-(2-
hydroxyethoxy)ethoxy)benzoate (3.52, 0.300 g, 1.25 mmol) in dry THF (5 mL) at 0 °C was 
treated Et3N (193 uL, 1.37 mmol) followed by MsCl (106 µL, 1.37 mmol) and stirred at 0 °C for 
2 h, diluted with satd. aqueous NaHCO3 and extracted with Et2O (3 x 20 mL). The combined 
organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure to give the 
crude mesylate (0.369 g, 1.16 mmol) as a colorless solid. 
A solution of the crude mesylate (0.230 g, 0.723 mmol) in DMF (1.5 mL) was treated 
with Et3N (0.16 mL, 1.54 mmol) and NaN3 (0.142 g, 2.18 mmol). This mixture was heated to 50 
°C behind a blast shield for 17 h where analysis by TLC (hexanes/EtOAc; 1:1) indicated that the 
mesylate intermediate was completely consumed. The reaction was cooled to rt, diluted with 
H2O (5 mL) and brine (10 mL) and extracted with Et2O (3 x 10 mL). The combined organic 
layers were washed with brine, dried (Na2SO4), concentrated under reduced pressure to give the 
crude methyl 4-(2-(2-azidoethoxy)ethoxy)benzoate (0.170 g, 0.449 mmol) as a colorless wax. 
To a solution of crude methyl 4-(2-(2-azidoethoxy)ethoxy)benzoate (0.161 g, 1.70 mmol 
(contaminated with ~30% PPh3O)) in THF (2 ml) was added triphenyl phosphine (0.223 g, 0.850 
mmol) and H2O (30 uL, 1.70 mmol) then heated to 50 °C for 17 h, and concentrated under 
reduced pressure. The residue was dissolved in CH2Cl2 and 1 M aqueous HCl (10 mL) and the 
aqueous layer was washed with CH2Cl2 (2x). The aqueous layer was neutralized with solid 
K2CO3 to pH 10. The aqueous layer was washed with CH2Cl2 (3 x 30 mL). The combined 
organic layers were dried (Na2SO4), filtered and concentrated under reduced pressure to give 
3.53 (0.0893 g, 0.373 mmol, 55% (3 steps)) as a clear oil that solidified in the freezer: Mp ~10-
20 °C; (CH2Cl2) 3368, 2945, 1707, 1603, 1249, 1169, 1103, 846 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.94 (dt, J = 9.0, 2.6 Hz, 2 H), 6.90 (dt, J = 9.0, 2.6 Hz, 2 H), 4.14 (dd, J = 5.4, 4.1 Hz, 
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2 H), 3.84 (s, 3 H), 3.80 (dd, J = 5.4, 4.1 Hz, 2 H), 3.54 (t, J = 5.4 Hz, 2 H), 2.85 (bs, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 166.7, 162.4, 131.4, 122.6, 114.1, 73.6, 69.2, 67.4, 51.7, 41.7; 
HRMS (ESI) m/z calcd for C12H18O4N ([M+H]+) 240.1230, found 240.1229. 
BocN
H
NO O O
O
O
H
 
3.54 
tert-Butyl (1SR,3RS,5RS)-3-(2-(3-((2-(2-(4-
(methoxycarbonyl)phenoxy)ethoxy)ethyl)amino)-3-oxopropyl)phenyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (3.54). A solution of (1SR,3RS,5RS)-tert-butyl 3-(2-(3-
ethoxy-3-oxopropyl)phenyl)-8-azabicyclo[3.2.1]octane-8-carboxylate (3.45, 0.380 g, 0.981 
mmol) in THF (4 mL) at 0 °C was treated with 2 M aqueous LiOH (0.98 mL, 1.96 mmol) and 
the reaction was stirred at 0 °C for 30 min and warmed to rt. A precipitate was noted after 
addition of the LiOH. The reaction was stirred at rt for 24 h where analysis by TLC (EtOAc) 
indicated the SM remained. The reaction was heated to 50 °C for 5 h where analysis by TLC 
(EtOAc) indicated the SM was consumed. The THF was removed under reduced pressure and 
the aqueous layer was acidified with 1 M aqueous HCl. The aqueous layer was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were dried (MgSO4), filtered and concentrated 
under reduced pressure to give 3-(2-((1SR,3RS,5RS)-8-(tert-butoxycarbonyl)-8-
azabicyclo[3.2.1]octan-3-yl)phenyl)propanoic acid (0.289 g, 0.804 mmol) as a colorless solid. 
A solution of 3-(2-((1SR,3RS,5RS)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]octan-3-
yl)phenyl)propanoic acid (0.100 g, 0.278 mmol), HATU (0.127 g, 0.334 mmol), and HOAt 
(0.0464 g, 0.334 mmol) in DMF (1 mL) at 0 °C was treated with DIPEA (0.19 mL, 1.11 mmol). 
(The pale yellow solution became dark yellow). After 30 min at 0 °C, a solution of methyl 4-(2-
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(2-aminoethoxy)ethoxy)benzoate (3.53, 0.0732 g, 0.306 mmol) in DMF (0.4 mL) was added and 
the reaction mixture was stirred at 0 °C for 1 h, rt for 21 h, diluted with EtOAc (50 mL) and satd. 
aqueous NaHCO3 (2 x) and brine, dried (Na2SO4) and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (100% EtOAc) to give 3.54 (0.150 g, 
0.259 mmol, 76% (2 steps)) as a colorless foam: IR (CH2Cl2) 2969, 1711, 1655, 1603, 1411, 
1253, 1167, 1107, 841, 770 cm-1; 1H NMR (600 MHz, DMSO-d6) δ 7.91-7.86 (m, 3 H), 7.27 (d, 
J = 7.8 Hz, 1 H), 7.14  (dt, J = 7.8, 1.8 Hz, 1 H), 7.08-7.04 (m, 4 H), 4.16 (t, J = 4.5 Hz, 2 H), 
4.12-4.10 (m, 2 H), 3.81 (s, 3 H), 3.72 (t, J = 4.5 Hz, 2 H), 3.44 (t, J = 5.9 Hz, 2 H), 3.22-3.17 
(m, 2 H), 2.79-2.76 (m, 2 H), 2.67 (tt, J = 12.6, 6.5 Hz, 1 H), 2.31-2.26 (m, 4 H), 2.00-1.93 (m, 2 
H), 1.72-1.66 (m, 2 H), 1.42 (s, 9 H), 1.37-1.31 (m, 2 H); 13C NMR (150 MHz, DMSO-d6) δ 
171.0, 165.8, 162.3, 153.9, 142.2, 138.5, 131.2, 128.8, 127.6, 126.3, 125.7, 121.9, 114.5, 78.3, 
69.3, 68.5, 67.4, 51.8, 51.0, 50.3, 38.5, 37.8, 36.6, 31.9, 31.2, 30.7, 28.7, 28.2, 27.6; HRMS 
(ESI) m/z calcd for C33H45O7N2 ([M+H]+) 581.3221, found 581.3222. 
N
H
NO O O
O
O
O
SO
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3.55 
Methyl 4-(2-(2-(3-(2-((1SR,3RS,5RS)-8-(2-(((3,5-dimethylisoxazol-4-
yl)methyl)thio)acetyl)-8-azabicyclo[3.2.1]octan-3-
yl)phenyl)propanamido)ethoxy)ethoxy)benzoate (3.55). A solution of (1SR,3RS,5RS)-tert-
butyl 3-(2-(3-((2-(2-(4-(methoxycarbonyl)phenoxy)ethoxy)ethyl)amino)-3-oxopropyl)phenyl)-8-
azabicyclo[3.2.1]octane-8-carboxylate (3.54, 0.230 g, 0.396 mmol) in THF (4 mL) was cooled to 
0 ºC, treated with 4M HCl in dioxane (3.0 mL, 30 eq) and stirred at 0 ºC and slowly warmed to rt 
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for 12 h. The solution was concentrated under reduced pressure and the residue was sonicated 
with dry THF (4 x 10 mL) and concentrated under reduced pressure each time and dried under 
high vacuum to give methyl 4-(2-(2-(3-(2-((1SR,3RS,5RS)-8-azabicyclo[3.2.1]octan-3-
yl)phenyl)propanamido)ethoxy)ethoxy)benzoate hydrochloride (0.202 g, 0.419 mmol) as a 
colorless solid that was taken on to the coupling reaction with no further purification. 
A solution of 2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)acetic acid (3.26, 0.0620 g, 
0.308 mmol), HATU (0.141 g, 0.370 mmol), and HOAt (0.0513 g, 0.370 mmol) in DMF (1.5 
mL) at 0 °C was treated with DIPEA (214 µL, 1.23 mmol) and stirred for 20 min at 0 °C where a 
deep orange solution developed, and treated with a solution of methyl 4-(2-(2-(3-(2-
((1SR,3RS,5RS)-8-azabicyclo[3.2.1]octan-3-yl)phenyl)propanamido)ethoxy)ethoxy)benzoate 
hydrochloride (0.191 g, 0.370 mmol) in DMF (1.6 mL) was added and the reaction was stirred at 
0 °C for 30 min and warmed to rt for 12 h. The reaction was diluted with EtOAc (50 mL) and 
washed with satd. aqueous NaHCO3 (2 x 20 mL), followed by brine (20 mL), dried (Na2SO4), 
filtered, and concentrated under reduced pressure. The crude material was purified by 
chromatography on SiO2 (2% MeOH/EtOAc w/ 2% Et3N) to give 3.55 (0.122 g, 0.183 mmol, 
60% (2 steps)) as a colorless foam: IR (CH2Cl2) 2947, 1709, 1603, 1433, 1253, 1167, 1113, 887 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.94 (dt, J = 8.8, 2.5 Hz, 2 H), 7.16-7.13 (m, 2 H), 7.10-7.06 
(m, 2 H), 6.89 (dt, J = 8.8, 2.5 Hz, 2 H), 6.22 (t, J = 5.5 Hz, 1 H), 4.65 (t, J = 8.0 Hz, 1 H), 4.13 
(t, J = 8.0 Hz, 1 H), 4.11 (t, J = 4.5 Hz, 2 H), 3.84 (s, 3 H), 3.77-3.72 (m, 3 H), 3.59-3.54 (m, 3 
H), 3.46-3.35 (m, 2 H), 3.19 (d, J = 13.8 Hz, 1 H), 3.06 (d, J = 13.8 Hz, 1 H), 2.97-2.89 (m, 2 H), 
2.86 (dt, J = 12.7, 6.1 Hz, 1 H), 2.46-2.39 (m, 5 H), 2.33 (td, J = 8.0, 2.7 Hz, 2 H), 2.26 (s, 3 H), 
2.13 (ddt, J = 11.5, 6.9, 4.4 Hz, 1 H), 2.03 (ddt, J = 11.5, 7.6, 3.5 Hz, 1 H), 1.80-1.69 (m, 2 H), 
1.44 (td, J = 13.0, 3.5 Hz, 2 H); 13C NMR (125 MHz, CDCl3) δ 172.0, 166.9, 166.8, 166.6, 
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162.3, 159.7, 141.4, 138.5, 131.5, 129.4, 127.3, 126.6, 126.2, 122.7, 114.0, 109.9, 69.9, 69.1, 
67.3, 53.2, 51.7, 49.5, 40.0, 39.1, 38.9, 38.3, 32.6, 32.0, 31.0, 29.5, 28.9, 23.7, 10.9, 10.0; HRMS 
(ESI) m/z calcd for C36H46O7N3S ([M+H]+) 664.3051, found 664.3050. 
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3.56 
4-(2-(2-(3-(2-((1SR,3RS,5RS)-8-(2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)acetyl)-8-
azabicyclo[3.2.1]octan-3-yl)phenyl)propanamido)ethoxy)ethoxy)benzoic acid (3.56). To a 
solution of methyl 4-(2-(2-(3-(2-((1SR,3RS,5RS)-8-(2-(((3,5-dimethylisoxazol-4-
yl)methyl)thio)acetyl)-8-azabicyclo[3.2.1]octan-3-
yl)phenyl)propanamido)ethoxy)ethoxy)benzoate (3.55, 0.0616 g, 0.0928 mmol) in THF (0.5 mL) 
and MeOH (0.5 mL) was treated with 2 M aqueous LiOH 4(0.46 mL) and the solution was 
stirred at rt for 13 h where analysis by TLC (100% EtOAc) indicated the starting material still 
remained. By TLC there was still a small amount of remaining SM but the reaction was diluted 
with H2O (1 mL), washed with Et2O (2 x 5 mL), and the aqueous layer was acidified to pH 2 
with 1 M aqueous HCl at 0 °C. The aqueous layer was extracted with EtOAc (3 x 6 mL). The 
combined organic layers were dried (MgSO4), filtered and concentrated under reduced pressure 
to give 3.56 (0.0367 g, 0.0565 mmol, 61%) as a colorless foam: IR (CH2Cl2) 2949, 1702, 1603, 
1452, 1249, 1167, 1122, 734 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.98 (d, J = 8.7 Hz, 2 H), 7.18-
7.09 (m, 4 H), 6.86 (d, J = 8.7 Hz, 2 H), 6.44 (s, 1 H), 4.70 (t, J = 7.5 Hz, 1 H), 4.16 (t, J = 7.5 
Hz, 1 H), 4.07 (t, J = 4.4 Hz, 2 H), 3.75 (t, J = 4.4 Hz, 2 H), 3.56 (t, J = 4.4 Hz, 3 H), 3.50-3.47 
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(m, 1 H), 3.37-3.34 (m, 1 H), 3.23-3.20 (m, 1 H), 3.04-2.89 (m, 3 H), 2.50-2.41 (m, 5 H), 2.37-
2.32 (m, 2 H), 2.29 (s, 3 H), 2.18-2.06 (m, 2 H), 1.82-1.74 (m, 2 H), 1.51 (t, J = 12.8 Hz, 1 H), 
1.45 (t, J = 12.8 Hz, 1 H); 13C NMR (150 MHz, CDCl3) δ 172.3, 1 69.7, 167.2, 162.8, 141.5, 
138.8, 132.1, 129.8, 127.4, 126.7, 126.4, 122.4, 114.2, 70.0, 69.3, 67.3, 40.3, 39.2, 39.1, 38.3, 
32.7, 31.7, 31.2, 29.5, 29.1, 23.7, 11.1, 10.2; HRMS (ESI) m/z calcd for C35H44O7N3S ([M+H]+) 
650.2894, found 650.2888. 
Bead conjugation Conjugation of 3.56 to the Carboxylink Agarose beads 
Activation of the carboxylic acid as the NHS ester: A solution of 4-(2-(2-(3-(2-
((1R,3s,5S)-8-(2-(((3,5-dimethylisoxazol-4-yl)methyl)thio)acetyl)-8-azabicyclo[3.2.1]octan-3-
yl)phenyl)propanamido)ethoxy)ethoxy)benzoic acid (3.56, 0.0120 g, 0.0185 mmol) in dry DMF 
(0.2 mL) was treated with N-hydroxysuccinimide (0.0657 g, 0.0554 mmol) followed by EDCI 
(0.0108 g, 0.0554 mmol). The resulting solution was stirred at rt under an argon atmosphere for 
16 h. The reaction was diluted with dry DMF (0.5 mL) to give the activated ester solution. 
Conjugation reaction: A short (1 cm diameter) column fitted with a magnetic stir bar 
and a drain cap was loaded suspension of Carboxylink Coupling Gel (1.0 mL) and washed with 
DMF (5 x 4 mL) allowing the solvent to drain after each addition of DMF. The washed gel was 
treated with the activated ester solution and gently stirred at rt under Ar for 48 h. The beads 
were transferred to a 1.5 mL eppendorf tube and placed on the little shot rotator for 2 d at rt. The 
suspension was centrifuged and the DMF was removed via pipet, the pellet was suspended in 
DMF (1 mL) and centrifuged (5 min in speed vac centrifuge). This washing was repeated 5 times 
with DMF. The gel was further washed with PBS buffer (3 x 1 mL), and (HPLC grade) water (3 
x 1 mL), respectively. Similar method to the DMF washing. The gel was suspended with 1.0 mL 
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of 0.05% wt. sodium azide solution in HPLC water and stored at 4 °C to give the 3.57 
conjugated beads. 
NO
O
O
O
 
2,5-dioxopyrrolidin-1-yl acetate. (N-acetoxysuccinimide).489 A solution of N-
Hydroxysuccinimide (1.00 g, 8.69 mmol) in acetic anhydride (2.5 mL, 26.1 mmol) was stirred at 
rt for 18 h. A white precipitate had formed and the reaction was cooled to 0 °C and the colorless 
solid was collected by vacuum filtration and washed with an excess of hexanes to give N-
acetoxysuccinimide (0.793 g, 5.04 mmol, 58%) as a colorless solid: 1H NMR (300 MHz, CDCl3) 
δ 2.81 (s, 4 H), 2.32 (bd, J = 0.9 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 169.1, 165.5, 25.5, 
17.5. 
N
N
TBSO
O
 
3.60 
(4-(2-(3-((tert-Butyldimethylsilyl)oxy)prop-1-yn-1-yl)phenyl)piperazin-1-
yl)((1RS,2SR)-2-phenylcyclopropyl)methanone (3.60). A solution of (1SR,2RS)-2-
phenylcyclopropanecarboxylic acid (3.11, 0.0260 g, 0.160 mmol) and HATU (0.0914 g, 0.240 
mmol) in CH2Cl2 (1 mL), was cooled to 0 °C and treated with DIPEA (83 µL, 0.481 mmol) and 
warmed to rt over 45 min. The solution was cooled to 0 °C and treated with a solution of 1-(2-(3-
((tert-butyldimethylsilyl)oxy)prop-1-yn-1-yl)phenyl)piperazine (3.59, 0.0583 g, 0.176 mmol) in 
CH2Cl2 (0.5 mL) and stirred at rt 16 h, diluted with H2O, washed with EtOAc (2 × 10 mL). The 
combined organic layers were washed with 1 M aqueous NaHSO4, satd. aqueous NaHCO3, dried 
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(Na2SO4), and concentrated under reduced pressure. The crude residue was purified twice by 
automated chromatography SiO2 column (4g column, liquid load CH2Cl2, gradient 
hexanes/EtOAc, 6:1 to hexanes/EtOAc, 2.5:1) to give 3.60 (0.00763 g, 0.0161 mmol, 10%) as a 
pale yellow oil: IR (CH2Cl2) 2951, 2855, 1640, 1459, 1370, 1251, 1226, 1079, 1027, 833, 777 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.36 (dd, J = 15.0, 1.5 Hz, 1 H), 7.24-7.19 (m, 3 H), 7.15-
7.13 (m, 1 H), 6.92 (dt, J = 7.5, 1.0 Hz, 1 H), 4.55 (s, 2 H), 3.93 (bd, J = 13.0 Hz, 1 H), 3.76 (app 
d, J = 13.0 Hz, 1 H), 3.60 (ddd, J = 12.3, 9.0, 2.5 Hz, 1 H), 3.30 (ddd, J = 12.3, 9.0, 3.0 Hz, 1 H), 
3.12-3.09 (m, 2 H), 2.47-2.40 (m, 2 H), 2.20-2.13 (m, 2 H), 1.85 (dd, J = 12.5, 6 Hz, 1 H), 1.35 
(ddd, J = 14.0, 8.5, 5.5 Hz, 1 H),  0.93 (s, 9 H), 0.14 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 
167.3, 153.6, 137.6, 133.9, 129.3, 128.1, 127.4, 126.4, 122.1, 117.7, 116.7, 93.2, 82.9, 52.4, 51.4, 
50.9, 45.4, 42.0, 25.9, 24.4, 24.1, 18.3, 10.6, -5.1; HRMS (ESI) m/z calcd for C29H39SiO2N2 
([M+H]+) 475.2775, found 475.2769. 
N
N
HO
O
 
(4-(2-(3-Hydroxyprop-1-yn-1-yl)phenyl)piperazin-1-yl)((1RS,2SR)-2-
phenylcyclopropyl)methanone (3.58). A solution of (4-(2-(3-((tert-
butyldimethylsilyl)oxy)prop-1-yn-1-yl)phenyl)piperazin-1-yl)((1SR,2RS)-2-
phenylcyclopropyl)methanone (0.0200 g, 0.0421 mmol) in TBAF (1 M solution in THF) (126 
µL, 0.126 mmol) was stirred at rt for 30 min where analysis by TLC (1:1 hexanes/EtOAc) 
indicated the starting material had been consumed. The reaction was diluted with EtOAc and 
washed with satd. aqueous NH4Cl, dried (Na2SO4), filtered and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (1:2, hexanes/EtOAc) to 
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give the product (0.00784 g, 0.0218 mmol, 52%) as a colorless solid: Mp 121.1-124.3 °C; IR 
(EtOAc) 3383, 2904, 2820, 1616, 1486, 1437, 1226, 1027, 751, 697 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.37 (dd, J = 7.6, 1.2 Hz, 1 H), 7.25-7.21 (m, 4 H), 7.16-7.13 (m, 3 H), 6.93 (dt, J = 
7.6, 1.2 Hz, 1 H), 6.68 (d, J = 7.6 Hz, 1 H), 4.51 (d, J = 6.0 Hz, 2 H), 3.93 (app d, J = 13.0 Hz, 1 
H), 3.74 (app d, J = 13.0 Hz, 1 H), 3.64-3.61 (m, 1 H), 3.33-3.30 (m, 1 H), 3.11-3.07 (m, 2 H), 
2.48-2.41 (m, 2 H), 2.21-2.15 (m, 2 H), 1.84 (q, J = 6.2 Hz, 1 H), 1.78 (t, J = 6.2 Hz, 1 H), 1.35 
(ddd, J = 14.0, 8.4, 5.2 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 167.4, 153.6, 137.6, 133.9, 
129.6, 128.1, 127.3, 126.4, 122.2, 117.8, 116.3, 92.6, 83.9, 51.8, 51.4, 50.9, 45.4, 42.0, 24.5, 
24.1, 10.6; HRMS (ESI) m/z calcd for C23H25O2N2 ([M+H]+) 361.1911, found 361.1908. 
5.5 CHAPTER 4 EXPERIMENTAL PART 
5.5.1 First Approach 
Br
TMS  
4.99 
(4-Bromobut-1-yn-1-yl)trimethylsilane (4.99).459-461 A solution of 3-butyn-1-ol (4.98, 
5.4 mL, 71.3 mmol) in dry THF (200 mL) cooled to -78 °C was treated dropwise with n-BuLi 
(63.0 mL, 2.5M, 157 mmol). Upon the completion of addition the reaction mixture became 
cloudy. Stirring was continued at -78 °C for 1 h, when freshly distilled TMSCl (27.4 mL, 214 
mmol) was added dropwise. The reaction was stirred at -78 for another 15 min. The reaction 
mixture was allowed to warm to rt and stirred for another 1.5 h when 2 M aqueous HCl (25 mL) 
was added. The aqueous layer was extracted with EtOAc. The organic layers were combined, 
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washed with satd. aqueous NaHCO3, H2O, brine, dried (Na2SO4), filtered and concentrated in 
vacuo to provide crude 4-(trimethylsilyl)but-3-yn-1-ol (10.2 g, 71.7 mmol) as a clear oil that was 
taken on to the next step with no further purification. 
A solution of the crude 4-(trimethylsilyl)but-3-yn-1-ol (10.2 g, 71.7 mmol) in dry CH2Cl2 
(210 mL) cooled to -30 °C was treated with CBr4 (30.0 g, 90.3 mmol) in one portion. After 
stirring for 15 min a solution of PPh3 (19.7 g, 75.3 mmol) in CH2Cl2 (75 mL) was added by 
cannula. The solution was stirred for 1.5 h at -30 °C and for another 1 h at 0 °C. The crude 
reaction mixture was filtered through small plug of silica gel, washing with hexanes, and was 
concentrated until 1/3 of the original volume was left in the flask. Cold hexanes were added to 
the solution and the solids were suspended, and filtered through Celite and the cake washed with 
cold hexanes. The filtrate was concentrated under reduced pressure (rotovap bath at 0 °C) and 
purified by chromatography on SiO2 (100% hexanes) to give 4.99 (9.86 g, 48.1 mmol, 67% (2 
steps)) as a colorless liquid: 1H NMR (300 MHz, CDCl3) δ 3.42 (t, J = 7.5 Hz, 2 H), 2.77 (t, J = 
7.5 Hz, 2 H), 0.16 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ 103.2, 87.0, 29.1, 24.3, -0.1. 
O
O
O
O  
4.103 
Methyl 2-oxotetrahydrofuran-3-carboxylate (4.103).462 A solution of LHMDS (1 M in 
hexanes, 23.2 mL, 23.2 mmol) in THF (15 mL) was cooled to -78 °C and treated dropwise over 
10 min with a solution of γ-butyrolactone (4.100, 1.00 g, 11.6 mmol) in THF (12 mL). After 
stirring for 10 min at -78 °C, the reaction was treated with dimethyl carbonate (1.04 ml, 12.2 
mmol). The mixture was allowed to slowly warm to room temperature and stirring was 
continued for 8 h, poured onto a mixture of conc. HCl (5 ml) and ice (5 g), extracted with 
EtOAc. The organic layers were combined washed with brine, dried (Na2SO4), filtered and 
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concentrated under reduced pressure to give 4.103 (1.63 g, 10.8 mmol, 93%) as light brown oil. 
The residue was used in subsequent reactions without further purification: 1H NMR (300 MHz, 
CDCl3) δ 4.41-4.27 (m, 1 H), 4.25-4.19 (m, 1 H), 3.69 (s, 3 H), 3.50 (dt, J = 8.1, 2.4 Hz, 1 H) 
2.60-2.38 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 172.2, 168.1, 67.2, 52.7, 45.5, 26.1. 
TsO  
4.104 
But-3-yn-1-yl 4-methylbenzenesulfonate (4.104).490 A solution of 3-butyn-1-ol (5.00 g, 
71.3 mmol) in CH2Cl2 (71 mL) cooled to 0 °C was treated with Et3N (10.0 mL, 71.3 mmol) and 
TsCl (12.4 g, 64.9 mmol). The reaction was warmed to rt and stirred for 11 h, diluted with H2O 
(100 mL), and the aqueous layer was extracted with CH2Cl2 (3 × 100 mL). The combined 
organic layers were washed with brine (200 mL), dried (Na2SO4) and concentrated under 
reduced pressure to give 4.104 (14.3 g, 63.9 mmol, 99%) as a light brown oil: 1H NMR (300 
MHz, CDCl3) δ 7.76 (d, J = 8.4 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H), 4.05 (dt, J = 6.9, 1.2 Hz, 2 
H), 2.53-2.48 (m, 2 H), 2.40 (s, 3 H), 1.95 (t, J = 2.4 Hz, 2 H); 13C NMR (75 MHz, CDCl3) δ 
144.9, 132.6, 129.7, 127.7, 78.3, 70.6, 67.3, 21.4, 19.2. 
O
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4.105 
Methyl 3-(but-3-yn-1)-2-oxotetrahydrofuran-3-carboxylate (4.105). A solution of 
methyl 2-oxotetrahydrofuran-3-carboxylate (4.103, 0.100 g, 0.659 mmol) in dry DMF (1.5 mL) 
at rt was added K2CO3 (0.228 g, 1.64 mmol), and NaI (0.247 g, 1.65 mmol). The mixture was 
stirred for 15 min and a solution of but-3-yn-1-yl 4-methylbenzenesulfonate (4.104, 0.177 g, 
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0.791 mmol) in DMF (0.5 mL) was added. After the mixture was stirred at rt for 16 h, and heated 
to 60 °C for 24 h, cooled to rt, diluted with H2O and extracted with Et2O (3 x 20 mL) The 
organic layers were combined washed with H2O, brine, dried (MgSO4), and concentrated under 
reduced pressure. The residue was purified by automated chromatography on SiO2 (4g column, 
liquid load CH2Cl2, gradient 100% hexanes to 60% EtOAc/hexanes) to give 4.105 (0.0383 g, 
0.195 mmol, 30%) as a colorless oil: IR (CH2Cl2) 3286, 2924, 1772, 1732, 1436, 1378, 1213, 
1167, 1029 cm-1 1H NMR (400 MHz, CDCl3) δ 4.37-4.33 (m, 2 H), 3.77 (s, 3 H), 2.81-2.75 (m, 1 
H), 2.41-2.23 (m, 4 H), 2.08-1.98 (m 1 H), 1.98 (t, J = 1.6 Hz, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 174.1, 169.4, 82.4, 69.5, 66.2, 53.5, 53.2, 32.6, 31.8, 14.4; HRMS (ESI) m/z calcd for 
C10H13O4 ([M+H]+) 197.0808, found 197.0808. 
O
O
 
4.97 
3-(But-3-yn-1-yl)dihydrofuran-2(3H)-one (4.97). A solution of methyl 3-(but-3-yn-1-
yl)-2-oxotetrahydrofuran-3-carboxylate (4.105, 0.100 g, 0.510 mmol) in wet DMSO (100 uL) 
was treated with LiCl (0.0432 g, 1.02 mmol) and the mixture was heated to 150 °C in a sandbath 
for 2.5 h, cooled to rt, diluted with H2O the extracted with EtOAc (3 x 20 mL). The organic 
layers were combined washed with H2O (3 x 20 mL), brine, dried (Na2SO4), and concentrated. 
The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to give 4.97 
(0.0484 g, 0.350 mmol, 69%) as a clear oil: IR (CH2Cl2) 3286, 2919, 1764, 1455, 1377, 1204, 
1154, 1024 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.33 (td, J = 8.8, 2.5 Hz, 1 H), 4.17 (ddd, J = 
10.0, 9.2, 6.4 Hz, 1 H), 2.70 (dtd, J = 10.8, 8.8, 5.2 Hz, 1 H), 2.48-2.37 (m, 2 H), 2.28 (m, J = 
6.6, 2.6 Hz, 1 H), 2.08 (dddd, J = 13.6, 8.0, 6.8, 5.6 Hz, 1 H), 1.99-1.88 (m, 2 H); 13C NMR (100 
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MHz, CDCl3) δ 178.8, 82.6, 69.4, 66.4, 38.0, 28.9, 28.5, 16.4; HRMS (ESI) m/z calcd for 
C8H11O2 ([M+H]+) 139.0754, found 139.0754. 
OMe
Cr(CO)5
OMe
 
4.80 
Pentacarbonyl(methoxy(2-methoxyphenyl)methylene)chromium (4.80).491 A solution 
of 2-bromoanisole (4.106, 3.00 mL, 23.6 mmol) in Et2O (60 mL) was treated at -50 °C with a 
solution of n-BuLi (2.5 M in hexanes, 10.4 mL, 25.9 mmol) and stirred at -50 °C for 30 min and 
then at 0 °C for another 30 min. The resulting solution was cannulated to a cold (-20 °C) 
suspension of chromium hexacarbonyl (6.29 g, 28.3 mmol) in Et2O (60 mL). The reaction 
mixture (brown at first and then yellow suspension) was allowed to warm to rt and stirred at rt 
for 3 h and concentrated under reduced pressure. The residue was dissolved in H2O, filtered 
through Celite that was washed (H2O) and then washed with hexanes. The layers were separated 
and the aqueous layer was added CH2Cl2 (100 mL) (in the separatory funnel) and treated with 
trimethyloxonium tetrafluoroborate (6.18 g, 40.1 mmol) until acidic pH (the mixture turned red 
right away). The aqueous layer was further extracted with CH2Cl2 (3 x 100 mL) until it was no 
longer red. The combined organic layers were washed with brine, dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified by column chromatography 
on SiO2 (hexanes/EtOAc, 9:1) to give 4.80 (6.63 g, 19.4 mmol, 82%) as red crystals: 1H NMR 
(300 MHz, CDCl3) δ 7.29 (t, J = 7.5 Hz, 1 H), 7.04 (t, J = 7.5 Hz, 1 H), 6.92 (d, J = 8.4 Hz, 1 H), 
6.79 (d, J = 7.5 Hz, 1 H), 4.16 (brs, 3 H), 3.83 (s, 3 H). Note: for best purification column must 
be preequilibrated with 9:1 hexanes/EtOAc. 
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OMe
OMeOMe
OO
 
4.96 
3-(2-(1,4,5-Trimethoxynaphthalen-2-yl)ethyl)dihydrofuran-2(3H)-one (4.96). A 
solution of the chromium carbene (4.80, 1.00 g, 2.78 mmol) and 3-(but-3-yn-1-yl)dihydrofuran-
2(3H)-one (4.97, 0.460 g, 3.33 mmol) in dry deoxygenated THF (55 mL) and stirred at 50 °C for 
36 h. After 36 h, Cs2CO3 (2.71 g, 8.33 mmol) and MeI (0.53 mL, 8.33 mmol) were added and the 
resulting suspension was stirred at rt for 24 h, filtered through Celite, washed (CH2Cl2), and the 
filtrate was concentrated under reduced pressure. The crude residue was purified by 
chromatography on SiO2 (hexanes/EtOAc, 2:1) to give 4.96 (0.378 g, 1.14 mmol, 41%) as a red 
orange oil: IR (CH2Cl2) 2930, 2837, 1761, 1597, 1581, 1377, 1260, 1126, 1068, 1021, 755 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.64 (dd, J = 8.4, 0.8 Hz, 1 H), 7.40 (t, J = 8.0 Hz, 1 H), 6.85 (d, J 
= 7.2 Hz, 1 H), 6.67 (s, 1 H), 4.33 (dt, J = 8.8, 2.4 Hz, 1 H), 4.13 (dt, J = 9.6, 6.8 Hz, 1 H), 3.96 
(s, 3 H), 3.94 (s, 3 H), 3.84 (s, 3 H), 2.94-2.89 (m, 2 H), 2.57-2.50 (m, 1 H), 2.47-2.40 (m, 1 H), 
2.34-2.26 (m, 1 H), 2.03-1.93 (m, 1 H), 1.88-1.81 (m, 1 H); 13C NMR (75 MHz) δ 179.4, 157.4, 
153.5, 147.2, 131.4, 129.2, 126.7, 117.4, 114.6, 107.8, 106.1, 66.5, 61.8, 56.9, 56.4, 38.7, 31.1, 
28.9, 27.4; HRMS (ESI) m/z calcd for C19H23O5 ([M+H]+) 331.1540, found 331.1538. 
5.5.2 Second Approach 
O
O
N
 
4.110 
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2-Oxotetrahydrofuran-3-carbonitrile (4.110).492-493 A 3L 3-Necked flask was charged 
with ethyl 2-cyanoacetate (4.114, 370 g, 350 mL, 3.27 mol), 1,2-dibromoethane (509 mL, 5.88 
mol) and K2CO3 (903 g, 6.54 mol), and acetone (1.3 L), the flask was equipped with a 
thermometer/thermometer adapter, a mechanical string rod with a teflon stir head and a stir rod 
condenser, and a reflux condenser. The mixture was mechanically stirred for 24 h at 68 °C 
(internal temp) reflux. The reaction was monitored by 1HNMR for the disappearance of the SM 
singlet at 3.44 ppm (CDCl3, 300 MHz). The reaction mixture was cooled to rt diluted with 
EtOAc (0.5 L), filtered, washed (EtOAc (3 L)) until the washes became colorless and the 
combined filtrates were concentrated in vacuo to afford a crude oil. The oil was dissolved in 
Et2O (1 L) and H2O (500 mL). The organic layer was separated and the aqueous layer was 
further extracted with Et2O (2 x 500 mL). The organic layers were combined, dried (MgSO4), 
filtered through a fritted filtered that was washed with Et2O (200 mL), and concentrated by 
rotary evaporation (water bath at 50 °C) to give crude 4.115 (461 g, 2.85 mol, (86% pure 
contaminated with excess dibromoethane) as a orange oil that was taken on with no further 
purification to the saponification.  
A 4 L Erlenmeyer flask containing a solution of ethyl 1-cyanocyclopropanecarboxylate 
(4.115, 300 g, 1.85 mol) in THF (0.9 L) cooled to 0 °C was treated with NaOH (2M aqueous) 
(1.9 L, 2 eq) in one portion and the solution was stirred for 1 h at 0 °C where analysis by TLC 
(1:1 hexanes:EtOAc, KMnO4) indicated that the starting material was consumed. The reaction 
was acidified at 0 °C with portion-wise addition of 6 M aqueous HCl (620 mL over 10 min) to a 
pH of 2 and the aqueous layer was extracted portion-wise with EtOAc (2 x (3 x 500 mL)). The 
organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo (water bath at 
35 °C). The crude residue was concentrated from hexanes (1 L) to afford the product (191 g, 1.55 
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mol (90% pure)) as an off-white waxy solid. This solid was taken on to the lactone formation 
with no further purification.  
To a 3L 3-necked flask equipped with a thermometer, mechanical stirrer, and condenser 
connected to a N2 bubbler was added 1-cyanocyclopropanecarboxylic acid (4.113, 191 g, 1.55 
mol), triethylammonium bromide (254 g, 1.39 mol) and dry MeCN (2.5 L) and was heated to 85 
°C for 24 h where analysis by 1H NMR indicated that the cyclopropane had been consumed. The 
reaction was cooled to rt, concentrated under reduced pressure, the residue was suspended in 
EtOAc (1 L) and filtered, washed with ethyl acetate (4 x 500 mL) and concentrated in vacuo. 
The crude residue was purified by short path distillation (165 °C) (internal temp 140 °C) to give 
4.110 (138 g, 1.25 mol, 60% (3 steps)) as a pale yellow oil: 1H NMR (300 MHz, CDCl3) δ 4.54 
(ddd, J = 9.3, 8.3, 3.3 Hz, 1 H), 4.35 (td, J = 9.3, 6.7 Hz, 1 H), 3.72 (t, J = 9.3 Hz, 1 H), 2.81-
2.57 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 168.6, 114.8, 67.3, 31.4, 27.6.  
 
Triethylammonium Hydrobromide. To a 1 L 1-neck flask containing a solution 
triethylamine (110 mL, 785 mmol) in acetone (0.6 L). The solution was cooled to 0 °C (ice bath) 
and added HBr (48% aqueous) (89 mL, 785 mmol) dropwise over 30 min. The solution was let 
stir for 1 h, diluted with Et2O (400 mL) and the precipitated salt was filtered through a buchner 
funnel with filterpaper. The solid was washed Et2O (1.4 L) and dried under vacuum (50 torr) at 
45 °C to give the product (62.0 g, 340 mmol, 80%) as a colorless solid:  Mp 256-258 (Lit 248) 
General procedure for screening conditions in Table 5.2:  
A solution 1-cyanocyclopropanecarboxylic acid (4.110, 0.0500 g, 0.450 mmol) in dry 
ACN (3 mL) was added additive (See Table 5.2) (0.0225 mmol, 5 mol%) and stirred at 75 °C for 
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24, 48, or 72 h and reaction progress was monitored by TLC and 1HNMR using CDCl3 as a 
solvent. Reactions with no product formation after 24 h were not analyzed further. 
 
Table 5.2. Screening conditions for lactone formation. 
N
HO
O
ACN, rt to 75°C
5 mol% cat.
O
O
N
4.113 4.110  
Entry 
Conditions and analysis 
Cat. (5 mol%) 24h 75 °C 48h 75 °C 72h 75 °C 
1 NiBr2ab 12%d 30%d 50%d 
2 PtBr2ab NRd ND ND 
3 Rh2(OAc)4ab NRd ND ND 
4 Pd(PPh3)4ab NRd ND ND 
5 I2a NRd ND ND 
6 Yb(OTf)3a NRd ND ND 
7 ZnCl2a NRd ND ND 
8 Sn(OTf)2a NRd ND ND 
9 MgI2a 60%d >95%d ND 
10 Ti(OiPr)4a NRd ND ND 
11 NiCl2•6H2Oa NRd NRd ND 
12 CaCl2a NRd NRd ND 
13 CaI2a 15%d 25%d 30%d 
14 MnCl2•4H2Oa NRd NRd ND 
15 MnBr2a NRd NRd ND 
16 Bu4NBra ND 12% ND 
17 NiI2a ND 76%d ND 
18 CuIa ND 5%d ND 
19 NaIa ND 94%d ND 
20 NaIc ND 77%e (42 h) ND 
a50 mg scale; breaction was degassed by sparging with Ar; c10 g scale; dconversion by 1HNMR; 
eisolated yield; NR, no reaction; ND, not determined. 
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Lactonization using sodium iodide: 
N
HO
O
ACN, rt to 75°C
5 mol% NaI
O
O
N
 
A solution of 1-cyanocyclopropanecarboxylic acid (4.113, 10.0 g, 81.0 mmol) in dry 
MeCN (162 mL) was treated with NaI (0.607 g, 4.05 mmol) and the reaction was heated to 80 °C 
for 42 h where analysis by 1HNMR indicated that the cyclopropane starting material had been 
consumed. The reaction was concentrated under reduced pressure and the residue was suspended 
in EtOAc (150 mL), filtered, washed (EtOAc), the filtrates were combined, and concentrated 
under reduced pressure. The crude residue was purified by short path distillation (150 °C at 0.25 
mmHg) (internal temp 120 °C) to give 4.110 (6.97 g, 62.8 mmol, 77%) as an orange oil. NMR 
data matches what was previously reported for the synthesis of this compound. 
N
HO
H
 
4.118 
2-(2-Hydroxyethyl)hex-5-ynenitrile (4.118). A solution of 2-oxotetrahydrofuran-3-
carbonitrile (4.110, 22.0 g, 198 mmol) in acetone (570 mL) at rt was treated with K2CO3 (41.1 g, 
297 mmol) and but-3-yn-1-yl 4-methylbenzenesulfonate (4.104, 44.4 g, 198 mmol) and the 
mixture was stirred at 65 °C for 7 days. The reaction was concentrated under reduced pressure 
and the solid was dissolved in CH2Cl2 (300 mL) and H2O (300 mL) and the layers separated. The 
aqueous layer was extracted with CH2Cl2 (3 x 200 mL).  The combined organic layers were dried 
(MgSO4), filtered, and concentrated under reduced pressure to give the crude 4.116 (35.4, 86.8 
mmol, (40% pure) as a brown oil. This oil was taken on with no further purification. 
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A solution of 3-(but-3-yn-1-yl)-2-oxotetrahydrofuran-3-carbonitrile (4.116, 35.4 g, 86.8 
mmol) in THF (30 mL) at rt was treated with aqueous cesium hydroxide (52 mL, 104 mmol, 2 
M, 1.2 eq) and stirred at rt for 2 h where analysis by TLC (1:1, hexanes/EtOAc, KMnO4 Stain) 
indicated that the SM had been consumed. The reaction was concentrated under reduced pressure 
(rotovap bath ~25 °C) and washed with EtOAc (3 x 200 mL) and decanted where the washes 
became colorless. The aqueous layer was concentrated under reduced pressure (Azeotrope with 
toluene (3 x 100 mL) (rotovap bath at 50 °C) and the product was dried under high vacuum to 
give crude 4.117 (26.4 g, 84.4 mmol, 97% crude) as a waxy orange solid that was taken on to the 
decarboxylation with no further purification. 
A solution of cesium 2-cyano-2-(2-hydroxyethyl)hex-5-ynoate (4.117, 26.4 g, 84.4 
mmol) in THF (100 mL) and toluene (50 mL) was heated at 85 °C for 24 h, cooled to rt, and 
filtered. The solid/oil remaining in the flask was washed with EtOAc (3 x 100 mL) and filtered. 
The combined filtrates were concentrated under reduced pressure to give 4.118 (7.28 g, 53.1 
mmol, 27% (3 steps) as a light orange oil: IR (CH2Cl2) 3452, 3288, 2952, 2887, 2239, 1433, 
1053, 749 cm-1; 1H NMR (300 MHz, CDCl3) δ 3.79-3.69 (m, 2 H), 2.99 (quint, J = 7.5 Hz, 1 H), 
2.57 (s, 1 H), 2.45-2.28 (m, 2 H), 2.01 (t, J = 2.4 Hz, 1 H), 1.88-1.74 (m, 4 H); 13C NMR (75 
MHz, CDCl3) δ 121.2, 81.8, 70.0, 59.1, 34.2, 30.7, 27.1, 16.3; HRMS (ESI) m/z calcd for 
C8H12NO ([M+H]+) 138.0913, found 138.0914. 
N
BnO
H
 
4.119 
2-(2-(Benzyloxy)ethyl)hex-5-ynenitrile (4.119). A solution of 2-(2-hydroxyethyl)hex-5-
ynenitrile (4.118, 7.28 g, 53.1 mmol) in THF (132 mL) at rt was treated with NaH (60% 
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dispersion in mineral oil) (4.67 g, 117 mmol) portion-wise over 5 min with vigorous stirring. 
After stirring for 20 min the reaction mixture was treated with BnBr (12.7 mL, 106 mmol), 
stirred at rt for 24 h, diluted with satd. aqueous NH4Cl, and extracted with EtOAc (3 x 200 mL). 
The combined organic layers were dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 6:1) to 
give 4.119 (10.8 g, 47.6 mmol, 90%) as a yellow oil: IR (CHCl3) 3290, 2889, 2242, 1495, 1452, 
1094, 907, 731 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.39-7.29 (m, 6 H), 4.54 (d, J = 8.0 Hz, 2 
H), 3.65 (dd, J = 6.3, 5.5 Hz, 2 H), 3.06 (tt, J = 8.9, 6.1 Hz, 1 H), 3.06 (tt, J = 8.9, 6.1 Hz, 1 H), 
2.50-2.35 (m, 2 H), 2.03 (t, J = 2.6 Hz, 1 H), 1.95-1.78 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 
137.8, 128.3, 127.7, 127.6, 121.1, 81.8, 73.2, 69.9, 66.7, 32.1, 30.8, 27.5, 16.4; HRMS (ESI) m/z 
calcd for C15H18NO ([M+H]+) 228.1383, found 228.1380. 
OMe
OMe
OMe
N
OBn
 
4.120 
4-(Benzyloxy)-2-(2-(1,4,5-trimethoxynaphthalen-2-yl)ethyl)butanenitrile (4.120). A 
solution of pentacarbonyl[methoxy(methoxy-2-phenyl)carben]chromium(IV) (4.80, 8.01 g, 21.1 
mmol) and 2-(2-(benzyloxy)ethyl)hex-5-ynenitrile (4.119, 7.18 g, 31.6 mmol) in dry 
deoxygenated THF (420 mL) was stirred at 50 °C for 14 h. The reaction was cooled to rt and 
added dry SiO2 and concentrated under reduced pressure to a free flowing powder. The crude 
residue was purified by chromatography on SiO2 solid load (hexanes/EtOAc, 2:1) to give the 
naphthol intermediate (8.1 g) that was taken on to the methylation.  
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A solution of the naphthol intermediate in dry DMF (42 mL) was treated with MeI (5.3 
mL, 84.3 mmol) and K2CO3 (11.7 g, 84.3 mmol) and the reaction was stirred at rt 24 h. Analysis 
by LCMS indicated that the SM appeared to be consumed. The reaction was diluted with H2O 
(250 mL) and brine (150 mL) and extracted with Et2O (3 x 250 mL). The combined organic 
layers were washed with brine, dried (MgSO4), filtered, and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 3:1) to 
give the product as a red oil. This oil was filtered through basic Al2O3 (hexanes/EtOAc, 1:1) to 
give 4.120 (5.49 g, 13.1 mmol, 62%) as a dark orange oil: IR (CH2Cl2) 2930, 2861, 1597, 1581, 
1450, 1379, 1260, 1124, 1070, 1003, 734 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.65 (dd, J = 8.4, 
1.0 Hz, 1 H), 7.42 (t, J = 8.1 Hz, 1 H), 7.35-7.28 (m, 5 H), 6.86 (dd, J = 7.5, 0.5 Hz, 1 H), 6.64 
(s, 1 H), 4.50 (q, J = 10.2 Hz, 2 H), 3.97 (s, 3 H), 3.94 (s, 3 H), 3.86 (s, 3 H), 3.64 (t, J = 5.9 Hz, 
2 H), 3.02 (ddd, J = 13.5, 9.2, 5.6 Hz, 1 H), 2.93-2.87 (m, 2 H), 2.02-1.91 (m, 4 H); 13C NMR 
(125 MHz, CDCl3) δ 157.4, 153.5, 147.2, 137.9, 131.5, 128.8, 128.4, 127.7 (2 C), 126.7, 121.9, 
117.6, 114.6, 108.0, 106.2, 73.3, 67.0, 61.8, 56.9, 56.4, 33.1, 32.5, 28.5, 28.1; HRMS (ESI) m/z 
calcd for C26H30NO4 ([M+H]+) 420.2169, found 420.2167. 
OMe
OMeOMe
O
OBn
 
4.121 
4-(Benzyloxy)-2-(2-(1,4,5-trimethoxynaphthalen-2-yl)ethyl)butanal (4.121). A 
solution of 4-(benzyloxy)-2-(2-(1,4,5-trimethoxynaphthalen-2-yl)ethyl)butanenitrile (4.120, 
0.650 g, 1.55 mmol) in CH2Cl2 (7.8 mL) was cooled to -78 °C and treated with DIBAL (1.2 M in 
toluene, 1.4 mL, 1.70 mmol) over 5 min. The mixture was stirred at -78 °C for 30 min and 
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allowed to warm to rt over 2.5 h. The reaction was treated with satd. aqueous NH4Cl solution (~ 
1.5 mL) followed by Celite/florisil at 0 °C. The mixture was diluted with CH2Cl2 (20 mL), 
warmed slowly to room temperature, and stirred till all aluminum precipitated (20 min) and dried 
(MgSO4). The solid was filtered through a pad of Celite/florisil and washed with CH2Cl2 (100 
mL) and EtOAc (50 mL), and the combined filtrates were concentrated in vacuo. The crude 
residue was purified by chromatography on SiO2 (CH2Cl2/EtOAc, 4:1) to give 4.121 (0.384 g, 
0.909 mmol, 59%) as a red/brown oil: IR (CH2Cl2) 2934, 2841, 1720, 1600, 1583, 1454, 1381, 
1263, 1071, 909, 729 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.64 (dd, J = 8.5, 0.9 Hz, 1 H), 7.40 (t, 
J = 8.1 Hz, 1 H), 7.34-7.27 (m, 5 H), 6.84 (d, J = 7.7 Hz, 1 H), 6.62 (s, 1 H), 4.46 (s, 2 H), 3.97 
(s, 3 H), 3.93 (s, 3 H), 3.82 (s, 3 H), 3.56-3.48 (m, 2 H), 2.77 (ddd, J = 9.0, 6.9, 2.1 Hz, 2 H), 
2.58-2.50 (m, 1 H), 2.07 (tt, J = 14.4, 7.1 Hz, 2 H), 1.94-1.76 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 204.5, 157.4, 153.4, 147.0, 138.1, 131.4, 129.9, 128.4, 127.6 (2 C), 126.6, 117.4, 
114.6, 108.1, 106.0, 73.1, 67.7, 61.7, 56.9 (2 C), 56.4, 49.0, 29.6, 27.6; HRMS (ESI) m/z calcd 
for C26H31O5 ([M+H]+) 423.2166, found 423.2177. 
OMe
O
O H CO2Me
OBn
H
 
4.126 
Methyl (3S,6S,6aS,12aR)-3-(2-(benzyloxy)ethyl)-8-methoxy-7,12-dioxo-
1,2,3,3a,6,6a,7,12-octahydrocyclopenta[d]anthracene-6-carboxylate (4.126). A solution of 4-
((benzyloxy)-2-(2-(1,4,5-trimethoxynaphthalen-2-yl)ethyl)butanal (4.121, 0.655 g, 1.55 mmol) 
in dry degassed CH2Cl2 (11 mL) at 0 °C was treated with (E)-methyl 4-
(triphenylphosphoranylidene)but-2-enoate470 (4.122, 1.55 g, 3.87 mmol) and the reaction was 
warmed to 50 °C for 24 h. The reaction was concentrated in vacuo and the crude residue was 
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purified by chromatography on SiO2 (hexanes/EtOAc, 2:1) to give 4.123 (0.437 g, 0.867 mmol) 
as a light brown oil that was taken on with no further purification. 
A solution of (2E,4E)-methyl 8-(benzyloxy)-6-(2-(1,4,5-trimethoxynaphthalen-2-
yl)ethyl)octa-2,4-dienoate (4.123, 0.437 g, 0.866 mmol) in CH3CN (44 ml) was treated with a 
solution of CAN (1.14 g, 2.08 mmol) in H2O (14 ml) at 0 °C and stirred for 10 min at 0 °C. The 
orange solution was diluted with CH2Cl2 (50 ml). The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (1 x 50 ml). The organic layers were combined, dried (Na2SO4), 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (hexanes/EtOAc, 1:1) to give 4.124 (0.387 g, 0.814 mmol) as a orange/brown oil. 
A solution of quinone (4.124, 0.387 g, 0.816 mmol) in dry CH2Cl2 (27 mL) was treated 
with BF3•OEt2 (0.60 mL, 4.89 mmol) at 0 °C and stirred at rt for 4 h. Analysis by TLC 
(hexanes/EtOAc, 1:1) the starting material had been consumed. The reaction was diluted with 
satd. aqueous NaHCO3 solution and the reaction mixture was extracted with CH2Cl2 (3 x 20 
mL). The organic layers were combined, dried (Na2SO4), and concentrated under reduced 
pressure. The crude residue was purified by chromatography on SiO2 (hexanes/EtOAc, 1:2) to 
give 4.126 (0.181 g, 0.382 mmol, 25% (3 steps)) as a dark brown oil: IR (CH2Cl2) 2943, 1732, 
1689, 1582, 1273, 1226, 1098, 995, 732, 697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.63-7.56 (m, 
2 H), 7.31-7.27 (m, 5 H), 7.21 (dd, J = 7.8, 1.7 Hz, 1 H), 6.26 (dt, J = 10.1, 2.3 Hz, 1 H), 5.58 
(dt, J = 10.1, 3.0 Hz, 1 H), 4.51 (s, 2 H), 3.97 (s, 3 H), 3.79-3.74 (m, 1 H), 3.55 (t, J = 7.0 Hz, 2 
H), 3.39 (d, J = 10.4 Hz, 1 H), 3.03 (s, 3 H), 2.78-2.68 (m, 1 H), 2.00-1.87 (m, 3 H), 1.78-1.66 
(m, 3 H), 1.59-1.52 (m, 1 H), 1.50-1.42 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 196.8, 195.4, 
171.4, 158.6, 138.4, 136.5, 134.8, 131.1, 128.3, 127.6, 127.5, 122.7, 122.2, 119.1, 116.7, 77.3, 
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77.0, 76.7, 73.0, 69.4, 59.6, 59.4, 56.4, 52.3, 51.4, 43.5, 36.3, 33.8, 29.3; HRMS (ESI) m/z calcd 
for C29H31O6 ([M+H]+) 475.2115, found 475.2107. 
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O
O H
OH
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4.130 
(3S,6S,6aS,12aR)-Methyl 3-(2-hydroxyethyl)-8-methoxy-7,12-dioxo-
1,2,3,3a,4,5,6,6a,7,12-decahydrocyclopenta[d]anthracene-6-carboxylate (4.130). A solution 
of methyl (3S,6S,6aS,12aR)-3-(2-(benzyloxy)ethyl)-8-methoxy-7,12-dioxo-1,2,3,3a,6,6a,7,12-
octahydrocyclopenta[d]anthracene-6-carboxylate (4.126, 0.311 g, 0.678 mmol) in THF (14 mL) 
was added 10% Pd/C (0.0722 g, 0.0678 mmol) and stirred at room temperature under hydrogen 
atmosphere for 2 d. The reaction mixture was filtered through Celite (eluting with EtOAc) and 
concentrated under reduced pressure. The crude residue was purified by chromatography on SiO2 
(4:1, EtOAc/hexanes to 100% EtOAc) to give 4.130 (0.217 g, 0.562 mmol, 83%) as a tan foam: 
IR (CH2Cl2) 3543, 2928, 2869, 1732, 1679, 1584, 1465, 1433, 1275, 1228, 1199, 999, 729 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.64-7.61 (m, 2 H), 7.23 (quint, J = 4.6 Hz, 1 H), 3.98 (s, 3 H), 
3.73-3.68 (m, 2 H), 3.22-3.19 (m, 1 H), 2.92 (s, 3 H), 2.89 (d, J = 6.6 Hz, 1 H), 2.65-2.55 (m, 1 
H), 2.23-2.12 (m, 2 H), 1.97-1.89 (m, 1 H), 1.84-1.71 (m, 3 H), 1.60-1.46 (m, 3 H), 1.38-1.27 (m, 
2 H), 1.06-1.00 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 197.0, 196.4, 173.3, 159.2, 137.7, 
134.9, 122.0, 119.0, 116.7, 62.3, 60.4, 56.9, 56.5, 55.0, 50.8, 42.2, 39.0, 36.7, 36.2, 28.9, 28.1, 
21.1; HRMS (ESI) m/z calcd for C22H27O6 ([M+H]+) 387.1802, found 357.1802. 
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O
O H
OH
O
H
 
 301 
4.131 
(2aS,2a1S,5S,7aR,12bS)-5-(2-Hydroxyethyl)-12-methoxy-2a1,3,4,4a,5,6,7,12b-
octahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.131). A solution of 
((3S,6S,6aS,12aR)-methyl 3-(2-hydroxyethyl)-8-methoxy-7,12-dioxo-1,2,3,3a,6,6a,7,12-
octahydrocyclopenta[d]anthracene-6-carboxylate (4.130, 0.0630 g, 0.163 mmol) in 
CH2Cl2/MeOH (1:3, 9.3 mL) at -30 °C (cryocool) was treated with NaBH4 (0.0154 g, 0.408 
mmol) and warmed to rt over 3 h. Analysis by TLC (4:1, EtOAc/hexanes) and LCMS indicated 
that the starting material was consumed. The reaction was diluted with 1 M HCl at 0 °C, warmed 
to rt, and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried (MgSO4), 
and concentrated under reduced pressure. The crude residue was purified by chromatography on 
SiO2 (4:1, EtOAc/hexanes) to give 4.131 (0.0368 g, 0.103 mmol, 63%) as a colorless foam: IR 
(CHCl3) 3536, 2934, 2865, 2252, 1754, 1679, 1588, 1471, 1273, 1182, 1061, 973, 731 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 8.0, 1.1 Hz, 1 H), 7.46 (t, J = 8.0 Hz, 1 H), 7.14 (dd, J = 
8.0, 1.1 Hz, 1 H), 6.16 (d, J = 10.0 Hz, 1 H), 3.92 (s, 3 H), 3.69 (t, J = 7.1 Hz, 2 H), 3.26 (t, J = 
10.0 Hz, 1 H), 2.84 (ddd, J = 13.8, 11.3, 5.0 Hz, 1 H), 2.55 (qt, J = 10.0, 5.0 Hz, 1 H), 2.04-1.79 
(m, 5 H), 1.71-1.66 (m, 1 H), 1.54-1.28 (m, 6 H); 13C NMR (100 MHz, CDCl3) δ 198.9, 178.3, 
158.3, 132.5, 130.8, 125.6, 118.9, 115.6, 72.1, 62.1, 56.1, 53.6, 52.2, 45.9, 39.4, 38.7, 37.0, 30.4, 
23.7, 21.9; HRMS (ESI) m/z calcd for C21H25O5 ([M+H]+) 357.1697, found 357.1693. 
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4.135 
2-((2aS,2a1S,5S,7aR,12bS)-12-Methoxy-2,8-dioxo-2a,2a1,3,4,4a,5,6,7,8,12b-
decahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-5-yl)acetaldehyde (4.135). A solution of 
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the (2aS,2a1S,5S,7aR,12bS)-5-(2-hydroxyethyl)-12-methoxy-2a1,3,4,4a,5,6,7,12b-octahydro-
2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.131, 0.0667 g, 0.187 mmol) in 
CH2Cl2 (10.0 mL) at rt was treated with DMP (0.160 g, 0.374 mmol) and stirred at 0 °C for 2.5 
h, diluted with CH2Cl2 (50 mL), 1 M Na2S2O3 (25 mL) and satd. aqueous NaHCO3 (25 mL). The 
organic layer was separated, and the aqueous layer was washed with CH2Cl2 (2 x 20 mL). The 
combined organic layers were washed with satd. aqueous NaHCO3 (2 x 25 mL), 1 M Na2S2O3 
(25 mL), dried (Na2SO4) and concentrated under reduced pressure to give 4.135 (0.0632 g, 0.178 
mmol, 95%) as a yellow-orange amorphous solid: IR (CH2Cl2) 3059, 2937, 2870, 1760, 1719, 
1681, 1588, 1273, 1077, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 9.79 (t, J = 2.3 Hz, 1 H), 7.55 
(dd, J = 8.0, 1.1 Hz, 1 H), 7.48 (t, J = 8.0 Hz, 1 H), 7.16 (dd, J = 8.0, 1.1 Hz, 1 H), 6.18 (d, J = 
9.9 Hz, 1 H), 3.93 (s, 3 H), 3.27 (t, J = 10.5 Hz, 1 H), 3.05 (dtd, J = 14.9, 9.9, 5.3 Hz, 1 H), 2.84 
(ddd, J = 13.8, 11.3, 5.1 Hz, 1 H), 2.63 (ddd, J = 15.8, 5.3, 2.3 Hz, 1 H), 2.35 (ddd, J = 15.8, 8.8, 
2.3 Hz, 1 H), 2.12-1.99 (m, 2 H), 1.93-1.81 (m, 2 H), 1.77-1.70 (m, 1 H), 1.51-1.33 (m, 4 H); 13C 
NMR (100 MHz, CDCl3) δ 202.2, 198.7, 178.1, 158.4, 132.4, 131.0, 125.6, 119.0, 115.8, 72.0, 
56.1, 53.5, 51.6, 50.1, 45.8, 39.3, 37.0, 36.5, 30.2, 23.6, 21.5; HRMS (ESI) m/z calcd for 
C21H23O5 ([M+H]+) 355.1540, found 355.1539. 
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4.136 
2-((2aS,2a1S,5R,7aR,12bS)-12-Methoxy-2,8-dioxo-2a,2a1,3,4,4a,5,6,7,8,12b-
decahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-5-yl)-2-(phenylselanyl)acetaldehyde 
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(4.136). A solution of 2-((2aS,2a1S,4aS,5S,7aR,12bS)-12-methoxy-2,8-dioxo-
2a,2a1,3,4,4a,5,6,7,8,12b-decahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-5-yl)acetaldehyde 
(4.135, 0.0632 g, 0.178 mmol) and N-(phenylseleno)phthalimide (0.0719 g, 0.214 mmol) in 
anhydrous CH2Cl2 (1.8 mL) at rt was treated with L-prolinamide (0.0010 g, 0.00892 mmol). 
After 2 h, analysis by TLC (2:1, EtOAc/hexanes) indicated the starting material was consumed. 
H2O (5 mL) was added and the reaction was extracted with CH2Cl2 (3 × 10 mL). The combined 
organic layers were dried (Na2SO4), and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (hexanes/EtOAc, 1:1) to give 4.136 (0.0650 g, 0.128 
mmol, 72%) as a colorless foam as a 4:1 mixture of diastereomers (by 1HNMR): IR (CH2Cl2) 
3374, 3070, 2934, 2867, 1758, 1702, 1588, 1471, 1273, 1202, 1014, 979, 738 cm-1; 
Characteristic 1H NMR peaks for major diastereomer 1H NMR (400 MHz, CDCl3) δ 9.44 (d, J = 
5.2 Hz, 1 H), 7.56-7.53 (m, 3 H), 7.49 (t, J = 8.0 Hz, 1 H), 7.34-7.29 (m, 4 H), 7.16 (dd, J = 8.0, 
1.0 Hz, 1 H), 6.19 (d, J = 9.9 Hz, 1 H), 3.94 (s, 3 H), 3.62 (dd, J = 8.3, 5.2 Hz, 1 H), 3.30 (t, J = 
10.6 Hz, 1 H), 3.11-3.03 (m, 1 H), 2.81 (ddd, J = 14.1, 11.4, 5.2 Hz, 1 H), 2.16-1.94 (m, 3 H), 
1.87-1.69 (m, 6 H), 1.62-1.56 (m, 2 H), 1.36-1.24 (m, 2 H); Characteristic peaks for major 
diastereomer 13C NMR (100 MHz, CDCl3) δ 198.4, 192.8, 178.0, 177.9, 158.4, 132.0, 131.0, 
129.5, 129.4, 128.7, 127.2, 125.6, 119.0, 115.9, 72.0, 61.3, 54.6, 54.1, 45.6, 40.6, 39.1, 29.2, 
23.5, 22.0; HRMS (ESI) m/z calcd for C27H27O5Se ([M+H]+) 511.1018, found 511.1019. 
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4.138 
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(2aS,2a1S,7aR,12bS)-5-(2-Hydroxyethylidene)-12-methoxy-2a1,3,4,4a,5,6,7,12b-
octahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.138). A solution of 2-
((2aS,2a1S,4aS,5R,7aR,12bS)-12-methoxy-2,8-dioxo-2a,2a1,3,4,4a,5,6,7,8,12b-decahydro-2H-
cyclopenta[4,4a]anthra[9,1-bc]furan-5-yl)-2-(phenylselanyl)acetaldehyde (4.136, 0.0467 g, 
0.0917 mmol) in THF (1.2 mL) at 0 °C was added a solution of NaIO4 (0.0784 g, 0.367 mmol, 4 
equiv.) in HPLC H2O (1.2 mL) dropwise over 2 min and the mixture was stirred at 0 °C for 10 
min and allowed to warm to rt over 3 h where by TLC the reaction looked complete. The 
reaction was cooled to 0 °C diluted with EtOAc (1 mL) and Satd. NaHCO3 (1 mL) were added 
sequentially. The layers were separated; the aqueous layer was extracted with EtOAc (4 x 2 mL). 
The combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The crude enal 4.137 (0.0247 g) was carried on to the Luche reduction with no further 
purification. 
A solution of crude 2-((2aS,2a1S,7aR,12bS)-12-methoxy-2,8-dioxo-2a,3,4,4a,6,7-
hexahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-5(2a1H,8H,12bH)-ylidene)acetaldehyde 
(4.137, 0.0247 g, 0.0701 mmol) in THF (1.2 mL) and EtOH (0.2 mL) was cooled to 0 °C and 
treated with cerium (III) chloride heptahydrate (0.0522 g, 0.140 mmol) and NaBH4 (0.0053 g, 
0.140 mmol) and stirred at 0 °C for 2 h. The reaction was diluted with Satd. NH4Cl (1 mL) and 
allowed to warm to rt for 10 min where the reaction was extracted with EtOAc (4 x 3 mL). The 
combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo. The crude 
residue was dissolved in MeOH and concentrated onto C18-SiO2 and purified by automated 
reverse phase chromatography on C18 (solid load, 10% ACN:H2O to 95% ACN:H2O) to give 
4.138 (0.0070 g, 0.0198 mmol, 21% (2 steps)) as a 2:1 mixture of isomers as a pale yellow oil: 
Characteristic NMR for major isomer 1H NMR (600 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 1 H), 
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7.48 (t, J = 8.0 Hz, 1 H), 7.17 (d, J = 8.0 Hz, 1 H), 6.20 (d, J = 10.0 Hz, 1 H), 5.56 (dd, J = 7.2, 
4.6 Hz, 1 H), 4.33 (dd, J = 12.0, 6.6 Hz, 1H), 4.22-4.19 (m, 1 H), 3.94 (s, 3 H), 3.36 (t, J = 10.5 
Hz, 1 H), 2.89-2.83 (m, 1 H), 2.57-2.42 (m, 4 H), 2.29 (td, J = 16.0, 8.4 Hz, 1 H), 2.22-2.17 (m, 
1 H), 2.07-2.03 (m, 2 H), 1.80 (ddd, J = 13.1, 6.0, 2.9 Hz, 2 H), 1.55 (dd, J = 11.6, 8.8 Hz, 1 H), 
1.32-1.19 (m, 2 H); 13C NMR (150 MHz, CDCl3) δ 197.5, 178.1, 158.5, 145.7, 131.6, 131.0, 
125.7, 119.6, 118.9, 116.0, 72.2, 59.7, 56.2, 54.4, 47.7, 45.1, 39.0, 35.9, 32.1, 23.7, 23.4; HRMS 
(ESI) m/z calcd for C21H23O5 ([M+H]+) 355.1540, found 355.1539. 
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4.140 
(2aS,2a1S,4aS,5R,7aR,12bS)-5-(2-Hydroxyethyl)-12-methoxy-2a1,3,4,4a,5,6,7,12b-
octahydro-2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.140). A solution of 
(2aS,2a1S,7aR,12bS,Z)-5-(2-hydroxyethylidene)-12-methoxy-2a1,3,4,4a,5,6,7,12b-octahydro-
2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.138, 0.00400 g, 0.0113 mmol) in dry 
degassed CH2Cl2 (0.2 mL) in a 1 dram vial equipped with a magnetic stirbar was added 
Crabtree's catalyst (0.0010 g, 0.00113 mmol) under Ar. The vial was placed in a Parr bomb 
under Ar, sealed, purged with Ar, then purged with H2 (3 x) and pressurized to 21 bar and stirred 
at rt for 4 h. Analysis by 1H NMR and LCMS showed SM remaining. The reaction was treated 
with additional Crabtree's catalyst (0.0010 g, 0.00113 mmol) under Ar. The vial was placed in a 
Parr bomb under Ar, sealed, purged with Ar, then purged with H2 (3 x), pressurized to 20 bar and 
stirred at rt for 16 h. The reaction was concentrated under reduced pressure. Crude 1H NMR 
indicates consumption of the allylic alcohol SM and the product mass of 4.140 is present in the 
LCMS. Crude NMR peaks: 1H NMR (400 MHz, CDCl3) δ 7.55-7.44 (m, 2 H), 7.15 (d, J = 7.0 
 306 
Hz, 1 H), 6.21-6.16 (m, 1 H), 3.99-3.91 (m, 3 H), 3.73-3.68 (m, 1 H), 3.36-3.22 (m, 1 H), 2.99-
2.84 (m, 1 H), 2.33-2.17 (m, 2 H), 1.90-1.61 (m, 4 H), 1.51-1.16 (m, 4 H), 1.06-1.01 (m, 2 H), 
0.89-0.85 (m, 2 H); HRMS (ESI) m/z calcd for C21H25O5 ([M+H]+) 357.1697, found 357.1695. 
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4.141 
(2aS,2a1S,4aS,4a1R,5R,8aS,12bS)-12-methoxy-2a,2a1,3,4,4a,5,6,7,8a,12b-decahydro-
2H-4a1,5-ethanofuro[4',3',2':4,10]anthra[9,1-bc]oxepin-2-one (4.141). A solution of crude 
(2aS,2a1S,4aS,5R,7aR,12bS)-5-(2-Hydroxyethyl)-12-methoxy-2a1,3,4,4a,5,6,7,12b-octahydro-
2H-cyclopenta[4,4a]anthra[9,1-bc]furan-2,8(2aH)-dione (4.140, 0.0050 g, 0.0140 mmol) in dry 
CH2Cl2 (7.0 mL) cooled to 0 °C was treated with a freshly prepared solution of TMSOTf  (1M in 
CH2Cl2) (28 µL, 0.0281 mmol) followed by Et3SiH (6.7 µL, 0.0421 mmol) and stirred at 0 °C for 
1 h. The reaction was warmed to rt for 4 h where analysis by TLC (EtOAc/hexanes, 4:1; CAM 
stain) indicated the formation of a new more non-polar spot. The reaction was cooled to 0 °C and 
diluted with Satd. NaHCO3 (2 mL) and extracted with CH2Cl2 (3 x 2 mL). The combined organic 
layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude residue 
was purified by chromatography on SiO2 (gradient, hexanes/EtOAc, 1:1 to EtOAc) to afford 
mostly recovered SM along with a mixed fraction of two non-polar spots (>0.5 mg): HRMS 
(ESI) m/z calcd for C21H25O4 ([M+H]+) 341.1747, found 341.1746.  
 
307 
APPENDIX A 
X-RAY DATA
A.1 X-RAY STRUCTURE AND DATA FOR (1R,2S)-JJ450
Figure A.1. X-ray crystal structure of (1R,2S)-JJ450. 
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Table A.1. Crystal data and structure refinement for (1R,2S)-JJ450. 
Identification code (1R,2S)-JJ450 
Chemical formula C21H22ClFN2O 
Formula weight 372.85 g/mol 
Temperature 230(2) K 
Wavelength 1.54178 Å 
Crystal size 0.010 x 0.020 x 0.160 mm 
Crystal system Monoclinic 
Space group P 1 21 1 
Unit cell dimensions a = 8.9297(6) Å α = 90° 
b = 10.0143(7) Å β = 93.382(5)° 
c = 10.7194(8) Å γ = 90° 
Volume 956.91(12) Å3 
Z 2 
Density (calculated) 1.294 g/cm3 
Absorption coefficient 1.942 mm-1 
F(000) 392 
Diffractometer Bruker Apex II CCD 
Radiation source IMuS micro-focus source, Cu 
Theta range for data collection 4.13 to 68.31° 
Index ranges -10<=h<=10, -11<=k<=12, -12<=l<=12
Reflections collected 13088
Independent reflections 3491 [R(int) = 0.1250]
Absorption correction multi-scan
Max. and min. transmission 0.9800 and 0.7500
Structure solution technique direct methods
Structure solution program SHELXS-97 (Sheldrick, 2008)
Refinement method Full-matrix least-squares on F2
Refinement program SHELXL-97 (Sheldrick, 2008)
Function minimized Σ w(Fo2 - Fc2)2
Data / restraints / parameters 3491 / 1 / 237
Goodness-of-fit on F2 1.725
Δ/σmax 0.004
Final R indices  [I>2σ(I)] R1 = 0.1107, wR2 = 0.2229
R indicies (all data) R1 = 0.2637, wR2 = 0.2932
Weighting scheme w=1/[σ
2(Fo2)+(0.0680P)2]
where P=(Fo2+2Fc2)/3
Absolute structure parameter 0.05(7)
Extinction coefficient 0.0760(100)
Largest diff. peak and hole 0.555 and -0.639 eÅ-3
R.M.S. deviation from mean 0.143 eÅ-3
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Table A.2. Atomic coordinates and equivalent isotropic atomic displacement parameters (Å2) for (1R,2S)-
JJ450. 
x/a y/b z/c U(eq) 
Cl1 0.8388(4) 0.4211(5) 0.6385(4) 0.0959(19) 
F1 0.7333(11) 0.6332(12) 0.2209(12) 0.142(5) 
O1 0.1000(13) 0.2703(13) 0.1361(11) 0.096(4) 
N1 0.2734(15) 0.4723(13) 0.5135(14) 0.084(4) 
N2 0.0834(15) 0.4113(18) 0.2985(18) 0.099(5) 
C1 0.377(2) 0.5931(17) 0.692(2) 0.087(5) 
C2 0.500(2) 0.6171(17) 0.7724(18) 0.088(5) 
C3 0.6389(19) 0.5680(16) 0.7653(16) 0.080(5) 
C4 0.6607(17) 0.4813(17) 0.660(2) 0.095(6) 
C5 0.5424(19) 0.4540(14) 0.5773(16) 0.085(5) 
C6 0.4026(18) 0.5086(19) 0.5993(19) 0.085(5) 
C7 0.2290(17) 0.6514(18) 0.7079(14) 0.089(5) 
C8 0.2331(17) 0.5738(15) 0.4151(16) 0.083(5) 
C9 0.082(2) 0.5420(19) 0.3531(19) 0.104(6) 
C10 0.2783(18) 0.3412(19) 0.4524(17) 0.090(6) 
C11 0.1289(17) 0.3017(17) 0.3865(16) 0.084(5) 
C12 0.074(2) 0.384(2) 0.173(3) 0.134(12) 
C13 0.0245(17) 0.487(2) 0.0836(19) 0.094(6) 
C14 0.071(2) 0.4722(19) 0.9512(17) 0.104(6) 
C15 0.1354(19) 0.5830(16) 0.0329(17) 0.091(6) 
C16 0.299(2) 0.588(2) 0.0775(16) 0.090(5) 
C17 0.358(2) 0.717(2) 0.1101(15) 0.092(6) 
C18 0.504(3) 0.731(2) 0.159(2) 0.117(7) 
C19 0.591(2) 0.622(3) 0.1697(19) 0.100(6) 
C20 0.536(2) 0.501(3) 0.1398(18) 0.108(7) 
C21 0.388(2) 0.482(2) 0.0893(16) 0.097(6) 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
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Table A.3. Bond lengths (Å) for (1R,2S)-JJ450. 
Cl1-C4 1.728(16) F1-C19 1.36(2) 
O1-C12 1.23(2) N1-C10 1.47(2) 
N1-C6 1.478(19) N1-C8 1.494(17) 
N2-C12 1.37(3) N2-C9 1.43(2) 
N2-C11 1.49(2) C1-C6 1.33(2) 
C1-C2 1.38(2) C1-C7 1.46(2) 
C2-C3 1.34(2) C2-H2A 0.94 
C3-C4 1.45(2) C3-H3A 0.94 
C4-C5 1.365(19) C5-C6 1.40(2) 
C5-H5A 0.94 C7-H7A 0.97 
C7-H7B 0.97 C7-H7C 0.97 
C8-C9 1.50(2) C8-H8A 0.98 
C8-H8B 0.98 C9-H9A 0.98 
C9-H9B 0.98 C10-C11 1.525(19) 
C10-H10A 0.98 C10-H10B 0.98 
C11-H11A 0.98 C11-H11B 0.98 
C12-C13 1.46(3) C13-C15 1.51(2) 
C13-C14 1.51(2) C13-H13A 0.99 
C14-C15 1.51(2) C14-H14A 0.98 
C14-H14B 0.98 C15-C16 1.51(2) 
C15-H15A 0.99 C16-C21 1.33(2) 
C16-C17 1.43(2) C17-C18 1.39(2) 
C17-H17A 0.94 C18-C19 1.34(3) 
C18-H18A 0.94 C19-C20 1.34(3) 
C20-C21 1.41(2) C20-H20A 0.94 
C21-H21A 0.94 
Table A.4. Bond angles (°) for (1R,2S)-JJ450. 
C10-N1-C6 117.0(14) C10-N1-C8 107.8(13) 
C6-N1-C8 114.7(13) C12-N2-C9 125.7(19) 
C12-N2-C11 118.2(19) C9-N2-C11 115.0(16) 
C6-C1-C2 114.3(16) C6-C1-C7 122.5(18) 
C2-C1-C7 123.1(18) C3-C2-C1 127.3(19) 
C3-C2-H2A 116.4 C1-C2-H2A 116.4 
C2-C3-C4 115.6(16) C2-C3-H3A 122.2 
C4-C3-H3A 122.2 C5-C4-C3 119.4(15) 
C5-C4-Cl1 121.8(17) C3-C4-Cl1 118.7(14) 
C4-C5-C6 118.6(17) C4-C5-H5A 120.7 
C6-C5-H5A 120.7 C1-C6-C5 124.7(16) 
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C1-C6-N1 117.2(17) C5-C6-N1 118.2(19) 
C1-C7-H7A 109.5 C1-C7-H7B 109.5 
H7A-C7-H7B 109.5 C1-C7-H7C 109.5 
H7A-C7-H7C 109.5 H7B-C7-H7C 109.5 
N1-C8-C9 109.9(13) N1-C8-H8A 109.7 
C9-C8-H8A 109.7 N1-C8-H8B 109.7 
C9-C8-H8B 109.7 H8A-C8-H8B 108.2 
N2-C9-C8 110.3(15) N2-C9-H9A 109.6 
C8-C9-H9A 109.6 N2-C9-H9B 109.6 
C8-C9-H9B 109.6 H9A-C9-H9B 108.1 
N1-C10-C11 113.0(14) N1-C10-H10A 109.0 
C11-C10-H10A 109.0 N1-C10-H10B 109.0 
C11-C10-H10B 109.0 H10A-C10-H10B 107.8 
N2-C11-C10 107.5(14) N2-C11-H11A 110.2 
C10-C11-H11A 110.2 N2-C11-H11B 110.2 
C10-C11-H11B 110.2 H11A-C11-H11B 108.5 
O1-C12-N2 120.(3) O1-C12-C13 120.(3) 
N2-C12-C13 120.(2) C12-C13-C15 120.7(14) 
C12-C13-C14 117.4(19) C15-C13-C14 59.8(12) 
C12-C13-H13A 115.8 C15-C13-H13A 115.8 
C14-C13-H13A 115.8 C15-C14-C13 60.0(12) 
C15-C14-H14A 117.8 C13-C14-H14A 117.8 
C15-C14-H14B 117.8 C13-C14-H14B 117.8 
H14A-C14-H14B 114.9 C14-C15-C16 122.3(16) 
C14-C15-C13 60.2(10) C16-C15-C13 123.4(15) 
C14-C15-H15A 113.6 C16-C15-H15A 113.6 
C13-C15-H15A 113.6 C21-C16-C17 119.2(18) 
C21-C16-C15 124.7(18) C17-C16-C15 116.1(17) 
C18-C17-C16 120.4(19) C18-C17-H17A 119.8 
C16-C17-H17A 119.8 C19-C18-C17 119.(2) 
C19-C18-H18A 120.7 C17-C18-H18A 120.7 
C20-C19-C18 121.(2) C20-C19-F1 120.(2) 
C18-C19-F1 119.(2) C19-C20-C21 122.6(19) 
C19-C20-H20A 118.7 C21-C20-H20A 118.7 
C16-C21-C20 118.2(18) C16-C21-H21A 120.9 
C20-C21-H21A 120.9 
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Table A.5. Anisotropic atomic displacement parameters (Å2) for (1R,2S)-JJ450. 
U11 U22 U33 U23 U13 U12 
Cl1 0.068(3) 0.090(3) 0.129(4) -0.012(3) -0.001(2) 0.004(2) 
F1 0.073(8) 0.145(10) 0.209(13) -0.035(9) 0.009(7) 0.001(6) 
O1 0.102(10) 0.091(10) 0.092(8) 0.007(8) -0.018(7) -0.008(8)
N1 0.091(11) 0.040(8) 0.121(12) 0.009(9) 0.010(9) 0.012(7) 
N2 0.081(10) 0.074(13) 0.142(15) 0.003(14) 0.014(10) 0.010(10) 
C1 0.076(13) 0.056(11) 0.130(16) -0.009(12) 0.020(12) 0.010(10) 
C2 0.059(11) 0.082(12) 0.125(16) 0.013(11) 0.010(11) -0.011(10)
C3 0.073(13) 0.074(12) 0.093(13) 0.010(11) -0.008(10) -0.001(9)
C4 0.043(10) 0.079(13) 0.161(18) -0.013(12) -0.003(11) 0.005(8) 
C5 0.074(12) 0.069(12) 0.113(13) 0.013(10) 0.013(10) -0.003(10)
C6 0.038(10) 0.071(12) 0.145(17) 0.017(12) -0.012(10) -0.013(9)
C7 0.082(12) 0.110(15) 0.076(12) -0.003(10) 0.009(9) -0.001(10)
C8 0.089(13) 0.059(12) 0.103(13) -0.008(11) 0.015(10) -0.004(10)
C9 0.092(15) 0.069(14) 0.149(19) -0.006(13) -0.017(12) 0.008(11) 
C10 0.054(11) 0.092(16) 0.124(15) 0.033(13) 0.005(10) 0.010(10) 
C11 0.073(13) 0.071(12) 0.111(14) 0.015(12) 0.015(10) 0.002(10) 
C12 0.054(13) 0.061(15) 0.28(4) -0.02(2) -0.024(18) 0.017(10) 
C13 0.040(10) 0.108(17) 0.132(18) -0.008(13) -0.015(10) 0.003(10) 
C14 0.135(17) 0.096(15) 0.078(13) 0.002(11) -0.008(12) -0.012(11)
C15 0.078(13) 0.064(12) 0.129(16) 0.021(12) -0.002(11) 0.003(10) 
C16 0.102(15) 0.069(14) 0.103(13) 0.004(11) 0.036(11) 0.003(13) 
C17 0.088(16) 0.099(17) 0.089(14) -0.001(11) 0.010(12) 0.015(12) 
C18 0.096(18) 0.115(17) 0.142(19) 0.004(14) 0.038(15) 0.019(15) 
C19 0.039(11) 0.123(18) 0.139(17) -0.014(14) 0.005(10) -0.002(13)
C20 0.069(15) 0.13(2) 0.122(17) 0.019(15) 0.000(12) 0.012(13) 
C21 0.088(14) 0.083(14) 0.119(16) -0.005(11) 0.004(11) 0.016(11) 
The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 U11 + ... + 2 h 
k a* b* U12 ] 
Table A.6. Hydrogen atomic coordinates and isotropic atomic displacement parameters (Å2) for (1R,2S)-
JJ450. 
x/a y/b z/c U(eq) 
H2A 0.4847 0.6743 0.8400 0.106 
H3A 0.7170 0.5885 0.8249 0.096 
H5A 0.5548 0.3996 0.5072 0.102 
H7A 0.2343 0.7099 0.7802 0.134 
H7B 0.1974 0.7023 0.6340 0.134 
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x/a y/b z/c U(eq) 
H7C 0.1572 0.5806 0.7204 0.134 
H8A 0.3090 0.5741 0.3527 0.1 
H8B 0.2308 0.6628 0.4530 0.1 
H9A 0.0058 0.5460 0.4148 0.125 
H9B 0.0569 0.6084 0.2881 0.125 
H10A 0.3070 0.2735 0.5154 0.108 
H10B 0.3556 0.3427 0.3913 0.108 
H11A 0.1397 0.2179 0.3407 0.101 
H11B 0.0528 0.2891 0.4477 0.101 
H13A -0.0778 0.5223 0.0925 0.113 
H14A 0.1377 0.3976 -0.0671 0.124 
H14B -0.0017 0.4961 -0.1168 0.124 
H15A 0.0921 0.6718 0.0119 0.109 
H17A 0.2965 0.7933 0.0983 0.11 
H18A 0.5417 0.8152 0.1841 0.14 
H20A 0.5977 0.4259 0.1531 0.13 
H21A 0.3538 0.3968 0.0647 0.116 
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APPENDIX B 
CIRCULAR DICHROISM SPECTRA 
All CD spectra were measured on a Jasco J-815 CD spectrometer using a quartz cuvette (0.1 cm) 
in length. All samples were dissolved in HPLC grade methanol using a 2 mL volumetric flask.  
Figure B.1. CD spectra for enantiomers of JJ450. 
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Figure B.2. CD spectra for enantiomers of 3.23. 
Figure B.3. CD spectra for enantiomers of 3.21c. 
Figure B.4. CD spectra for enantiomers of 3.21f. 
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Figure B.5. CD spectra for enantiomers of 3.21h. 
Figure B.6. CD spectra for enantiomers of 3.21k. 
Figure B.7. CD spectra for enantiomers of 3.21n. 
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APPENDIX C 
EC50 CURVES 
All EC50’s are preliminary and were calculated using GraphPad prism using data obtained from 
the luciferase assay performed in the Wang lab. All data was normalized (0%, Y = 0; 100%, First 
value in data set). The normalized data was analyzed using a nonlinear regression (curve fit) 
(log(inhibitor) vs normalized response – Variable slope) with a least squares fit.  
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Figure C.1. EC50 curves for 3.13a. 
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Figure C.2. EC50 curves for 3.13b. 
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Figure C.3. EC50 curves for 3.21a. 
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Figure C.4. EC50 curves for (1S,2R)-3.21a. 
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Figure C.5. EC50 curves for (1R,2S)-3.21a. 
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Figure C.6. EC50 curves for 3.21b. 
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Figure C.7. EC50 curves for 3.21c. 
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Figure C.8. EC50 curves for (1S,2R)-3.21c. 
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Figure C.9. EC50 curves for (1R,2S)-3.21c. 
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Figure C.10. EC50 curves for 3.21d. 
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Figure C.11. EC50 curves for (1S,2R)-3.21d. 
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Figure C.12. EC50 curves for (1R,2S)-3.21d. 
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Figure C.13. EC50 curves for 3.21e. 
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Figure C.14. EC50 curves for (1S,2R)-3.21e. 
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Figure C.15. EC50 curves for (1R,2S)-3.21e. 
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Figure C.16. EC50 curves for 3.21f. 
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Figure C.17. EC50 curve for (1S,2R)-3.21f. 
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Figure C.18. EC50 curve for (1R,2S)-3.21f. 
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Figure C.19. EC50 curves for 3.21g. 
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Figure C.20. EC50 curves for (1S,2R)-3.21g. 
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Figure C.21. EC50 curves for (1R,2S)-3.21g. 
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Figure C.22. EC50 curves for 3.21h. 
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Figure C.23. EC50 curves for (1S,2R)-3.21h. 
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Figure C.24. EC50 curves for (1R,2S)-3.21h. 
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Figure C.25. EC50 curves for 3.21i. 
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Figure C.26. EC50 curves for 3.21j. 
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Figure C.27. EC50 curves for 3.21k. 
-1.0 -0.5 0.0 0.5 1.0 1.5
0
50
100
150
log[(1S,2R)-3.21k], µM
N
or
m
al
iz
ed
 R
es
po
ns
e
Normalize of Log-Dose vs Response
(1S,2R)-3.21k
(1S,2R)-3.21k
Figure C.28. EC50 curves for (1S,2R)-3.21k. 
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Figure C.29. EC50 curves for (1R,2S)-3.21k. 
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Figure C.30. EC50 curves for 3.21l. 
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Figure C.31. EC50 curves for (1S,2R)-3.21l. 
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Figure C.32. EC50 curves for (1R,2S)-3.21l. 
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Figure C.33. EC50 curves for 3.21m. 
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Figure C.34. EC50 curves for 3.21n. 
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Figure C.35. EC50 curves for (1S,2R)-3.21n. 
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Figure C.36. EC50 curves for (1R,2S)-3.21n. 
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Figure C.37. EC50 curves for 3.21o. 
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Figure C.38. EC50 curves for (1S,2R)-3.21o. 
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Figure C.39. EC50 curves for (1R,2S)-3.21o. 
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Figure C.40. EC50 curves for 3.21p. 
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Figure C.41. EC50 curves for 3.21q. 
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Figure C.42. EC50 curves for 3.21r. 
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Figure C.43. EC50 curves for 3.23. 
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Figure C.44. EC50 curves for (1S,2R)-3.23. 
-1.0 -0.5 0.0 0.5 1.0 1.5
0
50
100
150
log[(1R,2S)-3.23], µM
N
or
m
al
iz
ed
 R
es
po
ns
e
Normalize of Log-Dose vs Response
(1R,2S)-3.23
(1R,2S)-3.23
Figure C.45. EC50 curves for (1R,2S)-3.23. 
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Figure C.46. EC50 curves for 3.24. 
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Figure C.47. EC50 curves for 3.25. 
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Figure C.48. EC50 curves for 3.55. 
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Figure C.49. EC50 curves for 3.58. 
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3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m 1.398
1.412
1.419
1.433
1.440
1.454
1.754
1.899
1.914
1.930
1.945
2.099
2.105
2.127
2.149
2.155
2.204
2.211
2.234
2.257
2.271
2.278
2.280
2.295
2.315
2.501
2.519
2.524
2.541
2.546
2.563
2.745
2.753
2.767
2.775
2.787
2.799
2.827
3.222
3.228
3.252
3.276
3.282
3.566
3.573
3.589
3.597
3.605
3.620
3.627
3.778
3.810
3.910
3.942
6.957
7.211
7.214
7.232
7.236
7.260
7.290
7.309
7.358
7.378
7.398
7.580
7.583
7.603
7.605
7.613
7.617
1.01
1.02
1.06
5.01
0.99
2.00
0.96
1.00
1.02
0.96
1.00
2.01
0.99
1.01
1.98
741
−38
−1
−
C
D
Cl3
−400B
O
N
N
CF
3
SF
5
3.21n 
391 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
p
p
m
10.90
17.76
23.94
24.03
42.15
45.54
51.57
51.75
76.68
77.00
77.32
115.89
115.92
115.96
116.00
120.04
120.29
120.32
120.36
120.40
122.74
123.85
123.90
123.94
123.99
124.03
125.45
125.59
125.64
125.68
125.73
125.78
128.15
128.50
128.83
129.15
129.47
130.32
131.34
136.81
138.99
151.01
153.53
153.70
153.87
154.03
154.20
166.51
741
−38
−1
−
C
D
Cl3
−400B
O
N
N
CF
3
SF
5
3.21n 
392 
−100
−90
−80
−70
−60
−50
−40
−30
−20
−10
110
100
90
80
70
60
50
40
30
20
10
0
p
p
m
−62.42
62.55
62.94
83.67
84.07
84.47
84.86
85.27
741
−38
−
F19
−
C
D
Cl3
−400Mhz
O
N
N
CF
3
SF
5
3.21n 
393 
−0.5
10.5
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m 1.466
1.480
1.487
1.501
1.508
1.522
1.928
1.942
1.959
1.973
2.303
2.347
2.362
2.370
2.384
2.390
2.405
2.418
2.424
2.436
2.445
2.454
2.465
2.533
2.555
2.572
2.594
2.749
2.756
2.764
2.773
2.785
2.793
2.800
2.869
2.876
2.882
2.892
2.906
2.910
2.918
3.470
3.494
3.502
3.513
3.655
3.661
3.678
3.687
3.692
3.721
3.729
3.740
3.747
3.761
3.772
3.779
7.024
7.220
7.244
7.248
7.260
7.269
7.573
7.576
7.594
7.596
7.602
7.618
7.623
8.636
1.06
1.05
3.12
3.62
1.19
1.29
1.54
1.10
3.46
1.02
2.82
2.02
1.00
759
−34
−1
−
C
D
Cl3
−400Mhz
O
CF
3
N
N
N
CF
3
3.21o 
394 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
p
p
m
10.96
17.87
21.46
23.67
42.28
45.59
51.49
51.96
76.68
77.00
77.32
115.81
115.85
115.89
115.92
117.51
119.77
119.80
119.83
119.85
120.01
120.23
120.39
120.43
120.47
120.50
122.71
122.95
125.41
125.67
128.12
128.62
128.94
129.26
129.58
131.45
135.48
136.72
136.86
145.75
146.10
146.44
146.79
150.50
150.85
166.40
759
−34
−1
−
C
D
Cl3
−400Mhz
O
CF
3
N
N
N
CF
3
3.21o 
395 
−200
−190
−180
−170
−160
−150
−140
−130
−120
−110
−100
−90
−80
−70
−60
−50
−40
−30
−20
−10
10
0
p
p
m
−67.77
−62.37
759
−34
−
F19
−
C
D
Cl3
−400Mhz
O
CF
3
N
N
N
CF
3
3.21o 
396 
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m 1.351
1.364
1.371
1.385
1.393
1.406
1.749
1.765
1.779
1.794
2.133
2.148
2.154
2.155
2.170
2.175
2.190
2.244
2.359
2.365
2.388
2.393
2.400
2.419
2.443
2.449
2.492
2.509
2.514
2.531
2.536
2.553
2.752
2.763
2.772
2.791
2.829
3.314
3.320
3.345
3.367
3.374
3.608
3.615
3.630
3.639
3.648
3.662
3.669
3.837
3.869
3.949
3.982
6.554
6.565
6.575
6.785
6.791
6.956
6.961
6.976
6.982
7.075
7.096
7.260
1.09
1.05
1.12
3.13
5.14
1.09
2.04
0.97
1.03
1.06
1.00
2.04
1.02
1.06
1.06
721
−88
−
C
D
Cl3
−400Mhz
O
N
N
Cl
S3.21p 
397 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
p
p
m
12.21
15.26
17.29
19.30
24.11
42.34
45.66
51.69
51.81
76.67
76.99
77.31
119.74
123.53
124.10
125.00
131.07
131.68
131.94
137.49
138.23
152.06
167.19
721
−88
−1
−
C
D
Cl3
−400Mhz
O
N
N
Cl
S3.21p 
398 
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m 1.353
1.367
1.374
1.388
1.396
1.409
1.742
1.757
1.772
1.787
2.135
2.150
2.156
2.172
2.177
2.193
2.334
2.377
2.404
2.416
2.424
2.433
2.439
2.446
2.468
2.474
2.499
2.522
2.539
2.561
2.779
2.800
2.809
2.819
2.828
2.837
2.846
2.857
3.318
3.342
3.366
3.610
3.617
3.632
3.641
3.649
3.664
3.671
3.860
3.893
3.986
4.018
6.546
6.548
6.554
6.557
6.575
6.583
7.041
7.224
7.245
7.248
7.257
7.278
1.03
1.03
1.05
3.09
3.34
1.63
1.09
2.03
0.98
1.05
1.03
1.00
1.97
1.02
2.50
721
−95
−
C
D
C
L3
−400Mhz
O
N
N
CF
3
S3.21q 
399 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
p
p
m
12.26
15.10
17.86
19.41
24.14
42.34
45.67
51.73
51.83
76.68
77.00
77.32
115.91
115.95
115.99
116.03
120.22
120.25
120.29
120.33
122.83
124.23
124.93
125.53
128.24
128.47
128.78
129.10
129.42
131.39
136.95
137.58
138.27
151.36
167.23
721
−95
−
C
D
C
L3
−400Mhz
O
N
N
CF
3
S3.21q 
400 
−200
−190
−180
−170
−160
−150
−140
−130
−120
−110
−100
−90
−80
−70
−60
−50
−40
−30
−20
−10
10
0
p
p
m
−62.23
721
−95
−1
−
C
D
Cl3
−400Mhz
O
N
N
CF
3
S3.21q 
401 
−0.5
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m
−0.003
1.362
1.376
1.383
1.397
1.405
1.418
1.423
1.660
1.744
1.759
1.774
1.789
2.131
2.146
2.152
2.168
2.173
2.189
2.255
2.261
2.283
2.305
2.312
2.401
2.408
2.430
2.456
2.458
2.488
2.505
2.510
2.527
2.531
2.549
2.751
2.776
2.802
3.203
3.209
3.234
3.258
3.264
3.537
3.544
3.560
3.568
3.576
3.592
3.599
3.859
3.892
4.061
4.094
6.580
6.589
6.603
6.606
6.612
6.614
7.033
7.036
7.202
7.206
7.224
7.227
7.260
7.530
7.551
1.13
1.03
1.05
1.05
4.10
0.93
2.02
0.99
1.02
1.04
1.00
1.93
0.99
1.02
1.00
741
−35
−2
−
C
D
Cl3
−400Mhz
O
N
N
CF
3
Cl
S3.21r 
402 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
p
p
m
−0.04
12.44
15.29
19.43
24.36
42.36
45.65
53.19
53.60
76.68
77.00
77.32
119.43
122.14
124.03
124.81
124.86
125.08
125.51
125.82
126.11
126.40
127.57
128.30
128.36
128.41
128.46
137.38
138.52
138.63
153.18
167.14
741
−35
−2
−
C
D
Cl3
−400Mhz
O
N
N
CF
3
Cl
S3.21r 
403 
−200
−190
−180
−170
−160
−150
−140
−130
−120
−110
−100
−90
−80
−70
−60
−50
−40
−30
−20
−10
0
p
p
m
−60.39
741
−35
−2
−
C
D
Cl3
−400Mhz
O
N
N
CF
3
Cl
S3.21r 
404 
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
p
p
m 1.114
1.118
1.148
1.178
1.181
1.249
1.647
1.658
1.679
1.689
1.708
1.711
1.740
1.743
1.796
1.806
1.819
1.827
1.837
1.849
1.860
2.029
2.038
2.046
2.058
2.077
2.178
2.182
2.195
2.212
2.240
2.367
2.436
2.441
2.458
2.465
2.474
2.479
2.490
2.797
2.855
2.871
2.888
3.062
3.078
3.094
3.109
3.125
3.223
3.236
3.692
3.712
4.100
4.114
4.228
4.248
4.268
4.454
4.467
4.473
4.489
4.615
4.635
4.656
5.292
7.125
7.128
7.140
7.144
7.146
7.156
7.159
7.163
7.242
7.245
7.258
7.264
7.280
7.283
7.339
7.341
7.358
7.362
1.13
2.42
1.16
1.33
1.00
3.10
2.94
1.29
0.48
0.97
1.13
1.91
2.00
0.93
0.98
2.06
0.96
2.07
1.68
1.00
J
K
J
−71
−565
−1
−
C
D
C
L3
−400Mhz
S
O
ON
N
OH
H
3.25 
405 
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
p
p
m
10.04
10.93
24.18
31.02
32.73
33.11
36.60
38.57
50.16
51.24
53.53
76.67
76.98
77.30
83.11
93.44
109.74
122.67
125.58
126.12
128.47
131.43
132.01
144.96
159.72
166.86
168.11
J
K
J
−71
−565
−1
−
C
D
C
L3
−400Mhz
S
O
ON
N
OH
H
3.25 
406 
N
O
O
O
O
OBn
O
S
O
ON
H
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
ppm 1.436
1.457
1.479
1.492
1.514
1.535
1.636
1.734
1.741
1.755
1.769
1.774
1.780
1.798
1.813
1.819
2.048
2.055
2.060
2.068
2.074
2.080
2.086
2.100
2.116
2.120
2.125
2.132
2.139
2.143
2.150
2.160
2.170
2.313
2.446
2.485
2.503
2.516
2.526
2.569
2.582
2.595
2.959
2.971
2.983
3.015
3.038
3.158
3.181
3.602
3.626
3.637
3.644
3.652
3.703
3.708
3.711
3.717
3.806
3.830
4.170
4.178
4.186
4.732
4.745
4.758
5.171
7.116
7.120
7.128
7.140
7.185
7.195
7.198
7.206
7.218
7.260
7.321
7.323
7.328
7.335
7.344
1.89
1.85
1.92
2.81
4.45
1.92
2.75
0.95
1.00
4.91
1.99
0.88
4.47
0.26
0.87
1.80
1.84
1.95
4.57
J
K
J
−627
−79
−1
−CDCL3
−600Mhz
3.25 
407 
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
p
p
m
10.21
11.07
23.62
27.68
29.48
31.11
31.43
32.88
35.67
38.83
40.13
49.15
53.19
63.55
66.51
68.63
69.06
70.53
70.87
76.79
77.00
77.21
109.99
126.31
126.74
127.45
128.40
128.44
128.59
129.30
135.37
138.16
141.87
159.88
166.42
167.05
170.24
172.60
J
K
J
−627
−79
−1
−
C
D
C
L3
−600Mhz
N
O
O
O
O
OBn
O
S
O
ON
H
3.25 
408 
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m
−0.026
1.411
1.417
1.436
1.440
1.443
1.463
1.468
1.716
1.732
1.739
1.747
1.752
1.770
1.776
2.020
2.042
2.116
2.265
2.314
2.321
2.331
2.335
2.347
2.352
2.407
2.430
2.446
2.456
2.856
2.909
2.921
2.926
2.939
2.953
3.040
3.068
3.177
3.204
3.386
3.397
3.410
3.420
3.542
3.553
3.562
3.590
3.721
3.750
3.760
3.770
3.836
4.102
4.111
4.120
4.134
4.150
4.632
4.648
4.664
6.211
6.222
6.233
6.872
6.877
6.891
6.895
6.900
7.074
7.082
7.089
7.098
7.153
7.155
7.160
7.260
7.920
7.926
7.929
7.939
7.943
7.949
2.05
2.05
1.13
1.06
3.02
2.08
5.41
3.15
0.99
1.00
2.06
3.09
3.11
3.05
3.07
1.00
0.95
2.01
2.10
2.06
2.00
655
−18
−5
−
C
D
Cl3
−500Mhz
N
HN
O
O
O
O
O
O
S
ON
H
3.25 
409 
210
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
0
p
p
m
−0.130
10.025
10.898
23.662
28.940
29.448
30.988
31.979
32.619
38.298
38.858
39.045
39.959
49.453
51.727
53.151
67.316
69.064
69.862
76.743
76.999
77.253
109.874
114.026
122.750
126.233
126.592
127.294
129.428
131.455
138.473
141.419
159.666
162.291
166.589
166.761
166.937
171.986
655
−18
−5
−
C
D
Cl3
−500Mhz
N
HN
O
O
O
O
O
O
S
ON
H
3.25 
410 
N
N
HO
O
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
p
p
m 1.326
1.340
1.347
1.361
1.369
1.382
1.595
1.766
1.781
1.797
1.819
1.834
1.850
1.865
2.154
2.169
2.175
2.177
2.190
2.192
2.198
2.213
2.408
2.419
2.430
2.436
2.440
2.458
2.481
3.074
3.085
3.097
3.102
3.113
3.299
3.309
3.317
3.332
3.610
3.618
3.633
3.640
3.725
3.734
3.743
3.766
3.904
3.937
4.502
4.517
6.656
6.675
6.676
6.914
6.916
6.932
6.935
6.951
6.954
7.126
7.133
7.134
7.138
7.143
7.148
7.152
7.155
7.160
7.209
7.213
7.223
7.228
7.229
7.234
7.240
7.242
7.248
7.252
7.260
7.364
7.367
7.383
7.386
1.00
0.93
0.98
1.90
1.90
1.90
0.95
0.98
0.96
0.96
1.94
0.94
0.97
2.86
4.07
1.00
J
K
J
−25
−584
−1
−
C
D
C
L3
−400Mhz
3.25 
411 
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
p
p
m
10.62
24.06
24.47
41.96
45.35
50.86
51.44
51.75
76.67
76.99
77.31
83.88
92.63
116.27
117.77
122.22
126.37
127.33
128.14
129.61
133.91
137.59
153.64
167.36
J
K
J
−25
−584
−1
−
C
D
C
L3
−400Mhz
N
N
HO
O
3.25 
412 
11.5
11.0
10.5
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
p
p
m
2.586
2.616
2.619
2.629
2.643
2.647
2.656
2.659
2.663
2.676
2.686
2.690
2.696
2.709
2.719
2.727
2.731
2.739
2.750
2.762
2.770
2.775
2.783
2.793
2.805
3.636
3.668
3.700
4.314
4.337
4.345
4.367
4.376
4.398
4.514
4.526
4.541
4.545
4.553
4.557
4.572
4.585
7.259
1.98
0.93
1.00
1.02
665
−48
−1
−
C
D
C
L3
−300Mhz
O
O
N
4.110 
413 
200
190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10
p
p
m
27.63
31.40
67.30
76.57
77.00
77.42
114.82
168.57
J
K
J
−665
−46
−1
−
C
D
C
L3
−300Mhz
O
O
N
4.110 
414 
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
p
p
m
1.741
1.746
1.751
1.768
1.792
1.812
1.825
1.833
1.854
1.869
1.877
2.004
2.013
2.021
2.283
2.293
2.306
2.317
2.340
2.349
2.362
2.367
2.371
2.382
2.386
2.390
2.398
2.406
2.415
2.427
2.438
2.442
2.447
2.451
2.569
2.943
2.968
2.993
3.019
3.043
3.691
3.713
3.728
3.736
3.749
3.755
3.771
3.774
3.791
4.744
4.754
4.765
4.776
4.786
5.072
5.095
5.118
5.140
5.163
7.260
3.94
0.86
2.06
1.00
0.93
2.00
0.08
0.04
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